,id,ticker,title,category,content,date,provider,url,article_id
7248,228763,LH,U S  stocks higher at close of trade  Dow Jones Industrial Average up 0 56 ,news,"Investing com   U S  stocks were higher after the close on Wednesday  as gains in the Technology  Healthcare and Financials sectors led shares higher 
At the close in NYSE  the Dow Jones Industrial Average rose 0 56   while the S P 500 index climbed 0 49   and the NASDAQ Composite index climbed 0 67  
The best performers of the session on the Dow Jones Industrial Average were UnitedHealth Group Incorporated  NYSE UNH   which rose 2 11  or 6 11 points to trade at 295 90 at the close  Meanwhile   American Express  Company  NYSE AXP  added 1 73  or 2 13 points to end at 125 54 and  Visa Inc  Class A  NYSE V  was up 1 71  or 3 23 points to 191 92 in late trade 
The worst performers of the session were Walgreens Boots Alliance Inc  NASDAQ WBA   which fell 5 84  or 3 46 points to trade at 55 83 at the close   Boeing Co   NYSE BA  declined 1 75  or 5 91 points to end at 331 37 and  Exxon Mobil  Corp  NYSE XOM  was down 1 51  or 1 06 points to 69 23 
The top performers on the S P 500 were Constellation Brands Inc Class A  NYSE STZ  which rose 3 64  to 190 29  Vertex Pharmaceuticals Inc  NASDAQ VRTX  which was up 3 26  to settle at 231 09 and Laboratory Corporation of America Holdings  NYSE LH  which gained 2 77  to close at 173 84 
The worst performers were Walgreens Boots Alliance Inc  NASDAQ WBA  which was down 5 84  to 55 83 in late trade   Cabot Oil   Gas  Corporation  NYSE COG  which lost 3 82  to settle at 16 85 and Phillips 66  NYSE PSX  which was down 3 74  to 104 10 at the close 
The top performers on the NASDAQ Composite were  ShiftPixy  Inc  NASDAQ PIXY  which rose 138 54  to 19 25   Midatech Pharma  PLC ADR  NASDAQ MTP  which was up 52 65  to settle at 1 040 and  Toughbuilt Industries  Inc  NASDAQ TBLT  which gained 46 31  to close at 0 40 
The worst performers were Genetic Technologies Ltd  NASDAQ GENE  which was down 27 72  to 3 260 in late trade   Zion Oil   Gas Inc   NASDAQ ZN  which lost 24 14  to settle at 0 294 and Apex Global Brands Inc  NASDAQ APEX  which was down 22 55  to 0 79 at the close 
Rising stocks outnumbered declining ones on the New York Stock Exchange by 1627 to 1182 and 94 ended unchanged  on the Nasdaq Stock Exchange  1536 rose and 1117 declined  while 76 ended unchanged 
Shares in Vertex Pharmaceuticals Inc  NASDAQ VRTX  rose to all time highs  rising 3 26  or 7 30 to 231 09  Shares in Visa Inc Class A  NYSE V  rose to all time highs  gaining 1 71  or 3 23 to 191 92  Shares in ShiftPixy Inc  NASDAQ PIXY  rose to all time highs  up 138 54  or 11 18 to 19 25  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was down 2 47  to 13 45 
Gold Futures for February delivery was down 1 05  or 16 60 to  1557 70 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in February fell 4 34  or 2 72 to hit  59 98 a barrel  while the March Brent oil contract fell 0 03  or 0 02 to trade at  65 86 a barrel 
EUR USD was up 0 05  to 1 1109  while USD JPY fell 0 03  to 109 08 
The US Dollar Index Futures was up 0 35  at 97 037 ",2020-01-08,Investing.com,https://www.investing.com/news/stock-market-news/us-stocks-higher-at-close-of-trade-dow-jones-industrial-average-up-056-2055462,2055462
7463,228978,LH,Notable earnings before Wednesday s open,news,ANTM  AOS  APH  AVX  AVY  AXTA  BA  BABY  BCO  BKU  BOKF  BSX  BTU  CHKP  CMCSA  CVE  CYOU  DPS  DTE  ETR  EVR  FLIR  GD  GLPI  GRA  GT  HES  IART  IR  LAD  LH  MDCO  MHO  MKTX  NDAQ  NOC  NSC  NYCB  OC  PAG  PB  QNST  RES  ROK  ROL  SIRI  SLAB  SLGN  SOHU  STM  STNG  TEL  TMO  TPH  TROW  TRVG  TUP  TWTR  UMC  USG  VIAB  YNDX For Seeking Alpha s full earnings season calendar  click here Now read ,2018-04-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/notable-earnings-before-wednesdays-open-1412234,1412234
7464,228979,LH,LabCorp Q1 revenues up 18   non GAAP EPS up 31   raises revenue guidance,news,Laboratory Corporation of America  LH  0 5   Q1 results  Revenues   2 848 3M   18 0    Operating Income   305 4M   4 0    Net Income   173 2M   5 4    EPS   1 67   4 6    Non GAAP EPS   2 78   30 5    Quick Assets   361 8M   14 2    CF Ops   154 7M   31 5   2018 Guidance  Net Revenue Growth  10 0    12 0  from 9 5    11 5   LabCorp Diagnostics Revenue Growth  3 5    5 5  from 3 0    5 0   Covance Revenue Growth  21 0    25 0  from 20 0    24 0   Non GAAP EPS   11 30   11 70  unch   FCF   1 1B   1 2B  unch  Now read ,2018-04-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/labcorp-q1-revenues-up-18-nongaap-eps-up-31-raises-revenue-guidance-1413567,1413567
7465,228980,LH,Glenview added Express Scripts  exited Apple in Q1,news,Larry Robbins and Mark Horowitz s Glenview Capital discloses the addition of Express Scripts  NASDAQ ESRX  to its investments while exiting Apple  NASDAQ AAPL  in Q1  according to its 13F filing  Top new buys  ESRX  TMUS  APTV  ABC  HUM  FB  Increased stakes in FDX  CAH  NWL  ARMK  PNR  AGN  LOW  WBA  MCK  SHPG  Top exits  AAPL  WP  ABBV  DNB  CCE  LYB  MON  KMI  KND  TLRD  Reduced stakes in DWDP  FMC  ANTM  FLEX  CI  V  DXC  LH  CHTR  GOOGL  Now read ,2018-05-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/glenview-added-express-scripts-exited-apple-in-q1-1448893,1448893
7466,228981,LH,Notable earnings before Wednesday s open,news,AB  ALXN  APH  AVX  BA  BABY  BCO  BKU  BOKF  BPOP  BSX  CHKP  CRS  DTE  EVR  FCX  FSV  GD  GRA  HLT  IR  ITW  LAD  LH  MHO  MKTX  NDAQ  NOC  NSC  NYCB  OC  PB  POL  QSR  RES  ROL  SCHN  SCL  SIRI  SLAB  SLGN  SMPL  STM  T  TDY  TMO  TNC  TPH  TRVG  TUP  TZOO  UMC  UPSFor Seeking Alpha s full earnings season calendar  click here  Now read ,2018-10-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/notable-earnings-before-wednesdays-open-1656719,1656719
7467,228982,LH,U S  stocks higher at close of trade  Dow Jones Industrial Average up 0 79 ,news,"Investing com   U S  stocks were higher after the close on Friday  as gains in the Telecoms  Utilities and Healthcare sectors led shares higher 
At the close in NYSE  the Dow Jones Industrial Average added 0 79   while the S P 500 index climbed 0 81   and the NASDAQ Composite index climbed 0 79  
The best performers of the session on the Dow Jones Industrial Average were  Caterpillar  Inc  NYSE CAT   which rose 4 18  or 5 44 points to trade at 135 67 at the close  Meanwhile  Intel Corporation  NASDAQ INTC  added 3 38  or 1 61 points to end at 49 31 and Coca Cola Company  NYSE KO  was up 2 90  or 1 42 points to 50 40 in late trade 
The worst performers of the session were  Goldman Sachs Group  Inc  NYSE GS   which fell 2 13  or 4 16 points to trade at 190 69 at the close  Walt  Disney  Company  NYSE DIS  declined 0 96  or 1 12 points to end at 115 49 and The Travelers Companies Inc  NYSE TRV  was down 0 20  or 0 26 points to 130 37 
The top performers on the S P 500 were  AbbVie Inc   NYSE ABBV  which rose 4 85  to 94 270   Raymond James Financial Inc   NYSE RJF  which was up 4 54  to settle at 79 73 and  American Airlines Group   NASDAQ AAL  which gained 4 53  to close at 40 16 
The worst performers were Laboratory Corporation of America  NYSE LH  which was down 9 99  to 145 64 in late trade   Hasbro Inc   NASDAQ HAS  which lost 6 04  to settle at 91 00 and Marriott International Inc  NASDAQ MAR  which was down 5 59  to 115 03 at the close 
The top performers on the NASDAQ Composite were Borqs Technologies Inc  NASDAQ BRQS  which rose 122 66  to 5 70  Adial Pharmaceuticals Inc  NASDAQ ADIL  which was up 37 14  to settle at 3 84 and Determine Inc  NASDAQ DTRM  which gained 29 15  to close at 0 607 
The worst performers were  China Ceramics  Co Ltd  NASDAQ CCCL  which was down 27 65  to 1 2300 in late trade  Tonix Pharmaceuticals Holding Corp  NASDAQ TNXP  which lost 25 54  to settle at 5 190 and  AeroVironment  Inc  NASDAQ AVAV  which was down 16 45  to 76 60 at the close 
Rising stocks outnumbered declining ones on the New York Stock Exchange by 1680 to 1409 and 78 ended unchanged  on the Nasdaq Stock Exchange  1463 rose and 1205 declined  while 79 ended unchanged 
Shares in Laboratory Corporation of America  NYSE LH  fell to 52 week lows  falling 9 99  or 16 17 to 145 64  Shares in China Ceramics Co Ltd  NASDAQ CCCL  fell to 3 years lows  down 27 65  or 0 4700 to 1 2300  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was down 3 83  to 18 07 
Gold Futures for February delivery was down 0 24  or 3 00 to  1227 40 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January fell 1 42  or 0 73 to hit  50 72 a barrel  while the February Brent oil contract fell 1 15  or 0 69 to trade at  59 22 a barrel 
EUR USD was down 0 66  to 1 1318  while USD JPY rose 0 04  to 113 53 
The US Dollar Index Futures was up 0 46  at 97 145 ",2018-11-30,Investing.com,https://www.investing.com/news/stock-market-news/us-stocks-higher-at-close-of-trade-dow-jones-industrial-average-up-079-1706968,1706968
7468,228983,LH,Opko Health says over 400 000 customers likely affected by data breach,news, Reuters    Opko Health Inc said on Thursday it was notified by its former billing collections vendor about unauthorized access to information on about 422 600 customers  making it the third healthcare company to be affected by the incident  American Medical Collection Agency  AMCA  informed Opko Health that the compromised data may include credit card and bank account information  email addresses and other data such as address  phone number and balance information  However  the company said no social security numbers  bank account passwords or security questions were compromised in the unauthorized activity that occurred between August 1  2018 and March 30  2019   Earlier this week  rivals Quest Diagnostics  NYSE DGX  Inc and Laboratory Corporation of America  NYSE LH  Holdings also announced that they were apprised of unauthorized access to their customer data stored on AMCA system  The data breach is estimated to have affected about 11 9 million customers of Quest Diagnostics and about 7 7 million of LabCorp  AMCA said in an emailed statement it is investigating the incident and has also hired an external forensics firm  Meanwhile  the company has migrated its web payments services to a third party vendor  The company told Opko Health it was notifying state attorneys general and other state agencies and nearly 6 600 customers that availed Opko s testing services and whose credit card or bank account details were stored in AMCA s affected system  Shares of Opko were down 1 5  at  1 92 in afternoon trading  Opko Health said it has not yet received the list of affected customers and had not been able to verify the accuracy of the information received from AMCA  Opko Health said its affected unit  BioReference Laboratories Inc  suspended collection requests to AMCA since October last year  and has asked the vendor to stop working on any pending collection requests involving the company s customers ,2019-06-06,Reuters,https://www.investing.com/news/technology-news/opko-health-says-over-400000-customers-likely-affected-by-data-breach-1890471,1890471
9511,231026,LH,LabCorp Hits New 52 Week High  What s Driving The Stock ,opinion,"Shares of Laboratory Corporation of America Holdings   NYSE LH   or LabCorp reached a new 52 week high of  179 35 on Jan 13  closing the session marginally lower at  179 22  The stock has rallied 9 1  since its third quarter earnings announcement on Oct 24 The company witnessed strong third quarter results  backed by the focus on high growth priorities   including expansion through acquisitions and partnerships   as well as broadening of the product line  Its strong underlying performance prompted the uptrend Let us delve deeper  
 Q3 PerformanceLabCorp ended the third quarter of 2019 on a strong note  with better than expected results  It witnessed year over year revenue improvements in both business segments  The company is upbeat about strong underlying performance and organic revenue growth across both Diagnostics and Drug Development businesses  It is banking on solid execution of three fundamental strategies   delivering advanced diagnostics  bringing new medicines to patients faster and using technology to improve patient care Over and above  the company s revised guidance for 2019 indicates that it will be able to maintain its ongoing bullish momentum in the fourth quarter as well Other Key DriversPartnerships  Investors are optimistic about LabCorp s slew of partnerships  the latest one being that of an innovative business swap transaction with Envigo  a provider of non clinical contract research services and research models  Per the terms of the agreement  LabCorp purchased Envigo s non clinical contract research service business in exchange of the sale of the Covance Research Products business  Among other partnerships  the ones with UnitedHealthcare and Aetna  NYSE AET  are significant This apart  acquisition of the diagnostic clinical laboratory testing business of South Bend Medical Foundation   SBMF   significantly enhanced LabCorp s opportunity to serve the local hospitals  physicians and patients in various regions of Indiana  Michigan  Ohio and Illinois Covance Drug Development  CDD  Arm  Investors are optimistic about the recent performance of LabCorp s CDD arm  The company is leaving no stone unturned to expand its range of diagnostic offerings to strengthen its position  It is aggressively enhancing CDD through acquisitions like that of MI Bioresearch  which is likely to enable CDD to move from preclinical to clinical development  LabCorp s plan of acquiring Regulatory and Clinical Research Institute  RCRI  further buoys optimism  In 2020  LabCorp is also expected to benefit from the integration of Chiltern LaunchPad in Diagnostics  The company made impressive strides in the Covance LaunchPad initiative in the third quarter  which may help it maintain the ongoing momentum  Its recently launched Phase II of LaunchPad initiative in the Diagnostics arm is expected to generate savings  Phase II of LaunchPad is expected to streamline LabCorp s business and help it grow Zacks Rank   Key PicksCurrently  LabCorp carries a Zacks Rank  3  Hold  Some better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE    Hill Rom Holdings  Inc   NYSE HRC   and Medtronic plc   NYSE MDT   Haemonetics  currently flaunting a Zacks Rank  1  Strong Buy   has a projected long term earnings growth rate of 13 5   You can see Hill Rom s long term earnings growth rate is estimated at 11 7   The company currently carries a Zacks Rank  2  Buy  Medtronic s long term earnings growth rate is estimated at 7 4   It currently carries a Zacks Rank  2 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/labcorp-hits-new-52week-high-whats-driving-the-stock-200498651,200498651
9518,231033,LH,LabCorp To Expand Hematology Suite With Sysmex America Deal,opinion,Laboratory Corporation of America Holdings   NYSE LH   or LabCorp recently extended its existing hematology automation pactwith medical diagnostic instrument manufacturer and information systems developer Sysmex America  With this development  LabCorp Diagnostics  primary reference laboratories will get Sysmex America s latest  enhanced XN Series technology Financial terms of the deal have been kept under wraps SysmexDeal at a GlanceBack in 2006  LabCorp initiated its partnership with Sysmex by signing a five year agreement under which the latter provided its fully automated hematology systems for the  primary testing laboratories of the former Per the terms of the agreement  LabCorp will get to use Sysmex  advanced XN 9100 system  a scalable  modular automation system that incorporates sample sorting robotics from Yaskawa Motoman  the provider of automation solutions for labor intensive  high throughput areas of the clinical diagnostic lab Going by the press release  the XN 9100 system reduces the turnaround time and optimizes labor utilization while maintaining high quality patient results  This frees up laboratory space to be used for other operational needs Is the Latest Deal Strategic Fit The initial deal with Sysmex is claimed to have aided LabCorp to improve its test volumes by approximately 50  while using less laboratory space  LabCorp expects to see a similar improvement with the latest Sysmex deal  According to LabCorp  the update on XN 9100 will help put its 10 year planned growth on track The company also believed that this collaboration with Sysmex America and Yaskawa Motoman has helped upgrade the design of compact and efficient hematology work cells that are integral to the XN 9100 system Strategic Alliances Add Stimulus to LabCorp LabCorp has strengthened its foothold in the diagnostics space through both organic and inorganic means and plans to coordinate with leading companies and academic institutions to provide a wider portfolio of tests  Among the company s recent alliances  worth mentioning are collaborations with UnitedHealthcare and CVS Health s   NYSE CVS   Aetna  NYSE AET   which enabled LabCorp to emerge as a contracted laboratory provider for all major national plans  Jul 1  2019 onward  all LabCorp brands are included in UnitedHealthcare s preferred lab network The company is optimistic about the opportunity to expand volume with UnitedHealthcare through the Preferred Lab Network in 2020 and beyond  Further  in the last reported quarter  LabCorp announced the Mount Sinai digital pathology and artificial intelligence collaboration as well as finalized several other new relationships  The company is also progressing well under its broad tie up with Walgreens   NASDAQ WBA   on patient engagement  health and wellness offerings plus the creation of a next generation contract research organization  CRO  Meanwhile  we make a note that LabCorp s direct peer Quest Diagnostics   NYSE DGX   has also struck a partnership deal last month with hc1  a major bioinformatics player in the field of precision testing  Under this alliance  both unveiled a service called Quest Lab Stewardship powered by hc1 to help optimize laboratory test utilization 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/labcorp-to-expand-hematology-suite-with-sysmex-america-deal-200470000,200470000
9519,231034,LH,LabCorp  LH  Names Two Leaders For Major Business Wings,opinion,Laboratory Corporation of America Holdings   NYSE LH   or LabCorp has come out with a major management reshuffle  This follows the company s June announcement about the quitting of its current chairman  president and CEO David P  King  As planned  King has to step down on Oct 31 and the following day  Adam H  Schechter will succeed him as the president and CEO of LabCorp The latest declaration highlights two new leadership roles for the company s business segments  namely LabCorp Diagnostics and Covance Drug Development   Effective Nov 1  2019  the Covance unit s existing CEO John Ratliff will take the reins as the CEO of LabCorp Diagnostics  While Dr  Paul Kirchgraber  the reigning senior vice president and head of Covance s clinical trial testing solutions  will fill Ratliff s shoes as the CEO of Covance LabCorp is highly optimistic about this recent top brass reshuffle as according to the company  John Ratliff  who has already demonstrated his transformational leadership capability in the Covance business  is also intensely involved with the LabCorp Diagnostics business over the past three years  He joined LabCorp as the CEO of Covance in October 2016 Meanwhile  Kirchgraber efficiently runs one of Covance s most successful divisions   clinical trial testing solutions  This business unit includes the very prosperous central laboratories  bioanalytical laboratories  and chemistry manufacturing as well as serves clinical trials in more than 100 countries Management believes that under Schechter s tenure with Kirchgraber and Ratliff s support  LabCorp is well poised to grow and flourish in the years ahead LabCorp s Progress With Growth Strategy In this regard  we note that as part of its three key strategic plans  LabCorp is working hard on innovations with academic institutions in order to capture the growing lab testing market with its advanced assays and tools In Diagnostics  the company successfully continues to provide the foundation for new collaborations with health systems  large physician groups and managed care partners LabCorp has also created avenues of growth opportunities in women s health  medical drug monitoring  genetics and oncology testing as well as in tough collaborations with Walgreens and 23andMe  Also  its partnerships with UnitedHealthcare and Aetna  NYSE AET  have helped LabCorp become a contracted laboratory provider for all major national plans Within Covance Drug Development  the company s ongoing strategic investments in precision medicine  therapeutic expertise  FSP solutions and biologic drug development capabilities steadily increase its win rate with existing partners and new customers  The acquisition of Chiltern is significantly strengthening LabCorp s strategic position in clinical development and accelerating revenue plus profit growth within Covance  This apart  the company s recent strategic technology contract with QIAGEN is expected to garner a positive outcome down the line Challenging Market CompetitionLabCorp currently faces a close contest from its major rival Quest Diagnostics   NYSE DGX   besides other commercial laboratories and hospitals  A significant player in the clinical diagnostic testing market is Bio Rad Laboratories   NYSE BIO    Within the CRO  Contract Research Organisation  space  Charles River Laboratories International  Inc    NYSE CRL   is a prominent name Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-10-07,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-names-two-leaders-for-major-business-wings-200471510,200471510
9520,231035,LH,Here s Why You Should Hold On To Quest Diagnostics Stock Now,opinion,Quest Diagnostics  Inc    NYSE DGX   is progressing well with its two point strategy of restoring growth and driving operational excellence In the past three months  the company s shares have outperformed the   The stock has rallied 3 7  against the industry s 2 3  decline This leading provider of commercial laboratory services in North America has a market cap of  14 21 billion  The company has an expected earnings growth rate of 7 4  for the next three to five years Courtesy of impressive prospects  this Zacks Rank  3  Hold  stock is worth retaining at the moment Focus on Growth Acceleration  Through the second quarter  QuestDirect consumer testing business has been gaining popularity  Recently  the company launched a consumer initiative for Lyme disease tests  This is expected to enhance the consume base of the company  thereby contributing to its top line during the third quarter  Operational Excellence a Goal  The company s Invigorate cost cutting initiatives have been successful so far  At the end of the second quarter  the company noted that it is on track to deliver 3  cost efficiencies in 2019 led by a continuous ramp up in productivity This trend should continue through the third quarter as well  improving the company s operating margin Strategic Collaboration  We are currently looking forward to Quest Diagnostics  recently formed partnership with hc1 to launch Quest Lab Stewardship that should enable the optimization of laboratory tests  Starting from the third quarter  this should have contributed to the company s organic growth Strong Guidance  Similar to the first half of the year  the company expects strong revenue growth from increasing volumes in the rest of 2019  Further  one extra revenue day in the third quarter should contribute to the company s third quarter top line  We are also impressed about the company expecting to maintain earnings growth through the rest of 2019 However  there are a few factors marring growth for the company Market Headwinds Weigh Heavy  The current market environment is quite challenging for Quest Diagnostics in the form of continued decline in healthcare utilization rate  softer volume  commercial pricing pressure and reimbursement Competitive Landscape  Quest Diagnostics continues to face intense competition  primarily from Laboratory Corporation of America  NYSE LH   IDEXX Laboratories and Sonic Healthcare  among others Which Way Are Estimates Treading For the third quarter of 2019  the Zacks Consensus Estimate for earnings is pegged at  1 71  which indicates 1 8  rise from the year ago quarter s figure  The same for revenues is pegged at  1 94 billion  calling for year over year growth of 2 8  from the prior year quarter s number The Zacks Consensus Estimate for 2019 earnings is pegged at  6 50  suggesting 3 01  year over year growth from the year ago figure  The same for revenues is pegged at  7 71 billion  suggesting 2 4  rise from the prior year number Key PicksA few better ranked stocks in the broader medical space are Styker   NYSE SYK    Medtronic   NYSE MDT   and Haemonetics   NYSE HAE    While Haemonetics carries a Zacks Rank  1  Strong Buy    the other two each carry a Zacks Rank  2  Buy  You can see  Stryker s long term earnings growth rate is expected to be 10 04  Medtronic s long term earnings growth rate is projected at 7 32  Haemonetics  long term earnings growth rate is expected to be 13 5  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all  This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-quest-diagnostics-stock-now-200469640,200469640
9536,231051,LH,LabCorp s Covance Launches Laboratory Data Management Service,opinion,Laboratory Corporation of America Holdings   NYSE LH    popularly known as LabCorp  recently announced that its Covance Drug Development arm launched a laboratory solution within its functional service provider  FSPx  portfolio  This new laboratory data management FSPx will cater to the pharmaceutical and biotechnology customers LabCorp  one of the major players in the global healthcare contract research organization  CRO  business  has been offering FSP services through Covance to its customers for more than 30 years now  The acquisition of Chiltern in 2017 provided it a major boost  which significantly enhanced the company s FSP offerings  The new service was renamed as FSPx  which included clinical analytics service and clinical operations capabilities Significance of the LaunchWith the latest launch  clinical analytics now includes Laboratory FSPx  which delivers customized global data solutions that enable clients to better manage laboratory data acquisition and site interactions  Clinical operations include clinical research associates and related functions The company believes that Laboratory FSPx will help customers improve data readiness by assimilating FSPx and central laboratory data teams from study setup to completion  It will also enable faster study start up by implementing standards  shorter processes and combined roles  Why is Laboratory Data Management Service Better Currently  various pharmaceutical and biotech companies are increasingly using the LabCorp s FSPx model  with the target of cost reduction  reconciliation and streamlining of operations  This is made possible by integrating a specialized group of highly experienced professionals  who will help clinical teams interface with central  local and specialty labs  including biomarker and pharmacokinetics labs Laboratory FSPx s capabilities at Covance aim to provide end to end solutions to assist clients in managing laboratory operations The company believes that the FSPx portfolio will strengthen its foothold in the CRO business as it is expected to meet growing demands of the industry for flexible and best in class solutions for clinical research Industry ProspectsPer   the global healthcare CRO market s size is expected to reach  54 7 billion by 2025  at a CAGR of 6 6  between 2014 and 2025  The major factor driving this industry is the increasing cost of drug development With such a positive outlook for the market  this launch has come at just the right time Some Recent DevelopmentsAmong a series of new developments  in July  LabCorp announced that it made an important expansion to its Pixel by LabCorp platform  which will allow consumers to purchase testing online  visit a convenient LabCorp patient service center  PSC  for specimen collection by a LabCorp phlebotomist and receive confidential results through a secure online portal In June  the company announced taking another step toward its goal of improving laboratory services and patient care by partnering with the Mount Sinai Health System  an integrated healthcare delivery system based in New York City  The companies will work to establish Mount Sinai Digital and AI enabled Pathology Center of Excellence Another milestone of the company in June was incorporating a new companion diagnostic test  therascreen PIK3CA PCR mutation analysis  It is now available through LabCorp and its Integrated Oncology specialty laboratory  Also  the company announced the completion of the acquisition deal with Envigo to strengthen and enhance the way their respective businesses support research in the biopharmaceutical and life sciences industries Share Price PerformanceShares of the company have gained 32 8  in a year compared with the  s growth of 10 5  and the S P 500 index s rally of 13 5  Zacks Rank   Stocks to ConsiderCurrently  LabCorp carries a Zacks Rank  3  Hold   A few better ranked stocks from the broader medical space are GW Pharmaceuticals PLC   NASDAQ GWPH    EssilorLuxottica SA   OTC ESLOY   and Haemonetics Corporation   NYSE HAE   GW Pharmaceuticals estimates third quarter earnings growth rate to be 72 8   It currently sports a Zacks Rank  1  Strong Buy   You can see EssilorLuxottica s long term earnings growth rate is projected at 8 7   It currently carries a Zacks Rank  2  Buy  Haemonetics  with a Zacks Rank  2  has a projected long term earnings growth rate of 13 5  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-29,Zacks Investment Research,https://www.investing.com/analysis/labcorps-covance-launches-laboratory-data-management-service-200460374,200460374
9537,231052,LH,LH Vs  CNMD  Which Stock Is The Better Value Option ,opinion,"Investors with an interest in Medical   Dental Supplies stocks have likely encountered both LabCorp  LH  and Conmed  CNMD   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
LabCorp and Conmed are sporting Zacks Ranks of  2  Buy  and  3  Hold   respectively  right now  This means that LH s earnings estimate revision activity has been more impressive  so investors should feel comfortable with its improving analyst outlook  But this is just one piece of the puzzle for value investors 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
LH currently has a forward P E ratio of 15 52  while CNMD has a forward P E of 34 17  We also note that LH has a PEG ratio of 1 81  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  CNMD currently has a PEG ratio of 2 56 
Another notable valuation metric for LH is its P B ratio of 2 43  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  CNMD has a P B of 3 48 
These are just a few of the metrics contributing to LH s Value grade of B and CNMD s Value grade of C 
LH sticks out from CNMD in both our Zacks Rank and Style Scores models  so value investors will likely feel that LH is the better option right now ",2019-07-16,Zacks Investment Research,https://www.investing.com/analysis/lh-vs-cnmd-which-stock-is-the-better-value-option-200440882,200440882
9538,231053,LH,LabCorp  LH  Expected To Beat Earnings Estimates  Can The Stock Move Higher ,opinion,"Wall Street expects a year over year decline in earnings on higher revenues when LabCorp  LH  reports results for the quarter ended June 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on July 25  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This medical laboratory operator is expected to post quarterly earnings of  2 90 per share in its upcoming report  which represents a year over year change of  2 7  
Revenues are expected to be  2 90 billion  up 1  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 12  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for LabCorp 
For LabCorp  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  2 69  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination indicates that LabCorp will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that LabCorp would post earnings of  2 53 per share when it actually produced earnings of  2 62  delivering a surprise of  3 56  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
LabCorp appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-expected-to-beat-earnings-estimates-can-the-stock-move-higher-200441399,200441399
9539,231054,LH,Will LabCorp s  LH  Q2 Earnings Gain From Overall Growth ,opinion,Laboratory Corporation of America Holdings   NYSE LH   also known as LabCorp is slated to report second quarter 2019 results on Jul 25  before the market opens  In the last reported quarter  the company s adjusted earnings exceeded the Zacks Consensus Estimate by 3 56   the average trailing four quarter beat being 0 67  Let s see how things are shaping up for this announcement Factors at PlayLabCorp s underlying core business is currently putting up a stable performance  Within Diagnostcs  the company expects to generate revenues in the second quarter of 2019  banking on the following facts First  January 2019 marked the official collaboration with UnitedHealthcare  Horizon NJ and Aetna  NYSE AET   placing LabCorp in network under all major national plans  Ever since  after a dip in volume during the month  the company has been registering consistent organic growth on the back of these partnerships  This upside should get reflected in the company s second quarter results Laboratory Corporation of America Holdings Price and EPS Surprise   Second  although the company expects to gain a judicial and legislative relief from the second round of PAMA  Protecting Access to Medicare Act  price reductions  there is an increasing industry wide awareness about PAMA s true impact  Owing to this  LabCorp believes to be offered a string of attractive tuck in lab acquisition opportunities  which would typically deliver significant synergies and high returns on its invested capital Third  the company is highly optimistic about the Phase II of LaunchPad initiative in Diagnostics  which is expected to deliver  200 million of savings in another three years  This should contribute to the company s operational results in the second quarter itself Within Covance Drug Development  LabCorp is focused on driving profitable growth through expanded solutions and enhanced operational capabilities  The Chiltern integration has significantly strengthened the company s strategic position in clinical development and is accelerating revenues and profit growth within Covance  On this front  the company is keeping a good pace with its objective to streamline the drug development process  It is important to note that it is winning awards through its integrated Covance and Chiltern offering Additionally  the company has progressed with the Covance LaunchPad initiative  In the first phase  as expected  the company generated pre tax savings of  20 million  At the exit of first quarter 2019  it remained on track to deliver  150 million of net savings by the end of 2020  The company is also on course to realize  30 million in cost synergies from the consolidation of Chiltern by the end of 2019 This apart  the innovative business swap transaction with Envigo is projected to contribute to the company s top line in the second quarter  The transaction provides Covance with better global non clinical research capabilities while maintaining access to a bigger research models and services through a multi year renewable supply agreement All the above factors should together constantly favor the top line at LabCorp s Covance Drug Development in the yet to be reported quarter  Overall  the company expects 2019 Covance Drug Development revenue growth within 5 9  For 2019  on an overall basis  LabCorp envisions modest growth in total revenues and the adjusted EPS  The company expects another year of approximately  1 billion in free cash flow  These should get reflected in the second quarter itself What the Quantitative Model SuggestsThe proven Zacks model conclusively shows that a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive  LabCorp has a Zacks Rank  2  which increases the predictive power of ESP  It also has an Earnings ESP of  3 56   together which a likely positive surprise is predicted for the stock this earnings season The Zacks Consensus Estimate for second quarter earnings of  2 53 indicates an 8 9  decline from the year ago reported figure  Revenue estimate is pegged at  2 82 billion  suggesting a 0 86  slip from the prior year reported number  You can uncover the best stocks to buy or sell before they re reported with our  Other Stocks to ConsiderHere are a few other medical stocks worth considering from the broader medical space as these too comprise the right mix of elements to exceed expectations this reporting cycle DENTSPLY SIRONA   NASDAQ XRAY   has an Earnings ESP of  6 95  and a Zacks Rank of 1  You can see  Thermo Fisher Scientific Inc    NYSE TMO   has an Earnings ESP of  0 54  and a Zacks Rank of 2 Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 24  and is a Zacks  2 Ranked player Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-21,Zacks Investment Research,https://www.investing.com/analysis/will-labcorps-lh-q2-earnings-gain-from-overall-growth-200442685,200442685
9540,231055,LH,Medical Products  Earnings Roster For Jul 25  SYK  BAX   More,opinion,The  companies within the broader  sector are likely to put up an impressive show this earnings season  Focus on research and development is a key growth strategy for the companies in this space  Currently  these industry players are benefiting from the R D  research and development  innovation  courtesy of the temporary repeal of 2 3  Medical Device tax in 2018 The past few months have been remarkable for the medical device space in terms of R D  Riding high on the path breaking inventions like wireless brain sensors  Bluetooth enabled smart inhalers  artificial pancreas  human brain pacemaker  electronic skin that displays vital signs of the body  needle free injections  precision medicine and many more  the medical device space has gone from strength to strength Solid growth in the emerging markets is expected to be an added positive this reporting cycle  Backed by the rising medical awareness and economic prosperity  emerging economies are witnessing strong demand for the medical products  Notably  an aging population  relaxed regulations  cheap skilled labor  increasing wealth and the government focus on healthcare infrastructure make these markets a happy hunting ground for the global medical device players However  the U S  Medical Products industry has confronted short term hurdles pertaining to the trade war with China  Per a Medical Imaging   Technology Alliance  MITA  survey  tariffs will cost the companies nearly  138 million every year In the wake of the levy of U S  tariff and the Chinese retaliation to counter the same  the medical product fraternity is facing a huge bottom line pressure  especially on the companies with production in China   However  the latest update on the U S  exemptions of some medical devices from 25  tariff alongside both countries  efforts to temporarily resume trade negotiations comes as a relief for investors The latest  predicts the Medical sector to deliver positive earnings surprises this time around  as of Jul 19   For the quarter under review  earnings growth rate is projected at 1 7  on 4 8  revenue growth What Our Model SaysThe proven Zacks model clearly indicates that a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive   Conversely  a Zacks Rank  4  Sell  or 5  Strong Sell  stocks are best avoided  especially if the companies are witnessing negative estimate revisions  You can uncover the best stocks to buy or sell before they re reported with our  Considering the above factors  we take a look at the following five Medical Products behemoths that are set to release earnings results on Jul 25 Stryker Corporation   NYSE SYK    In second quarter 2019  the company is expected to gain traction from strength in the MedSurg segment  This business is likely to deliver a sturdy performance  primarily driven by anticipated growth across its aforementioned three subsegments  The segment is forecast to deliver considerable worldwide organic growth in the to be reported quarter  fueled by a better than expected uptick in instruments  Overall  Stryker is likely to have displayed broad based growth across its divisions and regions   read more    Stryker Corporation Price and EPS Surprise   Stryker has a Zacks Rank  2  which increases the predictive power of ESP  It also has an Earnings ESP of  0 24   together which a likely positive surprise is indicated for the stock this reporting cycle  You can see  Baxter International Inc    NYSE BAX    The company is expected to see second quarter revenue growth  led by a robust sale of Spectrum IQ and Evo IQ infusion pumps  This apart  a few strategic alliances signed by Baxter are likely to impact the second quarter results  On the flip side  headwinds related to Baxter s U S  business and the exit of the in center hemo dialysis Bloodline business are feared to hurt the core Renal Care arm   read more    Baxter International Inc  Price and EPS Surprise   Baxter has an Earnings ESP of 0 00  and a Zacks Rank  3  a combination that makes surprise prediction difficult Laboratory Corporation of America Holdings   NYSE LH   or LabCorp  LabCorp s underlying core businesses are putting up a stable performance over the last few quarters  Within Diagnostics  the company expects to generate revenues in the second quarter of 2019  banking on the strategic execution of its in network laboratory collaboration with UnitedHealthcare  Horizon NJ and Aetna  NYSE AET   Within Covance Drug Development  LabCorp deepens its focus on driving profitable growth in the second quarter through expanded solutions and enhanced operational capabilities   read more    Laboratory Corporation of America Holdings Price and EPS Surprise   LabCorp s Earnings ESP of  3 56  and a Zacks Rank of 2 make us reasonably confident about an earnings beat this time around ResMed Inc    NYSE RMD    The company is expected to register strong revenue growth across all geographical regions in its fourth quarter fiscal 2019  attributable to solid results from Software as a Service businesses as well as new mask products and devices  Within Software as a Service  Brightree service offerings and the buyouts of MatrixCare and HEALTHCAREfirst should firmly contribute to the top line ResMed Inc  Price and EPS Surprise   The Zacks Consensus Estimate for revenues in the fiscal fourth quarter is pinned on  701 7 million  implying a 12 5  improvement from the year ago reported figure  The same for earnings is pegged at 92 cents  suggesting a 3 2  dip from the prior year reported number  In the trailing four quarters  the company exceeded the consensus mark  the average being 4 51  ResMed s Earnings ESP of 0 00  and a Zacks Rank of 3 together make surprise prediction difficult West Pharmaceutical Services  Inc    NYSE WST    The company is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products  Headquartered in Exton  PA  the company s wide business network spreads across North and South America  Europe  Asia and Australia The Zacks Consensus Estimate for second quarter 2019 revenues is pinned on  462 8 million  indicating a 3 4  ascent from the year earlier reported figure  The same for earnings stands at 72 cents  suggesting a 2 86  climb from the year ago reported number  In the preceding four quarters  the company outpaced the consensus mark  the average being 7 06  West Pharmaceutical Services  Inc  Price and EPS Surprise   West Pharmaceutical s combination of an Earnings ESP of  0 70  and a Zacks Rank  4 decreases the odds of a positive surprise prediction this earnings season The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-23,Zacks Investment Research,https://www.investing.com/analysis/medical-products-earnings-roster-for-jul-25-syk-bax--more-200444060,200444060
9541,231056,LH,LabCorp s  LH  Q2 Earnings Beat Estimates  Margins Fall,opinion,Laboratory Corporation of America Holdings   NYSE LH   or LabCorp reported second quarter 2019 adjusted earnings per share  EPS  of  2 93  down 1 7  from the year ago quarter  However  the bottom line edged past the Zacks Consensus Estimate by 1  On a reported basis  net earnings came in at  1 93 per share  declining 14 9  from the year earlier figure Revenues in the quarter under review edged up 0 5  year over year to  2 88 billion  However  the top line lagged the Zacks Consensus Estimate of  2 90 billion Laboratory Corporation of America Holdings Price  Consensus and EPS Surprise   This marginal year over year improvement was primarily led by 1 4  growth from acquisitions and organic growth of 1 7   which includes the negative impact from Protecting Access to Medicare Act or PAMA of 0 9    partially offset by a 1 9  negative impact from the disposition of businesses and an adverse foreign currency translation of approximately 0 7  Quarter Under ReviewLabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development In the second quarter  LabCorp Diagnostics reported revenues of  1 76 billion  reflecting a 2 9  dip year over year  This downside was primarily due to a 2 8  headwind from the disposition of businesses and 0 3  lower organic revenues  including a 1 5  negative impact from the implementation of the PAMA   In addition  unfavorable foreign currency translation reduced revenues by approximately 0 2   Growth from acquisitions was 0 4  in the quarter Excluding the disposition of businesses  the company reported a 0 9  slip in total volume  measured by requisition  and a 1  rise in revenue per requisition in the quarter under consideration Covance Drug Development s revenues improved 6 8  to  1 13 billion in the second quarter  This upside was primarily attributed to 3 3  growth from acquisitions and organic growth of 5 5   partially offset by the 1 6  adverse impact of foreign currency translation and a business disposition of 0 3  Gross margin contracted 51 bps to 28 6  in the reported quarter  Also  adjusted operating income was down 6 9  year over year to  410 million  Moreover  adjusted operating margin contracted 114 bps from the year ago quarter to 14 2  LabCorp exited the second quarter with cash and cash equivalents of  265 4 million compared with  348 8 million at the end of the first quarter  Further  year to date  operating cash flow was  419 3 million  down from  567 1 million in the year ago period  Additionally  free cash flow came in at  239 9 million in the period  down from  407 4 million a year ago In the quarter under discussion  the company returned  199 9 million to shareholders via share repurchases  LabCorp currently has  1 05 billion of authorization remaining under its existing share buyback plan Outlook LabCorp has updated its 2019 guidance Revenue growth expectation has been tightened to the band of 1 2  from 2018  earlier projected band was 0 5 2 5    This includes a projected adverse impact from the disposition of businesses of around 1 5  and a negative foreign currency movement of roughly 0 5   The Zacks Consensus Estimate for current year revenues is pegged at  11 46 billion Adjusted EPS estimate for 2019 has been narrowed to a range of  11 10  11 40 from the earlier band of  11 05  11 45  The consensus mark of  11 28 for the metric is within this guided range Free cash flow is predicted from  950 million to  1 05 billion  unchanged  Our TakeLabCorp exited the second quarter on a mixed note with earnings ahead of the Zacks Consensus Estimate but revenues lagging the mark  While increasing acquisitions and a favorable mix contributed to LabCorp s Diagnostics business in the quarter  the disposition of certain businesses and the implementation of PAMA dented the company s growth However  Covance Drug Development delivered year over year growth  Here too  the strength from acquisitions and organic growth were partially negated by the hostile impact of foreign currency translation Zacks Rank   Other Key PicksLabCorp currently carries a Zacks Rank  2  Buy   A few other top ranked stocks in the broader medical space are Hologic Inc    NASDAQ HOLX    DENTSPLY SIRONA Inc    NASDAQ XRAY   and Teleflex Inc    NYSE TFX   Hologic is scheduled to release second quarter 2019 results on Jul 31  The Zacks Consensus Estimate for the quarter s adjusted EPS is pegged at 61 cents and for revenues  stands at  834 6 million  The stock carries a Zacks Rank of 2  You can see  DENTSPLY SIRONA is scheduled to release second quarter 2019 results on Aug 2  The Zacks Consensus Estimate for its adjusted EPS is pinned on 62 cents and for revenues  stands at  1 03 billion  The stock sports a Zacks Rank  1 Teleflex is expected to release second quarter 2019 results on Aug 1  The Zacks Consensus Estimate for its adjusted EPS is  2 59 and for its top line   636 7 million  The stock has a Zacks Rank of 2 Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/labcorps-lh-q2-earnings-beat-estimates-margins-fall-200444871,200444871
9542,231057,LH,Will Pharmacy International Hit Walgreens  WBA  Q3 Earnings ,opinion,Walgreens Boots Alliance  Inc    NASDAQ WBA   is slated to release third quarter fiscal 2019 results on Jun 27  before market open In the last reported quarter  the company witnessed a negative earnings surprise of 3 53   However  its earnings outperformed the Zacks Consensus Estimate in three of the last four quarters  the average positive surprise being 1 36  Let s take a look at how things are shaping up prior to this announcement Key CatalystsWithin retail Pharmacy USA division  accounting for more than 76 1  of total second quarter fiscal 2019 revenues   Walgreens Boots is benefiting from the transfer of prescriptions from Rite Aid stores  It continues to believe that the underlying trend in terms of prescription volumes and market share in the United States has been in its favor for quite some time now  This can have a bearing on its upcoming quarterly release Walgreens Boots Alliance  Inc  Price and EPS Surprise   Several planned developments  early benefits from new pharmacy contract wins and volume expansion owing to previously announced pharmacy partnerships have been driving growth in this space  The retail pharmacy market has been witnessing a rise in expenditure on account of prescription drugs and growing demand for specialty drugs  Walgreens Boots has also been witnessing comparable sales growth in the health  wellness and beauty groups  driven by investments in its top stores Thus  a widening pharmacy network  healthy prescription volumes and contributions from Rite Aid are expected to contribute to Walgreens Boots  top line in the to be reported quarter  On the flip side  Walgreens Boots  revenue growth within retail Pharmacy USA division of late is slightly getting hampered bylow pharmacy margins and a decline in front end comparable sales In the last reported quarter  comparable retail sales decreased as the company was facing challenging comparisons related to an exceptionally strong prior year cough  cold and flu season  Further  a persistent de emphasizing of tobacco is hurting growth  which should get reflected once again in the results for the fiscal third quarter Overall  the Zacks Consensus Estimate for total revenues in the fiscal third quarter at the Retail Pharmacy USA division is pegged at  26 16 billion  indicating a rise of 0 95  from the year ago reported figure Meanwhile  tough market conditions  particularly in retail  have been inducing sluggishness in the Retail Pharmacy International division  Contracting U K  prescription volumes and lingering reimbursement pressure from the U K  government are headwinds  Walgreens Boots is investing in new stores and digital content to improve its U K  retail performance The Zacks Consensus Estimate of  2 84 billion for revenues from the Retail Pharmacy International division suggests a 5 1  dip from the prior year reported number Strong growth in certain emerging markets is expected to consistently drive the company s Pharmaceutical Wholesale division The Zacks Consensus Estimate of  5 99 billion for Pharmaceutical Wholesale division implies 0 55  growth from the year earlier reported figure Here is what our quantitative model predicts Walgreens Boots does not have the right combination of two main ingredients   a positive   and a Zacks Rank  3  Hold  or higher   which are needed for increasing the odds of an earnings beat Earnings ESP  Walgreens Boots has an Earnings ESP of  1 40   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Walgreens Boots carries a Zacks Rank  4  Sell   We caution against stocks with a Zacks Rank of 4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions The Zacks Consensus Estimate for earnings of  1 43 indicates a 6 5  fall from the year ago reported tally Stocks Worth a LookHere are a few medical stocks worth considering as these have the perfect combination of elements to come up with earnings beat in the quarter to be reported Laboratory Corporation of America Holdings   NYSE LH   has an Earnings ESP of  5 24  and a Zacks Rank  2  Buy  Merck   Co   Inc    NYSE MRK   has an Earnings ESP of  1 13  and a Zacks Rank of 2  You can see  Merit Medical Systems  Inc    NASDAQ MMSI   has an Earnings ESP of  2 00  and a Zacks Rank of 3 stock More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2019-06-23,Zacks Investment Research,https://www.investing.com/analysis/will-pharmacy-international-hit-walgreens-wba-q3-earnings-200434148,200434148
9555,231070,LH,LabCorp Diagnostics Shows Robust Growth Amid Price Declines,opinion,On Jun 14  we issued an updated research report on LabCorp   NYSE LH    The stock carries a Zacks Rank  2  Buy  This Burlington  NC based healthcare diagnostics company  providing comprehensive clinical laboratory services and an end to end drug development support  has been grappling with multiple issues of late  Economic uncertainties including a challenging volume environment for testing laboratories and softness in utilization are headwinds for LabCorp Over the past three months  shares of LabCorp have climbed 7 5  against the  s 4 1  decline In first quarter 2019  the company reported a strong underlying performance and organic revenue growth across both Diagnostics and Drug Development businesses  banking on a solid execution of three fundamental strategies  which are delivering advanced diagnostics  bringing new medicines to patients faster and using technology to improve the patient care Laboratory Corporation of America Holdings Price   During the quarter under review  Diagnostics business grew organically in terms of both revenues and volumes despite additional price reductions due to PAMA and the loss of exclusivity in two of the company s largest managed care contracts  Revenues from all aspects of companion diagnostics surged more than 30  across the enterprise in the first quarter Covance Drug Development also rose organically despite an adverse impact of the foreign currency translation  During the reported quarter  the company enhanced Covance s offerings through strategic acquisitions like MI Bioresearch that bring about specialized preclinical capabilities in cell and gene therapy plus oncology testing In April  the company announced an innovative business swap transaction with Envigo  This strategic move provides Covance with enhanced global non clinical research capabilities while maintaining access to bigger research models and services through a multi year renewable supply agreement  This apart  the Covance LaunchPad initiative is well on track to deliver  150 million of net savings by the end of 2020 On the flip side  the current economic volatility comprising a tough volume environment for the testing laboratories and utilization weaknesses are looming downsides for the company  This apart  the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act  PAMA  dented growth  Moreover  an unfavorable currency movement persists as a major woe  The company also expects 2019 to continue witnessing similar hurdles Other Key PicksSome other top ranked stocks in the broader medical space are Cerner Corporation   NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Strong Buy   Penumbra and Bruker carry a Zacks Rank of 2  You can see  Cerner s long term earnings growth rate is expected to be 13 5  Penumbra s long term earnings growth rate is projected at 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Radical New Technology Creates  12 3 Trillion OpportunityImagine buying Microsoft  NASDAQ MSFT  stock in the early days of personal computers  or Motorola  NYSE MSI  after it released the world s first cell phone  These technologies changed our lives and created massive profits for investors Today  we re on the brink of the next quantum leap in technology  7 innovative companies are leading this  4th Industrial Revolution    and early investors stand to earn the biggest profits ,2019-06-16,Zacks Investment Research,https://www.investing.com/analysis/labcorp-diagnostics-shows-robust-growth-amid-price-declines-200432149,200432149
9559,231074,LH,LabCorp  LH  Q1 Earnings Top Mark  Revenues Lag Estimates,opinion,"Laboratory Corporation of America Holdings   NYSE LH    or LabCorp  reported first quarter 2019 adjusted earnings per share  EPS  of  2 62  down 5 8  from the year ago quarter  However  the bottom line surpassed the Zacks Consensus Estimate by 3 6  
On a reported basis  net earnings came in at  1 86 per share as compared with  1 67 a year ago 
Revenues in the quarter under review dipped 2 1  year over year to  2 79 billion  The top line also lagged the Zacks Consensus Estimate of  2 82 billion 
The year over year decline was primarily due to a 1 8  negative impact from the disposition of businesses and foreign currency translation of approximately 0 9   partially offset by growth from acquisitions of 0 5  and organic growth of 0 2   which includes the negative impact from Protecting Access to Medicare Act or PAMA of 0 9   
Quarter Under Review
LabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development Laboratory Corporation of America Holdings Price  Consensus and EPS Surprise

   In the first quarter  LabCorp Diagnostics reported revenues of  1 72 billion  a 2 7  drop year over year  The decline was primarily due to a 2 9  headwind from the disposition of businesses and a 1 5  negative impact from the implementation of the PAMA  In addition  foreign currency translation reduced revenue by approximately 0 3  
Excluding the disposition of businesses  the company reported a 0 8  rise in total volume  measured by requisition  and a 0 4  decline in revenue per requisition in the quarter under review 
Covance Drug Development reported a 0 4  decline in revenues to  1 07 billion in the first quarter  The downside was primarily due to the adverse impact of foreign currency translation of nearly 210 bps  partially offset by partially offset by growth from acquisitions of 1 2  and organic growth of 0 5  
Gross margin expanded 94 bps to 28 3  in the reported quarter  Adjusted operating income was up 3 6  year over year to  395 9 million  Also  adjusted operating margin expanded 77 bps from the year ago quarter to 14 2  
LabCorp exited the first quarter with cash and cash equivalents of  348 8 million compared with  426 8 million at the end of 2018 At the end of the first quarter  operating cash flow was  165 8 million  down from  179 7 million in the year ago period  Free cash flow came in at  71 6 million in this period  down from  107 2 million a year ago 
During the quarter under discussion  the company returned  100 million to shareholders via share repurchases  LabCorp currently has  1 25 billion of authorization remaining under its existing share repurchase plan 
Outlook 
LabCorp has updated its 2019 guidance 
Revenue growth expectation has been reiterated in the band of 0 5 2 5  from 2018  This includes a projected adverse impact from the disposition of businesses of around 1 2  and foreign currency translation of roughly 0 5   The Zacks Consensus Estimate for current year revenues is pegged at  11 47 billion 
Adjusted EPS expectation for 2019 has been raised to a range of  11 05 to  11 45 from the earlier range of  11 to  11 40  The consensus mark of  11 22 for the metric is within the guided range 
Free cash flow is projected in the band of  950 million  1 05 billion  unchanged  
Our Take
LabCorp exited the first quarter on a mixed note with earnings ahead of the Zacks Consensus Estimate and revenues lagging the mark  While increasing acquisitions and favorable mix positively contributed to LabCorp s Diagnostics business in the quarter  the disposition of certain businesses and the implementation of PAMA dented growth 
Covance Drug Development also reported a year over year decline  The strength from acquisitions and organic growth were negated by adverse impact of foreign currency translation 
Zacks Rank   Key Picks
LabCorp carries a Zacks Rank  3  Hold  
Some better ranked stocks which posted solid results this earning season are Stryker Corp    NYSE SYK    Abbott Laboratories   NYSE ABT   and CONMED Corp    NASDAQ CNMD    each carrying a Zacks Rank of 2  Buy   You can see  
Stryker delivered first quarter 2019 EPS of  1 88  beating the Zacks Consensus Estimate by 2 2   Revenues of  3 52 billion were also in line with the Zacks Consensus Estimate 
Abbott reported first quarter 2019 adjusted EPS of 63 cents  beating the Zacks Consensus Estimate by 3 3   Worldwide sales totaled  7 54 billion  above the Zacks Consensus Estimate of  7 47 billion 
CONMED posted first quarter 2019 EPS of 57 cents  which beat the Zacks Consensus Estimate of 54 cents  Revenues were  218 4 million  surpassing the consensus estimate of  213 million 
Is Your Investment Advisor Fumbling Your Financial Future  
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-30,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-q1-earnings-top-mark-revenues-lag-estimates-200413284,200413284
9560,231075,LH,LH Or ALGN  Which Is The Better Value Stock Right Now ,opinion,"Investors looking for stocks in the Medical   Dental Supplies sector might want to consider either LabCorp  LH  or Align Technology  ALGN   But which of these two stocks is more attractive to value investors  We ll need to take a closer look to find out 
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Currently  both LabCorp and Align Technology are holding a Zacks Rank of   2  Buy   This means that both companies have witnessed positive earnings estimate revisions  so investors should feel comfortable knowing that both of these stocks have an improving earnings outlook  But this is just one piece of the puzzle for value investors 
Value investors also tend to look at a number of traditional  tried and true figures to help them find stocks that they believe are undervalued at their current share price levels 
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics  These include the long favored P E ratio  P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that help us determine a company s fair value 
LH currently has a forward P E ratio of 14 25  while ALGN has a forward P E of 59 67  We also note that LH has a PEG ratio of 1 63  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  ALGN currently has a PEG ratio of 2 55 
Another notable valuation metric for LH is its P B ratio of 2 22  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  By comparison  ALGN has a P B of 20 68 
These are just a few of the metrics contributing to LH s Value grade of A and ALGN s Value grade of D 
Both LH and ALGN are impressive stocks with solid earnings outlooks  but based on these valuation figures  we feel that LH is the superior value option right now ",2019-04-30,Zacks Investment Research,https://www.investing.com/analysis/lh-or-algn-which-is-the-better-value-stock-right-now-200413717,200413717
9561,231076,LH,LabCorp Grows On Strong Diagnostics Arm Amid Contract Losses,opinion,On May 17  we issued an updated research report on LabCorp   NYSE LH    The stock carries a Zacks Rank  3  Hold  This Burlington  NC based healthcare diagnostics company  providing comprehensive clinical laboratory services and end to end drug development support  has been grappling with multiple issues of late  Economic uncertainties including a challenging volume environment for testing laboratories and softness in utilization are headwinds for LabCorp Over the past three months  shares of LabCorp have climbed 9 8  against the  s 0 9  decline In first quarter 2019  the company reported a strong underlying performance and organic revenue growth across both Diagnostics and Drug Development businesses  banking on a solid execution of three fundamental strategies  which are delivering advanced diagnostics  bringing new medicines to patients faster and using technology to improve patient care Laboratory Corporation of America Holdings Price   During the quarter  Diagnostics business grew organically in terms of both revenues and volumes despite additional price reductions due to PAMA and the loss of exclusivity in two of the company s largest managed care contracts  Revenues from all aspects of companion diagnostics surged more than 30  across the enterprise in the first quarter Covance Drug Development also rose organically despite an adverse impact of the foreign currency translation  During the quarter under review  the company enhanced Covance s offerings through strategic acquisitions like MI Bioresearch that bring about specialized preclinical capabilities in cell and gene therapy plus oncology testing In April  the company announced an innovative business swap transaction with Envigo  The strategic move provides Covance with enhanced global non clinical research capabilities while maintaining access to bigger research models and services through a multi year renewable supply agreement  This apart  the Covance LaunchPad initiative is well on track to deliver  150 million of net savings by the end of 2020 On the flip side  the current economic volatility including a challenging volume environment for the testing laboratories and utilization weaknesses are looming downsides for the company  This apart  the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act  PAMA  dented growth  Moreover  an unfavorable currency movement persists as a major woe  The company also expects 2019 to continue witnessing similar hurdles Key PicksA few better ranked stocks in the broader medical space are Masimo Corporation   NASDAQ MASI    CONMED   NASDAQ CNMD   and DENTSPLY SIRONA   NASDAQ XRAY    each currently carrying a Zacks Rank  2  Buy   You can see  Masimo s long term earnings growth rate is projected at 16 1 CONMED s long term earnings growth rate is expected at 13 3  DENTSPLY SIRONA s long term earnings growth rate is predicted at 11 5  This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities  These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-05-19,Zacks Investment Research,https://www.investing.com/analysis/labcorp-grows-on-strong-diagnostics-arm-amid-contract-losses-200423081,200423081
9562,231077,LH,Can Covance Business Growth Aid LabCorp  LH  In Q1 Earnings ,opinion,Laboratory Corporation of America Holdings   NYSE LH   also known as LabCorp  is slated to report first quarter 2019 results on Apr 30  before the market opens  In the last reported quarter  the company s adjusted earnings exceeded the Zacks Consensus Estimate by 1 61   The average trailing four quarter beat was 1 11  Let s see how things are shaping up for this announcement Factors at PlayLabCorp s underlying core business is currently showing a stable performance  Within Diagnostcs  the company expects to generate revenues in the first quarter of 2019  banking on the following number of facts First  the company already reported that the January volume related to contract changes has been in line with the company s expectations  Second  referral volumes from hospitals and health systems should increase during the first quarter Laboratory Corporation of America Holdings Price and EPS Surprise   Third  although the company expects to gain a judicial and legislative relief from the second round of PAMA  Protecting Access to Medicare Act  price reductions  there is an increasing industry wide awareness about PAMA s true impact  Per LabCorp  with this  the company will be offered a string of attractive tuck in lab acquisition opportunities  which would typically deliver significant synergies and high returns on invested capital Fourth  the company is highly optimistic about the Phase II of LaunchPad initiative in Diagnostics  which is expected to deliver  200 million of savings in another three years  This should start contributing to the company s operational results from the first quarter itself This apart  in the first quarter  LabCorp is expected to particularly benefit from its several recent collaborations  Among the company s recent alliances  worth mentioning are the company s tie ups with UnitedHealthcare and Aetna  NYSE AET   which helped LabCorp become a contracted laboratory provider for all major national plans  With the latest agreement  LabCorp will continue to be a national in network laboratory for all UnitedHealthcare plan participants on a long term basis  This apart  starting this January onward  LabCorp also became a national  in network provider of laboratory services for substantially all Aetna members  We expect to see some strong top line contributions from these alliances in the first quarter However  within Diagnostics  the fourth quarter of 2018 witnessed trouble regarding a number of nonoperational items  causing a 400 basis point decline in the reported operating margin   The same has been apprehended for the yet to be reported quarter Within this segment  2019 revenues are expected in the range of a negative 2 4  as compared to 2018  inclusive of a foreign currency translation of approximately negative 30 basis points  This apart  PAMA is expected to trim Diagnostics revenues by approximately 1 6  in 2019 Within Covance Drug Development  LabCorp is focused on driving future profitable growth through expanded solutions and enhanced operational capabilities  Chiltern integration has significantly strengthened the company s strategic position in clinical development and is accelerating revenues and profit growth within Covance  On this front  the company is keeping a good pace with its objective to streamline the drug development process  Significantly  it is winning new awards through its integrated Covance and Chiltern offering Additionally  the company has progressed with the Covance LaunchPad initiative  In the first phase  as expected  the company generated pre tax savings of  20 million   At the exit of fourth quarter 2018  it remains on track to deliver  150 million of net savings from Covance LaunchPad by the end of 2020 and another  30 million of cost synergies from the Chiltern buyout by 2019 end All the above factors should together constantly favor the top line at LabCorp s Covance Drug Development in the yet to be reported quarter  Overall  the company currently expects 2019 Covance Drug Development revenue growth within 5 9  For 2019  on an overall basis  LabCorp expects modest growth in total revenues and the adjusted EPS  The company expects another year of approximately  1 billion in free cash flow  These should get reflected in the first quarter itself What the Quantitative Model SuggestsOur proven Zacks model conclusively shows that a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive  LabCorp has a Zacks Rank  3  which increases the predictive power of ESP  It also has an Earnings ESP of  0 36   together which a likely positive surprise is predicted for the stock this earnings season The Zacks Consensus Estimate for first quarter earnings of  2 53 indicates an 8 9  decline from the year ago reported figure  Revenue increase is pegged at  2 82 billion  suggesting a 0 86  slip from the prior year number  You can uncover the best stocks to buy or sell before they re reported with our  Other Stocks to ConsiderHere are a few other medical stocks worth considering from the broader medical space as these too comprise the right mix of elements to exceed expectations this reporting cycle Evolus  Inc    NASDAQ EOLS   has an Earnings ESP of  24 39  and a Zacks Rank of 3 NanoString Technologies Inc    NASDAQ NSTG   has an Earnings ESP of  3 08  and is a Zacks  3 Ranked player  You can see  Aurora Cannabis  Inc    TO ACB   has an Earnings ESP of  73 33  and is a  3 Ranked player Radical New Technology Creates  12 3 Trillion OpportunityImagine buying Microsoft  NASDAQ MSFT  stock in the early days of personal computers  or Motorola  NYSE MSI  after it released the world s first cell phone  These technologies changed our lives and created massive profits for investors Today  we re on the brink of the next quantum leap in technology  7 innovative companies are leading this  4th Industrial Revolution    and early investors stand to earn the biggest profits ,2019-04-24,Zacks Investment Research,https://www.investing.com/analysis/can-covance-business-growth-aid-labcorp-lh-in-q1-earnings-200411199,200411199
9577,231092,LH,LabCorp  LH  Expected To Beat Earnings Estimates  Should You Buy ,opinion,"LabCorp  LH  is expected to deliver a year over year decline in earnings on lower revenues when it reports results for the quarter ended March 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on April 30  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This medical laboratory operator is expected to post quarterly earnings of  2 53 per share in its upcoming report  which represents a year over year change of  9  
Revenues are expected to be  2 82 billion  down 0 9  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 31  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for LabCorp 
For LabCorp  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 36  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that LabCorp will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that LabCorp would post earnings of  2 48 per share when it actually produced earnings of  2 52  delivering a surprise of  1 61  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
LabCorp appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-22,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-expected-to-beat-earnings-estimates-should-you-buy-200409468,200409468
9579,231094,LH,LabCorp  LH  Tops Q4 Earnings And Revenue Estimates,opinion,"LabCorp  LH  came out with quarterly earnings of  2 52 per share  beating the Zacks Consensus Estimate of  2 48 per share  This compares to earnings of  2 45 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 61   A quarter ago  it was expected that this medical laboratory operator would post earnings of  2 87 per share when it actually produced earnings of  2 74  delivering a surprise of  4 53  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
LabCorp  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  2 79 billion for the quarter ended December 2018  surpassing the Zacks Consensus Estimate by 0 15   This compares to year ago revenues of  2 80 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
LabCorp shares have added about 11 8  since the beginning of the year versus the S P 500 s gain of 9  
What s Next for LabCorp 
While LabCorp has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for LabCorp was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 69 on  2 86 billion in revenues for the coming quarter and  11 21 on  11 51 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 43  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-02-06,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-tops-q4-earnings-and-revenue-estimates-200384939,200384939
9580,231095,LH,LabCorp s  LH  Q4 Earnings And Revenues Surpass Estimates,opinion,"Laboratory Corporation of America Holdings   NYSE LH    or LabCorp  reported fourth quarter 2018 adjusted earnings per share  EPS  of  2 52  up 11  from the year ago quarter  The bottom line surpassed the Zacks Consensus Estimate by 1 6  On a reported basis  net earnings came in at  1 56 per share as compared with  6 63 a year ago Adjusted EPS in 2018 came in at  11 02  up 19 8  year over year  The figure also surpassed the Zacks Consensus Estimate of  11 by a slight margin Revenues in the quarter under review increased 1 6  year over year to  2 79 billion  The year over year rise was backed by 0 7  growth from acquisitions and organic growth of 2 9   partially offset by a 1 6  negative impact from the disposition of businesses and a 40 basis point  bps  impact of foreign currency translation  The top line beat the Zacks Consensus Estimate by 0 2  
Laboratory Corporation of America Holdings Price  Consensus and EPS Surprise   Revenues in 2018 came in at  11 33 billion  up 9 9  year over year  The figure was in line with the Zacks Consensus Estimate Quarter Under ReviewLabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development In the fourth quarter  LabCorp Diagnostics reported revenues of  1 69 billion  a 2 8  drop year over year  While revenues were fueled by tuck in acquisitions  a favorable mix and organic volume  measured by requisitions   this was offset by the negative impact from the disposition of businesses and the implementation of the Protecting Access to Medicare Act  PAMA   In addition  foreign currency translation reduced revenue by approximately 0 2  Excluding the disposition of businesses  the company reported a 0 3  rise in total volume  measured by requisition  and a 0 4  decline in revenue per requisition in the quarter under review Covance Drug Development reported a 9 6  rise in revenues to  1 10 billion in the fourth quarter  The upside was primarily driven by acquisitions and organic growth  partially offset by the adverse impact of foreign currency translation of nearly 90 bps Gross margin deteriorated 210 bps to 27 7  in the reported quarter  Adjusted operating income was down 6 1  year over year to  375 5 million  Also  adjusted operating margin contracted 110 bps from the year ago quarter to 13 5  LabCorp exited 2018 with cash and cash equivalents of  426 8 million compared with  316 6 million at the end of 2017  In 2018  operating cash flow was  1 31 billion  down from  1 50 billion in the year ago period  Free cash flow came in at  925 6 million in this period  down from  1 19 billion a year ago During the quarter under discussion  the company returned  400 million to shareholders via share repurchases  LabCorp informed that the company s existing share repurchase plan has been replaced with a new plan authorizing repurchase of up to  1 25 billion Outlook LabCorp has provided its 2019 guidance Revenue growth is expected in the band of 0 5 2 5  from 2018  This includes the adverse impact from the disposition of businesses of around 1  and foreign currency translation of roughly 0 4   The Zacks Consensus Estimate for current year revenues is pegged at  11 51 billion Adjusted EPS for 2019 is projected in the range of  11 to  11 40  The consensus mark of  11 21 for the metric is within the guided range Free cash flow is projected in the band of  950 million  1 05 billion Our TakeLabCorp exited the fourth quarter on a promising note  While increasing acquisitions and a favorable mix positively contributed to LabCorp s Diagnostics business in the quarter  the disposition of certain businesses and the implementation of PAMA dented growth Covance Drug Development  however  reported sturdy growth  The strength primarily came from acquisitions and robust organic growth  Nevertheless  adverse currency translation impacted the top line Zacks Rank   Key PicksLabCorp carries a Zacks Rank  4  Sell  Some better ranked MedTech stocks that posted solid quarterly results are Varian Medical Systems   NYSE VAR    AngioDynamics   NASDAQ ANGO   and CONMED Corporation   NASDAQ CNMD   Varian reported fiscal first quarter adjusted EPS of  1 06  in line with the Zacks Consensus Estimate  Revenues of  741 million outpaced the consensus mark of  717 9 million  The stock has a Zacks Rank  2  Buy  AngioDynamics  fiscal second quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny  Revenues totaled  91 5 million  which surpassed the consensus estimate by 2 9   The stock sports a Zacks Rank  1  Strong Buy   You can see  CONMED delivered fourth quarter adjusted EPS of 73 cents  in line with the Zacks Consensus Estimate  Revenues of  242 4 million beat the Zacks Consensus Estimate of  229 2 million  The stock carries a Zacks Rank of 2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-02-06,Zacks Investment Research,https://www.investing.com/analysis/labcorps-lh-q4-earnings-and-revenues-surpass-estimates-200385185,200385185
9581,231096,LH,Why Is LabCorp  LH  Down 0 6  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for LabCorp  LH   Shares have lost about 0 6  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is LabCorp due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Acquisition and Organic Growth Strong for LabCorp in Q4LabCorp reported fourth quarter 2018 adjusted earnings per share  EPS  of  2 52  up 11  from the year ago quarter  The bottom line surpassed the Zacks Consensus Estimate by 1 6  On a reported basis  net earnings came in at  1 56 per share as compared with  6 63 a year ago Adjusted EPS in 2018 came in at  11 02  up 19 8  year over year  The figure also surpassed the Zacks Consensus Estimate of  11 by a slight margin Revenues in the quarter under review increased 1 6  year over year to  2 79 billion  The year over year rise was backed by 0 7  growth from acquisitions and organic growth of 2 9   partially offset by a 1 6  negative impact from the disposition of businesses and a 40 basis point  bps  impact of foreign currency translation  The top line beat the Zacks Consensus Estimate by 0 2  Revenues in 2018 came in at  11 33 billion  up 9 9  year over year  The figure was in line with the Zacks Consensus Estimate Quarter Under ReviewLabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development In the fourth quarter  LabCorp Diagnostics reported revenues of  1 69 billion  a 2 8  drop year over year  While revenues were fueled by tuck in acquisitions  a favorable mix and organic volume  measured by requisitions   this was offset by the negative impact from the disposition of businesses and the implementation of the Protecting Access to Medicare Act  PAMA   In addition  foreign currency translation reduced revenue by approximately 0 2  Excluding the disposition of businesses  the company reported a 0 3  rise in total volume  measured by requisition  and a 0 4  decline in revenue per requisition in the quarter under review Covance Drug Development reported a 9 6  rise in revenues to  1 10 billion in the fourth quarter  The upside was primarily driven by acquisitions and organic growth  partially offset by the adverse impact of foreign currency translation of nearly 90 bps Gross margin deteriorated 210 bps to 27 7  in the reported quarter  Adjusted operating income was down 6 1  year over year to  375 5 million  Also  adjusted operating margin contracted 110 bps from the year ago quarter to 13 5  LabCorp exited 2018 with cash and cash equivalents of  426 8 million compared with  316 6 million at the end of 2017  In 2018  operating cash flow was  1 31 billion  down from  1 50 billion in the year ago period  Free cash flow came in at  925 6 million in this period  down from  1 19 billion a year ago During the quarter under discussion  the company returned  400 million to shareholders via share repurchases  LabCorp informed that the company s existing share repurchase plan has been replaced with a new plan authorizing repurchase of up to  1 25 billion OutlookLabCorp has provided its 2019 guidance Revenue growth is expected in the band of 0 5 2 5  from 2018  This includes the adverse impact from the disposition of businesses of around 1  and foreign currency translation of roughly 0 4   The Zacks Consensus Estimate for current year revenues is pegged at  11 51 billion Adjusted EPS for 2019 is projected in the range of  11 to  11 40  The consensus mark of  11 21 for the metric is within the guided range Free cash flow is projected in the band of  950 million  1 05 billion 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
Currently  LabCorp has an average Growth Score of C  however its Momentum Score is doing a bit better with a B  Charting a somewhat similar path  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  LabCorp has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-03-08,Zacks Investment Research,https://www.investing.com/analysis/why-is-labcorp-lh-down-06-since-last-earnings-report-200396104,200396104
9582,231097,LH,Should Value Investors Consider Laboratory Corporation  LH  ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Laboratory Corporation of America Holdings   NYSE LH   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Laboratory Corporation has a trailing twelve months PE ratio of 13 88  as you can see in the chart below This level actually compares favorably with the market at large  as the PE for the S P 500 stands at about 17 69  If we focus on the long term PE trend  Laboratory Corporation s current PE level puts it much below its midpoint of 16 05 over the past five years Further  the stock s PE also compares pretty favorably with the Medical Market s trailing twelve months PE ratio  which stands at 20 5  At the very least  this indicates that the stock is much undervalued right now  compared to its peers We should also point out that Laboratory Corporation has a forward PE ratio  price relative to this year s earnings  of 13 75  which is lower than the current level  So  it is fair to say that a bit more value oriented path may be ahead for Laboratory Corporation stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Laboratory Corporation has a P S ratio of just 1 37  This is quite lower than the S P 500 average  which comes in at 3 22 right now  Also  as we can see in the chart below  this stands below the highs for this stock in particular over the past few years Broad Value OutlookIn aggregate  Laboratory Corporation currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes Laboratory Corporation a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for Laboratory Corporation is just 1 75  a level that is lower than the industry s average ratio of 2 23  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Clearly  LH is a solid choice on the value front from multiple angles What About the Stock Overall Though Laboratory Corporation might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has Growth and Momentum Scores of C  This gives LH a Zacks VGM score   or its overarching fundamental grade   of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen one upward revision in the past sixty days compared to six downward revisions  while the full year estimate has seen four upward and three downward revisions in the same time period This has had a mixed impact on the consensus estimate as the current quarter consensus estimate has declined by 5 2  in the past two months  while the full year estimate has inched up by 0 2   You can see the consensus estimate trend and recent price action for the stock in the chart below Laboratory Corporation of America Holdings Price and Consensus   This somewhat mixed trend is why the stock has a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term 
Bottom Line
Laboratory Corporation is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  a strong industry rank  among Top 31  of more than 250 industries  instils our confidence 
However  with a Zacks Rank  3 it is hard to get too excited about this company overall  Also  over the past two years  the broader industry has underperformed the market at large  as you can see below 

So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick 
Is Your Investment Advisor Fumbling Your Financial Future 
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-25,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-consider-laboratory-corporation-lh-200401089,200401089
9583,231098,LH,LabCorp  LH  QIAGEN Form Alliance In In Vitro Diagnostics,opinion,Laboratory Corporation of America Holdings or LabCorp   NYSE LH   recently entered into a master service agreement with Sample to Insight solutions provider  QIAGEN Inc    NYSE QGEN    in the field of companion diagnostics Per this deal  LabCorp will participate in the QIAGEN s Day One Lab Readiness program under which  the former will provide physicians and patients with faster access to Qiagen s companion diagnostic products post the regulatory approval of the tests and associated drugs  These drugs are genomically targeted  which gradually became important therapies for a growing variety of cancers Is the Contract Strategic Fit Per the FDA s modernized regulatory approach  QIAGEN s Day One Lab Readiness program enables molecular diagnostic labs like LabCorp to begin implementing the activities necessary to prepare for the commercial launch of new drugs and IVD tests once the FDA approval is obtained Assays for multiple indications including the novel companion diagnostics across a range of cancers ranging from lung  breast  colorectal  bladder to eventually the pan tumor disease areas are currently in LabCorp s Day One Lab Readiness pipeline According to news  this tie up will help a broad base of patients as LabCorp s skill in the commercial use of companion diagnostics will offer them a better access to advanced tools for precision medicine In recent times  the biomarkers and advanced technologies are getting increasingly used to in vitro diagnostics  IVD   which in turn  makes the companion diagnostic testing complex  Under such circumstances  both companies are extremely hopeful about this alliance as LabCorp s extensive experience in these areas is a strong complement to QIAGEN s personalized health collaborations with the pharmaceutical giants Market ProspectsThe global in vitro diagnostics  IVD  market is booming with prospects now  According to   the market is expected to reach  98 99 billion by 2025  It is anticipated to see a CAGR of 6 6  over the next five years Per the geriatric population report  growth is one of the major drivers  Further  the rising prevalence cardiovascular disorders  cancer  diabetes and other chronic diseases along with surging demand for onsite diagnostics are expected to boost the in vitro diagnostics  IVD  market in the upcoming period Taking this into consideration  we expect LabCorp s recent deal for expanding in this field to be perfectly strategic and well timed Share Price PerformanceIn the past three months  shares of LabCorp have outperformed its industry  The stock has rallied 23 4  as compared with the industry s 15  rise Zacks Ranks and Key PicksBoth LabCorp and QIAGEN currently carry a Zacks Rank of  3  Hold   Two better ranked stocks in the broader medical space are Stryker Corporation   NYSE SYK   and Amedisys  Inc   NASDAQ AMED    each stock currently carrying a Zacks Rank  2  Buy   You can see  Stryker s long term earnings growth rate is projected at 10 Amedisys s long term earnings growth rate is predicted at 19 7  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-03,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lhqiagen-form-alliance-in-invitro-diagnostics-200403929,200403929
9584,231099,LH,What s In Store For Align Technology  ALGN  In Q1 Earnings ,opinion,Align Technology  Inc    NASDAQ ALGN   is set to report first quarter 2019 results on Apr 24  after the closing bell In the last reported quarter  the company delivered a positive earnings surprise of 3 5   Further  it has an average four quarter positive surprise of 11 6  Let s take a look at how things are shaping up prior to this announcement Invisalign System  A Key CatalystAlign Technology is expected to gain from continued adoption of Invisalign Technology in the first quarter of 2019  The company estimates Invisalign case shipments in the band of 340 000 345 000  up 25 27  from the year ago quarter  This projected improvement is likely to contribute substantially to the company s top line in the to be reported quarter Invisalign portfolio expansion  anticipated higher revenues at the Clear Aligner segment on the back of sustained Invisalign case volume growth across customer channels and geographies  and estimated growth in the teen segment  are likely to aid the company in delivering strong results in the to be reported quarter  Notably  the company estimates Invisalign volume to be in mid range of its long term model target of 20  to 30  for the full year 2019  Additionally  gross margin and operating margin are expected to improve throughout 2019 However  it is important to note here that the arbitration decision with SDC Entities requires Align Technology to close Invisalign Stores by Apr 3  2019  This is expected to result in a material charge in the first quarter  Nevertheless  the store closures are likely to have minimal impact on the company s revenues Strong Scanner and Service BusinessAlign Technology has been generating solid revenues from the Scanner and Service business over the past few quarters  Moreover  the company has been witnessing increased adoption of iTero scanners for Invisalign case submissions instead of PVS impressions  especially in North America  Management anticipates this trend to reflect in the company s first quarter results In the quarter under review  the company introduced the iTero Element 5D Imaging system  It offers a comprehensive approach to clinical application  workflows and user experience  while broadening the iTero portfolio Moreover  the company entered into a distribution agreement with Benco Dental during the first quarter  The deal will improve the iTero Element portfolio of intraoral scanning technology The company is also gaining from the adoption of iTero platform by dental service organizations or DSO partners  As announced previously  Aspen Dental s decision to initiate the rollout of iTero scanners in third quarter 2018 will continue throughout the first quarter  Consequently  positive contribution from this rollout is anticipated to positively impact the results in the to be reported quarter Overall  Align Technology projects earnings per share  EPS  of 78 84 cents on revenues of  525  535 million for first quarter 2019  The Zacks Consensus Estimate for revenues is pegged at  530 19 million  indicating an improvement of 21 4  from the year ago reported figure Align Technology  Inc  Price and EPS Surprise    However  the company expects to incur operating expenses in the range of  290 million to  294 million in the first quarter due to sales force expansion and higher legal expenses  The operating margin in this time period is estimated to be in the band of 15 1 16 1  Further  continuation of the company s operational expansion efforts can result in capital expenditure in the first quarter in the range of around  60 million to  65 million  Depreciation and amortization is estimated to range between  19 million and  20 million What Our Quantitative Model SuggestsPer the proven Zacks model  a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Align Technology has a Zacks Rank  3 and an Earnings ESP of 0 00   a combination that makes surprise prediction difficult The Zacks Consensus Estimate for first quarter earnings is pinned at 83 cents per share  reflecting a decline of 29 1  on a year over year basis Stocks Worth a LookHere are some stocks from the broader medical space worth considering from the same space as these have the right combination of elements to beat on earnings this time around Teleflex Incorporated   NYSE TFX   has an Earnings ESP of  0 96  and a Zacks Rank  3 Laboratory Corporation of America Holdings   NYSE LH   has an Earnings ESP of  0 36  and a Zacks Rank  3 Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  1 13  and a Zacks Rank  3 You can see   Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-17,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-align-technology-algn-in-q1-earnings-200408431,200408431
9585,231100,LH,Thermo Fisher  TMO  To Report Q1 Earnings  What s In Store ,opinion,Thermo Fisher Scientific Inc    NYSE TMO   is slated to report first quarter 2019 results  before the opening bell on Apr 24  In the last reported quarter  the company delivered a positive earnings surprise of 1 88   Moreover  its key metrics surpassed estimates in the trailing four quarters  recording an average of 3 13  Which Way Are Estimates Trending The Zacks Consensus Estimate for first quarter earnings per share is pegged at  2 74  reflecting a year over year improvement of 9 6  from the year ago reported figure The same for revenues stands at  6 02 billion  suggesting an improvement of 2 9  over the prior year reported quarter Let s see how things are shaping up prior to this announcement Key CatalystsWith respect to the company s analytical instruments business  higher global demand  sturdy Thermo Scientific brand  substantial impact from the electron microscopy business  and robust volume expansion and productivity is expected to drive this line of business in the to be reported quarter The Zacks Consensus Estimate for Analytical Instruments revenues is pegged at  1 27 billion  suggesting an improvement of 1 2  from the year ago reported figure Now turning to the life science solutions business  continued strength in the company s Ion Torrent line of Next Gen sequences with the GeneStudio S5 series of benchtop instruments and the introduction of Invitrogen EVOS M5000 digital microscope for cell imaging is likely to contribute to the company s top line in the to be reported quarter For 2019  the company estimates revenues to range between  24 88 billion and  25 28 billion  resulting in a reported revenue growth of 2 4  The company stands to benefit from its successful growth strategy through the launch of innovative products and building scale in high growth in emerging markets  It is also likely to gain by bolstering customer value proposition Other Factors Likely to Influence Q1The company s focus on bolstering growth through implementation of strategies and consolidation of product offerings is encouraging  These initiatives might in turn  help it report impressive results during the first quarter The company s aim of expanding capabilities across the rapidly growing Asia Pacific belt and the emerging markets is also likely to enhance quarterly results  Outside the United States  the company s largest market lies in China and it has taken steps to sustain momentum in this market  We expect the company s commercial infrastructure  in particular  to drive strong growth in the soon to be reported quarter Moreover  expected improvement in the applied markets such as environmental and food safeties apart from life science is likely to drive first quarter results Turning to Pharma and Biotech  consistent strength in all the businesses serving this end market along with the wide range and depth of capabilities provided to its customer base might boost the company s performance in the first quarter On the back of prudent growth strategy  effective capital deployment  strong analytical instruments business and product portfolio expansion  the company estimates adjusted EPS for 2019 to range between  12 and  12 20 per share  suggesting growth of 8 10  year over year Thermo Fisher Scientific Inc  Price and EPS Surprise    However  we are anxious about Thermo Fisher facing a foreign exchange headwind pertaining to 2019 revenues and adjusted EPS  With regards to forex  the company projects year over year headwind of about  400 million of revenues or 1 6  and 21 cents per share of adjusted EPS or 1 9  in 2019  The major portion of this headwind is expected in the first half of the year Moreover  a hostile macroeconomic condition remains a headwind  Further  stiff competition continues to pose challenges to the stock s value Here s What the Quantitative Model Predicts Our proven Zacks model clearly shows that a company with a solid Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Thermo Fisher has a Zacks Rank  2 and an Earnings ESP of  0 49   the combination makes us reasonably confident of an earnings beat Other Stocks Worth a LookHere are a few other stocks worth considering from the broader medical space as these too have the right combination of elements to beat on earnings this time around Laboratory Corporation of America Holdings   NYSE LH   has an Earnings ESP of  0 36  and a Zacks Rank  3 Teleflex Incorporated   NYSE TFX   has an Earnings ESP of  0 96  and a Zacks Rank  3 Cardinal Health  Inc    NYSE CAH   has an Earnings ESP of  1 13  and a Zacks Rank  3  You can see   Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-17,Zacks Investment Research,https://www.investing.com/analysis/thermo-fisher-tmo-to-report-q1-earnings-whats-in-store-200408429,200408429
9586,231101,LH,Will Diagnostics Business Ail LabCorp  LH  In Q4 Earnings ,opinion,Laboratory Corporation of America Holdings   NYSE LH   also known as LabCorp  is slated to report fourth quarter 2018 results on Feb 7  before the market opens  In the last reported quarter  the company s adjusted earnings lagged the Zacks Consensus Estimate by 4 53   However  average trailing four quarter beat was 1 55  Let s see how things are shaping up for this announcement Factors at PlayWithin Diagnostics  the previous reported quarter witnessed trouble related to certain ransomware attack last July and an adverse impact of hurricane Florence  This induced lower than expected organic revenues for that quarter  To counter this effect  LabCorp has come up with its initiative to make certainorganizational changes for strengthening its leadership and operational performance  The company is also on track to launch the next phase of Diagnostics LaunchPad  which will result in multiyear cost savings of a similar magnitude like LaunchPad Phase I  under the drug development business  In the fourth quarter  LabCorp is expected to particularly gain from its collaboration with Walgreens  Per the company  this partnership underpins the LabCorp Walgreens channel  which is uniquely positioned to deliver a wide range of personalized  integrated  consumer facing services over time We are also looking forward to the company s alliance with European provider of clinical laboratory testing  Unilabs  This collaboration has started to broaden the network of laboratories used by biopharmaceutical companies to support companion diagnostic development and commercialization  Per LabCorp  companion diagnostics is a global opportunity and the tie up with Unilabs is the first step toward extending its companion Dx offering worldwide Laboratory Corporation of America Holdings Price and EPS Surprise   Overall  from the fourth quarter itself  the company expects to deploy more capital for near  and long term value creation including internal capital investments and strategic acquisitions and partnerships within its Diagnostics wing  However  how much this can contribute to the company s top line in the quarter to be reported is unclear The company currently projects to report LabCorp Diagnostics revenues for the full year in the range of 2 1 2 5   a reduction from the earlier provided band of3 3 5  Within Covance Drug Development  we note that after suffering a dull phase for several quarters  the segment started to gross higher revenues exactly a year ago on the back of Chiltern acquisition and a strong organic growth profile besides a favorable foreign currency translation The Chiltern buyout proved accretive to LabCorp s portfolio with the addition of highly complementary capabilities to the company s offerings including scale expansion in the Asia Pacific region  a broader reach in the rapidly growing emerging and mid tier biopharma customer segments a well as the company s expertise in the oncology drug development Apart from Chiltern  LabCorp continues to add Covance s offerings to its portfolio through targeted tuck in acquisitions and partnerships  The latest on this list is the comprehensive laboratory collaboration with Baptist Health  the largest not for profit system in Kentucky  As part of this association  the company will utilize its fully standardized laboratory solutions  operational expertise and a comprehensive test menu to support the delivery of care across eight hospital based labs  This apart  the company s consolidation of Sciformix Corporation  a scientific process outsourcing company  is projected to cement LabCorp s position in the later phases of drug and device development  particularly for post marketing pharmacovigilance and market access solutions All these factors should together constantly benefit the top line at LabCorp s Covance Drug Development in the yet to be reported quarter The company is also optimistic about the development regarding its multi year project  LaunchPad  LabCorp currently remains on track to deliver  150 million of net savings from Covance LaunchPad by the end of 2020 and  30 million of cost synergies from the integration of Chiltern by the end of 2019 Overall  the company currently expects 2018 Covance Drug Development revenue growth within 24 26  Per LabCorp s modified guidance for 2018  revenue rise is anticipated in the 9 9 10 3  band from 2017  Adjusted EPS forecast for the current year lies within the  10 95  11 05 range What the Quantitative Model SuggestsOur proven Zacks model conclusively shows that a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive  LabCorp has a Zacks Rank  3  Hold   which increases the predictive power of ESP  However  its Earnings ESP of 0 00  makes surprise prediction difficult The Zacks Consensus Estimate for fourth quarter earnings of  2 48 reflects 1 22  growth year over year  Revenue increase is pegged at  2 78 billion  a 0 46  slip year over year  You can uncover the best stocks to buy or sell before they re reported with our  Stocks to ConsiderHere are a few medical stocks worth considering from the same space as these comprise the right mix of elements to exceed expectations this reporting cycle DexCom  Inc    NASDAQ DXCM   has an Earnings ESP of  8 93  and a Zacks Rank  2  You can see  MacroGenics  Inc    NASDAQ MGNX   has an Earnings ESP of  8 15  and is a Zacks  2 Ranked player NanoString Technologies  Inc    NASDAQ NSTG   has an Earnings ESP of  4 64  and a Zacks Rank of 2 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-02-03,Zacks Investment Research,https://www.investing.com/analysis/will-diagnostics-business-ail-labcorp-lh-in-q4-earnings-200383252,200383252
9596,231111,LH,LabCorp  LH  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"Wall Street expects a year over year increase in earnings on lower revenues when LabCorp  LH  reports results for the quarter ended December 2018  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on February 7  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This medical laboratory operator is expected to post quarterly earnings of  2 48 per share in its upcoming report  which represents a year over year change of  1 2  
Revenues are expected to be  2 78 billion  down 0 5  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 23  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for LabCorp 
For LabCorp  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  4 
So  this combination makes it difficult to conclusively predict that LabCorp will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that LabCorp would post earnings of  2 87 per share when it actually produced earnings of  2 74  delivering a surprise of  4 53  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
LabCorp doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-30,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200381939,200381939
9602,231117,LH,LabCorp  Unilabs Tie Up To Expand In Companion Diagnostics,opinion,Laboratory Corporation of Americas Holdings   NYSE LH    popularly known as LabCorp  recently collaborated with Unilabs   a leading European provider of clinical laboratory testing and medical diagnostic imaging services  The terms of the deal have been kept under wraps Per LabCorp  the companies will start with commercialization of assays which have been designed and tested analytically and clinically by LabCorp and its Covance drug development business  Through this collaboration  LabCorp and Unilabs aim at increasing access to commercialization channels for companion diagnostics in North America and Europe The companies also intend to drive the uptake of companion diagnostics by widening the laboratories network accessed by biopharmaceutical companies  Starting with oncology  particularly immuno oncology  LabCorp and Unilabs will work toward simplifying the technical  regulatory and clinical complexities related with critical assays Collaborations on TrackLabCorp has strengthened its foothold in the diagnostics space through organic and inorganic means and plans to collaborate with leading companies and academic institutions to offer a wider portfolio of tests Among the recent alliances  the company has announced the extension of its existing partnership agreement with Aetna   NYSE AET    Of late  the company has been dominating the headlines on its announcement of expanding partnership with UnitedHealthcare  a business of UnitedHealth Group   NYSE UNH   to continue to serve as UnitedHealthcare s exclusive national laboratory provider till Jan 1  2019 Further  the company s comprehensive laboratory collaboration with Appalachian Regional Healthcare  an 11 hospital health system in Kentucky and West Virginia  is worth a mention  This apart  the company has expanded its relationship with Mount Sinai to consolidate all of the latter s reference work and streamline its inpatient labs Also  LabCorp s Covance business recently entered a strategic technology agreement with GlaxoSmithKline plc   NYSE GSK    Under the terms of the agreement  GlaxoSmithKline will use Covance s Xcellerate Monitoring  Xcellerate Insights and Xcellerate Clinical Data Hub solutions as a software as a service model Other recent partnerships include the one with Thermo Fisher   NYSE TMO    which enabled the launch of Thermo Fisher Oncomine Dx target panel for non small cell lung cancer patients  Also  LabCorp works on developing and operating patient service centers within select Walgreens stores through its drug retailer Walgreens   NASDAQ WBA   Share Price PerformanceOver the past six months  shares of this Zacks Rank  3  Hold  company have outperformed its   The stock has gained 17 7  compared with the industry s 3 4  gain  You can see The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-06-04,Zacks Investment Research,https://www.investing.com/analysis/labcorp-unilabs-tie-up-to-expand-in-companion-diagnostics-200322261,200322261
9603,231118,LH,Why You Should Retain Quest Diagnostics In Your Portfolio,opinion,With a market capitalization of approximately  20 26 billion  Quest Diagnostics Incorporated   NYSE DGX   has been benefiting from consistent strategic buyouts  a solid balance sheet and positive demographic trends  However  with the recently implemented PAMA  Protecting Access to Medicare Act  rule  a persistent decline in healthcare utilization rate  softer volume  commercial pricing pressure and cutthroat competition in the niche space are denting the stock s growth Pressure on volume due to a difficult macro economic situation and pricing  constitutes the primary risk for Quest Diagnostics  Nevertheless  we have observed some changes in the volume trend over the past couple of quarters  In the last reported quarter  volume measured by a number of requisitions increased 2 2  year over year  driven by acquisitions while organic growth remained essentially flat Per the company  the impact of weather presented a headwind of approximately 60 basis points to volume in first quarter 2018 We also expect a low level of employment and slow growth of commercially insured lives to continuously affect the company s overall improvement until the economy rebounds Buoyed by the above mixed trends  the stock has a Zacks Rank  3  Hold  Here we take a quick look at the major factors responsible for continuously ailing Quest Diagnostics and also the brighter prospects indicating a near term recovery Factors Plaguing Quest DiagnosticsComing back to PAMA  the year opened with the first quarter operating under the clinical IP schedule  accounting for approximately 12  of the company s revenues last year  The company still expected the impact of the final rates under PAMA to cause an approximate 4  revenue reduction in 2018 while nearly 10  in both 2019 and 2020 as well Quest Diagnostics faces intense competition  primarily from Laboratory Corporation of America Holdings   NYSE LH    other commercial laboratories and hospitals  Hospitals control an estimated 60  of the diagnostic test market compared with Quest Diagnostic s 15  share While pricing is an important factor in choosing a testing lab  hospital affiliated physicians expect a high level of service including accurate and rapid turnaround of testing results  As a result  Quest Diagnostics and other commercial labs compete with hospital affiliated labs  primarily on the basis of service quality Why Should You Hold We are optimistic about Quest Diagnostics  consistent efforts to refocus on core diagnostic information services business and a disciplined capital deployment  The company s latest acquisitions and collaborations with hospitals and integrated delivery networks continue to act as major growth drivers We are also upbeat about the company entering into an expanded long term strategic partnership agreement with UnitedHealthcare  a business of UnitedHealth Group   NYSE UNH    to operate as a preferred national laboratory for all the company s members starting Jan 1  2019  This extended pact will provide in network access to Quest Diagnostics  complete portfolio of laboratory services to more than 48 million eligible members Under the widened tie up  the companies are going to join forces on a variety of value based programs  Further  Quest Diagnostics  merger and acquisition activity is being executed successfully  Recently  the company completed the acquisition of MedXM  a leading national provider of home based health risk assessments related services In 2017  the company announced seven acquisition activities  which should help exceed Quest Diagnostics  long term M A objective of 1 2  top line growth for 2018  Among these buyouts  worth noting is the company s recently closed buyout of the Cleveland HeartLab from Cleveland Clinic Price PerformanceQuest Diagnostics has outperformed its  in a month s time  The stock has gained 9  compared with the industry s rise of 7 3   Key PickA better ranked stock in the broader medical space is Genomic Health   NASDAQ GHDX   Genomic Health has a long term earnings growth rate of 19 3   The stock sports a Zacks Rank  1  Strong Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-21,Zacks Investment Research,https://www.investing.com/analysis/why-you-should-retain-quest-diagnostics-in-your-portfolio-200327185,200327185
9604,231119,LH,Morgan Stanley Calls Labs  Safe Havens   Stocks To Watch,opinion,It takes just one super deal to turn the odds in your favor  Did the clinical laboratory services market just spin the wheel of fortune  Let s see what happened On May 24  Quest Diagnostics announced an expanded long term strategic partnership agreement with UnitedHealthcare  a business of UnitedHealth Group   NYSE UNH    to operate as a preferred national laboratory for all of the company s members starting Jan 1  2019  This expanded agreement will provide in network access to Quest Diagnostics  complete portfolio of laboratory services to more than 48 million eligible members Under the expanded tie up  the companies are going to join forces on a variety of value based programs  At the same time  Laboratory Corporation of Americas Holdings   NYSE LH    popularly known as LabCorp  has been hogging the spotlight on the news of the company losing its exclusive right to serve UnitedHealthcare post Jan 1  Meanwhile  LabCorp announced the extension of its partnership agreement with Aetna   NYSE AET   the next day  Per the expanded agreement  LabCorp will serve as a preferred national laboratory for almost all of the company s members starting next year  The extended agreement will provide in network access to LabCorp s complete portfolio of laboratory services to over 20 million eligible members According to CNBC  Quest Diagnostics will lose its exclusivity to serve as a preferred laboratory partner to Aetna s members Notably  both the diagnostic testing lab stalwarts  stocks have been trading higher than the S P 500 index since May 24 Per Morgan Stanley s analyst Ricky Goldwasser  these deals will result in the elimination of the long time problem of contract overhang and will thereby result in a cognitive environment for pricing in the near term  He also commented      Labs are relative safe havens within the health care services sector  Conforming to this idea  we believe that there are other factors which work as growth drivers for the clinical laboratory services market  Let s delve deeper Here we need to consider MarketsandMarkets data which shows that the global clinical laboratory services market is headed to reach a worth of  146 41 billion by 2022  at a CAGR of 5 2  between 2017 and 2022 Most of the analysts believe an aging demography is primarily acting in favor of this  Per an article commissioned by the National Institute on Aging  part of the National Institutes of Health  8 5  of the global population is aged 65 years and above Strengthening emerging markets are also going to provide impetus to the burgeoning global clinical laboratory services market  According to an article published in Report Buyer  the Asia Pacific  APAC  region will be the largest market for the clinical laboratory services between 2017 and 2022  Growing disposable income among the middle class people along with increasing access to state of the art clinical laboratory technologies will drive the upside According to some analysts  technological advancements in the form of integrated workflow management systems and database management tools are helping the companies expand their sample processing ability every year  Meanwhile  enhancements in laboratory testing technology will continue to boost demand for laboratory services Stocks to Watch Out ForHere we highlight three companies that are striving to cash in on the bountiful opportunities in the clinical laboratory services market Genomic Health  Inc    NASDAQ GHDX    Based in Redwood City  CA  Genomic Health develops and markets genomic based clinical laboratory services that analyze the underlying biology of cancer  enabling physicians and patients to make treatment related decisions This Zacks Rank  1  Strong Buy  company has delivered a positive earnings surprise in two of the trailing four quarters  the average beat being 226 4    You can see Quest Diagnostics   NYSE DGX    Headquartered in Secaucus  NJ  Quest Diagnostics is a leading provider of diagnostic testing information and services in the United States and globally This Zacks Rank  3  Hold  company has beat estimates in three of the trailing four quarters  the average earnings beat being 3 4  DaVita Inc    NYSE DVA    Headquartered in Denver  CO  DaVita is a leading provider of kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease  It also provides related lab services in outpatient dialysis centers This Zacks Rank  3 company has delivered positive earnings surprise in three of the last four quarters  the average beat being 0 9  PAMA  A DownerLike all other markets  the clinical lab space has its own issues to deal with Changes in governmental regulations may have a significant impact on company operations  In the last couple of years  several reimbursement issues have been hurting revenues  Majority of the companies are concerned about the CMS   Centers for Medicare   Medicaid Services  latest Medicare reimbursement reduction as a result of the implementation of the Protecting Access to Medicare Act  PAMA  This has been a major dampener for testing laboratories  As said by LabCorp earlier  the new PAMA rates published by CMS do not reflect the intent of Congress when it directed CMS to implement market based Medicare rates for lab testing  The statement says   The process CMS followed to determine these rates was fatally flawed and failed to account for significant segments of the lab market by excluding 99 percent of all U S  labs from reporting data and limiting data collection to 1 percent of laboratories  dominated by independent labs  However  per an article on GenomeWeb  companies like Myriad Genetics   NASDAQ MYGN    Veracyte and Luminex Corporation among others  which have their own proprietary tests  will for obvious reasons enjoy an edge and more control over pricing Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-03,Zacks Investment Research,https://www.investing.com/analysis/morgan-stanley-calls-labs-safe-havens-stocks-to-watch-200321948,200321948
9620,231135,LH,LabCorp Extends Aetna Agreement  Expands Diagnostics Business,opinion,Laboratory Corporation of Americas Holdings   NYSE LH    popularly known as LabCorp  has announced the extension of its existing partnership agreement with Aetna   NYSE AET    Of late  the company has been dominating the headlines on its announcement of expanding partnership with UnitedHealthcare  a business of UnitedHealth Group   NYSE UNH   to continue to serve as UnitedHealthcare s exclusive national laboratory provider until Jan 1  2019  Per the expanded agreement with Aetna  LabCorp will serve as a preferred national laboratory for almost all of the company s members starting Jan 1  2019  The extended agreement will provide in network access to LabCorp s complete portfolio of laboratory services to over 20 million eligible members Collaborations Play a Big RoleLabCorp has strengthened its foothold in the diagnostics space through organic and inorganic means and plans to collaborate with leading companies and academic institutions to offer a wider portfolio of tests  The company continues to increase its scale and competencies in clinical laboratory medicine through acquisitions ranging from routine capabilities to highly esoteric testing Among recent alliances  the company s comprehensive laboratory collaboration with Appalachian Regional Healthcare  an 11 hospital health system in Kentucky and West Virginia  is worth a mention  This apart  the company has expanded its relationship with Mount Sinai to consolidate all of the latter s reference work and streamline its inpatient labs Also  LabCorp s Covance business recently entered into a strategic technology agreement with GlaxoSmithKline plc   NYSE GSK    Under the terms of the agreement  GlaxoSmithKline will use Covance s Xcellerate Monitoring  Xcellerate Insights  and Xcellerate Clinical Data Hub solutions as a software as a service model Other recent partnerships include the one with Thermo Fisher   NYSE TMO    which enabled the launch of Thermo Fisher Oncomine Dx target panel for non small cell lung cancer patients  Also  LabCorp works on developing and operating patient service centers within select Walgreens stores through its drug retailer Walgreens   NASDAQ WBA   This apart  the company has an important tie up with Japan based Sysmex Corporation  a foremost clinical laboratory services provider and Roche  the world s reputed biotech company Share Price PerformanceOver the past six months  shares of LabCorp have outperformed its   The stock has gained 17  compared with the industry s 0 6  gain Zacks RankLabCorp carries a Zacks Rank  3  Hold   You can see Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-05-30,Zacks Investment Research,https://www.investing.com/analysis/labcorp-extends-aetna-agreement-expands-diagnostics-business-200320986,200320986
9621,231136,LH,CONMED  CNMD  Beats On Q1 Earnings  Lifts FY18 Guidance,opinion,"CONMED Corporation   NASDAQ CNMD   reported first quarter 2018 adjusted earnings per share of 53 cents  beating the Zacks Consensus Estimate by 23 3   Adjusted earnings also improved 39 5  year over year 
Revenues came in at  202 1 million  outpacing the Zacks Consensus Estimate by 2 6   Revenues increased 8 3  year over year as reported and 6 8  at constant currency  cc  
CONMED s domestic revenues in the reported quarter  which represents 52 6  of total revenues  rose 6 9  on a year over year basis  courtesy of growth in both General Surgery and Orthopedics  Internationally  revenues increased 10  as reported and 4 7  at cc  representing 47 4  of total revenues 
Meanwhile  in the past three months  CONMED has rallied 10 2   outperforming the  s decline of 11 4  CONMED Corporation Price  Consensus and EPS Surprise

   Segment Details
Orthopedic Surgery
Orthopedic surgery accounted for 53 9  of the company s revenues in the quarter  The segment registered revenues worth  108 9 million  up 4 9  on a year over year basis  driven by robust growth in capital sales 
Domestically  Orthopedics revenues recorded growth in two consecutive quarters after a long time  Internationally  Orthopedics revenues increased 1 6  year over year  marking the eighth consecutive quarter of growth 
General Surgery
This segment contributed 46  to the quarter s total revenues  For the quarter under review  the segment s revenues came in at  93 2 million  up 12 6  year over year 
Per management  growth can be attributed to strong performances across the product portfolio  Furthermore  domestically  first quarter General Surgery sales increased to 12 8   and internationally  General Surgery sales rose 12 1  
Margins
Adjusted gross margin increased 50 basis points  bps  year over year to 54 2  of revenues  Gross profit rose 9 7  on a year over year basis 
Adjusted EBITDA margin in the first quarter was 17 1   compared with 16 4  in the year ago quarter  EBITDA grew 13 9  on a year over year basis 
Financial Condition
The company s cash balance at the end of the first quarter was  21 1 million  compared with  32 6 million in the prior year quarter 
Cash flow from operations was  25 million in the first quarter of 2018 compared with  15 3 million in the prior year quarter 
Long term debt at the end of the quarter was  442 4 million  down 6 2  sequentially 
View Raised
Encouraged by the solid first quarter performance  CONMED raised its financial guidance 
The company now expects full year 2018 constant currency sales growth in the range of 4 5  to 5 5   higher than the previous range of 4 0  to 5 0   Notably  the Zacks Consensus Estimate for 2018 revenues is pegged at  831 2 million 
Adjusted net earnings per share are expected within  2 15 2 20  compared to the earlier  2 11 2 17  This shows 14  to 16  growth over 2017  Notably  the Zacks Consensus Estimate of  2 14 is below the guidance 
Additionally  management expects full year gross margin to improve 50 to 100 bps  primarily driven by the company s cost saving initiatives 
Full year R D expenses are expected in the range of 4 5 5  as a percentage of total revenues 
Our Take
CONMED exited the first quarter of 2018 on strong top line growth and margin expansion  Domestic and international revenues witnessed solid year over year growth across the company s core segments  Orthopedic revenues outside the United States surged for the eighth consecutive quarter  which deserves a special mention  Long term debt at the end of the quarter was also high  raising concerns 
Zacks Rank   Key Picks
CONMED carries a Zacks Rank  4  Sell  
A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Laboratory Corporation of America Holdings   NYSE LH    Chemed Corp    NYSE CHE   and Intuitive Surgical  Inc    NASDAQ ISRG    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   LabCorp and Chemed carry a Zacks Rank  2  Buy   You can see  
LabCorp reported first quarter 2018 adjusted earnings per share of  2 78  beating the Zacks Consensus Estimate by 5 3   Revenues came in at  2 85 billion  exceeding the Zacks Consensus Estimate of  2 78 billion 
Chemed posted first quarter 2018 adjusted earnings per share of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million 
Intuitive Surgical reported first quarter 2018 adjusted earnings of  2 44 per share  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the Zacks Consensus Estimate by 10 6  
More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/conmed-cnmd-beats-on-q1-earnings-lifts-fy18-guidance-200309891,200309891
9622,231137,LH,Varian Medical  VAR  Beats Q2 Earnings   Revenue Estimates,opinion,Maintaining its streak of positive earnings surprises  Varian Medical Systems  Inc    NYSE VAR   reported second quarter fiscal 2018 adjusted earnings of  1 15 per share  which beat the Zacks Consensus Estimate of  1 06  Adjusted earnings improved 27 8  on a year over year basis Revenues totaled  729 9 million  which beat the Zacks Consensus Estimate of  659 6 million  On a year over year basis  revenues rose 10 1  or 6  at cc  The company strengthened its foothold in the radiation therapy as the market grew 3  on an order basis in the trailing 12 months Varian has a Zacks Rank  2  Buy   The company has outperformed its  in a year s time  The stock has returned 28 4   comparing favorably with the industry s rise of 10 7  Let s delve deeper in the company s quarterly results Segment DetailsOncology SystemsIn the second quarter  oncology revenues totaled  698 million  up 6  at cc on a year over year basis  Varian Medical s worldwide net installed base is 7 954 units  up 3  or 263 units on a year over year basis As a whole  gross orders were  664 million  up 1  from the year ago quarter at cc Gross orders in Americas inched up 1  on a year over year basis at cc  In EMEA  gross orders were flat year over year  In APAC  gross orders inched up 1  year over year Operating earnings in the segment rose 16  year over year In February  Varian Medical acquired a small privately held quality assurance software company  Mobius Medical Systems  Per management  Mobius  market leading software   Mobius3D and DoseLab   are solid enhancements to Varian Medical s existing portfolio of patient treatment plan QA and machine QA technologies Strong performance in the Software  Hardware and Service revenues boosted Varian Medical s oncology systems in the second quarter Particle TherapyRevenues in this segment inched up 2  on a year over year basis to  32 million Notably  the company did not book any new ProBeam orders in the quarter In March  Varian Medical announced the first patient treatment at the St  Petersburg Proton Therapy Center in Russia  an important step in expanding access to proton therapy around the world Varian Medical Systems  Inc  Price and Consensus     Halcyon Drive RevenuesIn the second quarter  the Halcyon platform witnessed 81 total orders since its inception in 2017  with majority from greenfield sites  This reflects solid demand for the platform in the quarters ahead  The projected growth will be driven by solid new scaled configurations optimized for different customer segments and with advanced capabilities MarginsTotal company gross profit in the reported quarter was  318 5 million  up 15 6  year over year  Gross margin in the reported quarter is 43 6   which expanded 200 basis points  bps  on a year over year basis Oncology gross margin in the reported quarter was 45 7  as a percentage of revenues  up 168 bps  This is primarily driven by revenue growth across hardware  software and services as well as margin rate expansion in Europe from pricing discipline and ongoing operational excellence Financial ConditionThe company ended the quarter with cash and cash equivalents of  740 million and debt of  255 million Cash flow from operations was  66 million  up 104  year over year  driven by operating income performance and working capital efficiencies Guidance Revenue growth is expected in the range of 6 9  on a year over year basis for fiscal 2018  The Zacks Consensus Estimate of revenues is pegged at  2 78 billion at the moment Adjusted operating earnings  as a percentage of revenues  is expected in the range of 18 19  Adjusted earnings per share is expected in the range of  4 43  4 53  The Zacks Consensus Estimate of earnings is pegged at  4 33 at the moment Cash flow from operations is expected in the range of  475  550 million for 2018 In ConclusionVarian Medical ended the second quarter on a solid note  with the Halcyon platform driving the top line Solid revenues from Oncology  growing adoption of Particle Therapy and strong overseas presence  particularly in the emerging countries are positives Varian Medical signed an agreement to acquire Sirtex  an Australian based company focused on interventional oncology therapies for approximately AUD 1 6 billion  In Varian 360 Oncology care management platform  the company acquired Evinance Innovation  a small  privately held Montreal based company specializing in clinical decision support software A solid guidance for fiscal 2018 instills confidence in the stock On the flip side  the company did not book any new orders in the Proton Therapy unit  The company competes with large electronic companies as well as smaller and more specialized radiation therapy equipment manufacturers  Thus  competition is likely to mar revenues Q1 Earnings of MedTech Majors at a GlanceA few other top ranked stocks in the medical space  which reported impressive results this earnings season  are Laboratory Corporation of America Holdings   NYSE LH    Chemed Corp    NYSE CHE   and Intuitive Surgical  Inc    NASDAQ ISRG    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   LabCorp and Chemed carry a Zacks Rank  2  Buy   You can see  LabCorp reported first quarter 2018 adjusted earnings per share of  2 78  beating the Zacks Consensus Estimate by 5 3   Revenues came in at  2 85 billion  exceeding the Zacks Consensus Estimate of  2 78 billion Chemed posted first quarter 2018 adjusted earnings per share of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Intuitive Surgical reported first quarter 2018 adjusted earnings of  2 44 per share  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the Zacks Consensus Estimate by 10 6  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/varian-medical-var-beats-q2-earnings--revenue-estimates-200310150,200310150
9623,231138,LH,Stryker  SYK  Q1 Earnings Beat Estimates  2018 View Solid,opinion,"Stryker Corporation   NYSE SYK   reported first quarter 2018 adjusted earnings per share  EPS  of  1 68  beating the Zacks Consensus Estimate by 5   The EPS figure exceeded the high end of the guidance and also increased 13 5  year over year The Michigan based medical device company reported first quarter revenues of  3 24 billion  beating the Zacks Consensus Estimate of  3 20 billion by a narrow margin  Revenues also increased 9 7  on a year over year basis Organic sales growth was an impressive 7  and the performance in Japan  China  Australia and emerging markets was striking as well Meanwhile  in the last six months  the stock has rallied 8 2   compared with the  s gain of 4 5  Stryker Corporation Price  Consensus and EPS Surprise
    Segment DetailsOrthopaedicsRevenues in this segment came in at  1 22 billion  up 4 7  at cc  The upside can be attributed to the Knees division which reported sales worth  491 million  up 5  at cc  Moreover  organic net sales in the segment rose 4 7  Per management  the flagship Mako Total Knee platform saw a significant uptick in new robot installations year over year MedSurgThis segment registered revenues of  1 43 billion  up 9 1  at cc  Organic net sales in the segment increased 7 8  despite supply issues related to the company s Puerto Rico facility ramp up The growth was mainly driven by the sub segments Instruments  Endoscopy and Medical  Instruments saw 4 1  growth at cc to  412 million  Endoscopy grew 18 7  to  444 million and Medical rose 7 2  to  511 million Per management  the Medical division witnessed U S  organic growth of 4 8   driven by strong performance of core bed and power cot products as well as physio business Neurotechnology and SpineRevenues in this segment came in at  598 million  up 13 5  at cc  Organic net sales in the segment increased 10 1  Neurotechnology registered revenues worth  410 million  up 20 8  at cc  while Spine revenues came in at  188 million  up 0 3  at cc However  in the reported quarter  the Spine business saw softness as well as low double digit price declines across core product lines  The segment is also gaining from the recent integration of Entellus Medical Geographical DetailsSales in the United States came in at  2 31 billion  up 8 3  at constant currency  cc  International sales totaled  927 million  up 8  at cc Per management  Stryker had strong performances in Japan  South Pacific and Canada  The company also registered double digit growth on a year over year basis in the emerging markets However  the company s performance in Europe lacked luster in the first quarter MarginsIn the quarter under review  operating margin expanded 70 basis points  bps  to 25  Adjusted gross margin of 66 3  improved nominally from the prior year quarter  Per management  gross margin was favorably impacted by productivity  efficiency and foreign exchange gains  offset by business mix and price Financial ConditionStryker continues to maintain a strong position with  2 5 billion of cash and marketable securities  of which approximately 55  was held outside the United States  Cash flow in the first quarter was approximately  297 million  Total debt on the balance sheet at the end of the quarter was  7 9 billion GuidanceBuoyed by the stellar first quarter performance  Stryker now expects second quarter earnings per share within  1 70  1 75  Notably  the Zacks Consensus Estimate for second quarter earnings is pegged at  1 70  which is pretty encouraging Moreover  organic net sales growth in 2018 is expected within 6 5 7  and adjusted net earnings per diluted share in the range of  7 18  7 25 Management is also confident of a 30 50 bps improvement in operating margin Our TakeStryker s strong first quarter 2018 show was largely backed by solid performance by all segments  Moreover  the company witnessed high domestic and international growth in revenues  A strong guidance for the current quarter and full year buoys optimism on the company  Moreover  surging operating margins reflect strength in the company s prospects However  supply issues in the Puerto Rico facility and a declining gross margin raise concern Zacks Ranks   Other Key PicksStryker carries a Zacks Rank  2  Buy  A few other top ranked stocks which delivered solid results this earnings season are Laboratory Corporation of America Holdings   NYSE LH    Chemed Corporation   NYSE CHE   and Intuitive Surgical  Inc    NASDAQ ISRG    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   LabCorp and Chemed carry a Zacks Rank  2  You can see  LabCorp reported first quarter 2018 adjusted EPS of  2 78  beating the Zacks Consensus Estimate by 5 3   Revenues came in at  2 85 billion  steering past the Zacks Consensus Estimate of  2 78 billion Chemed posted first quarter 2018 adjusted EPS of  2 72  surpassing the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  beating the Zacks Consensus Estimate of  420 million Intuitive Surgical reported first quarter 2018 adjusted EPS of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the consensus estimate by 10 6  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/stryker-syk-q1-earnings-beat-estimates-2018-view-solid-200310148,200310148
9624,231139,LH,GNC Holdings  GNC  Beats On Q1 Earnings  Plans Store Shutdown,opinion,GNC Holdings  Inc    NYSE GNC   reported first quarter 2018 adjusted earnings per share  EPS of 24 cents  reflecting a 36 8  year over year decline  Adjusted EPS surpassed the Zacks Consensus Estimate of 20 cents by 20  RevenuesRevenues  which now exclude Lucky Vitamin in all periods  in the reported quarter dropped 7 2  year over year to  607 5 million The drop was primarily because of the sale of Lucky Vitamin in September 2017 and the termination of the Gold Card program Same store sales increased 0 5  in domestic company owned stores  including GNC com sales  in the quarter under review  Notably  this is the third straight quarter of growth  In domestic franchise locations  same store sales dropped 1 9  GNC Holdings  Inc  Price  Consensus and EPS Surprise    Segments in DetailsGNC Holdings reports operations under three segments  U S    Canada  including company owned stores in the United States  Puerto Rico and Canada  franchise stores in the United States and e commerce   International  including franchise locations in approximately 50 countries  The Health Store and China operations   and Manufacturing Wholesale  comprising manufactured products sold to other segments  third party contract manufacturing and sales to wholesale partners  During the reported quarter  GNC Holdings  revenues from the U S    Canada segment decreased 4 5  to  512 4 million  In domestic franchise locations  revenues declined  7 8 million due to a decrease in retail same store sales along with a reduction in the number of franchise stores Revenues at the International segment increased 0 8  to  40 1 million driven by higher cross border e commerce sales in China Revenues at the Manufacturing Wholesale segment  excluding intersegment revenues  declined 1 4  to  55 1 million  Within this segment  third party contract manufacturing sales fell by  0 9 million  However  Intersegment sales increased  3 4 million on the company s increased focus on proprietary products  MarginGross profit declined 5 9  in the reported quarter to  206 9 million  However  gross margin expanded 48 basis points  bps  to 34 1  on rising penetration of the company s private label brands Selling  general and administrative expenses contracted 3 2  to  160 7 million  Accordingly  adjusted operating margin dropped 62 bps to 7 6  Financial PositionGNC Holdings exited first quarter 2018 with cash and cash equivalents of  53 9 million  up from  64 million at the end of 2017  Long term debt was  1 06 billion in quarter under review  compared with  1 29 billion at 2017 end  Net cash flow from operating activities totaled  25 07 million  compared with  46 10 million a year ago Further  the company generated free cash flow of  37 4 million as compared with  33 4 million in the year ago quarter One New GNC Plan UpdateEarlier  management had announced plans to revamp its existing business model  dubbed as the  One New GNC   Till now  more than 13 million consumers have joined the company s loyalty programs  including approximately 935 000 customers enrolled under the PRO Access membership Store Count UpdateAs of Mar 31  2018  GNC Holdings had 3 385 corporate stores in the United States and Canada  1 083 domestic franchise locations  2 428 Rite Aid franchise store within a store locations and 2 009 international locations  The company currently has 8 905 store locations globally  The company intends to shutter approximately 200 stores in 2018 as part of the ongoing optimization of the company s store portfolio   The company has also announced plans to open a limited number of new stores in 2018 Our Take        GNC Holdings exited the first quarter of 2018 on a mixed note  The year over year fall in adjusted earnings and revenues is dampening The company has been firing on all cylinders to strengthen its international presence  In this regard  GNC Holdings recently announced that its proposal to enter into a strategic partnership and China joint venture agreement with Harbin Pharmaceutical Group Holding Co   Ltd   Hayao   has received Hayao shareholders  vote  Further  the company has recently entered into a master franchise agreement with Rapid Nutrition to foray in Australia  At the same time  GNC Holdings has also announced plans to expand presence in India where it operates in collaboration with the master franchise partner   Guardian Healthcare Services Pvt  Ltd  Thus  all these developments help in boosting investors faith on the stock Zacks Rank   Key PicksGNC Holdings has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Laboratory Corporation of America Holdings   NYSE LH    Chemed Corporation   NYSE CHE   and Intuitive Surgical  Inc    NASDAQ ISRG    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   LabCorp and Chemed carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 EPS of  2 44 per share  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the Zacks Consensus Estimate by 10 6  LabCorp reported first quarter 2018 EPS of  2 78  beating the Zacks Consensus Estimate by 5 3   Revenues came in at  2 85 billion  steering past the Zacks Consensus Estimate of  2 78 billion Chemed posted first quarter 2018 EPS of  2 72  beating the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  surpassing the Zacks Consensus Estimate of  420 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/gnc-holdings-gnc-beats-on-q1-earnings-plans-store-shutdown-200310263,200310263
9625,231140,LH,Omnicell  OMCL  Earnings   Revenues Beat Estimates In Q1,opinion,Omnicell  Inc    NASDAQ OMCL   reported adjusted earnings per share of 29 cents in first quarter 2018  beating the Zacks Consensus Estimate of 27 cents Earnings improved from the year ago figure of 7 cents and are above the company s guided range of 22 28 cents Revenues in DetailAdjusted revenues in the first quarter increased 22 9  year over year to  182 6 million  also above the Zacks Consensus Estimate of  177 4 million Omnicell  Inc  Price  Consensus and EPS Surprise     On a segmental basis  Automation and Analytics revenues increased 23 9  year over year in the first quarter to  151 4 million Also  revenues at the Medication Adherence segment rose 18 3  year over year to  31 2 million Operational UpdateOmnicell s gross profit during the reported quarter increased 32 6  to  82 5 million  Gross margin expanded 330 basis points  bps  to 45 2  SG A expenses in the first quarter increased 5 4  year over year to  65 3 million  Research and development expenses decreased 1 6  year over year to  16 5 million  Operating expenses were  81 8 million in the first quarter  up 3 9  year over year Operating profit in the quarter totaled  0 6 million  compared with  16 6 million in the year ago quarter Financial UpdateOmnicell exited first quarter 2018 with cash and cash equivalents of  43 8 million  compared with  32 4 million at the end of fourth quarter 2017 2018 GuidanceFor the second quarter of 2018  Omnicell expects adjusted revenues in the band of  185  190 million  which includes the impact of reclassification of selling costs as a reduction of revenues  The company expects second quarter 2018 adjusted earnings per share in the band of 36 42 cents  The Zacks Consensus Estimate for second quarter revenues is pegged at  194 7 million and earnings per share at 45 cents  Both the estimates fall above the guided range For 2018  Omnicell reaffirmed the product bookings at the range of  625  660 million  Also  the company expects adjusted revenues in the band of  780  800 million  which includes the impact of reclassification of selling costs as a reduction of revenues  The company also projects adjusted earnings in the band of  1 85  2 05 per share The Zacks Consensus Estimate for full year earnings is pegged at  2 00  within the company s guided range  The Zacks Consensus Estimate for full year revenues stands at  789 4 million  within the company s guided range Our TakeOmnicell s first quarter 2018 performance was impressive  Further  both the company s segments witnessed year over year growth  We are encouraged to note that the company is working on product innovation through R D  Also  Omnicell is expected to gain from recent launches and strategic partnerships However  a tough competitive landscape acts as a dampener Zacks Rank   Key PicksOmnicell has a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Laboratory Corporation of America Holdings   NYSE LH    Chemed Corporation   NYSE CHE   and Intuitive Surgical  Inc    NASDAQ ISRG    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   LabCorp and Chemed carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 EPS of  2 44 per share  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the Zacks Consensus Estimate by 10 6  LabCorp reported first quarter 2018 EPS of  2 78  beating the Zacks Consensus Estimate by 5 3   Revenues came in at  2 85 billion  steering past the Zacks Consensus Estimate of  2 78 billion Chemed posted first quarter 2018 EPS of  2 72  beating the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  surpassing the Zacks Consensus Estimate of  420 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/omnicell-omcl-earnings--revenues-beat-estimates-in-q1-200310261,200310261
9626,231141,LH,Zimmer Biomet  ZBH  Q1 Earnings Top Estimates  Margins Drop,opinion,"Zimmer Biomet Holdings  Inc    NYSE ZBH   reported first quarter 2018 adjusted earnings per share of  1 91  down 10 3  year over year and ahead of the Zacks Consensus Estimate of  1 87 Reportedly  net earnings came in at 85 cents per share compared with the year ago quarter s  1 47 Revenue DetailsFirst quarter net sales came in at  2 02 billion  marking a 2 3  increase  down 1 5  at constant exchange rate or CER  year over year  Net sales also surpassed the Zacks Consensus Estimate of  1 98 billion During the quarter under review  sales generated in the Americas totaled  1 21 billion  down 2  year over year at CER   while the same in EMEA  Europe  the Middle East and Africa  grossed  496 5 million  down 3    Asia Pacific  however  registered 2 6  growth at CER to  313 million SegmentsSales at Knees were down 2 1  year over year at CER to  713 3 million  Hips recorded a drop of 0 9  at CER from the prior year quarter to  492 million  Revenues from S E T   Surgical  Sports Medicine  Foot and Ankle  Extremities and Trauma  were up 1 1  year over year to  442 3 million Among the other segments  Spine   CMF were down 3 8  at CER to  183 1 million  while Dental declined 4 8  to  107 6 million  Other revenues fell 4  to  79 3 million 
Zimmer Biomet Holdings  Inc  Price  Consensus and EPS Surprise
    MarginsGross margin came in at 71 5   reflecting a contraction of 250 bps in the first quarter  Selling  general and administrative expenses were up 3 5  to  785 1 million  Further  research and development expenses rose 5  to  95 7 million  Adjusted operating margin declined 300 bps to 27 9  during the quarter Cash PositionZimmer Biomet exited the first quarter with cash and cash equivalents of  1 77 billion  compared with  524 4 million as of 2017 end  Total long term debt was  9 49 billion compared with  8 92 billion at the end of 2017 First quarter operating cash flow was  490 5 million compared with  275 4 million in the year ago quarter  The company also paid  48 6 million in dividends during the quarter 2018 OutlookThe company has issued full year 2018 guidance  Sales are projected to grow in the range of 1 5 3 5   Per management  projected sales growth figures include 200 to 300 basis points of impact from a favorable currency movement  The Zacks Consensus Estimate for revenues is pegged at  7 96 billion for the current year Adjusted EPS for 2018 is expected to be in the band of  7 60 to  7 80  The Zacks Consensus Estimate of  7 80 coincides with the high end of the guided range Our TakeZimmer Biomet ended the quarter on a positive note  We are also encouraged by the company s consistent efforts in product and renovation through research and development  We are optimistic about synergies from the LDR Holding acquisition  which should broaden and complement the company s musculoskeletal range  We are also impressed by the strong strategic and financial goals which the combined entity expects to reach However  the company s declining sales at its Knees  Hips and other segments at CER disappoint  Moreover  supply headwinds related with the major brands within the company s Knee  Hip and S E T  segments affected the first quarter performance to some extent Zacks Rank   Key PicksZimmer Biomet has a Zacks Rank  4  Sell   A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Laboratory Corporation of America Holdings   NYSE LH    Chemed Corporation   NYSE CHE   and Intuitive Surgical  Inc    NASDAQ ISRG    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   LabCorp and Chemed carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings of  2 44 per share  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the Zacks Consensus Estimate by 10 6  LabCorp reported first quarter 2018 adjusted earnings per share of  2 78  beating the Zacks Consensus Estimate by 5 3   Revenues came in at  2 85 billion  exceeding the consensus estimate of  2 78 billion Chemed posted first quarter 2018 adjusted earnings per share of  2 72  beating the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  steering past the Zacks Consensus Estimate of  420 million More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2018-04-25,Zacks Investment Research,https://www.investing.com/analysis/zimmer-biomet-zbh-q1-earnings-top-estimates-margins-drop-200309484,200309484
9639,231154,LH,Align Technology  ALGN  Beats On Earnings And Revenues In Q1,opinion,Align Technology  Inc  s   NASDAQ ALGN   first quarter 2018 adjusted earnings per share  EPS  came in at  1 17  up 37 6  year over year  Earnings were also higher than the company s guided range of 94 98 cents  The figure comfortably beat the Zacks Consensus Estimate of 98 cents as well RevenuesRevenues grew 40 8  year over year to  436 9 million in the quarter  surpassing the Zacks Consensus Estimate of  408 3  million  Revenues were well ahead of the company s guided range of  400  410 million Per management  the top line was driven by a 30 8  year over year increase in Invisalign case shipments to 272 235 in the quarter  The upside was supported by growth in North America and international regions on an expanded customer base and increased utilization along with a solid worldwide teen case growth  Moreover  increased revenues from iTero scanner contributed majorly Segments in DetailRevenues at the Clear Aligner segment  88 2  of total revenues  soared 36 5  year over year to  385 5 million in the reported quarter  primarily driven by continued strong Invisalign case volume growth across all customer channels and geographical regions In the first quarter  Invisalign case shipments amounted to 272 235  up 30 8  year over year  aided by growth across all regions as well as expansion of customer base  During the quarter  Align Technology Invisalign cases were shipped to 46 805 doctors worldwide  of which 27 105 were to North America and 19 700 to international regions Align Technology  Inc  Price  Consensus and EPS Surprise    Revenues from Scanner and Service  11 8   improved a significant 84  to  51 4 million MarginsGross margin in the quarter under review was down 100 basis points  bps  year over year to 74 9  on a 46 6  rise in cost of net revenues During the quarter  Align Technology witnessed a 32 1  year over year increase in selling  general and administrative expenses to  199 6 million and a 29 8  rise in research and development  R D  expenses to  29 6 million  The operating margin expanded 260 bps to 22 5  Financial DetailsAlign Technology exited the first quarter with cash and cash equivalents and short term marketable securities of  662 7 million  compared with  721 5 million at the end of 2017 In the reported quarter  Align Technology repurchased 0 4 million shares of stock for  100 million under the April 2016 stock repurchase program  The company currently has approximately  100 0 million left under the buy back program GuidanceFor the second quarter of 2018  the company projects EPS of  1 02  1 06 on revenues of  460  470 million  The company projects Invisalign case shipments in the band of 296 000 301 000  up 28 30  from a year ago  Meanwhile  the Zacks Consensus Estimate for second quarter 2018 EPS is  1 03 on revenues of  452 4 million  While the earnings estimate is within the projected range  the estimate for revenues falls below the same Our TakeAlign Technology ended the first quarter on a solid note  We are upbeat about the continued strength in Invisalign volumes  In North America  the company continued to witness an expanding GP Dentist customer base along with sustained strength in Invisalign utilization by orthodontists  We are also encouraged by the solid performance in the EMEA and Asia Pacific markets Within Scanners and Service  the company witnessed rapid uptake of iTero scanners across all geographies  Moreover  the company continues to see increased adoption of iTero scanners for Invisalign case submissions instead of PVS impressions  thereby driving Invisalign utilization  Further  Align Technology recently announced the receipt of China Food and Drug Administration  CFDA  approval for the commercial launch of the iTero Element intraoral scanner We are also upbeat about the company expanding the iTero Element portfolio with the lauch of iTero Element 2 and iTero Element Flex scanners in the United States and majority of European countries  covering France  Germany  Italy  Spain  and the United Kingdom Align Technology has a strong cash balance that enables it to carry out share repurchases and in turn provide solid returns to investors On the flip side  the company is exposed to foreign exchange fluctuations  seasonal demand fluctuations  higher operating expenses pertaining to increased head count along with higher investments targeted toward expansion of geographical presence and portfolio Zacks Rank   Key PicksAlign Technology currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Laboratory Corporation of America Holdings  NYSE LH   Chemed Corporation  CHE  and Intuitive Surgical  Inc   NASDAQ ISRG   While Intuitive Surgical currently sports a Zacks Rank  1  Strong Buy   LabCorp and Chemed carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings of  2 44 per share  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the Zacks Consensus Estimate by 10 6  LabCorp reported first quarter 2018 adjusted earnings per share of  2 78  beating the Zacks Consensus Estimate by 5 3   Revenues came in at  2 85 billion  exceeding the consensus estimate of  2 78 billion Chemed posted first quarter 2018 adjusted earnings per share of  2 72  beating the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  steering past the Zacks Consensus Estimate of  420 million More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2018-04-25,Zacks Investment Research,https://www.investing.com/analysis/align-technology-algn-beats-on-earnings-and-revenues-in-q1-200309401,200309401
9643,231158,LH,Can ResMed  RMD  Repeat Stable Device Growth In Q3 Earnings ,opinion,ResMed Inc    NYSE RMD   is slated to report third quarter fiscal 2018 results after market close on Apr 26  Last quarter  the company delivered a positive earnings surprise of 28 2   Moreover  the company surpassed estimates in all the trailing four quarters with an average beat of 8 6  Let s see  how things are shaping up for this announcement Key CatalystsResMed is expected to gain from a strong performance on the domestic as well as international front like the previous quarter  In the past few earnings  the company s domestic revenues were driven by solid growth in devices and masks as well as a continued double digit software sales rise  Moreover  the sleep apnea patient volume consistently witnessed steady growth  We expect these trends to find reflection in the impending third quarter results as well Internationally  revenues across Europe  Asia and other markets are likely to register a solid increase  banking on a strong device and masks performance  Within devices  sleep apnea patient volume should continue to expand through the company s marketing efforts and channel partners  In Canada and Latin America  a sturdy uptake of AirSense 10 device platform and the Air Solutions cloud based software platform should further add value to the company s portfolio ResMed Inc  Price and EPS Surprise    In France  the company s receipt of French reimbursement approval for telemonitoring buoys optimism in the stock  The company believes  this reimbursement grant will continue to drive the uptake of Air Solutions ecosystem including the AirSense 10 and the AirCurve 10 device platforms as well as AirView and myAir software platforms in the to be reported quarter  Moreover  the company keeps investing and expanding its footprint in the high growth markets of China  South Korea  India  Brazil and several countries in Eastern Europe Within mask and accessories outside the United States  the company is expected to benefit from nasal and full face categories  namely AirFit N20 and the AirFit F20  respectively Per ResMed  with more than 1 5 billion nights of medical sleep and medical respiratory care data  the company is successfully working on simplifying workflow and improving patient outcomes  This improvement should drive the company s top line performance in the quarter  yet to be reported The Zacks Consensus Estimate of  217 million for international revenues indicates a rise of 19 2  from the year ago quarter Domestically  ResMed is extremely upbeat about the latest tax reform  which sees a transformation into a territorial tax system  This  in fact allows the company to invest its global cash assets without any artificial constraints  Per ResMed  it is now free to invest in three new ways  firstly  growing upon its existing strong U S  manufacturing footprint  secondly  expanding its existing U S  based research and development capability and finally  building upon its existing valuable U S  based intellectual property assets  Effective January  this is expected to remain accretive to the company s operational result in the fiscal third quarter The Zacks Consensus Estimate of  366 million for domestic revenues  including contributions from Brightree  reflects an increase of 10 2  from the year ago quarter Other Factors Likely to Influence ResMed s Q3ResMed continues to progress on the back of its three pronged growth strategy  In this regard  the company diligently aims at growth in the adjacent product and geographic markets including homecare ventilation for Chronic Obstructive Pulmonary Disease  COPD   Amyotrophic Lateral Sclerosis  ALS  and other respiratory disorders as well as the emerging markets of China  India and Brazil  ResMed still considers portable oxygen concentrators  POCs  an important addition to its menu of respiratory care products Moreover  since ResMed s acquisition of Brightree in fiscal 2016  the former has strongly progressed with the latter s software as a service business  latest offerings targeting the home health and hospice market  We expect this upside to further boost ResMed s top line in the third quarter  The Zacks Consensus Estimate of  39 7 million for Brightree revenues marks an increase of 13 4  from the year ago quarter Here s what the quantitative model predicts Per the proven Zacks model  a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive  ResMed has a Zacks Rank  2  which increases the predictive power of ESP  However  an Earnings ESP of  0 00  makes surprise prediction difficult  Thus  the combination does not suggest that the company is likely to beat on earnings this quarter We caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions You can uncover the best stocks to buy or sell before they re reported with our  Stocks to ConsiderHere are a few medical stocks worth considering with the right combination of elements to beat estimates this time around Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  0 97  and a Zacks Rank of 2  You can see  Laboratory Corporation of America Holdings   NYSE LH   has an Earnings ESP of  1 52  and is a Zacks  2 Ranked player Quest Diagnostics Incorporated   NYSE DGX   has an Earnings ESP of  0 57  and a Zacks Rank  2 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-04-18,Zacks Investment Research,https://www.investing.com/analysis/can-resmed-rmd-repeat-stable-device-growth-in-q3-earnings-200306956,200306956
9644,231159,LH,Edwards Lifesciences   EW  THVT Likely To Drive Q1 Earnings,opinion,"Edwards Lifesciences Corporation s   NYSE EW   Transcatheter Heart Valve Therapy segment  THVT  business has been on a strong growth trajectory of late  The company has been witnessing continued therapy adoption across all geographies with notable strength in the United States  over the past few quarters We expect this strength to get reflected in first quarter 2018 results  which are scheduled for release after the market closes on Apr 24 to know how the company s overall Q1 performance is expected to be Spotlight on THVT BusinessThe THVT business includes technologies designed to treat heart valve diseases using catheter based approaches as opposed to the open surgical techniques  Over the past few quarters  the THVT business has been a major contributor to the top line  Further  management continues to be bullish on the business  Accordingly  the Zacks Consensus Estimate for THVT net sales of  575 million reflects an increase of 6 7  from the year ago quarter In recent times THVT is on a strong growth trajectory in the United States  The company has been gaining from the receipt of FDA approval for aortic and mitral valve in valve procedures  using SAPIEN 3 transcatheter heart valve which is expected to boost the top line at the THVT segment in the to be reported quarter as well 
Edwards Lifesciences Corporation Price and EPS Surprise
    Further  the company is expected to continue to gain from strong SAPIEN 3 clinical performance in the United States  as well as strong therapy implementation across all regions  Accordingly  the Zacks Consensus Estimate for transcatheter heart valves  THV  sales in the United States of  471 million shows an increase of 1 3  from the year ago quarter Outside the United States  the underlying growth rate was impressive with contributions from all regions  Edwards Lifesciences continued to see strong TAVR therapy adoption in Japan driven by SAPIEN 3 The company has been fortifying its THVT business in Europe as well  In this regard  the company maintained double digit procedure growth in Europe last reported quarter  Further  Edwards Lifesciences announced the receipt of CE Mark for its self expanding CENTERA valve in February  The latest development is likely to enhance the company s prospects in Europe However  the Zacks Consensus Estimate for THV sales outside the United States of  212 million reflects a 11 7  drop from the year ago quarter  We believe the recent developments in THV space will help the company deliver superior performance compared to the last quarter  The Zacks Consensus Estimate for THV sales outside the United States reflects a sequential rise of 9 8  Zacks Rank   Stocks to ConsiderEdwards Lifesciences carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    Laboratory Corporation of America Holdings   NYSE LH   or LabCorp and Abiomed  Inc   NASDAQ ABMD   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see  It has a long term expected earnings growth rate of 15  LabCorp has a long term expected earnings growth rate of 10 1   The stock carries a Zacks Rank of 2  Buy  Abiomed has a long term expected earnings growth rate of 31 5   The stock carries a Zacks Rank of 2 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-04-19,Zacks Investment Research,https://www.investing.com/analysis/edwards-lifesciences-ew-thvt-likely-to-drive-q1-earnings-200307269,200307269
9645,231160,LH,Can Hologic  HOLX  Diagnostics Growth Recur In Q2 Earnings ,opinion,Hologic  Inc    NASDAQ HOLX   is slated to report second quarter fiscal 2018 financial results on May 2 after the closing bell  Last quarter  the company delivered a positive surprise of 12 24   Notably  Hologic s earnings surpassed the Zacks Consensus Estimate in all the past four quarters with an average beat of 6 26  Let s see  how things are shaping up prior to this announcement Key CatalystWithin Diagnostics  Hologic once again expects a stellar performance banking on molecular diagnostics In the United States  the company is likely to gain from an increasing market share as well as utilization of fully automated Panther system along with market expansion by conforming to the testing guidelines Global growth within molecular diagnostics can be attributed to the Panther system  Hologic s fully automated molecular diagnostics instrument and also owing to a frequent utilization of Aptima women s health assays  Notably  Aptima assays have gained a huge customer base in testing for chlamydia and gonorrhea  HPV  human papillomavirus  and trichomonas  We are also hopeful about Hologic s expanded market for sexually transmitted disease testing Hologic  Inc  Price and EPS Surprise    Further  we are upbeat about Diagnostics business earning a regulatory clearance for several new products in the United States over the last six quarters  These include the first three respiratory assays on new Fusion platform and three viral load tests for HIV  for human immunodeficiency virus   hepatitis C and hepatitis B  This steady pace of domestic assay innovation strengthens the company s position to consolidate molecular testing on the Panther system  In January  the company again announced the PMA approval for the Aptima HBV Quant Assay for quantitation of hepatitis B viral load on the fully automated Panther system All the above developments are anticipated to contribute significantly to the company s topline in the to be reported quarter The Zacks Consensus Estimate of  155 million for Molecular Diagnostics revenues reflects an increase of 9 2  from the year ago quarter Other few factors likely to influence Hologic s results in the fiscal second quarter are as follows Hologic is optimistic about sustaining a solid earnings trend in 2018 courtesy of gains from the Breast Health segment  Sales from the same have improved on the basis of an established clinical superiority of the segmental products over the last three quarters  The company has witnessed a consistent rise in market share within Breast Health on the back of direct to consumer initiativesand insurance coverage Additionally  the company s adoption of new mammography systems  3Dimensions and 3D Performance  encourages us  These new products have already started to leverage the company s Genius brand and also lured customers to upgrade their existing 2D systems  The company is building a broader portfolio of Breast Health products and services around the core of Genius systems so that it can play an instrumental role in the Breast Health continuum of care  Noteworthy in this regard is the recent PMA approval from the FDA for Clarity HD high resolution 3D imaging and Intelligent 2D imaging technology  These products are now available in the 3Dimensions breast tomosynthesis system The Zacks Consensus Estimate of  293 million for the second quarter of fiscal 2018 remains 4 3  ahead of the prior year tally On the flip side  Hologic confronted challenges related to unfavorable foreign currency movement over the past few quarters  Escalating operating expenses and an intense competition  particularly in the tomosynthesis market  continue to raise a concern What Our Model SuggestsPer the proven Zacks model  a company with a solid Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has higher chances of beating estimates if it also has a positive  Hologic has a Zacks Rank  3  which increases the predictive power of ESP and an Earnings ESP of  0 94   which raises confidence about a positive surprise  Together  the combination suggests that the company is likely to beat on earnings this quarter  You can uncover the best stocks to buy or sell before they re reported with our  Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks Worth a LookHere are a few other medical stocks worth considering with the right combination of elements to also surpass estimates this time around Baxter International Inc    NYSE BAX   has an Earnings ESP of  0 86  and a Zacks Rank  2 Laboratory Corporation of America Holdings   NYSE LH   has an Earnings ESP of  1 52  and a Zacks Rank of 2 Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 13  and is a Zacks  2 Ranked player  You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-04-22,Zacks Investment Research,https://www.investing.com/analysis/can-hologic-holx-diagnostics-growth-recur-in-q2-earnings-200308021,200308021
9646,231161,LH,Can Steady Overall Growth Drive Align s  ALGN  Q1 Earnings ,opinion,"Align Technology  Inc    NASDAQ ALGN   is set to report first quarter 2018 earnings results on Apr 25  after market close Last quarter  the company posted a positive earnings surprise of 24   Align Technology has outperformed the Zacks Consensus Estimate in all of the preceding four quarters  the average positive earnings surprise being 22 6  Let s take a look at how things are shaping up prior to this announcement Invisalign System   A Major Growth DriverSimilar to prior quarters  Align Technology is expected to gain from continued adoption of Invisalign Technology in the first quarter of 2018 as well  Accordingly  the company projects Invisalign case shipments in the band of 264 000 269 000 in the to be reported quarter  up 26 9 29 3  from a year ago Notably  in November 2017  Align Technology announced the achievement of a milestone of five million patients undergoing treatment with its Invisalign system Interestingly  considering the fast expanding market for clear aligner therapy  Align Technology has undertaken several strategies to drive the adoption of its core Invisalign product line  These include product technology development  extending clinical effectiveness  promoting the Invisalign brand name and boosting international growth The company has also been focusing on increasing the Invisalign utilization by orthodontists  Particularly targeting the teenagers  Align Technology has adopted marketing strategies to accelerate consumer demand by allowing GP dentists to treat increased number of cases with the Invisalign system 
Align Technology  Inc  Price and EPS Surprise
    Strength in Scanner and Service BusinessAlign Technology has also been witnessing strong revenue growth from the Scanner and Service business over the past few quarters  Moreover  the company has been witnessing increased adoption of iTero scanners for Invisalign case submissions instead of PVS impressions  especially in North America  thereby driving Invisalign utilization  Management expects this bullish trend to reflect in the company s first quarter results as well At the same time  Align Technology has been focusing on expanding workflow options of iTero scanners  In this context  last November the company signed an agreement with Glidewell Dental to distribute the iTero Element intraoral scanning system with the latest glidewell io In Office Solution in North America Align Technology had also signed a distribution agreement with Patterson Dental to make available its iTero Element intraoral scanning system as part of Patterson Dental s CAD CAM portfolio in the United States and Canada Solid Global Prospects Align Technology had introduced a clear Aligner solution for teen Class II correction   the Invisalign Technology Teen with mandibular advancement   in certain markets of Canada  EMEA and APAC in 2017  These are indicative of the growing popularity of its dental products in the international market Further  over the recent past  Align Technology reported strong international Invisalign Technology volumes on continued strong performance in both EMEA and APAC regions In the last reported quarter  EMEA  volumes were up on continued adoption of Invisalign Technology in core markets like the U K   Spain and France  as well as rapid growth in smaller markets like Eastern Europe  Central Europe  Middle East and Africa  In the Asia Pacific region  the company witnessed an impressive volume growth led by China  Japan and Australia  We expect to see a similar trend in the yet to be reported quarter result as well Overall  Align Technology projects EPS of 94 98 cents on revenues of  400  410 million in the first quarter of 2018  The Zacks Consensus Estimate for total revenues of  408 million in first quarter 2018 indicates a rise of 37 4  from the year ago quarter What Our Quantitative Model SuggestsPer the proven Zacks model  a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive  Align Technology has an Earnings ESP of  0 97  and a Zacks Rank  2  a combination that suggests the company to likely beat on earnings this quarter  You can uncover the best stocks to buy or sell before they re reported with our  The Zacks Consensus Estimate for earnings of 98 cents reflects a 46 3  rise on a year over year basis Other Stocks to ConsiderHere are a few other medical stocks worth considering that have the right combination of elements to beat estimates this time around Laboratory Corporation Of America Holdings   NYSE LH   has an Earnings ESP of  1 52  and a Zacks Rank of 2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  2 53  and a Zacks Rank  3 Edwards Lifesciences Corporation   NYSE EW   has a Zacks Rank  3 and an Earnings ESP of  0 99  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-04-18,Zacks Investment Research,https://www.investing.com/analysis/can-steady-overall-growth-drive-aligns-algn-q1-earnings-200306890,200306890
9661,231176,LH,Can LaunchPad Aid LabCorp s  LH  Covance Arm In Q1 Earnings ,opinion,Laboratory Corporation of America Holdings   NYSE LH   also known as LabCorp  is slated to report first quarter 2018 results on Apr 25  before the market opens  Last quarter  the company delivered a positive earnings surprise of 3 38   It has an average trailing four quarter beat of 2 87  Let s see  how things are shaping up for this announcement Factors at PlayLabCorp is likely to repeat its success trend from the last quarter  The company is expected to gain from a strong LabCorp Diagnostics segment in the period to be reported  banking on a favorable price  mix  tuck in acquisitions and organic volume  Particularly  we are looking forward to the company s partnership with Mount Sinai and the former owners of Pathology Associates Medical Laboratories  PAML   Providence and Catholic Health  Earlier  the company anticipated these three partnerships to benefit from a full year ownership and growth to generate approximately  500 million as incremental profitable revenues in 2018  We expect this likely upside to get reflected in first quarter results itself Laboratory Corporation of America Holdings Price and EPS Surprise    Within Covance Drug Development  we note that after a dull show for several quarters  the segment has started to report revenue growth from third quarter 2017 onward on the back of the Chiltern acquisition  strong organic growth and a favorable foreign currency translation  With its buyout  Chiltern proved accretive to LabCorp s portfolio  adding highly complementary capabilities to the company s offerings including scale expansion in the Asia Pacific belt  a broader reach in the fast growing emerging and mid tier biopharma customer segments as well as expertise in the oncology drug development  All these factors should together continue to benefit the top line at LabCorp s Covance Drug Development in the yet to be reported quarter as well Significantly  the company is putting more emphasis on creating new growth opportunities in women s health  medical drug monitoring  genetics and oncology testing apart from critical collaborations such as Walgreens and 23andMe  Within Covance Drug Development  LabCorp expects these efforts to help fortifying its book to bill and net orders  driving its 2018 revenue conversion in the process Also  the multi year project LaunchPad  a business process improvement initiativeof LabCorp looks promising  The company s last year savings already achieved  20 million from the platform and further projects an additional net savings of  130 million through the three year period ending in 2020  thereby substantially expanding the Drug Development margins However  downsides might surface from the ongoing reimbursement issue  As stated by the company  the new PAMA  Protecting Access to Medicare Act  rates published by CMS  Centers for Medicare   Medicaid Services  do not reflect the intent of Congress when it directed CMS to implement the market based Medicare rates for lab testing  The statement reads that  The process CMS followed to determine these rates was fatally flawed and failed to account for significant segments of the lab market by excluding 99 percent of all U S  labs from reporting data and limiting data collection to 1 percent of laboratories  dominated by independent labs  We are therefore quite apprehensive about the entire scenario amid this current uproar  If the latest clinical lab fee schedule draft by CMS finally gets enforced sans amendment in favor of the testing laboratories  the continuation of LaunchPad  the projected growth at Covance  benefits from the Chiltern purchase and that from PAML and Mount Sinai plus the Covance LaunchPad process will all be offset by reduced PAMA rates Per LabCorp s previously provided guidance for 2018  revenue growth is expected to remain in the band of 9 5 11 5  from 2017 including a likely improvement of 60 bps from a positive foreign currency movement  The Zacks Consensus Estimate for current year revenues is pegged at  11 48 billion  Adjusted EPS outlook for 2018 has been projected in the  11 30  11 70 range  The consensus mark of  11 55 for the metric falls within the company s forecast What the Quantitative Model SuggestsPer the proven Zacks model  a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive  LabCorp has an Earnings ESP of  2 08  and a Zacks Rank  2  a combination that suggests the company to likely beat on earnings this quarter Conversely  the Sell rated stocks   4 or 5  should never be considered going into the earnings announcement  especially when the company is seeing negative estimate revisions You can uncover the best stocks to buy or sell before they re reported with our  Other Stocks to ConsiderHere are a few other medical stocks worth considering with the right combination of elements to beat estimates this time around Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  0 61  and a Zacks Rank of 2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  3 34  and a Zacks Rank  3 Quest Diagnostics Incorporated   NYSE DGX   has an Earnings ESP of  3 19  and is a Zacks  3 Ranked player Breaking News  Cryptocurrencies Now Bigger Than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-04-16,Zacks Investment Research,https://www.investing.com/analysis/can-launchpad-aid-labcorps-lh-covance-arm-in-q1-earnings-200306260,200306260
9663,231178,LH,LabCorp  LH  Q4 Earnings Beat Estimates   18 View Promising,opinion,Laboratory Corporation of America Holdings   NYSE LH   or LabCorp reported fourth quarter 2017 adjusted earnings per share  EPS  of  2 45  up 13 9  from the year ago quarter  The bottom line also exceeded the Zacks Consensus Estimate by 3 4   One time benefit related to the Tax Cuts and Jobs Act in the reported quarter  affected adjusted EPS by 5 cents  approximately On a reported basis  LabCorp s net earnings came in at  6 81 per share as compared to  1 75 in the year ago period Full year adjusted EPS was  9 60  missing the Zacks Consensus Estimate of  10 19  However  the metric registered 8 7  growth over the year ago adjusted number Net revenues for the fourth quarter increased 13 2  year over year to  2 70 billion  However  the top line lagged the Zacks Consensus Estimate of  2 71 billion by a close margin The year over year rise in net revenues was owing to 10  growth from acquisitions  organic growth  net revenue growth minus revenues from acquisitions for the first twelve months after the close of each acquisition  of 2 6  and a benefit of approximately 60 basis points from foreign currency translation Laboratory Corporation of America Holdings Price  Consensus and EPS Surprise    Net revenues for the year 2017 were  10 21 billion  up 8 2  over the preceding year s number  The metric is also ahead of the Zacks Consensus Estimate of  10 19 billion by 0 2  Quarter Under ReviewLabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development In the reported quarter  LabCorp Diagnostics reported net revenues of  1 82 billion  up 8 6  year over year  fueled by tuck in acquisitions  organic volume  measured by requisitions excluding requisitions from acquisitions for the first 12 months after the completion of each acquisition  and a gain from foreign currency translation of roughly 30 basis points  The company reported a 6 6  rise in total volume  measured by requisition  and a 1 8  increase in revenue per requisition in the concerning quarter After several quarters of drag in sales  Covance Drug Development reported a 23 8  rise in net revenues to  886 1 million in the fourth quarter  This upside was primarily on the back of Chiltern buyout  organic growth and the foreign currency translation benefit of nearly 140 basis points Gross margin deteriorated 92 bps to 30 4  in the reported quarter  Adjusted operating income declined 3 6  year over year to  328 6 million  Adjusted operating margin contracted 212 bps from the year ago quarter to 12 2  on a 21 1  rise in selling  general and administrative expenses to  492 4 million LabCorp exited the year 2017 with cash and cash equivalents of  316 7 million compared with  433 6 million at the end of 2016  Full year operating cash flow was  564 million  25 6  up from  448 9 million in the year ago period  Free cash flow came in at  1 1 billion in 2017  up 28  from the year ago quarter  During the quarter under discussion  the company returned  40 million to shareholders via share repurchases and has shares worth  407 4 million  remaining under its existing authorized share repurchase plan OutlookLabCorp has provided its 2018 guidance Revenue growth is expected to remain in the band of 9 5 11 5  from 2017 including a likely improvement of 60 bps from a foreign currency translation  The Zacks Consensus Estimate for current year revenues is pegged at  11 06 billion Adjusted EPS guidance for 2018 has been projected in the range of  11 30  11 70  The consensus mark of  10 67 for the metric falls below the guided range Free cash flow has been anticipated within  1 1  1 2 billion  growth in the band of 0 9 1  from the prior year Our TakeLabCorp posted a mixed fourth quarter performance with adjusted earnings topping the Zacks Consensus Estimate and net revenues falling short of the mark  On a positive note  strong year over year growth in both earnings and revenues were encouraging  LabCorp Diagnostics business was solid on the back of increasing acquisitions  organic volume expansion and a favorable foreign exchange scenario Also  after several quarters of dull performance  Covance Drug Development has been reporting sturdy growth over the past couple of terms  This uptrend was primarily owing to the Chiltern takeover  robust organic growth and a positive foreign currency translation  The 2018 guidance also looks promising We believe that with the integration of newer acquisitions  LabCorp is perfectly positioned to drive long term profitable growth through a combination of world class diagnostics  drug development expertise and knowledge services Zacks Rank   Key PicksLabCorp has a Zacks Rank  3  Hold   A few better ranked stocks having reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and ResMed   NYSE RMD    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and ResMed carry a Zacks Rank  2  Buy   You can see PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share of 44 cents were up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter ResMed posted second quarter fiscal 2018 adjusted earnings per share of  1  up 36 9  from the prior year quarter  Revenues increased 13 4  year over year  up 11  at constant exchange rate or CER  to  601 3 million More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2018-02-05,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-q4-earnings-beat-estimates-18-view-promising-200287519,200287519
9664,231179,LH,CAH Vs  HOLX  Which Will Fare Better This Earnings Season ,opinion,"We are in the thick of the fourth quarter earnings season  with 251 S P 500 members having reported their numbers  The current earnings season has seen an above average proportion of positive surprises  a favorable revision trend for the present and upcoming quarter along with a strong revenue momentum Per the latest   total earnings for the companies that have reported so far are up 16  year over year on 10 5  higher revenues  Of the total  80 5  beat earnings and 78 1  surpassed revenue estimates  With 92 S P 500 members lined up to release their quarterly results this week  we are decidedly bullish on the equity market  which is gradually demonstrating a sequential improvement MedTech Earnings So Far  one of the 16 Zacks sectors  is expected to stand out this quarter  The sector benefits from favorable consumer behavior  growing prevalence of minimally invasive surgeries  demand for liquid biopsy tests  use of IT for ensuring quick and improved patient care along with the shift of the payment system to a value based model This is evident from the results of MedTech heavyweights like Laboratory Corporation Of America Holdings   NYSE LH   or LabCorp and Becton  Dickinson and Company   NYSE BDX    The companies ended the fourth quarter on a solid note with earnings beating the Zacks Consensus Estimate An upbeat FY18 guidance also instills confidence  In this regard  LabCorp s adjusted EPS guidance for 2018 is in the range of  11 30  11 70  Further  Becton  Dickinson and Company expects adjusted earnings per share in the band of  10 85  11 00  up from the previous  10 55  10 65 For the fourth quarter  the expected earnings growth rate for the sector is 6 6  on 5 7  revenue growth CAH or HOLX  Which Will See Stronger Earnings Let s take a look at two major MedTech stocks Cardinal Health   NYSE CAH   and Hologic  Inc    NASDAQ HOLX   slated to release their quarterly reports on Feb 8 Cardinal Health is scheduled to release results before the market opens  Notably  the Zacks Consensus Estimate for second quarter fiscal 2018 revenues is pegged at  34 66 billion  up 4 6  year over year  With a diverse product portfolio  Cardinal Health is one of the largest distributors of pharmaceuticals and medical supplies However  the Zacks Consensus Estimate for second quarter earnings is pegged at  1 14  down 14 9  year over year  The company faces the risk of losing considerable business in case of loss of a major customer  which will severely impair the bottom line  In fact  Cardinal Health announced the loss of a large mail order customer  Prime Therapeutics  This dented revenues at the company s Specialty and Pharmaceutical Distribution segment in the last quarter 
Cardinal Health  Inc  Price and EPS Surprise   Moreover  our quantitative model does not conclusively show a beat for Cardinal Health  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Cardinal Health has a Zacks Rank  2 and an Earnings ESP of  0 70   You can uncover the best stocks to buy or sell before they re reported with our    read more    Hologic is set to report first quarter fiscal 2018 results  after market close  Notably  the Zacks Consensus Estimate for earnings is at 49 cents  down 5 8  on a year over year basis  The Diagnostics segment is expected to record revenues of  285 million  down 12 3  from the year ago quarter  Also  the Zacks Consensus Estimate of  279 million shows a 14 2  decline year over year  This can be blamed on the estimated loss from the divested blood screening franchise  Also  the company has been seeing weak sales of cytology and perinatal products of late On the bright side  the Zacks Consensus Estimate for first quarter revenues is pegged at  787 7 million  up 7 3  year over year  The company is expected to see stellar performance by Molecular Diagnostics  a major sub segment of Diagnostics  In the United States  the company is expected to gain from an expanding market and utilization of fully automated Panther system 
Hologic  Inc  Price and EPS Surprise   Our quantitative model indicates an earnings beat for Hologic this quarter as it has a favorable combination of an Earnings ESP of  1 42  and a Zacks Rank  3  You can see  Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2018-02-06,Zacks Investment Research,https://www.investing.com/analysis/cah-vs-holx-which-will-fare-better-this-earnings-season-200288014,200288014
9665,231180,LH,Here s Why You Should Invest In LabCorp  LH  Stock Right Now,opinion,Laboratory Corporation of America Holdings   NYSE LH   or LabCorp  has gained 19 8  over the last year  against the  s gain of 9 9   The stock has a market cap of  17 43 billion The company s five year historical growth rate is also favorable at 7 4  compared with the S P 500 index s 2 8  Considering the stable performance of the stock  we expect LabCorp to scale higher in the coming quarters  Also  the company s long term expected earnings growth rate of 10 3  looks promising  The company delivered a positive earnings surprise of 2 9  in the last four quarters With solid growth prospects  this Zacks Rank  2  Buy  stock is an attractive pick at present  Let s find out whether the recent positive trend is a sustainable one   The company has an impressive Growth Style Score of B  Our Growth  highlights all the vital metrics of a company s financials to obtain a clear picture of the quality and sustainability of growth  Our research shows that stocks with Style Scores of A or B when combined with a Zacks Rank  1  Strong Buy   2 or 3  Hold  offer the best investment opportunities  The stock has a VGM score of A Northward Revision  The current estimate revision trend is favorable  For the current year  12 estimates moved north compared with no movement in the opposite direction over the last two months  As a result  the Zacks Consensus Estimate for the full year rose 10 1  to  11 35 per share  The company s projected annualized earnings growth rate is 18 2  Strong Earnings  The market is upbeat about the company s fourth quarter 2017 results  The year over year increase in adjusted earnings and revenues is encouraging  LabCorp Diagnostics business was solid on the back of increasing acquisitions  organic volume expansion and a favorable foreign exchange scenario After several quarters of dull performance  Covance Drug Development has been delivering sturdy growth over the past couple of terms  This uptrend can be attributed to the Chiltern takeover  robust organic growth and a positive foreign currency translation  Also  the  guidance for 2018 looks promising We believe that with the integration of newer acquisitions  LabCorp is perfectly positioned to drive long term profitable growth through a combination of world class diagnostics  drug development expertise and knowledge services Solid Guidance  For full year 2018  revenue growth is estimated in the band of 9 5 11 5   which includes a likely improvement of 60 basis points  bps  from a foreign currency translation  The Zacks Consensus Estimate for current year revenues is pegged at  11 06 billion Adjusted earnings per share  EPS  guidance for 2018 is projected in the range of  11 30  11 70  The consensus mark of  10 67 for the metric falls below the guidance  Free cash flow has been projected within  1 1  1 2 billion  while growth is expected in the band of 0 9 1  from a year ago Other Key PicksA few other top ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI    Bio Rad Laboratories   NYSE BIO   and Becton  Dickinson and Company   NYSE BDX   Bio Rad Laboratories sports a Zacks Rank of 1  Strong Buy   You can see The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Becton  Dickinson is a Zacks  2 Ranked player  The company has a long term expected earnings growth rate of 13 3  Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2018-02-22,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-labcorp-lh-stock-right-now-200293540,200293540
9666,231181,LH,5 Best GARP Stocks Based On Discounted PEG ,opinion,With smart investment becoming the buzzword in today s investment world  millennials are frequently inclining toward hybrid investment patterns rather than traditional pure play theories like value or growth The logic behind this is the effectiveness of a mixed investment strategy as value or growth investing approaches come with their own share of pitfalls  A pure play value investor misses the chance of betting on stocks that have bright long term prospects  The same way  growth investors often end up investing in expensive stocks  In other words  to make a long term investment more effective  the principles of both value and growth strategies need to be combined The quest for a mixed investment strategy led to the introduction of the GARP  growth at a reasonable price  approach  What GARPers look for is whether the stocks are somewhat undervalued and have solid sustainable growth potential  Investopedia  One of the fundamental metrics for finding GARP is the price earnings growth ratio  PEG   Although it is categorized under value investing  this strategy follows the principles of both growth and value investing The PEG ratio is defined as   Price  Earnings  Earnings Growth RateIt relates the stocks P E ratio with future earnings growth rate While P E alone only gives the idea of stocks  which are trading at a discount  PEG while adding the GROWTH element to it  helps to find those stocks that have solid future potential A lower PEG ratio  preferably less than 1  is always better for GARP investors Say for example  if a stock s P E ratio is 10 and expected long term growth rate is 15   the company s PEG will come down to 0 66  a ratio which indicates both undervaluation and future growth potential Unfortunately  this ratio is often neglected due to investors  limitation to calculate the future earnings growth rate of a stock There are some drawbacks to using the PEG ratio though  It doesn t consider the very common situation of changing growth rates such as the forecast of the first three years at very high growth rate followed by a sustainable but lower growth rate in the long term Hence  PEG based investing can turn out to be even more rewarding if some other relevant parameters are also taken into consideration Here are the screening criteria for a winning strategy PEG Ratio less than X Industry MedianP E Ratio  using F1  less than X Industry Median  For more accurate valuation purpose Zacks Rank of 1  Strong Buy  or 2  Buy   Whether good market conditions or bad  stocks with a Zacks Rank  1  or  2 have a proven history of success  Market Capitalization greater than  1 Billion  This helps us to focus on companies that have strong liquidity  Average 20 Day Volume greater than 50 000  A substantial trading volume ensures that the stock is easily tradable Percentage Change F1 Earnings Estimate Revisions  4 Weeks  greater than 5  Upward estimate revisions add to the optimism  suggesting further bullishness Value Score of less than or equal to B Our research shows that stocks with a Style Score of A or B when combined with a Zacks Rank  1  2 or 3  Hold  offer the best upside potential  Here are five of the 17 stocks that qualified the screening Pfizer Inc    NYSE PFE    The company focuses on the development and commercialization of a wide range of products including human and animal biologic as well as small molecule medicines and vaccines  along with consumer health care products  Apart from a Zacks Rank  2 and a Value Score of B  the company also has an impressive expected five year growth rate of 7 7  Laboratory Corporation of America Holdings   NYSE LH    This is a leading healthcare diagnostics company  providing comprehensive clinical laboratory services and end to end drug development support  Apart from a discounted PEG and P E  the stock has a Value Score of B and holds a Zacks Rank  2 Hill Rom Holdings  Inc    NYSE HRC    This renowned medical device company partners with health care providers by focusing on patient care solutions that improve clinical and economic outcomes in five core areas  Advancing Mobility  Wound Care and Prevention  Clinical Workflow  Surgical Safety and Efficiency and Respiratory Health  The company has an impressive current year growth rate of 20   The stock currently has a Value Score of B and a Zacks Rank  2  You can see  HCA Healthcare  Inc    NYSE HCA    This is the largest non governmental operator of acute care hospitals in the  United States  Headquartered in Nashville  TN  it operates hospitals and related health care entities  It operates in two geographically organized groups   the National and American Groups  Apart from a discounted PEG and P E  the stock has a Value Score of A and sports a Zacks Rank  1 Terex Corporation   NYSE TEX    The company is a global equipment manufacturer catering to construction  infrastructure  and surface mining industries  The company s manufacturing facilities are located in the United States  Canada  Europe  Australia  Asia and South America  The stock currently sports a Zacks Rank  1 and has a Value Score of A  It also has an impressive long term historical earnings growth rate of 14 5  Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   Zacks Restaurant Recommendations  Inaddition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ,2018-02-25,Zacks Investment Research,https://www.investing.com/analysis/5-best-garp-stocks-based-on-discounted-peg-200294153,200294153
9667,231182,LH,LabCorp  LH  Up 1 1  Since Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Laboratory Corporation of America Holdings   NYSE LH    Shares have added about 1 05  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is LH due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers 
Recent Earnings
LabCorp reported fourth quarter 2017 adjusted earnings per share  EPS  of  2 45  up 13 9  from the year ago quarter  The bottom line also exceeded the Zacks Consensus Estimate by 3 4   One time benefit related to the Tax Cuts and Jobs Act in the reported quarter  affected adjusted EPS by 5 cents  approximately On a reported basis  LabCorp s net earnings came in at  6 81 per share as compared to  1 75 in the year ago period Full year adjusted EPS was  9 60  missing the Zacks Consensus Estimate of  10 19  However  the metric registered 8 7  growth over the year ago adjusted number Net revenues for the fourth quarter increased 13 2  year over year to  2 70 billion  However  the top line lagged the Zacks Consensus Estimate of  2 71 billion by a close margin The year over year rise in net revenues was owing to 10  growth from acquisitions  organic growth  net revenue growth minus revenues from acquisitions for the first twelve months after the close of each acquisition  of 2 6  and a benefit of approximately 60 basis points from foreign currency translation Net revenues for the year 2017 were  10 21 billion  up 8 2  over the preceding year s number  The metric is also ahead of the Zacks Consensus Estimate of  10 19 billion by 0 2  Quarter Under ReviewLabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development In the reported quarter  LabCorp Diagnostics reported net revenues of  1 82 billion  up 8 6  year over year  fueled by tuck in acquisitions  organic volume  measured by requisitions excluding requisitions from acquisitions for the first 12 months after the completion of each acquisition  and a gain from foreign currency translation of roughly 30 basis points  The company reported a 6 6  rise in total volume  measured by requisition  and a 1 8  increase in revenue per requisition in the concerning quarter After several quarters of drag in sales  Covance Drug Development reported a 23 8  rise in net revenues to  886 1 million in the fourth quarter  This upside was primarily on the back of Chiltern buyout  organic growth and the foreign currency translation benefit of nearly 140 basis points Gross margin deteriorated 92 bps to 30 4  in the reported quarter  Adjusted operating income declined 3 6  year over year to  328 6 million  Adjusted operating margin contracted 212 bps from the year ago quarter to 12 2  on a 21 1  rise in selling  general and administrative expenses to  492 4 million LabCorp exited the year 2017 with cash and cash equivalents of  316 7 million compared with  433 6 million at the end of 2016  Full year operating cash flow was  564 million  25 6  up from  448 9 million in the year ago period  Free cash flow came in at  1 1 billion in 2017  up 28  from the year ago quarter  During the quarter under discussion  the company returned  40 million to shareholders via share repurchases and has shares worth  407 4 million  remaining under its existing authorized share repurchase plan LabCorp has provided its 2018 guidance Revenue growth is expected to remain in the band of 9 5 11 5  from 2017 including a likely improvement of 60 bps from a foreign currency translation  The Zacks Consensus Estimate for current year revenues is pegged at  11 06 billion Adjusted EPS guidance for 2018 has been projected in the range of  11 30  11 70  The consensus mark of  10 67 for the metric falls below the guided range Free cash flow has been anticipated within  1 1  1 2 billion  growth in the band of 0 9 1  from the prior year  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There have been six revisions higher for the current quarter 
Laboratory Corporation of America Holdings Price and Consensus   VGM Scores
At this time  LH has a great Growth Score of A  a grade with the same score on the momentum front  Following the exact same course  the stock was also allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is equally suitable for value  growth  and momentum investors 
Outlook
Estimates have been trending upward for the stock and the magnitude of these revisions looks promising  Interestingly  LH has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-up-11-since-earnings-report-can-it-continue-200296731,200296731
9668,231183,LH,LabCorp   Interpace Team Up  Drive Specialty Diagnostics,opinion,Laboratory Corporation of America Holdings or LabCorp   NYSE LH   has recently entered into a national agreement with Interpace Diagnostics Group  Inc    NASDAQ IDXG   in the field of cytopathology  On one hand  this win win alliance will expand Interpace s nationwide network of cytology providers  supporting its Thyroid molecular business unit  While on the other  it will be helpful in strengthening LabCorp s core specialty diagnostics arm Notably  this is not the first time that LabCorp has partnered with Interpace  In fact  this latest agreement builds upon the original deal inked in 2016  The earlier contract enabled electronic ordering and result reporting via LabCorp for the Interpace s proprietary ThyGenX and ThyraMIR tests  The reports provided more specific diagnostic information about the presence of thyroid cancer in patients  whose initial biopsy fails to indicate if a thyroid nodule is malignant or benign Under the new agreement  Dianon Pathology   a member of the LabCorp Specialty Testing Group   will perform the thyroid biopsy analysis  If the result is indeterminate  then Interpace will perform the molecular tests  This apart  doctors can order an automatic reflex to Interpace s tests from Dianon in the event of an indefinite biopsy assessment  In either case  Dianon will automatically refer those samples to Interpace to perform the company s proprietary assays  ThyGenX and ThyraMIR It is important to note that LabCorp works hard on new innovations with academic institutions as part of its three key strategic plans to capture the growing lab testing market through advanced assays and tools In Diagnostics  the company successfully continues to provide foundation for new collaborations with health systems  large physician groups and managed care partners   It constantly increases its scale and competency levels in clinical laboratory medicine by resorting to acquisitions ranging from routine capabilities to highly esoteric testing Among the company s other recent tie ups  worth mentioning are its two major health systems partnerships namely Mount Sinai Health System and PAML  a Pacific Northwest based market leading reference and outreach laboratory Per LabCorp  these anchor health systems will gradually become research hubs  improving access to trials as well as Covance s site activation and investigator and patient recruitment capabilities LabCorp has also created ample growth opportunities for women s health with medical drug monitoring  genetics and oncology testing as well as effected critical collaborations such as Walgreens and 23andMe  Also  its partnerships with Mount Sinai and PAML s former owners  Providence and Catholic Health  continue to expand Additionally  LabCorp expects the above three transactions to benefit from full year ownership and growth to generate approximately  500 million in incremental profitable revenues for 2018 Share Price Performance Over the past three months  shares of LabCorp have outperformed its   The stock has gained 6 1  compared with the industry s growth of 0 1  Zacks Rank   Key PicksLabCorp carries a Zacks Rank  3  Hold   Two better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO   and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see The company has a long term expected earnings growth rate of 20  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-03-20,Zacks Investment Research,https://www.investing.com/analysis/labcorp--interpace-team-up-drive-specialty-diagnostics-200299717,200299717
9669,231184,LH,Is Laboratory Corporation  LH  A Great Stock For Value Investors ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Laboratory Corporation of America Holdings   NYSE LH   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Laboratory Corporation has a trailing twelve months PE ratio of 17 3  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 20 9  If we focus on the stock s long term PE trend  the current level puts Laboratory Corporation s current PE ratio slightly above its midpoint  which is 15 7  over the past five years Further  the stock s PE also compares favorably with the industry s trailing twelve months PE ratio  which stands at 18 9  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Laboratory Corporation has a forward PE ratio  price relative to this year s earnings  of just 14 7  so it is fair to say that a slightly more value oriented path may be ahead for Laboratory Corporation s stock in the near term too    P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Laboratory Corporation has a P S ratio of about 1 7  This is significantly lower than the S P 500 average  which comes in at 3 4 right now  Also  as we can see in the chart below  this is slightly below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms    Broad Value OutlookIn aggregate  Laboratory Corporation currently has a Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes LH a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for Laboratory Corporation is just 1 4  a level that is slightly lower than the industry average of 1 8  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Additionally  its P CF ratio  another great indicator of value  comes in at 11 3  which is somewhat better than the industry average of 12 4  Clearly  LH is a solid choice on the value front from multiple angles What About the Stock Overall Though Laboratory Corporation might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of A and a Momentum score of B  This gives LH a VGM score or its overarching fundamental grade of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been encouraging  The current quarter has seen nine estimates go higher in the past sixty days  compared to none lower  while the full year estimate has seen eleven upward and one downward revisions in the same time period This has had a favorable impact on the consensus estimate  as the current quarter consensus estimate has risen about 8 2  in the past two months  while the full year estimate has improved nearly 9 1   You can see the consensus estimate trend and recent price action for the stock in the chart below Laboratory Corporation of America Holdings Price and Consensus    The stock holds a Zacks Rank  3  Hold   which indicates expectations of in line performance from the company in the near term  However  Laboratory Corporation is enjoying bullish analyst sentiment  as indicated by the positive estimate revisions  and this works in the company s favor Bottom LineLaboratory Corporation is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  bottom 17  out of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past one year  the sector has clearly underperformed the broader market  as you can see below Despite positive estimate revision activity  investors should wait for broader factors and industry trends to turn around first   When they do  this stock could be a compelling value pick Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-03-22,Zacks Investment Research,https://www.investing.com/analysis/is-laboratory-corporation-lh-a-great-stock-for-value-investors-200300312,200300312
9670,231185,LH,Medical Product Stocks  Earnings On Feb 6  BDX  LH   More,opinion,"The fourth quarter earnings season has taken center stage  with 251 S P 500 members having reported their numbers  The season has turned out to be favorable so far  especially on the revenue front  A sturdy revenue momentum was witnessed in the season  above average proportion of positive surprises along with favorable revisions trend for the present and the upcoming quarters Per the latest   total earnings for the companies that have reported their results  are up 16  year over year on 10 5  higher revenues  Of the total companies  80 5  beat earnings and 78 1  surpassed revenue estimates  With 92 S P 500 members lined up to release their quarterly results this week  we are decidedly bullish on the equity market  which is gradually demonstrating a sequential improvement Medical  one of the 16 Zacks sectors  is expected to fare impressively  For the fourth quarter  the expected earnings growth rate for the sector is 6 6  on 5 7  revenue growth  Let us take a look at the major factors that are likely to influence the earnings results of Medical Product companies within the broader Medical universe Factors Influencing MedTech in Q4Tax BenefitsAs part of the tax overhaul  corporate tax rates have been slashed to 21  from 35   providing a huge relief for all sectors  Needless to say  the medical device companies cheered the legislation as well Further  the news of Congress delaying the 2 3  medical device tax for another two years was a huge boost for industry players and investors  Manufacturers appreciate the delay as it is likely to favor the companies  R D activities Favorable Consumer BehaviorDespite political issues in the healthcare space  the change in consumer demand and market dynamics led to a dramatic transformation in the entire U S  healthcare system over the last couple of years  This is evident from the growing prevalence of minimally invasive surgeries  rising demand for liquid biopsy tests  use of IT for ensuring quick and improved patient care along with the shift of the payment system to a value based model Let s take a look at four major Medical Product stocks slated to release their quarterly reports on Feb 6 Becton  Dickinson and Company   NYSE BDX  Becton  Dickinson is scheduled to report first quarter fiscal 2018 results before the opening bell Notably  the Zacks Consensus Estimate for first quarter revenues is pegged at  3 05 billion  up 4 2  year over year  The Zacks Consensus Estimate for first quarter earnings is  2 40  up 3  on a year over year basis The quarter is expected to show sluggishness in BD Medical   one of the major revenue components  While this can majorly dampen earnings in the first quarter  an expected improvement in revenues in other segments will help the company generate solid results  The Zacks Consensus Estimate for BD Medical revenues is pegged at  2 03 billion  This indicates a decline of 3 9  from the year ago quarter The company s innovative product pipeline is a key catalyst  A plethora of regulatory approvals in the United States and international markets are expanding the company s product portfolio   Read More   Our quantitative model does not indicate an earnings beat for Becton  Dickinson in this quarter  This is because a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to beat estimates  Becton  Dickinson s Earnings ESP is  0 63   The stock carries a Zacks Rank  2  You can uncover the best stocks to buy or sell before they re reported with our  Becton  Dickinson and Company Price and Consensus     
AmerisourceBergen Corporation   NYSE ABC   AmerisourceBergen is scheduled to report first quarter fiscal 2018 results before the market opens Notably  the Zacks Consensus Estimate for first quarter revenues is pegged at  40 37 billion  up 5 8  year over year  The Zacks Consensus Estimate for first quarter earnings is  1 35  down 0 7  on a year over year basis This quarter  AmerisourceBergen is expected to show steady growth in the pharmaceutical distribution segment  a significant contributor to revenues  The Zacks Consensus Estimate for the Pharmaceutical Distribution segment is at  38 74 billion for the quarter under review  up almost 5 9  from the year ago quarter  read more    Our proven model does not conclusively show earnings beat for AmerisourceBergen this quarter  AmerisourceBergen has an Earnings ESP of  1 40   The stock carries a Zacks Rank  3 AmerisourceBergen Corporation  Holding Co  Price  Consensus and EPS Surprise     
Laboratory Corporation of America Holdings   NYSE LH   Laboratory Corporation of America Holdings  also known as LabCorp  is slated to report fourth quarter 2017 results  before the market opens The Zacks Consensus Estimate for fourth quarter revenues is pegged at  2 71 billion  up 11 5  year over year  The Zacks Consensus Estimate for fourth quarter earnings is  2 37  up 10 2  on a year over year basis After several quarters of dismal performance  Covance Drug Development witnessed revenue growth in the third quarter  courtesy of strong organic growth  favorable foreign currency translation and the Chiltern acquisition Chiltern has added high complementary capabilities to LabCorp s offerings  including scale expansion in Asia Pacific  wider reach in the fast growing emerging and mid tier biopharma customer segment and expertise in oncology drug development  All these factors are likely to drive LabCorp s Covance Drug Development top line in the yet to be reported quarter   Read More   Our proven model does not predict earnings beat for the company this season  thanks to its Earnings ESP of  0 60  and Zacks Rank  3  You can see  Laboratory Corporation of America Holdings Price  Consensus and EPS Surprise     
Cerner Corporation   NASDAQ CERN   Cerner is set to report fourth quarter 2017 results  after the market closes The Zacks Consensus Estimate for fourth quarter revenues is pegged at  1 33 billion  up 5 5  year over year  The Zacks Consensus Estimate for fourth quarter earnings is 61 cents per share  flat on a year over year basis The company is expected to show steady growth in System Sales   one of the major revenue components  While this is expected to drive fourth quarter results  an expected improvement in revenues in other segments will help the company generate solid results  The Zacks Consensus Estimate for System Sales revenues is pegged at  357 million  up 10 2  from last quarter  With growth in Cerner s licensed software and subscriptions  Cerner is expected to witness strong performance in the segment  read more    Our quantitative model does not predict earnings beat for Cerner in the fourth quarter  The stock has a Zacks Rank  2 and Earnings ESP of  0 79  Cerner Corporation Price  Consensus and EPS Surprise     
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-02-04,Zacks Investment Research,https://www.investing.com/analysis/medical-product-stocks-earnings-on-feb-6-bdx-lh--more-200286992,200286992
9682,231197,LH,Will Covance Drug Development Drive LabCorp  LH  Q4 Earnings ,opinion,Laboratory Corporation of America Holdings   NYSE LH    also known as LabCorp  is slated to report fourth quarter 2017 results  before market opens on Feb 6  Last quarter  the company delivered a positive earnings surprise of 2 9   It has an average earnings beat of 2 3  for the trailing four quarters  Let s see how things are shaping up for this announcement Factors at PlaySimilar to last quarter  LabCorp is expected to gain on strength in the LabCorp Diagnostics segment in the fourth quarter  Notably  in the third quarter  revenues at this segment grew primarily banking on favorable price  mix  tuck in acquisitions and organic volume After several quarters of a weak show  Covance Drug Development has started to report revenue growth from the third quarter  on the back of the Chiltern acquisition  strong organic growth and favorable foreign currency translation  Chiltern has added highly complementary capabilities to LabCorp s offerings  including scale expansion in Asia Pacific  broader reach in the fast growing emerging and mid tier biopharma customer segment and expertise in oncology drug development  All these factors should continue to benefit LabCorp s Covance Drug Development topline in the yet to be reported quarter as well Laboratory Corporation of America Holdings Price and EPS Surprise   We are also looking forward to the company s latest deal with Agilent to make the latter s cancer diagnostic test available for expanded use  This development should start to contribute to LabCorp s top line from the fourth quarter itself  Also the company s comprehensive laboratory partnership with Capital Health is a positive As per LabCorp s earlier provided guidance for 2017  net revenue is now expected in the band of 8 8 5  year over year  This includes a 10 bps impact from unfavorable foreign exchange  The Zacks Consensus Estimate for revenues is pegged at  10 19 billion  Adjusted EPS is expected to remain in the range of  9 40  9 60  The Zacks Consensus Estimate of  9 53 is within the guided range However  over the last two years  LabCorp has faced several reimbursement issues that have hurt revenues  The company is concerned about the CMS  Centers for Medicare   Medicaid Services  proposal related to Protecting Access to Medicare Act  PAMA   We believe reimbursement pressure will affect the company s performance in the soon to be reported quarter as well LabCorp has been constantly trying to check the rise in operating expenses  which affected operating margin in the last reported quarter  Chances of a turnaround in the scenario any time soon are slim Here is what our quantitative model predicts LabCorp does not have the right combination of two main ingredients   a positive  and Zacks Rank  3  Hold  or higher   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for LabCorp is  0 07   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  LabCorp carries a Zacks Rank  3  which increases the predictive power of ESP  However  the negative ESP makes surprise prediction difficult Stocks to ConsiderHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  2  Buy   You can see  Myriad Genetics   NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 09  and a Zacks Rank  3 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/will-covance-drug-development-drive-labcorp-lh-q4-earnings-200285443,200285443
9686,231201,LH,LabCorp Forms Lab Alliance With Kentucky Based Health Firm,opinion,Over the last few days  Laboratory Corporation of Americas Holdings   NYSE LH    popularly known as LabCorp  has been dominating headlines on several strategic developments  Following its extended alliance with Interpace Diagnostics   NASDAQ IDXG   announced earlier this week  LabCorp has formed of one more  joint venture   this time with Appalachian Regional Healthcare This multi year  comprehensive laboratory collaboration will help LabCorp provide high quality  high value and standardized laboratory diagnostics to Appalachian Regional Healthcare s hospital based labs  Apart from technical services  LabCorp will aid in reference testing for Appalachian Regional Healthcare s entire network of facilities and clinicians plus make enhanced information technology and data analytics accessible to help improve the delivery of patient care This alliance is expected to strengthen LabCorp s diagnostic testing foothold in Eastern Kentucky and Southern West Virginia Progress on Strategic Collaborations We note that LabCorp has fortified its footprint in the diagnostics space through both organic and inorganic means plus plans to collaborate with the leading companies and academic institutions to build a wider portfolio of tests The company continues to increase its scale and competencies in clinical laboratory medicine via acquisitions ranging from routine capabilities to highly esoteric testing  Among its recent alliances  under the new agreement with Interpace Diagnostics  Dianon Pathology   a member of the LabCorp Specialty Testing Group   will perform the thyroid biopsy analysis This apart  worth mentioning are the company s two major health systems partnerships  Mount Sinai Health System and PAML  a market leading reference and outreach laboratory based in Pacific Northwest  Per LabCorp  these anchor health systems will gradually emerge as research hubs  improving access to trials as well as Covance s site activation and investigator  and patient recruitment capabilities Other recent collaborations include a strategic partnership with Thermo Fisher   NYSE TMO    through which  the Thermo Fisher Oncomine Dx target panel was launched for non small cell lung cancer patients  Also  riding on its partnership with drug retailer Walgreens   NASDAQ WBA    the company works on developing and operating patient service centers within select Walgreens stores  Besides these  significant is its tie up with Japan based Sysmex Corporation  a foremost clinical laboratory services provider and Roche  the world s reputed biotech company Share Price Performance Over the past three months  shares of LabCorp have outperformed its   The stock has gained 3 1  against the industry s 0 1  decline LabCorp carries a Zacks Rank  3  Hold   You can see Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-03-22,Zacks Investment Research,https://www.investing.com/analysis/labcorp-forms-laballiance-with-kentuckybased-health-firm-200300292,200300292
9689,231204,LH,LabCorp  LH  Beats Q3 Earnings Estimates  Raises Guidance,opinion,Laboratory Corporation of America Holdings   NYSE LH   or LabCorp reported third quarter 2017 adjusted earnings per share  EPS  of  2 46  up 9 3  from the year ago quarter  The quarter s adjusted EPS also exceeded the Zacks Consensus Estimate by 3 4   Simultaneous hurricanes in the reported quarter  adversely affected adjusted EPS by 9 cents approximately On a reported basis  LabCorp s net earnings came in at  1 74 per share  a 1 8  increase year over year Net revenue for the third quarter increased 9 5  year over year to  2 59 billion  The increase in net revenues was due to growth from acquisitions of 6 9   organic growth  net revenue growth less revenue from acquisitions for the first twelve months after the close of each acquisition  of 2 3   and the benefit from foreign currency translation of approximately 30 basis points  However  this was partially offset by a 0 7  adverse impact of multiple hurricanes during the quarter Laboratory Corporation of America Holdings Price  Consensus and EPS Surprise    Quarter under ReviewCurrently  LabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development In the reported quarter  LabCorp Diagnostics reported net revenue of  1 84 billion  up 9 9  year over year  fueled by price  mix  tuck in acquisitions  organic volume  measured by requisitions excluding requisitions from acquisitions for the first 12 months after the close of each acquisition  and the benefit from foreign currency translation of approximately 20 basis points  The company reported 7 3  increase in total volume  measured by requisition  and a 2 4  increase in revenue per requisition in the quarter After several quarters of drag in sales  Covance Drug Development reported an 8 6  rise in net revenue to  761 1 million in the third quarter  This was primarily on the back of the acquisition of Chiltern  organic growth and the benefit from foreign currency translation of approximately 60 basis points Gross margin expanded 75 bps to 33 9  in the quarter  Adjusted operating income increased 7 6  year over year to  417 5 million  Adjusted operating margin contracted 28 bps from the year ago quarter to 16 1  on a 16 2  rise in selling  general and administrative expenses to  465 3 million LabCorp exited the quarter with cash and cash equivalents of  409 3 million compared with  299 9 million at the end of the second quarter  Year to date operating cash flow was  895 4 million  up from  727 million in the year ago period  Free cash flow came in at  678 6 million  up from  522 4 million in the year ago period  During the quarter  the company returned  42 1 million to shareholders through share repurchases and currently has  444 7 million of authorization  remaining under its existing share repurchase plan OutlookBased on a strong third quarter show and considering a gradually improving foreign exchange scenario  the company increased its earlier provided 2017 outlook Net revenue growth is now expected to remain in the band of 8 8 5  year over year  ahead of the earlier range of 5 6 5   This includes a 10 bps impact from an unfavorable foreign exchange headwind  The current Zacks Consensus Estimate for revenues is pegged at  10 13 billion Adjusted EPS guidance for 2017 has been narrowed to the range of  9 40  9 60  previous range   9 30  9 65   The current Zacks Consensus Estimate of  9 51 falls within the guided range Free cash flow expectation has been raised to a new band of  970  1010 million  previous range   925  975 million  up 8 13  from the prior year Our TakeLabCorp s third quarter earnings topped the Zacks Consensus Estimate  Strong year over year increase in both earnings and revenues were encouraging too  LabCorp Diagnostics business was strong on improving price  mix  acquisition and favorable foreign exchange scenario Also after several quarters of dull performance  Covance Drug Development reported strong growth  This was primarily on the back of the acquisition of Chiltern  strong organic growth and favorable foreign currency translation  An increased guidance for 2017 boosts investors  confidence indicating chances of this bullish trend to be maintained in the fourth quarter too We believe that with the integration of newer acquisitions  LabCorp is perfectly positioned to drive long term profitable growth through a combination of world class diagnostics  drug development expertise and knowledge services Zacks Rank   Other Key PicksCurrently  LabCorp has a Zacks Rank  2  Buy  A few other top ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while both Abbott and Intuitive Surgical carry a Zacks Rank  2  You can see PetMed reported EPS of 43 cents for the second quarter of fiscal 2018  up 79 2  from 24 cents  reported in the year ago quarter  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-beats-q3-earnings-estimates-raises-guidance-200220981,200220981
9690,231205,LH,LabCorp  LH  Beats On Q3 Earnings   Revenue Estimates,opinion,Laboratory Corp  of America Holdings   NYSE LH   is a leading independent clinical laboratory  whose offerings include a broad range of routine tests  including blood chemistry analysis  urinalyses  blood cell count  thyroid test  Pap tests and HIV tests  as well as specialty testing operations or esoteric testing Currently  LabCorp has a Zacks Rank  2  Buy  but that could change following its third quarter 2017 earnings report which has just released   You can see   We have highlighted some of the key details from the just released announcement below Earnings  The Zacks Consensus Estimate is pegged at  2 38 per share over the last 30 days  LabCorp s adjusted earnings per share of  2 46 is also up 9 3  on year over year basis Laboratory Corporation of America Holdings Price and EPS Surprise   Sales  LabCorp posted sales of  2 65 billion  which has beaten the Zacks Consensus Estimate for sales of  2 56 billion  The figure is also up 9 9  on year over year basis Key Stats  Revenues from LabCorp Diagnostics segment increased 9 9  year over year to  1 84 billion in the third quarter  with total volume growth of 7 3   Revenues from Covance Drug Development segment increased 8 6  to  761 1 million  owing to the acquisition of Chiltern  as well as organic growth and the benefit from foreign currency translation Major Factors  Management seemed to be upbeat about LabCorp s impressive third quarter results  Per management  the Diagnostics business had witnessed strong organic and total volume growth despite the adverse impact from hurricanes  Also  the Drug development business witnessed solid growth on the back of increased net orders and improving net book to bill  The company has also increased its 2017 guidance Stock Price  Following the earnings release  share prices did not show any movement in the pre market trading sessionCheck back later for our full write up on this LabCorp earnings report later Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-beats-on-q3-earnings--revenue-estimates-200220962,200220962
9691,231206,LH,MedTech Stocks  BAX  VAR  TMO  LH  Earnings Preview  What You Should Know,opinion,"The third quarter earnings season has commenced on an encouraging note for most sectors  with releases from 87 S P 500 participants  24 7  of the total market cap  till October 20 Per the latest   total earnings for these members rose 9 4  on 7 3  higher revenues  With 180 S P 500 members lined up for releasing their quarterly results this week  we are decidedly bullish on the equity market  which is gradually demonstrating a sequential improvement Medical  one of the broader sectors among the 16 Zacks sectors  is expected to put up an impressive show in the quarter  For Q3  the expected earnings growth rate for the sector is 2 2  on 4 8  revenue growth  In comparison  the reported earnings growth rate during the second quarter of 2017 was quite impressive at 7  on 4 4  revenue growth Medical Products Amid Political UncertaintiesHowever  the Medical Product space  within the broader Medical universe  has been a precarious game for the Republicans since day one  courtesy of President Trump s repeated failure to repeal and replace Obamacare However  major MedTech players have been pinning their hopes on the abolition of the infamous 2 3  medical device sales tax  though the elimination of this tax is far from being achieved Considering these tax issues  investors interested in the Medical Product space will likely keenly await earnings reports from MedTech bigwigs like Baxter International Inc    NYSE BAX    Varian Medical   NYSE VAR    Thermo Fisher Scientific Inc     NYSE TMO   and Laboratory Corporation of America Holdings   NYSE LH    Notably  all the companies are expected to release their earnings results on Oct  25 For the third quarter  Baxter anticipates sales growth of about 4  at constant currency  cc   Adjusted earnings per share are forecasted in the range of 58 60 cents versus the year ago figure of 56 cents  We believe the company s solid sales in the Medical Products segment will be a key driver in the third quarter  Notably  the Zacks Consensus Estimate for the segment stands at  1 648 million  up 4 2  on a year over year basis  read more    Despite the solid prospects  our quantitative model does not conclusively show a beat for the company  given the combination of a Zacks Rank  2  Buy  and an  of  0 34   That is because  as per our model  a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy   2 or 3  Hold  to beat earnings Baxter International Inc  Price and Consensus
    We are upbeat about Varian Medical s oncology business  which is estimated to account for around 95  of the company s total revenue in the fourth quarter of fiscal 2017  The company has been addressing both the tier 1 and mid tier markets through its Edge  Truebeam and VitalBeam products  and has also been winning international contracts in the oncology space  For the fourth quarter of fiscal 2017  Varian expects adjusted earnings per share in the range of  1 15  1 23  Revenues are likely to increase about 3  on a year over year basis  read more    On the contrary  the Zacks Consensus Estimate for Varian Medical s revenues stands at  741 7 million  down 18 7  year over year  The consensus estimate for earnings is pegged at  1 19  down 14  year over year  Our proven model does not predict an earnings beat for the company this season  thanks to its Earnings ESP of 0 00  and Zacks Rank  3  You can see  Varian Medical Systems  Inc  Price and Consensus
    Laboratory Corporation  also known as LabCorp  will continue to face softness in its Covance Drug Development business in the third quarter of 2017  However  we are upbeat about the company s expectations of an improvement in the Covance Drug Development arm starting the second half of 2017  This should be reflected in its third quarter performance  read more     The Zacks Consensus Estimate for LabCorp s third quarter revenues stands at  2 56 billion  up 6 2  year over year LabCorp is concerned about the CMS  Centers for Medicare   Medicaid Services  proposal related to Protecting Access to Medicare Act  PAMA   We believe reimbursement pressure will affect the company s performance in the third quarter as well  In fact  our proven model does not predict an earnings beat for the company this season  This is because LabCorp has a Zacks Rank  2 and an Earnings ESP of  1 57   You can uncover the best stocks to buy or sell before they re reported with our  Laboratory Corporation of America Holdings Price and Consensus
    Thermo Fisher is gearing up for solid third quarter results  primarily driven by analytical instruments segmental growth  In the third quarter  the company expects to see a positive impact from the electron microscopy business as well as strong volume leverage and productivity The Zacks Consensus Estimate for Analytical Instruments operating income is pegged at  233 million  in line with last quarter s reported number  Total revenue estimate for this segment is at an impressive level of  1 11 billion  read more    Our quantitative model predicts an earnings beat for Thermo Fisher in Q3  The stock currently has a Zacks Rank  2 and an Earnings ESP of  0 19   The Zacks Consensus Estimate for revenues is at  5 03 billion for the third quarter  up 12 1  on a year over year basis Thermo Fisher Scientific Inc Price and Consensus
    Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/medtech-stocks-bax-var-tmo-lh-earnings-preview-what-you-should-know-200220750,200220750
9701,231216,LH,Anatomy Of Success   Exact Sciences Corp  EXAS ,opinion,"At Zacks we stress the value of the Zacks Ranking system  and specifically the few companies that earn the exclusive Zacks  1  Strong Buy  rank   Only 5  of the Zacks Rank universe receives this grade  and over a 1 3 month time frame it has a long history of outperforming the markets   The system helps you identify companies both big and small that are poised for near term growth   While the Zacks Rank is an excellent near term indicator for finding the best stocks  the system also helps you stay in the strongest ones while they continue to appreciate in price   Example  Exact Sciences CorpExact Sciences Corp    is a mid cap growth stock who uses applied genomics to develop effective  patient friendly screening technologies for use in the detection of cancer  Certain of its technologies have been licensed to Laboratory Corporation of America  NYSE LH  Holdings for a stool based DNA screening assay for colorectal cancer in the average risk population  The company believes that their genomics based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated On December 30  2016 Exact Sciences received a Zacks Rank  1 designation just after the company announced that they signed a contract with Humana  NYSE HUM  to cover Cologuard  a noninvasive at home colon cancer test  as an in network service  which would become effective on January 1  2017   On December 30th  the stock price closed at  13 36 per share Over the next three consecutive quarters EXAS beat both the Zacks consensus earnings and revenue estimates   At the same time future estimates saw a consistent quarter over quarter positive estimate revisions   Annual estimates were also positively revised after each quarterly beat   Cologuard remained a strong driver for the company  and still remains a big reason for their success   Exact Sciences also received a Zacks Rank  1 on July 14th  and October 13th of this year   As of the close on November 3rd  the stock was at  56 71 per share   This is a  324  gain from when it first became a Rank  1 on December 30th of 2016   As you can see in the chart below  the stock price has seen amazing price appreciation from December 30th  and the forward 12 month rolling EPS estimates have been consistently moving upwards as well 

Overall  by utilizing the Zack Ranking system you can easily find stocks that are best positioned to beat the market on a consistent basis  and how to retain the best stocks while they continue to grow 
More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2017-11-06,Zacks Investment Research,https://www.investing.com/analysis/anatomy-of-success--exact-sciences-corp-exas-200261333,200261333
9702,231217,LH,LabCorp Reports New Use Of Agilent s Cancer Diagnostic Test,opinion,Laboratory Corporation of America Holdings   NYSE LH   or LabCorp recently announced that Agilent s Dako pathology division s development   the PD L1 IHC 28 8 pharmDx assay   is now available in the United States for new expanded use  Per LabCorp  this test has got the U S  approval to be used as a complementary diagnostic with Bristol Myers Squibb Company s   NYSE BMY   OPDIVO  nivolumab  for two new indications   metastatic urothelial carcinoma or bladder cancer and squamous cell carcinoma of the head and neck   respectively It is encouraging to note that tests of the clinical studies that supported approval of the new indications for the assay were performed at the company s Center for Molecular Biology and Pathology laboratory  Per LabCorp  OPDIVO is already approved for the two aforementioned indications without use of the test  However  the PD L1 IHC 28 8 pharmDx test provides vital information about those patients  who are most likely to respond positively to OPDIVO  Earlier  the PD L1 IHC 28 8 pharmDx assay was approved for use as a complementary diagnostic with OPDIVO to treat certain patients with non squamous non small cell lung cancer  NSCLC  and melanoma  At that time too  LabCorp s central clinical trials laboratory was the only provider of testing to support the clinical trial for the 2015 approval of the non squamous NSCLC treatment indication  Per the company  this successfully demonstrates how the combined capabilities of LabCorp s clinical laboratory infrastructure and Covance s central clinical trials laboratory are paving new ways for clinical trials LabCorp s consistent efforts to expand in the growing field of complementary and companion diagnostics is gradually fetching unmatched results  Notably  the company has adopted this strategy to work closely with health systems that have expressed interest in becoming preferred partners in LabCorp and Covance s clinical trials  In this regard  the company has signed agreements with several major health systems recently  Earlier this year  the company entered into an agreement with Thermo Fisher Scientific  NYSE TMO  to join its NGS Companion Diagnostics Center of Excellence program  It has also inked an exclusive deal to distribute OmniSeq s immune profile and tumor profiling tests  Within Diagnostics  LabCorp has made a strong progress with consumer and patient facing initiatives  The company s LabCorp Walgreens collaboration is off to a terrific start with respect to patient volumes  Net Promoter Scores and patient feedback riding on years  experience at these sites Within drug development business  the company is focused on driving future profitable growth through expanded solutions and enhanced operational capabilities  The acquisition of Chiltern closed on Sep 1  is significantly strengthening LabCorp s strategic position in clinical development as well as accelerating revenue and profit growth within Covance   LabCorp was trading above the broader  over the last six months   The stock has gained 8 1  compared with the industry s 4 7  gain Zacks Rank   Key PicksLabCorp carries a Zacks Rank  3  Hold   Two better ranked medical stocks are PetMed Express  Inc    NASDAQ PETS   and Align Technology  Inc    NASDAQ ALGN    both sporting a Zacks Rank  1  Strong Buy   You can see PetMed has a long term expected earnings growth rate of 10   The stock has soared roughly 77 9  over a year Align Technology has a long term expected earnings growth rate of 28 9   The stock has skyrocketed 156 3  in a year s time Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-11-15,Zacks Investment Research,https://www.investing.com/analysis/labcorp-reports-new-use-of-agilents-cancer-diagnostic-test-200265756,200265756
9703,231218,LH,Quest Diagnostics  LabCorp Defend Lab Fee Suit Against HHS,opinion,Healthcare diagnostic majors and arch rivals Quest Diagnostics Incorporated   NYSE DGX   and Laboratory Corporation of America Holdings   NYSE LH   or LabCorp are on the same page regarding the much contentious topic of Protecting Access to Medicare Act   PAMA   on clinical lab fee schedule  Recently  both the companies as members of the American Clinical Laboratory Association   ACLA   have come forward to support a lawsuit filed by ACLA against the Acting Secretary of the U S  Department of Health and Human Services   HHS    The lawsuit charged that the Centers for Medicare   Medicaid Services   CMS    operating under the purview of HHS  have failed to follow a congressional directive to implement a market based laboratory payment system Per the lawsuit claims  CMS ignored the Congress directives stated under PAMA and instituted a highly flawed data reporting process of setting market rates in advance This prohibited the overwhelming majority of laboratories from reporting the private payer data used to determine Medicare rates for lab tests  The move has instead resulted in new Medicare lab rates  which are not market specific  Hence  the entire process clearly demonstrates CMS  failure to protect access to laboratory services for Medicare beneficiaries Per the press release from LabCorp  if the new rates are allowed to come into effect  it will affect the Medicare beneficiaries as well as disrupt the healthcare system  Per Quest diagnostics   this flawed process could cause serious financial harm to potentially thousands of hospitals  independent and physician office laboratories and make it harder for Medicare beneficiaries to get access to medical testing  particularly in remote rural areas and in nursing homes that depend on laboratory testing services   Earlier during the third quarter earnings release  both LabCorp and Quest Diagnostics had issued certain objections in response to the Sep 22 publication by CMS on the proposed 2018 Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule  CLFS  mandated by PAMA  Per the companies  only 1  of all laboratories submitted data and over 99  of hospitals and physician office laboratories were prevented from reporting their rates The above mentioned 1  of laboratories majorly denoted independent labs  To convey the severity of the situation in clear terms  Quest Diagnostics stated that based on data submitted through CMS  the company alone represented nearly 40  of all the market data that CMS collected Among other possibly badly hit clinical laboratories  thanks to the latest CMS mandate on clinical lab fee schedule  two names emerge as DaVita Inc    NYSE DVA   and PerkinElmer  Inc    NYSE PKI    While Quest Diagnostics  LabCorp and PerkinElmer carry a Zacks Rank  3  Hold   DaVita has a Zacks Rank  5  Strong Sell  Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2017-12-18,Zacks Investment Research,https://www.investing.com/analysis/quest-diagnostics-labcorp-defend-lab-fee-suit-against-hhs-200274370,200274370
9704,231219,LH,LabCorp  LH  At A 52 Week High  What s Driving The Stock ,opinion,Shares of Laboratory Corporation of America Holdings   NYSE LH   scaled a new 52 week high of  165 18 on Dec 20  closing nominally lower at  163 03  The company has gained 8 4  over the last six months  much higher than the broader  s gain of 2 4  with respect to share price  The stock has a market cap of  16 59 billion Taking the stable stock performance into consideration  we expect LabCorp to scale higher in the coming quarters  Also  the company s long term expected earnings growth rate of 9 9  holds promise Further  the company s estimate revision trend for the current year is favorable  In the past 60 days  five estimates moved up while four shifted down  Consequently  estimates were up from  9 51 per share to  9 52 Laboratory Corporation of America Holdings Price and Consensus    The company also has a trailing four quarter average positive earnings surprise of 2 3   Its positive long term growth of 9 9  holds promise as well LabCorp recently announced that Agilent s Dako pathology division s development   the PD L1 IHC 28 8 pharmDx assay   is now available in the United States for new expanded use  Per LabCorp  this test received U S  approval to be used as a complementary diagnostic with Bristol Myers Squibb Company s   NYSE BMY   OPDIVO  nivolumab  for two new indications   metastatic urothelial carcinoma or bladder cancer and squamous cell carcinoma of the head and neck   Encouraged by a strong third quarter show and a gradually improving foreign exchange scenario  the company raised its 2017 outlook Net revenue growth is maintained in the band of 8 8 5  year over year  ahead of the earlier range of 5 6 5   Free cash flow expectation has been raised to a new band of  970  1010 million  previous range   925  975 million  up 8 13  from the prior year In the recent past  the company successfully closed the Chiltern International Group s buyout  a specialty contract research organization  Chiltern is a major partner of LabCorp  serving the top 20 biopharma segments and helping the company focus on the high growth emerging and mid market biopharma segments  Following this takeover  the company s Covance Drug Development reported strong growth in the third quarter after several quarters of tepid performance Zacks Rank   Key PicksLabCorp carries a Zacks Rank  3  Hold  A few better ranked medical stocks are athenahealth  Inc    NASDAQ ATHN   and Align Technology  Inc    NASDAQ ALGN    both of which sport a Zacks Rank  1  Strong Buy   You can see athenahealth has a long term expected earnings growth rate of 22 3   The stock has rallied roughly 27 3  over a year Align Technology has a long term expected earnings growth rate of 28 9   The stock has gained 137 9  in a year Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-12-20,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-at-a-52week-high-whats-driving-the-stock-200275099,200275099
9705,231220,LH,LabCorp Grapples With Reimbursement Cuts  Stiff Competition,opinion,On Jan 2  we issued an updated research report on LabCorp   NYSE LH    The stock carries a Zacks Rank  4  Sell  This Burlington  NC based healthcare diagnostics company  providing comprehensive clinical laboratory services and end to end drug development support  has been grappling with multiple issues of late  Economic uncertainties  including a challenging volume environment for testing laboratories and softness in utilization  are looming headwinds for LabCorp Changes in governmental regulations had a significant impact on LabCorp s operations  The company raised certain objections in response to the Sep 22 publication by the Centers for Medicare and Medicaid Services  CMS  of proposed 2018 Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule  CLFS  mandated by the Protecting Access to Medicare Act  PAMA  Also  if the latest clinical lab fee schedule draft by CMS gets implemented without any amendment in favor of testing laboratories  the projected growth at LabCorp s Covance  the benefit from Chiltern  the benefit from PAML and Mount Sinai and the Covance LaunchPad process will all be adversely impacted Moreover  LabCorp faces intense competition from other commercial laboratories and hospitals  In a  55 billion U S  lab market  hospitals control an estimated 55  of the diagnostic test market  compared to LabCorp s 10  share  While pricing is an important factor in choosing a testing lab  hospital affiliated physicians expect a high level of service  including accurate testing results  As a result  LabCorp and other commercial labs compete with hospital affiliated labs primarily on the basis of quality of service On a positive note  LabCorp s Diagnostics business continues to remain strong on improving price  mix  acquisition and favorable foreign exchange  Also  after several quarters of dull show  Covance Drug Development reported strong growth on the back of Chiltern acquisition  strong organic growth and favorable foreign currency translation  Also  over the past six months LabCorp has been trading above the broader   The stock has gained 7 1  as against the industry s 0 5  fall   Key PicksA few better ranked medical stocks from the same space are Bio Rad Laboratories  Inc    NYSE BIO    Walgreens Boots Alliance  Inc    NASDAQ WBA   and Integer Holdings Corporation   NYSE ITGR   Bio Rad Laboratories flaunts a Zacks Rank  1  Strong Buy   The company has a long term expected earnings growth rate of 25  and has gained 6 2  over the past six months  You can see Walgreens Boots has a long term expected earnings growth rate of 10 1   The stock carries a Zacks Rank  2  Buy  and has gained 3 2  year to date Integer Holdings has a long term expected earnings growth rate of 15   The stock carries a Zacks Rank  2 and has gained 4 6  over the past six months Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2018-01-02,Zacks Investment Research,https://www.investing.com/analysis/labcorp-grapples-with-reimbursement-cuts-stiff-competition-200277306,200277306
9706,231221,LH,Quest Diagnostics To Buy MedXM  Boost Home Health Services,opinion,Quest Diagnostics   NYSE DGX   recently announced a definitive agreement to buy a leading national provider of home based health risk assessments and related services   Mobile Medical Examination Service  MedXM   The financial terms of the deal  slated to close in the first quarter of 2018  have been kept under wraps Based in Santa Ana  CA  MedXM has an extensive national network of more than 1 700 medical professionals  It provides enhanced member satisfaction for health plans  particularly Medicare Advantage and managed Medicaid  and also enriched quality of care  Thus  the acquisition will strengthen Quest Diagnostics  position in extended care and widen its scale and reach in the mobile home segment as well Going by data published in a report by Grand View Research  the deals seems to be lucrative as well as strategic  Per the report  the global home healthcare market is likely to see a CAGR of 7 8  between 2014 and 2025  Growth will mainly be driven by factors such as rising old age demography across the globe  growing need of cost effective healthcare  rising incidences of chronic diseases and technological advancements in devices We are also optimistic about the company s focus on its two point strategy  According to Quest Diagnostics  its planned divestiture of the Focus Diagnostics products business is part of its strategy to refocus on diagnostic information services  Additionally  several new collaborations with hospitals and integrated delivery networks have turned out to be major growth drivers in the past  In this regard  we are encouraged by the company s completion of thebuyout of outreach laboratory service operations of Hartford HealthCare hospitals   The William W  Backus Hospital and The Hospital of Central Connecticut  The company has also completed the acquisition of Med Fusion and Clear Point in Texas forming a national precision oncology center of expertise  Moreover  the company s agreement to purchase Shiel Medical Laboratory and plans to acquire the outreach laboratory services business of Cape Cod Healthcare buoy optimism We are also upbeat about Quest Diagnostics and Clinical Genomics  a major player in the field of colorectal cancer detection  jointly announced FDA clearance of the latter s InSure ONE  Notably  with the FDA approval  Quest Diagnostics will make InSure ONE available to its broad base of physicians  organized provider groups and Accountable Care Organizations  ACOs  in the United States  InSure ONE is expected to be commercially available in early 2018  This development is in line with Quest Diagnostics  consistent efforts to grow in cancer diagnostics The company s relationship with PeaceHealth has also been fortified  The partnership entails the acquisition of an outreach laboratory as well as a professional laboratory service agreement to manage laboratories at 11 PeaceHealth Medical Centers in Washington State  Oregon and Alaska Per the company  these tuck in acquisitions fit well within the ambit of the M A guidelines  Quest Diagnostics  takeover plans are consistent with its goal of contributing 1 2  to revenues annually through accretive acquisitions  Thus  we believe this latest buyout will widen the customer base of this leading diagnostic services information provider Quest Diagnostics faces intense competition in diagnostic testing laboratory space  primarily from Laboratory Corporation of America Holdings   NYSE LH   and other commercial laboratories and hospitals   Moreover  in the clinical laboratory market some of the major players are Myriad Genetics   NASDAQ MYGN   and Genomic Health   NASDAQ GHDX   Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-25,Zacks Investment Research,https://www.investing.com/analysis/quest-diagnostics-to-buy-medxm-boost-home-health-services-200284017,200284017
9708,231223,LH,What s In The Cards For LabCorp  LH  This Earnings Season ,opinion,"Laboratory Corporation of America Holdings   NYSE LH    also known as LabCorp  is slated to report third quarter 2017 results  before market opens on Oct 25  Last quarter  the company delivered a positive earnings surprise of 3 8   It has an average earnings beat of 1 1  for three of the trailing four quarters  Let s see how things are shaping up for this announcement 
Factors at Play
LabCorp s top line performance continues to be affected by softness in its Covance Drug Development business  as was the case in the last reported quarter as well  The weak performance was led by sluggish early development and central lab businesses  which were affected by a slower revenue conversion from backlog and cancellation by sponsors of two large clinical studies in 2016  Also  adverse foreign exchange rates affected the numbers to the tune of 140 basis points  bps  at this segment 
Meanwhile  we are upbeat about the company s expectations of an improvement in the Covance Drug Development arm starting the second half of 2017  This should get reflected in the third quarter performance 
Over the last two years  LabCorp has faced several reimbursement issues that have dented its revenues  The company is concerned about the CMS  Centers for Medicare   Medicaid Services  proposal related to Protecting Access to Medicare Act  PAMA   We believe reimbursement pressure will affect the company s performance in the soon to be reported quarter as well 
Laboratory Corporation of America Holdings Price and EPS Surprise
 
 
   Notably  the company are not positive about the latest Centers for Medicare and Medicaid Services  CMS  publication of proposed 2018 Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule  CLFS   However  this will most likely have no impact on its third quarter results 
Unfavorable foreign exchange continues to be a pressing concern for the company  Previously  LabCorp had anticipated an approximate 40 bps negative currency impact on 2017 revenues  The company currently expects a 20 bps impact from adverse foreign exchange on net revenue at Covance Drug Development in 2017 
LabCorp has been continuously grappling with the issue of rising operating expenses which has affected its margins in the last reported quarter  Also  the chances of a turnaround in the scenario any time soon are slim 
Meanwhile  on a positive note  LabCorp is focusing on research and development in collaboration with academic institutions in order to gain traction in the growing lab testing market  In July 2017  LabCorp launched ADAMTS13 test to distinguish diseases characterized by life threatening  acute thrombotic microangiopathy  TMA   Also  in May  company expanded its VistaSeq Hereditary Cancer portfolio through the addition of 10 new test panels with focus on the risk of specific hereditary cancer syndromes 
LabCorp recently teamed up with Walgreens Boots Alliance  Inc    NASDAQ WBA   to set up specimen collection service stations at various Walgreens stores across the United States  The company also expanded its reach by closing the acquisition of Mount Sinai Health System Clinical Outreach Laboratories in May 2017  LabCorp s highly differentiated portfolio will be used by the existing customers of Mount Sinai  These developments are expected to boost the top line in the third quarter 
LabCorp s companion diagnostics portfolio  which grew a robust 35  in the last couple of years  should maintain its momentum in 2017 
Earnings Whispers
Our proven model does not conclusively show that LabCorp is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below 
Zacks ESP   LabCorp has an Earnings ESP of  1 84   This is because the Most Accurate estimate is pegged at  2 35 and the Zacks Consensus Estimate stands at  2 40  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  LabCorp has a Zacks Rank  2 which increases the predictive power of ESP  However  we also need to have a positive ESP to be confident of a positive earnings surprise 
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter 
The Cooper Companies  Inc    NYSE COO   has an Earnings ESP of  0 43  and a Zacks Rank  2  You can see  
Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 67  and a Zacks Rank  3 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-20,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-labcorp-lh-this-earnings-season-200220098,200220098
9710,231225,LH,LabCorp s  1 2 Billion Chiltern Buyout Gets FTC Approval ,opinion,Healthcare diagnostics company Laboratory Corporation of America Holdings   NYSE LH   or LabCorp continues to expand through inorganic means  Apart from huge buyouts like Covance  the company is on a steady spree to add complementary capabilities via strategic mergers Following the company s announcement to acquire analytical testing services business of ChromaDex Corp    NASDAQ CDXC   last week  LabCorp is again on the headlines with the earlier announced impending acquisition of Chiltern International Group Limited  a specialty CRO  contract research organization  Per the company sources  the Federal Trade Commission  FTC  has granted its request for early termination of the waiting period for Chiltern s buyout under the Hart Scott Rodino Antitrust Improvements Act of 1976  HSR Act   The closing of the acquisition is expected on or around Sep 1  2017 and is still subject to other customary closing conditions Notably  last month  LabCorp had entered into a definitive agreement with Chiltern s shareholders to purchase the company for an all cash transaction value of  1 2 billion approximate  Per LabCorp  the consolidation will strengthen its position in innovative diagnostics and drug development solutions The buyout of Covance has already demonstrated the value of combining diagnostics with CRO capabilities  With this  LabCorp s CRO business has grown to nearly  3 billion in annual revenues Chiltern s addition is expected to further promote this development and will also provide LabCorp with enhanced capabilities across a broader client base  The combined entity will have approximately 11 100 employees in the Americas   7 100 in Europe  the Middle East and Africa  while 2 400 in Asia Pacific With the closure of the transaction  Chiltern will become a part of LabCorp s Covance segment  The former s integration will enhance the latter s offerings  Chiltern will be a major partner serving the top 20 biopharma segments and assist LabCorp to focus on the high growth emerging and mid market biopharma segments Last three months  LabCorp has been trading above the broader   Over this period  the stock has rallied 10 5  as against the industry s 0 9  loss Zacks Rank   Key Picks         LabCorp carries a Zacks Rank  3  Hold   Two better ranked medical stocks are IDEXX Laboratories  Inc    NASDAQ IDXX   and Edwards Lifesciences Corporation   NYSE EW    Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   while IDEXX Laboratories carries a Zacks Rank  2  Buy   You cansee IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock has gained around 6 2  over the last six months Lantheus Holdings has a long term expected earnings growth rate of 12 5   The stock has surged 34 9  over the last six months Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has rallied roughly 19 1  over the last six months More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2017-08-27,Zacks Investment Research,https://www.investing.com/analysis/labcorps-12-billion-chiltern-buyout-gets-ftc-approval-200209876,200209876
9711,231226,LH,LabCorp   Interpace Extend Deal  Boost Cancer Portfolio,opinion,Leading diagnostics testing company  Laboratory Corporation of America Holdings   NYSE LH   agreement with Interpace Diagnostics Group  Inc   IDXG  has been renewed and extended  Per the extended deal  the agreement will be deemed valid till January 2019  after the successful initial phase As per the press release  Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services to evaluate the risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management  LabCorp had originally entered into an agreement in January 2016 to offer Interpace Diagnostics  molecular tests   ThyGenX and ThyraMIR ThyGenX and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules  In simpler words  the tests provide the latest technology for the diagnosis of thyroid cancer in indeterminate thyroid nodules patients According to a report by Market Data Forecast  the Thyroid Cancer Market is estimated to reach a worth of  544 24 million by 2021  at a CAGR of 25 45   Considering the bountiful opportunities in this niche space  we believe this is a strategic move by the company Of late  LabCorp has been taking strategic initiative to specialize tests  It recently started offering a new proprietary ADAMTS13 test to distinguish diseases characterized by life threatening  acute thrombotic microangiopathy  TMA   Notably  TMA is relatively rare but serious syndrome  In TMA  small blood vessels develop blood clots  which result in the mechanical destruction of red blood cells The company also announced the availability of the PreTRM test in the United States  The PreTRM test is developed by Sera Prognostics  Inc It is the only validated blood test that offers an early and individualized prediction of preterm birth risk in pregnant women Further  LabCorp announced a significant enhancement to its proprietary VistaSeq Hereditary Cancer portfolio  with ten new test panels focusing on the risk of specific hereditary cancer syndromes In majority of the last three months  LabCorp has been trading above the broader   Over this period  the stock has gained 10 6  as against the industry s decline of 1 2   Zacks Rank   Key PicksLabCorp carries a Zacks Rank  3  Hold   A few better ranked medical stocks are IDEXX Laboratories  Inc    NASDAQ IDXX   and Lantheus Holdings  Inc    NASDAQ LNTH   and Edwards Lifesciences Corporation   NYSE EW    Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank  2  Buy   You cansee Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has rallied roughly 20 4  over the last six months Lantheus Holdings has a long term expected earnings growth rate of 12 5   The stock has gained 26 9  over the last six months IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock has gained around 2 3  over the last six months Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-28,Zacks Investment Research,https://www.investing.com/analysis/labcorp--interpace-extend-deal-boost-cancer-portfolio-200210139,200210139
9712,231227,LH,LabCorp Grows On Solid Diagnostics  Currency Woes A Drag,opinion,On Aug 28  we issued an updated research report on Burlington  NC based Laboratory Corporation of America Holdings   NYSE LH    popularly known as LabCorp  The company is a major player in healthcare diagnostics space  providing comprehensive clinical laboratory services and end to end drug development support Last three months  LabCorp has been trading above the broader   The stock has surged 10 6  as against the industry s 1 2  loss during this period  Despite the continued dull performance within the company s Covance drug development business  the market is upbeat about the Diagnostics business which has successfully demonstrated a solid show over the recent past Although Covance Drug Development s financial performance was down year over year in the recently reported second quarter 2017  the company is currently on track to achieve its target of  100 million in cost synergies through the three year period ending in 2017  It has also completed the remaining consolidation of central lab facilities in Europe and the United States Notably  the company s strategic focus on women s health and reproductive genetics  besides the acquisition of Sequenom  a leader in non invasive prenatal testing  has reenergized its larger genetic testing portfolio within Diagnostics  Also the market is looking forward to the long standing strategic collaboration with 23andMe  which has already demonstrated an impressive growth trajectory  providing further strategic collaboration opportunities On the flip side  an unfavorable foreign exchange remains a drag of late  The reduced guidance for 2017 also fails to indicate chances of any respite soon  There is also apprehension about a tough reimbursement scenario which the company is already facing to some degree Zacks Rank   Key PicksLabCorp carries a Zacks Rank  3  Hold   A few better ranked medical stocks are IDEXX Laboratories  Inc    NASDAQ IDXX    Lantheus Holdings  Inc    NASDAQ LNTH   and Edwards Lifesciences Corporation   NYSE EW    Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank  2  Buy   You cansee IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock has gained around 2 3  over the last six months Lantheus Holdings has a long term expected earnings growth rate of 12 5   The stock has surged 26 9  over the last six months Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has rallied roughly 20 4  over the last six months Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-28,Zacks Investment Research,https://www.investing.com/analysis/labcorp-grows-on-solid-diagnostics-currency-woes-a-drag-200210216,200210216
9713,231228,LH,Alexandria Real Estate  ARE  Down 2 1  Since Earnings Report  Can It Rebound ,opinion,"About a month has gone by since the last earnings report for Alexandria Real Estate Equities  Inc    NYSE ARE    Shares have lost about 2 1  in the time frame  underperforming the market 
Will the recent negative trend continue leading up to the stock s next earnings release  or is it due for a breakout  Before we dive into how investors and analysts have reacted of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts 
Alexandria Real Estate Equities Reports In Line Q2 FFOAlexandria reported second quarter 2017 adjusted FFO of  1 50 per share  The figure came in line with the Zacks Consensus Estimate  Moreover  adjusted FFO per share compares favorably with the prior year quarter tally of  1 36 Results reflect robust growth in rental rate and strong leasing metrics  driven by higher internal and external growth Total revenue for the quarter jumped 20 8  year over year to  273 million  In addition  the figure handily surpassed the Zacks Consensus Estimate of  253 million Behind the Headline NumbersAlexandria s total leasing activity aggregated around 1 1 million RSF during the quarter  The company carried out lease renewals and re leasing of space at a rental rate increase of 23 2  and 9 4   cash basis  in the reported quarter  Moreover  key leases executed in the quarter included 163 648 RSF leased to Takeda Pharmaceutical Company Ltd   and 109 780 RSF lease renewed with Laboratory Corporation of America  NYSE LH  On a year over year basis  same property net operating income  NOI  inched up 1 8   It climbed 7  on a cash basis  As of second quarter 2017  occupancy for operating properties in North America was 95 7  As of second quarter 2017  investment grade tenants accounted for 51  of annual rental revenue in effect  Furthermore  79  of the annual rental revenue is from Class A properties in AAA locations LiquidityAlexandria exited second quarter 2017 with cash and cash equivalents of  124 9 million  down from  151 2 million recorded at the end of the prior quarter  The company ended the reported quarter with  1 8 billion of liquidity 
How Have Estimates Been Moving Since Then 
Following the release  investors have witnessed an upward trend in fresh estimates  There have been two revisions higher for the current quarter compared to one lower 
Alexandria Real Estate Equities  Inc  Price and Consensus    VGM Scores
At this time  Alexandria Real Estate s stock has a subpar Growth Score of D  However  its Momentum is doing a lot better with an A  The stock was allocated a grade of F on the value side  putting it in the bottom 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
The company s stock is suitable solely for momentum investors based on our style scores 
Outlook
Estimates have been trending upward for the stock  The magnitude of these revisions also looks promising  Notably  the stock has a Zacks Rank  3  Hold   We expect in line returns from the stock in the next few months ",2017-08-31,Zacks Investment Research,https://www.investing.com/analysis/alexandria-real-estate-are-down-21-since-earnings-report-can-it-rebound-200210675,200210675
9714,231229,LH,LabCorp Completes  1 2 Billion Chiltern Buyout  Boosts CRO ,opinion,Laboratory Corporation of America Holdings   NYSE LH   or LabCorp recently announced the successful closure of the acquisition of Chiltern International Group Limited  a specialty CRO  contract research organization   Earlier  the company had entered into a definitive agreement with Chiltern s shareholders to purchase the company for an all cash transaction valued at roughly  1 2 billion LabCorp expects Chiltern to generate 2017 revenues of roughly  550 million and adjusted earnings before interest  taxes  depreciation and amortization of around  95 million  Excluding transaction related one time costs and cost synergies  LabCorp expects this deal to boost adjusted earnings and free cash flow in the first year and help earn cost of capital by the third year Post acquisition  Chiltern will form part of LabCorp s Covance Drug Development segment  Per management  Chiltern will be a major partner serving the top 20 biopharma segments and helping LabCorp focus on the high growth emerging and mid market biopharma segments  Per LabCorp  the buyout is expected to strengthen its position in innovative diagnostics and drug development solutions We encouragingly note that the new combined entity will have approximately 11 100 employees in the Americas   7 100 in Europe  the Middle East and Africa  and 2 400 in the Asia Pacific LabCorp has been consistently on the headlines owing to the Chiltern buyout deal  Earlier  the company had announced that the Federal Trade Commission  FTC  has granted its request for early termination of the waiting period for Chiltern s buyout under the Hart Scott Rodino Antitrust Improvements Act of 1976  HSR Act  Moreover  apart from the substantial buyouts like Covance  LabCorp has been consistently enhancing and adding capabilities via strategic mergers  In this regard  the company recently announced plans to acquire the analytical testing services business of ChromaDex Corporation   NASDAQ CDXC    The company also announced the renewal and extension of agreement with Interpace Diagnostics Group  Inc    NASDAQ IDXG   aimed at boosting its cancer portfolio Moreover  over the last three months  LabCorp has been trading above the broader   Over this period  the stock has rallied 12 6  as against the industry s 2 6  decline  We believe the Chiltern buyout will help the stock scale higher  Zacks Rank   Key PickLabCorp carries a Zacks Rank  3  Hold   A better ranked medical stock is Edwards Lifesciences Corporation   NYSE EW   sporting a Zacks Rank  1  Strong Buy   You can see Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has rallied roughly 26  over the last six months Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-09-04,Zacks Investment Research,https://www.investing.com/analysis/labcorp-completes-12billion-chiltern-buyout-boosts-cro-200211352,200211352
9715,231230,LH,LabCorp To Add ChromaDex s Arm  Inorganic Expansion On Track,opinion,Healthcare diagnostics company Laboratory Corporation of America Holdings   NYSE LH   or LabCorp successfully continues to expand through acquisition strategy  Apart from huge buyouts like Covance  the company continues to add complementary capabilities through targeted tuck in mergers Latest on the list is the company s agreement to purchase the analytical testing services business of ChromaDex Corp   CDXC   The transaction is expected to complete in early September  This newly acquired entity will become part of LabCorp s Covance Food Solutions business Notably  ChromaDex is a natural product company working on health  wellness and nutritional ingredients  creating science based solutions for dietary supplement  food and beverage  skin care  sports nutrition and pharmaceutical products Although both the companies haven t disclosed the deal s financial terms through press release  per a report by American City Business Journals  the deal value has been fixed at  8 5 million  Per this report   Covance will buy the analytical testing business for  7 5 million  Under the agreement  ChromaDex is also able to receive an earnout payment of up to  1 million  according to a filing with the Securities and Exchange Commission  It is important to make a note of LabCorp s  5 6 billion mega buyout of Covance by virtue of which  the company is full on force to expand a range of diagnostic offerings and create a new industry leader in both laboratory testing and CRO  contract research organization  spaces  slated to act as a leading provider of medical testing besides operating as a premier full service drug development organization Per the company  Covance Drug Development is the only CRO  providing full spectrum of drug development capabilities   from research to real world evidence studies   creating commercial and scientific advantage for LabCorp s partners Apart from Covance  another recent significant buyout is Sequenom  a prominent player in the field of non invasive prenatal testing  NIPT  for reproductive health  Sequenom s NIPT and genetic testing capabilities has further added an impetus to LabCorp s extensive women s health test menu  This inclusion has also expanded the company s geographic reach both domestically and internationally  particularly in the EU and Asia Pacific region  In May  the company acquired Pathology Associates Medical Laboratories  PAML  from former owners Providence Health   Services  Providence  and Catholic Health Initiatives  CHI   PAML is one of the nation s premier medical reference laboratories and a healthcare solutions company  All these acquisitions are consistent with the company s efforts to strengthen foothold in the personalized diagnostics testing market Last three months  LabCorp has been trading above the broader   Over this period  the stock has gained 9 2  as against the industry s 1 1  loss Zacks Rank   Key PicksLabCorp currently has a Zacks Rank  3  Hold   A few better ranked medical stocks are Edwards Lifesciences Corporation   NYSE EW    Lantheus Holdings  Inc    NASDAQ LNTH   and IDEXX Laboratories  Inc    NASDAQ IDXX    While Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank  2  Buy   You can see Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has rallied around 20 5  over the last six months Lantheus Holdings has a long term expected earnings growth rate of 12 5   The stock has surged 28 5  over the last six months IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock has gained roughly 6 8  over the last six months One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-23,Zacks Investment Research,https://www.investing.com/analysis/labcorp-to-add-chromadexs-arm-inorganic-expansion-on-track-200209407,200209407
9725,231240,LH,Should Value Investors Pick Laboratory Corporation  LH  Stock ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Laboratory Corporation of America Holdings   NYSE LH   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Laboratory Corporation has a trailing twelve months PE ratio of 16 6  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 20 5  If we focus on the stock s long term PE trend  the current level puts Laboratory Corporation s current PE ratio slightly above its midpoint  which is 15 3  over the past five years Further  the stock s PE also compares favorably with the industry s trailing twelve months PE ratio  which stands at 19 5  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Laboratory Corporation has a forward PE ratio  price relative to this year s earnings  of just 15 7  so it is fair to say that a slightly more value oriented path may be ahead for Laboratory Corporation s stock in the near term too   P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Laboratory Corporation has a P S ratio of about 1 6  This is substantially lower than the S P 500 average  which comes in at 3 2 right now  Also  as we can see in the chart below  this is slightly below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Laboratory Corporation currently has a Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes LH a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for Laboratory Corporation is just 1 7  a level that is noticeably lower than the industry average of 2 2  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Additionally  its P CF ratio  another great indicator of value  comes in at 10 9  which is somewhat better than the industry average of 12 8  Clearly  LH is a solid choice on the value front from multiple angles What About the Stock Overall Though Laboratory Corporation might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of B and a Momentum score of B  This gives LH a VGM score or its overarching fundamental grade of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen three estimates go higher in the past sixty days and four lower  while the full year estimate has seen ten upward and two downward revisions in the same time period This has had a noticeable impact on the consensus estimate  as the current quarter consensus estimate has fallen about 1 2  in the past two months  while the full year estimate has inched up 0 2   You can see the consensus estimate trend and recent price action for the stock in the chart below Laboratory Corporation of America Holdings Price and Consensus    This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineLaboratory Corporation is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  bottom 32  out of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past one year  the sector has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates  analyst sentiment and broader factors to turn favorable in this name first  but once that happen  this stock could be a compelling pick Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-01,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-pick-laboratory-corporation-lh-stock-200216487,200216487
9726,231241,LH,LabCorp  LH  Strong On Strategic Planning  Competition Rife,opinion,"On Oct 10  we issued an updated research report on Laboratory Corporation of America Holdings   NYSE LH    popularly known as LabCorp  The stock currently carries a Zacks Rank  2  Buy  
Over the last three months  this Burlington  NC based healthcare diagnostics company  providing comprehensive clinical laboratory services and end to end drug development support  has been outperforming the broader   The stock has lost 2  as compared with the industry s 4 4  decline during this period  The market seems to be upbeat about the Diagnostics business  which has delivered promising performance over the recent past in spite of persistent softness within the company s Covance drug development business 
We are also encouraged by the successful closure of the acquisition of Chiltern International Group  a specialty contract research organization Chiltern is a major partner serving the top 20 biopharma segments  helping the company focus on the high growth emerging and mid market biopharma segments 
 

 
Notably  LabCorp is steadily progressing on its three pronged strategy to drive growth  First  the company is focusing on research and development in collaboration with academic institutions in order to gain traction in the growing lab testing market 
Second  LabCorp is increasingly deploying its integrated testing capabilities  industry leading science and innovative technology offerings to establish strategic partnerships with providers  Moreover  investors are looking forward to the long standing strategic collaboration with 23andMe  which has already demonstrated an impressive growth trajectory 
Third  LabCorp s core diagnostic strategy is based on innovation in data integration and in tools to support enhanced connectivity  reporting and decision support  The company is also focusing on extending its core testing capabilities beyond the traditional health care setting  On the flip side  unfavorable foreign exchange is a threat  Moreover  the company operates in a tough competitive landscape  Meanwhile  apprehensions about a tough reimbursement scenario intensifies concerns for the company 
Other Key Picks
Other top ranked stocks in the medical sector are QIAGEN   NASDAQ QGEN    IDEXX Laboratories  Inc    NASDAQ IDXX   and Thermo Fisher Scientific Inc    NYSE TMO    QIAGEN  IDEXX Laboratories and Thermo Fisher carry a Zacks Rank  2  You can see 
QIAGEN has a long term expected earnings growth rate of 13 1   The stock has rallied roughly 31 9  last year 
IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock has gained 42 8  last year 
Thermo Fisher has a long term expected earnings growth rate of 11 7   The stock has gained 27 2  last year Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-11,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-strong-on-strategic-planning-competition-rife-200218396,200218396
9727,231242,LH,5 MedTech Momentum Picks Investors Will Love,opinion,The MedTech space received a sudden jolt on late night Thursday when White House pulled the plug on Obamacare subsidies that reduce health care costs for Americans with low incomes  This comes as no surprise for the lukewarm response to its replacement  The American Health Care Act  AHCA   has forced Republicans to continue to seek new avenues  In a bid to save its face  the Trump administration attempted a  skinny  repeal bill along with a Graham Cassidy bill  which failed to make any headway in the senate We believe that the impasse is slated to continue as President Trump has always been an outspoken critic of the ACA  Our apprehension comes from the uncertainty regarding the outcome of a slew of events  This includes the possibility of a rate hike by the Fed  a stronger dollar  and the stance of healthcare insurance companies over ACA  These are expected to spark bouts of volatility As of now  plenty of speculation has been made regarding the extent of interest rate hike by the Fed before the end of the year  Though  the Federal Reserve officials remained largely divided over raising interest rates  majority of the bankers vouched in favor of raising rates  The ones debating against increasing rates stated that hiking rates at a time when inflation is lower than the target of 2    an indication of a healthy economy   might cause major setbacks to the U S  economy  However  investors may also feel that  even if Fed decides to increase rate  it will hardly have any impact over the long term Nevertheless  it would be foolish to claim that volatility has vanished from the market  just because the global market has started to recover since yesterday  No doubt  such market uncertainty has made investors increasingly cautious about spending on stocks Interestingly in this phase of massive global sell offs  the MedTech sector has not only held its own  but also maintained a stable uptrend  This is based on some of its powerful long term tailwinds  including mergers   acquisitions  emerging market expansion  positive demographic trends and innovation of new products In fact a closer look at this sector s history will reveal the companies  undaunting spirit to expand their business whatever the market scenario is  Despite political conundrum over Obamacare  we have witnessed some big cross border mergers in recent times like the impending take over of C R  Bard Inc   NYSE BCR   by Becton  Dickinson and Company   NYSE BDX   What s the Rewarding Strategy   We believe investors can earn handsome profits by extrapolating the current bullish trends of the market into the future  Henceforth  seeking refuge in momentum investment strategy is a strategic investment gamble at this moment However  picking the right momentum stocks may baffle seasoned investors  let alone the new ones  who are planning to enter the uncharted world of jam packed trades Here  at Zacks  we use our  to single out stocks which can aid in beating the market The Zacks  indicates when the timing is best to grab a stock and take advantage of its momentum with the highest probability of success Our PicksAmid the present volatility across the global economy  we have found a handful of top Zacks Rank momentum stocks for you from the Medical Devices space that are going to gain from this share market turbulence  With a Style Score of B or better combined with favorable Zacks Rank  1  Strong Buy  or 2  Buy   these stocks are looking especially impressive right now  Below we have cited 5 stocks that are worth a look before you invest Steris Plc   NYSE STE    The company  based in Ohio  develops  manufactures and markets infection prevention  decontamination  microbial reduction  and surgical and gastrointestinal support products and services  You can see   The metrics that make this leading scientific instrument provider all the more desirable are     Momentum Score of B    Zacks Rank  2    Market Cap   7 70 billionLaboratory Corporation of America Holdings   NYSE LH    LabCorp is a leading healthcare diagnostics company  headquartered in Burlington  NC  providing comprehensive clinical laboratory services and end to end drug development support  The metrics that make the company more attractive are     Momentum Score of A       Zacks Rank  2    Market Cap   15 44 billionFresenius Medical Care Corporation   NYSE FMS    Fresenius Medical Care  FMS   based in Bad Homburg  Germany  is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure  The metrics that make this company all the more desirable are     Momentum Score of B    Zacks Rank  2    Market Cap   30 13 billionQuidel Corporation   NASDAQ QDEL    Quidel  based in San Diego  CA  discovers  develops  manufactures and markets point of care  rapid diagnostic tests for detection of medical conditions and illnesses  These products provide accurate  rapid and cost effective diagnostic information for acute and chronic conditions that affect women s health throughout the phases of their lives including reproductive status  pregnancy management and osteoporosis  The metrics that make Quidel an attractive choice are     Momentum Score of B    Zacks Rank  2    Market Cap   1 44 billionConforMIS Inc    NYSE FMS    The medical technology company  based in Bedford  MA   develops  manufactures and sells joint replacement implants  The company s iFit technology platform consists of iFit Design  iFit Printing and iFit Just in Time Delivery  The company serves orthopedic surgeons  hospitals and other medical facilities and patients  The metrics that make the company more attractive are     Momentum Score of B    Zacks Rank  2    Market Cap   185 17 MillionBottom LineYou can find stocks with good momentum scores any time of the year  but the present market scenario makes the task a little difficult  All of the aforementioned stocks may not be big  but they can certainly make an impact in the MedTech sector  If the worldwide bullish market continues for a few more days  these stocks have a high chance of performing well in the near future   4 Stocks to Watch after the Massive Equifax  NYSE EFX  HackCybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans  But which stocks are the best buy candidates right now  And what does the future hold for the cybersecurity industry Equifax is just the most recent victim  Computer hacking and identity theft are more common than ever  Zacks has just released Cybersecurity  An Investor s Guide to inform Zacks com readers about this  170 billion year space  More importantly  it highlights 4 cybersecurity picks with strong profit potential ,2017-10-12,Zacks Investment Research,https://www.investing.com/analysis/5-medtech-momentum-picks-investors-will-love-200218708,200218708
9729,231244,LH,LabCorp Partners OmniSeq To Grow In Immuno Oncology Space,opinion,"Leading healthcare diagnostics company Laboratory Corporation of America Holdings   NYSE LH   or LabCorp recently inked a distribution agreement with Roswell Park Cancer Institute s molecular diagnostics subsidiary  OmniSeq  Inc Per the deal terms  LabCorp will distribute OmniSeq s Immune Report Card and OmniSeq Comprehensive clinical assays across the United States and outside The company will get an exclusive right to distribute these OmniSeq tests to U S  based physicians through Integrated Oncology  a member of the LabCorp Specialty Testing Group  and globally to biopharmaceutical customers via its Covance Drug Development arm Laboratory Corporation of America Holdings Price
    Also  the chief scientific officer of LabCorp Diagnostics  Marcia Eisenberg  will join OmniSeq s board of directors  Plus  LabCorp has plans to participate in OmniSeq s Series B financing round  This financing will be used to conduct OmniSeq s ongoing retrospective and prospective clinical trials as well as to generate further evidence of the clinical utility of OmniSeq s comprehensive genomic and immune profiling services Notably  Immune Report Card is a comprehensive immune profiling test  designed to inform oncologists regarding checkpoint inhibitor  CPI  treatment decisions  This combines results for all common biomarker assays relevant to checkpoint inhibitors as well as other informative analyses  Per OmniSeq  this assessment will provide a comprehensive immune profile to help in identifying 20 40  patients  who are likely to respond to CPI monotherapy On the other hand  OmniSeq Comprehensive assay is a 144 gene  pan cancer  next generation sequencing tumor profiling diagnostic panel  It helps oncologists to determine a particular line of treatment Considering the fact that both Immune Report Card and OmniSeq Comprehensive trials have received the New York State s Clinical Laboratory Evaluation Program s approval  we expect this alliance to help LabCorp broaden its customer base in cancer immunotherapy diagnostics space  Notably  this market is growing in leaps and bounds in recent times Per the data provided by Radiant Insights  Inc  as published in Cision PR Newswrites  global cancer immunotherapies market is expected to witness a CAGR of 23 9  by 2022  Hence  we believe LabCorp s latest decision to widen its position in this market is perfectly strategic As part of its key tactical plans  LabCorp is consistently working hard on new innovations with academic institutions to capture the growing lab testing market with its advanced assays and tools During the second quarter of 2017  the company has opened a state of the art companion diagnostics laboratory in North Carolina and delivered a double digit increase in year over year revenues aided by continued growth in immuno oncology services The company also won  100 million in companion diagnostic related awards during the first half of the year  Its pipeline comprises a diverse range of oncology and non oncology indications with new and established clients that might position it well for consistent growth in the future LabCorp s latest partnership with OmniSeq as well as its decision to invest for latter s research and development should add further momentum to the company s growth trajectory Zacks Rank   Key PicksLabCorp currently carries a Zacks Rank  3  Hold   Some better ranked medical stocks are Edwards Lifesciences Corp    NYSE EW    Lantheus Holdings  Inc    NASDAQ LNTH   and Stryker Corporation   NYSE SYK    While Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   Lantheus Holdings and Stryker carry a Zacks Rank  2  Buy   You can see Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has climbed around 19 4  over the last six months Lantheus Holdings has a long term expected earnings growth rate of 12 5   The stock has surged 28 6  over the last six months Stryker Corporation has a long term expected earnings growth rate of 10 00   The stock has rallied roughly 12 8  over the last six months ",2017-08-21,Zacks Investment Research,https://www.investing.com/analysis/labcorp-partners-omniseq-to-grow-in-immunooncology-space-200208740,200208740
9730,231245,LH,Factors Setting Stage For CVS Health s  CVS  Q1 Earnings,opinion,"CVS Health   NYSE CVS   is scheduled to report first quarter 2018 results on May 2  before the opening bell  In the last reported quarter  the company delivered a positive earnings surprise of 1 6   Its trailing four quarter average positive earnings surprise is 2 5  
Let s take a look at how things are shaping up prior to this announcement 
Factors at Play
CVS Health has so far progressed well with its 2018 PBM selling season  Per the last reported numbers  gross new business wins totaled  6 2 billion while net new business wins grossed  2 4 billion along with an impressive client retention rate  This momentum is expected to continue in the to be reported quarter 
Despite tough pricing competition  CVS health is currently gaining on high level of service and execution  competitive pricing along with unique integrated model 
The company is also upbeat about sustaining the solid year over year earnings trend in the first quarter of 2018 on gains to be realized from the Pharmacy Services segment  The performance is being driven by higher specialty pharmacy and pharmacy network claim volumes as well as brand inflation 
Management stated that CVS Health s specialty business is its top priority to help the company expand its customer base  CVS Health is poised to capitalize on this opportunity on the back of wide and differentiated offerings  including Specialty Connect 
CVS Health Corporation Price and EPS Surprise
   Further  the company expects drug price inflation  product launches and higher utilization to fuel growth  We expect the Pharmacy Services segment to be a stable growth platform 
CVS Health also projects better than expected performance in the to be reported quarter primarily on the back ofscript utilization at retail  The company has projected a 1 5 3 25  rise in consolidated net revenues for the first quarter 
Further  a strong flu season has led to the improved outlook  Overall  for the first quarter of 2018  the company expects to register adjusted operating profit growth in the range of 0 5  to 4 5   The Zacks Consensus Estimate for total revenues of  45 82 billion reflects a 2 9  increase year over year 
Although CVS Health s Retail LTC business registered revenue growth after several quarters of a slump in the last reported quarter  there are multiple factors raising concerns  Firstly  the year over year growth was just a marginal 0 3  
Further  continued reimbursement pressure  increasing generic dispensing rate andrecent generic drug introductions have been affecting the business  This apart  marketplace changes that kept CVS Pharmacy from participating in certain networks had a 320 basis point negative impact on same store prescription volumes in the previously reported quarter 
However  CVS Health has been striving to return to growth in the Retail LTC business  Management claims that the company is focused on working with all payers to drive volumes and capture market share  CVS Health is also poised to gain from programs such as Health Tag and ExtraCare Health Card 
The company also expects to witness revenue growth of 4  to 5 5  and operating profit growth in the low to mid single digits range  within the Retail LTC business 
Here is What Our Quantitative Model Predicts 
Our proven model does not conclusively show that CVS Health will beat estimates this earnings season  This is because a stock needs to have both a positive  and a solid Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here  as you will see below 
Zacks ESP   CVS Health has an Earnings ESP of  1 94   You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  CVS Health carries a Zacks Rank  4  Sell  
Please note that stocks with a Zacks Rank  4 or 5  Strong Sell  should never be considered going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Meanwhile  the Zacks Consensus Estimate for first quarter adjusted EPS of  1 40 reflects a 19 7  increase year over year 
Stocks to Consider
Here are a few medical stocks worth considering with the right combination of elements to beat estimates this time around 
Laboratory Corporation of America Holdings   NYSE LH   has an Earnings ESP of  1 52  and a Zacks Rank  2 
Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  2 53  and a Zacks Rank  3 
Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  2 96  and is a Zacks  3 Ranked player 
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/factors-setting-stage-for-cvs-healths-cvs-q1-earnings-200308051,200308051
9731,231246,LH,Medical Product Stock Earnings Roster For Apr 25  LH   More,opinion,"The first quarter earnings season saw a starry start with most of the 87 S P 500 members beating earnings and maintaining revenue momentum as of Apr 20  However  the number of positive revenue surprises is lagging the preceding year s numbers but is on par with the sequential figures Per the latest   total earnings for the companies that have reported so far are up 25  year over year on 10 7  higher revenues  Of the total  82 8  beat earnings and 67 8  surpassed revenue estimates  This week  178 S P 500 members are lined up to release their quarterly results  We expect to get a clearer picture of what the first quarter earnings season has in the offing by the end of the week Medical Sector in a Snapshot  one of the 16 Zacks sectors  is expected to stand out this quarter  The sector benefits from favorable consumer behavior  growing prevalence of minimally invasive surgeries  demand for liquid biopsy tests  use of IT for ensuring quick and improved patient care along with the shift of the payment system to a value based model Broadly speaking  the latest Tax Cuts and Jobs Act  which among many other changes  slashed corporate tax rates to 21  from the earlier 35   has also buoyed optimism among inventors The Medical Product space  which is part of the broader Medical sector  has been hogging a lot of limelight on certain favorable developments  Considering favorable demographics  changing market dynamics toward Artificial Intelligence  AI    big data applications  upbeat consumer sentiment and increased business investments  this sector has been going strong Further  the Senate s decision to defer the implementation of an industry wide excise tax for another couple of years  known as the Medical Device tax  has instilled confidence in investors  The tax will be put into effect on Jan 1  2020  The bill also delays the so called Cadillac tax  a 40  tax on employer insurance  until 2022 Moreover  MedTech companies have been riding high on R D innovation  growing consolidation and focus on emerging market Against this backdrop  let s take a look at the major Medical Product stocks scheduled to release results on Apr 25 Per the quantitative Zacks model  stocks with the advantageous combination of a solid Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  and a positive  have higher chances of beating estimates  You can uncover the best stocks to buy or sell before they re reported with our  Laboratory Corporation of America Holdings   NYSE LH   or LabCorp s first quarter 2018 results are expected to reflect gains from a strong LabCorp Diagnostics segment  favorable price and mix  tuck in acquisitions along with organic volume The Zacks Consensus Estimate for earnings is pegged at  2 64  which indicates 18 92  year over year growth Further  we predict an earnings beat in the quarter as LabCorp has a Zacks Rank  2 and Earnings ESP of  1 52    Read more     You can see The stock surpassed the Zacks Consensus Estimate in all of the trailing four quarters  with an average beat of 2 9  as reflected in the chart below 
Laboratory Corporation of America Holdings Price and EPS Surprise
    Thermo Fisher Scientific Inc  s   NYSE TMO   has been progressing well with its analytical instrument businesses on rising global demand  The company s focus on growth through implementation of strategies and consolidation of product offerings is encouraging  These initiatives are likely to reflect in the first quarter 2018 results The Zacks Consensus Estimate for earnings is pegged at  2 42  which shows 16 35  year over year growth However  it is difficult to conclusively predict an earnings beat as Thermo Fisher has a Zacks Rank  3 and Earnings ESP of  1 92    Read more    The stock surpassed the Zacks Consensus Estimate in all of the last four quarters  the average beat being 3 1  as seen in the chart below 
Thermo Fisher Scientific Inc  Price and EPS Surprise
    Boston Scientific Corporation   NYSE BSX   has been gradually witnessing improving performance by Interventional Cardiology  IC   led by an innovative portfolio and efficient commercial teams globally  The WATCHMAN platform is set to see another stellar first quarter 2018 on consistent global momentum as Boston Scientific s efforts continue to drive growth The Zacks Consensus Estimate is pegged at 31 cents  which indicates 6 9  year over year growth Our model shows an earnings beat for Boston Scientific as it has a Zacks Rank  3 and Earnings ESP of  0 05    Read more    The stock beat the Zacks Consensus Estimate in one of the trailing four quarters  the average beat being a negative 0 03  as shown in the chart below 
Boston Scientific Corporation Price and EPS Surprise
    Align Technology  Inc  s   NASDAQ ALGN   first quarter 2018 results are likely to reflect gains from continued adoption of Invisalign Technology and a strong Scanner and Service business The Zacks Consensus Estimate for earnings is pegged at 98 cents  which reflects 15 3  year over year improvement We foresee a beat as Align Technology has a Zacks Rank  3 and Earnings ESP of  2 96    Read more    The stock trumped the Zacks Consensus Estimate in all of the trailing four quarters  with the average beat being 22 6  as seen in the chart below 
Align Technology  Inc  Price and EPS Surprise
    Varian Medical Systems Inc  s   NYSE VAR   favorable revenue opportunity from various Oncology and Imaging Component products  growing adoption of Proton Therapy and strong overseas presence are likely to have influenced the company s second quarter fiscal 2018 results The Zacks Consensus Estimate for earnings is pinned at  1 03  which highlights 15 73  year over year rise However  we don t see a beat for Varian as it has a Zacks Rank  3 and Earnings ESP of 0 00    Read more    The stock beat the Zacks Consensus Estimate in three of the trailing four quarters  with an average beat of 2 6  as demonstrated in the chart below 
Varian Medical Systems  Inc  Price and EPS Surprise
     Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/medical-product-stock-earnings-roster-for-apr-25-lh--more-200308257,200308257
9732,231247,LH,Can CAG Growth For IDEXX  IDXX  Stock Return In Q1 Earnings ,opinion,IDEXX Laboratories  Inc    NASDAQ IDXX   is scheduled to report its first quarter 2018 results on May 4  before the opening bell  Last quarter  the company delivered a positive earnings surprise of 5 48   Notably  the stock has outperformed the Zacks Consensus Estimate in each of the preceding four quarters  the average beat being 7 3  Let s take a look at how things are shaping up prior to this announcement Key Catalysts IDEXX is expected to continue with its gain momentum in the first quarter  courtesy of a strong global rise in Companion Animal Group  CAG  Diagnostics  revenues  Last time  this upside was driven by consistent strong double digit growth in reference labs and consumables plus owing to a high single digit increase registered in rapid assay sales  Management vouches for this trend to be retained further IDEXX Laboratories  Inc  Price and EPS Surprise    We are also upbeat about IDEXX enhancing its commercial capabilities in the United States to maintain recurring revenue growth at CAG Diagnostics  We expect first quarter results to reflect a rise in productivity as new sales representatives establish fresh customer relationships  Also  we anticipate the company to report exceptional customer retention rates for reference labs as well as instrument consumables in the United States and worldwide The Zacks Consensus Estimate of  460 million for CAG Diagnostics revenues represents a 5 9  improvement from the last reported quarter Notably  IDEXX s 13 14 5  revenue growth projection for the quarter to be reported  highlights its organic gains of 9 5 10 5   Overall  the Zacks Consensus Estimate for the total quarterly revenues is pegged at  525 million  Other factors predicted to influence IDEXX s first quarter results are We pin considerable hopes on progress in the Water Business  lying on a growth trajectory of late  backed by encouraging test results in the United States as well as benefits drawn from the global go direct initiatives  Moreover  the business witnessed 16  organic growth last quarter  Management also eyes gains from two favorable regulatory developments pertaining to wastewater in the United States and drinking water in Europe  The company earlier stated that it is perfectly on track for a continued high single digit organic revenue boost in this business through 2018  The consensus mark for Water revenues stands at  28 3 million for the yet to be reported quarter IDEXX carries on to expand its global footprint  It has been significantly drawing advantages from the bountiful opportunities in the emerging companion animal diagnostics markets  Further  management s consistent share buybacks underscores its robust free cash flow reserve  We believe the outcome of these endeavors will bear reflection on first quarter conference call On the flip side  foreign currency fluctuation is a major headwind  Another concern is the company s heavy reliance on third party distributors  The purchasing dynamics of distributors leave a significant impact on the company s sales of instrument consumables as well as its rapid assay products  Moreover  IDEXX has been witnessing a rise in operating expenses due to increased head count along with higher investments in portfolio development and expansion in the United States plus internationally Additionally  a competitive landscape in the domestic and overseas markets weighs on IDEXX s performance  Thus  the struggle to gain market traction might be a drag on first quarter results Here s what the quantitative model predicts Per the proven Zacks model  a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has higher chances of beating estimates if it also has a positive  IDEXX has a Zacks Rank  2  which increases the predictive power of ESP  However  the company s Earnings ESP of  0 90  leaves our surprise prediction inconclusive We caution against the Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions You can uncover the best stocks to buy or sell before they re reported with our  Stocks Worth a LookHere are a few medical stocks worth considering with the right combination of elements to surpass estimates this time around Baxter International Inc    NYSE BAX   has an Earnings ESP of  0 86  and is a Zacks  2 Ranked player Laboratory Corporation of America Holdings   NYSE LH   has an Earnings ESP of  1 52  and a Zacks Rank of 2 Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 13  and is a  2 Ranked player  You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/can-cag-growth-for-idexx-idxx-stock-return-in-q1-earnings-200308539,200308539
9733,231248,LH,LabCorp  LH  Beats On Q1 Earnings  Revenues  Lifts  18 View,opinion,"Laboratory Corporation of America Holdings   NYSE LH    or LabCorp  reported first quarter 2018 adjusted earnings per share  EPS  of  2 78  up 30 5  from the year ago quarter  The bottom line also exceeded the Zacks Consensus Estimate by 5 3  
On a reported basis  LabCorp s net earnings came in at  1 67 per share as compared to  1 75 in the year ago period 
Revenues for the first quarter increased 18  year over year to  2 85 billion  The top line exceeded the Zacks Consensus Estimate of  2 78 billion  The year over year rise in revenues was owing to 13 4  growth from acquisitions  organic growth of 3 2  and a benefit of approximately 150 basis points from foreign currency translation 
Quarter Under Review
LabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development 
In the reported quarter  LabCorp Diagnostics reported revenues of  1 77 billion  up 8  year over year  fueled by tuck in acquisitions  organic volume  measured by requisitions  and a gain from foreign currency translation of roughly 30 basis points  This was partially offset by lower Medicare reimbursement as a result of the implementation of the Protecting Access to Medicare Act  PAMA  and the impact from adverse weather Laboratory Corporation of America Holdings Price  Consensus and EPS Surprise

   The company reported a 6 9  rise in total volume  measured by requisition  and a 0 7  increase in revenue per requisition in the concerning quarter 
Covance Drug Development reported a 39 3  rise in revenues to  1 08 billion in the first quarter  This upside was primarily on the back of acquisitions  organic growth and the foreign currency translation benefit of nearly 390 basis points 
Gross margin deteriorated 211 bps to 27 3  in the reported quarter  Adjusted operating income was up 3 3  year over year to  382 million  However  adjusted operating margin contracted 190 bps from the year ago quarter to 13 4  on a 16 3  rise in selling  general and administrative expenses to  397 million 
LabCorp exited the first quarter of 2018 with cash and cash equivalents of  361 8 million compared with  316 7 million at the end of 2017  Operating cash flow at the end of the first quarter was  154 7 million  down 31 5  from  225 9 million in the year ago period  Free cash flow came in at  82 8 million in this period  down 46 5  from the year ago period 
During the quarter under discussion  the company returned  75 million to shareholders via share repurchases  On Apr 24  2018  the board authorized an increase in LabCorp s share repurchase program to a total of  1 billion 
Outlook
LabCorp has updated its 2018 guidance considering the adoption of ASC 606 
Revenue growth is expected to remain in the band of 10 12  from 2017  earlier projected band was 9 5 11 5   including a likely improvement of 90 bps  from projection of 60 bps improvement earlier  from a foreign currency translation  The Zacks Consensus Estimate for current year revenues is pegged at  11 48 billion 
Adjusted EPS projection for 2018 however  has been kept unchanged in the range of  11 30  11 70  However  this guidance now includes the projected negative impact of 20 cents to 30 cents for the full year 2018 from ASC 606  offset by strong first quarter results and an improved outlook for the remainder of the year  The consensus mark of  11 55 for the metric falls within the guided range 
Free cash flow has been anticipated within  1 1  1 2 billion  growth in the band of 0 9 1  from the prior year  unchanged  
Our Take
LabCorp posted a strong first quarter performance with adjusted earnings and revenues both exceeding the respective Zacks Consensus Estimate  Strong year over year growth in both earnings and revenues were encouraging  LabCorp Diagnostics business was solid on the back of increasing acquisitions  organic volume expansion and a favorable foreign exchange scenario 
Also  after several quarters of dull performance  Covance Drug Development has been reporting sturdy growth over the past few of terms  This uptrend was primarily owing to strategic acquisitions  robust organic growth and a positive foreign currency translation  The 2018 guidance also looks promising 
We believe that with the integration of newer acquisitions  LabCorp is perfectly positioned to drive long term profitable growth through a combination of world class diagnostics  drug development expertise and knowledge services 
Zacks Rank   Key Picks
LabCorp has a Zacks Rank  2  Buy  
Other top ranked stocks in the broader medical sector include Abaxis  Inc    NASDAQ ABAX    Bio Rad Laboratories  Inc    NYSE BIO   and ResMed Inc    NYSE RMD    While Abaxis and Bio Rad sport a Zacks Rank  1  Strong Buy  ResMed carries a Zacks Rank  2  Buy   You can see 
Abaxis is expected to release fourth quarter fiscal 2018 results on Apr 26  The Zacks Consensus Estimate for adjusted EPS is 32 cents and for revenues is  67 million 
Bio Rad is expected to report first quarter 2018 results on May 3  The Zacks Consensus Estimate for adjusted EPS is 90 cents and for revenues is  529 5 million 
ResMed is slated to release third quarter fiscal 2018 results on Apr 26  The Zacks Consensus Estimate for adjusted EPS is 83 cents and for revenues is  564 9 million 
Investor Alert  Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline 
Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2018-04-25,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-beats-on-q1-earnings-revenues-lifts-18-view-200309097,200309097
9734,231249,LH,LabCorp  LH  Tops Q1 Earnings  Misses On Sales  Tweaks View,opinion,"Laboratory Corporation of America Holdings   NYSE LH   or LabCorp reported first quarter 2017 adjusted earnings per share  EPS  of  2 22  up 8 3  from the year ago quarter  The quarter s adjusted EPS also exceeded the Zacks Consensus Estimate by 1 4   On a reported basis  LabCorp s net earnings came in at  1 84 per share  a 16 5  jump year over year Net revenue for the first quarter increased 4 9  year over year to  2408 million  However  the quarterly number lagged the Zacks Consensus Estimate of  2411 million  Strong growth in companion diagnostics and significant increase in organic volume growth contributed to the year over year top line growth  which was partially offset by poor show in Covance Drug Development  This apart  adverse currency exchange movement hampered the quarterly top line number to the tune of 40 basis points  bps  Organic revenue growth  net revenue growth less revenue from acquisitions excluding the currency impact  was 2 7  Laboratory Corporation of America Holdings Price and EPS Surprise
    Quarter Under ReviewCurrently  LabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development In the reported quarter  LabCorp Diagnostics reported net revenue of  1 72 billion  up 8  year over year  fueled by price  mix  tuck in acquisitions and organic volume  The company reported 4 3  increase in total volume  measured by requisition  and a 3 8  increase in revenue per requisition in the quarter Covance Drug Development reported a 1 8  drop in net revenue to  690 3 million in the first quarter  This was due to slower revenue conversion from the backlog and the impact of cancellation by sponsors of two large clinical studies in late 2016 for which Covance Drug Development used to provide central laboratory services  and 150 bps negative impact from foreign currency translation  At Constant Exchange Rate  CER  net revenue declined 0 3  year over year Gross margin improved 106 bps to 31 8  in the quarter  Adjusted operating income increased 18 9  year over year to  345 3 million  Adjusted operating margin expanded 170 bps from the year ago quarter to 14 3  despite a 1 2  rise in selling  general and administrative expenses to  419 4 million LabCorp exited the quarter with cash and cash equivalents of  365 million compared with  433 6 million at the end of 2016  Operating cash flow for the quarter was  233 8 million  up from  127 6 million in the year ago period  Free cash flow came in at  161 6 million  significantly up from  56 2 million in the year ago period  During the quarter  the company returned  150 million to shareholders through share repurchases and currently has  589 6 million of authorization remaining under its existing share repurchase plan OutlookBased on a dull show within Covance Drug Development  the company lowered its earlier provided 2017 outlook  The guidance considers expansion of LaunchPad in this segment as well as currently anticipated capital allocation  including acquisitions  share repurchases and debt repayment Net revenue growth is now expected to remain in the band of 3 5  to 5 5 year over year  lowered from earlier band of 4 5 6 5   This includes a 40 bps impact  earlier the projection was 60 bps impact  from unfavorable foreign exchange headwind resulting in constant currency revenue growth of 3 9  to 5 9   earlier projection was 5 1  to 7 1    The current Zacks Consensus Estimate for revenues is pegged at  9 94 billion Adjusted EPS guidance for 2017 has also been lowered to the range of  9 20  9 60   9 35  9 75   The current Zacks Consensus Estimate of  9 60 falls at the upper end of the guided range Free cash flow expectation  however  remains unchanged in the band of  925  975 million  up 3 9  from the prior year  Our TakeLabCorp kick started 2017 on a mixed note  While the first quarter earnings topped the Zacks Consensus Estimate  revenues marginally missed the mark  While LabCorp Diagnostics business was strong  Covance Drug Development provided dull numbers  dampening the overall top line performance  According to the company  slower revenue conversion from the backlog and the impact of the cancellation by sponsors of two large clinical studies in late 2016 impacted the results  This apart  unfavorable foreign exchange continues to hamper the company s overall results  The reduced guidance for 2017 also fails to indicate chances of respite anytime soon Nonetheless  we believe that with the integration of newer acquisitions  LabCorp is perfectly positioned to drive long term profitable growth through a combination of world class diagnostics  drug development expertise and knowledge services Zacks Rank   Key PicksLabCorp currently has a Zacks Rank  4  Sell   Better ranked stocks in the broader Medical space include Inogen  Inc    NASDAQ INGN    ZELTIQ Aesthetics  Inc    NASDAQ ZLTQ   and Hill Rom Holdings  Inc    NYSE HRC    While Inogen and ZELTIQ sport a Zacks Rank  1  Strong Buy   Hill Rom carries a Zacks Rank  2  Buy   You can see  Inogen gained 54 7  in the last one year  compared with the S P 500 s gain of 11 4   The company reported a stellar four quarter positive average earnings surprise of over 49 08  ZELTIQ Aesthetics surged 92 3  in the last one year  compared with the S P 500 s gain  Its four quarter average earnings surprise was a positive of 12 30  Hill Rom gained over 29 3  in the past one year  better than the S P 500 mark  It posted a trailing four quarter positive average earnings surprise of 3 1  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-24,Zacks Investment Research,"https://www.investing.com/analysis/labcorp-(lh)-tops-q1-earnings,-misses-on-sales,-tweaks-view-200184990",200184990
9735,231250,LH,LabCorp Offers Sera s PreTRM To Assess Preterm Birth Risk,opinion,Leading diagnostics testing company LabCorp   NYSE LH   recently announced the availability of Sera Prognostics  Inc  s PreTRM test at its laboratories in the U S  It is the only validated blood test offering an early and individualized prediction of preterm birth risk  At the beginning of this year  LabCorp had announced a strategic tie up with Sera for exclusive U S  distributorship of the test LabCorp has been a lead investor in Sera s recently closed Series C financing round  The purpose is to continue building clinical evidence to support reimbursement and insurance coverage decisions as well as extend the commercialization of the PreTRM test The test was supported by the landmark Proteomic Assessment of Preterm Risk study  evaluating over 5 500 pregnant women over 300 proteins in maternal blood  The study also identified a two protein signature which was highly predictive of spontaneous preterm birth  The test will help physicians easily predict the risk of preterm birth and intervene earlier to extend the pregnancy toward full term  PreTRM is performed on a standard blood specimen collected during weeks 19 and 20 of pregnancy Notably  LabCorp is quite optimistic about its partnership with Sera as the PreTRM test is part of the former s strategy to deliver world class diagnostic services  In this regard  we note that preterm birth is the leading cause of infant mortality and morbidity in the U S  and worldwide According to a March of Dimes report  around 400 000 of the 4 000 000 annual births in the U S  are preterm and up to 50  of women delivering prematurely do not have any identified risk factors for preterm birth  It has also been observed that the children born prematurely can require long term or lifetime care that comes at additional cost PreTRM is considered a significant addition to LabCorp s differentiated women healthcare and reproductive genetics portfolio  The company offers MaterniT 21  a clinically validated non invasive prenatal test  and the largest network of genetic counselors who can help patients understand genetic test results  LabCorp also offers patient focused services such as support to obtain insurance pre authorization before a test is performed and a personalized estimate of the out of pocket cost of services before specimen collection by the company Share Price MovementLabCorp has been consistently trading below the Zacks categorized  industry over the last one month  The stock has gained only 0 6   compared to 6  of the broader industry  However  the company s portfolio expansion  acquisitions and collaborations in recent times are expected to boost the stock price Zacks Rank   Key PicksLabCorp currently carries a Zacks Rank  4  Sell   Better ranked stocks in the broader medical sector are Luminex Corporation   NASDAQ LMNX    Inogen  Inc    NASDAQ INGN   and Edwards Lifesciences  Inc    NYSE EW    Notably  Luminex and Inogen sport a Zacks Rank  1  Strong Buy   while Edwards Lifesciences carries a Zacks Rank  2  Buy   You can see Luminex has an expected long term adjusted earnings growth of almost 16 3   The stock added roughly 7 1  over the last three months Inogen has a long term expected earnings growth rate of 17 5   The stock has a solid one year return of around 77 8  Edwards Lifesciences has an expected long term adjusted earnings growth of almost 16   last 3 5 years of actual earnings   The stock added roughly 19 9  over the last three months Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-05-23,Zacks Investment Research,https://www.investing.com/analysis/labcorp-offers-sera's-pretrm-to-assess-preterm-birth-risk-200191194,200191194
9736,231251,LH,LabCorp Trades Down On Weak 2017 View  Reimbursement Woes,opinion,"On May 30  we issued an updated research report on Burlington  NC based Laboratory Corporation of America Holdings   NYSE LH    popularly known as LabCorp  The company is a major player in healthcare diagnostics space  providing comprehensive clinical laboratory services and end to end drug development support 
LabCorp s shares have been consistently trading below the Zacks classified  industry mark since last month  following an unimpressive first quarter 2017 result  The company lost 1 8   compared to a 4 6  gain for the broader industry 

While LabCorp s diagnostics business was strong  its Covance Drug Development provided dull numbers  dampening the overall top line performance  The company s statistics reveal slower revenue conversion from backlog and cancellation of two large clinical studies by sponsors in 2016 to impact the result  This apart  unfavorable foreign exchange remains a drag over the recent past  The reduced guidance for 2017 also fails to indicate chances of respite anytime soon 
There is also apprehension about the tough reimbursement scenario the company is currently going through  During 2016  approximately 12 3  of LabCorp Diagnostics  revenue was reimbursed under the Clinical Laboratory Fee Schedule  CLFS  and approximately 0 8  was reimbursed under the Physician Fee Schedule  PFS   With changes in government regulations in 2017 and the probability of future net reduction in reimbursement revenue  we expect the scenario to get tougher for LabCorp over time 
Per management  the company has been able to positively compete in a growing addressable market  worth approximately  200 billion  It is expected that the combined revenue growth from a broader platform  increased scale and synergies along with strategic deployment of cash flow will create significant long term shareholders  value 
LabCorp continues to flourish with complementary capabilities via meaningful acquisitions  Management believes that the recent buyout of Sequenom will boost the company s women s health test menu  The inclusion is assumed to expand the company s geographic reach  both domestically and internationally 
Zacks Rank   Key Picks
LabCorp carries a Zacks Rank  4  Sell   Some better ranked stocks in the broader medical sector are Luminex Corporation   NASDAQ LMNX    Inogen  Inc    NASDAQ INGN   and Edwards Lifesciences Corporation   NYSE EW    Both Luminex and Inogen sport a Zacks Rank  1  Strong Buy   while Edwards Lifesciences carries a Zacks Rank  2  Buy   You can see 
Luminex has an expected long term adjusted earnings growth of almost 16 3   The stock added roughly 8 9  over the last three months 
Inogen has a long term expected earnings growth rate of 17 5   The stock has a solid one year return of roughly 84 2  
Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has roughly added 22  over last three months 
More Stock News  8 Companies Verge on Apple Like Run
Did you miss Apple  NASDAQ AAPL  s 9X stock explosion after they launched their iPhone in 2007  Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market  Demand could soar from almost nothing to  42 billion by 2025  Reports suggest it could save 10 million lives per decade which could in turn save  200 billion in U S  healthcare costs A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it  Like Apple in 2007  these companies are already strong and coiling for potential mega gains ",2017-05-31,Zacks Investment Research,"https://www.investing.com/analysis/labcorp-trades-down-on-weak-2017-view,-reimbursement-woes-200192471",200192471
9737,231252,LH,LabCorp To Grow In Precision Med With Cancer Diagnostics Lab,opinion,Laboratory Corporation of Americas Holdings   NYSE LH    popularly known as LabCorp  has taken major steps to strengthen its foothold in the hugely growing cancer diagnostics space  This life sciences company s Covance drug development business has recently opened a companion diagnostics laboratory in Morrisville  North Carolina to expand capabilities in precision medicine field Being quite a familiar term these days  precision medicine considers individual genes  environment and lifestyle for treatment and prevention of diseases  According to the National Institutes of Health    NIH  Per the company  this cutting edge treatment option has a huge scope for improved patient outcome  particularly with targeted therapies and immunotherapies for treatment of cancer  Also  it has scopes in other therapeutic areas and rare diseases Companion diagnostics in combination with targeted drugs and therapies help to categorize patients who may or may not benefit from a specific treatment regimen The latest development successfully combines Covance s advanced companion diagnostics capabilities and end to end drug development with commercialization capabilities of LabCorp  Market ProspectsWith cancer and other rare diseases spreading like endemics  the huge opportunities for players in this market are clearly visible  Per the latest Global Market Insights report  precision medicine market size was more than  39 billion in 2015  and is projected to grow at a CAGR of 10 5  from 2016 to 2023 On the other hand  per the Markets and Markets report  the global cancer diagnostics market is expected to reach a worth  13 1 billion by 2020 at a CAGR of 12 9  during 2015 2020  Both these data indicate toward bountiful opportunity that LabCorp may grip through the latest development What Others Are DoingLabCorp s direct competitor and a leading companion diagnostic player Quest Diagnostics  NYSE DGX  is also working on the same line  Earlier this week  the company appeared in headlines with the purchase of two laboratories in order to form a precision oncology center in Texas  This center of excellence will provide diagnostic services to detect and manage cancer for oncologists and patients all over the country  Price PerformanceFor major part of the last three months  LabCorp traded below the Zacks categorized  industry  The company has lost 2 2  in this period  compared with the 7 4  gain of the broader industry  The latest favorable development is expected to provide a slight impetus to the company to rebound the stock price Zacks Rank   Key PicksLabCorp currently bears a Zacks Rank  4  Sell   Few better ranked medical stocks are Align Technology  Inc    NASDAQ ALGN    Inogen  Inc    NASDAQ INGN   and Accelerate Diagnostics  Inc    NASDAQ AXDX    Align Technology and Inogen sport a Zacks Rank  1  Strong Buy   while Accelerate Diagnostics carries a Zacks Rank  2  Buy   You can see Align Technology has an expected long term adjusted earnings growth of almost 24 1   The stock has roughly added 30 9  over the last three months Inogen has a long term expected earnings growth rate of 17 5   The stock has a solid one year return of around 88  Accelerate Diagnostics has an expected long term adjusted earnings growth of 30   The stock has approximately added 20  over the last three months 3 Stocks to Ride a 588  Revenue ExplosionAt Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-06-14,Zacks Investment Research,https://www.investing.com/analysis/labcorp-to-grow-in-precision-med-with-cancer-diagnostics-lab-200195390,200195390
9738,231253,LH,Undervalued R D Leader With A 6  Yield,opinion,"Declining R D productivity and rising costs are driving bio pharma firms to increase the use of Contract Research Organizations  CROs   CROs represent a growing healthcare niche that benefits from significant barriers to entry and the trend towards outsourced R D  Among public companies in the CRO space  this one earns our Very Attractive rating and leads the group in return on invested capital  ROIC   the key driver of shareholder value 
ICON PLC  NASDAQ ICLR  is this week s  
Solid Revenue and Profit Growth  NOPAT 
Over the past decade  ICLR has grown after tax profit    by 22  compounded annually to  283 million in 2016  Revenues increased 14  compounded annually to  1 7 billion over the same period  while NOPAT margin increased to 17  in 2016 from 9  in 2006 
Over the past three years  revenue growth has moderated to 8  compounded annually  NOPAT growth  however  accelerated to 37  compounded annually due to more significant profit margin expansion  NOPAT margin increases averaged  3  per year over the last three years compared to the ten year average of  1  per year  The NOPAT margin trend largely reflects prior year investments paying off through operating leverage  as well as the effective implementation of process optimization initiatives 
Figure 1  ICLR Revenue   NOPAT Margin

Sources  New Constructs  LLC and company filings
In addition to impressive revenue and NOPAT growth  free cash flow    generation has increased as well  Over the past five years  ICLR has generated  370 million of cumulative free cash flow  9  of current market cap  2016 FCF of  136 million increased from  18 million in 2012 and represented nearly 40  of the five year total  ICLR s current 3   is in line with the average S P 500 stock 
Rising Return On Invested Capital  ROIC 
The company s 22  ROIC is top quintile among our  and is well above publicly traded medical laboratory research firms  median 8  ROIC  and the broader health care sector  median 4  ROIC   Prudent capital investment  steady revenue growth and expanding margins and have driven ROIC steadily higher each year since 2011 when ROIC bottomed at 5   2011 was a year where expense growth outpaced revenue growth by over 2 1  However  the investments ultimately paid off  and revenue growth has exceeded expense growth by nearly 2 1 since 
Figure 2  ICLR After Tax Profit  NOPAT  and Return on Invested Capital  ROIC 

 Sources  New Constructs  LLC and company filings
Improving ROIC Correlated with Increasing Shareholder Value
Per Figure 3  ROIC explains 76  of the valuation difference between ICLR and a peer group of twelve medical laboratory and research companies  Despite ICLR s 22  ROIC  almost three times the peer median  the stock trades at a discount as shown by its position below the trend line in Figure 3  If ICLR traded at parity with the group  it would be  125 share   39  above the current price  Given ICLR s well above average ROIC  one would think the stock would garner a premium valuation 
Figure 3  ROIC Explains 76  of Valuation for Medical Lab and Research Stocks
 
 Sources  New Constructs  LLC and company filings
Leading Profitability Reflects Competitive Advantages
The development process for a single new drug takes 10 15 years and can cost  2 6 billion  according to a  Accelerating the process by even a few months can help reduce costs and deliver additional revenue  Given this economic incentive  biopharmaceutical firms are increasingly outsourcing the R D process to CROs  which do it more efficiently due to specialization and focus  The global CRO market was valued at roughly  25 billion in 2015  has experienced double digit growth over the past decade and is projected to grow 8  annually to  45 billion by 2022  The market is highly concentrated with the top 10 firms controlling over 75  of the market 
Based on TTM data of public firms  ICLR is the fifth largest CRO with  1 7 billion of revenue behind Quintiles Transnational Holdings Inc  NYSE Q    7 7 billion   Laboratory Corporation of America  NYSE LH     9 7 billion   PAREXEL  NASDAQ PRXL   2 4 billion  and Charles River Laboratories  NYSE CRL    1 8 billion   These firms compete on the basis of their capabilities  brand reputation and price 
ICLR offers the full suite of planning  execution and analysis for Phase I to IV trials of the multi national  several thousand patient variety  Most importantly  CROs need a long and successful track record for bio pharma firms to entrust them with a potential multi billion dollar asset  ICLR s solid brand reputation is reflected in the 27 year relationship with Pfizer  NYSE PFE   its largest client 
Per Figure 4  below  ICLR s trailing twelve month  TTM  gross margin of 42  is below the CRO peer group of 53   This makes ICLR s 20  pre tax operating profit margin    even more impressive when compared against CRO peers at 13   reflecting a lean cost structure and better operational efficiency  We utilized NOPBT margin for operational efficiency comparisons given that being domiciled in Ireland represents a clear tax advantage for ICLR  These operational and tax advantages should result in ICLR being better able to absorb competitive pricing pressure or demand swings  while at the same time providing more flexibility to invest for the future without sacrificing its ROIC advantage 
Figure 4  ICLR Profit Margins  TTM  and ROIC vs  Medical Laboratory   Research Peers
 
 Sources  New Constructs  LLC and company filings
Bear Case Risks  Bio Pharma R D Budgets  Customer Concentration
Historically  the main risk to ICLR profitability has been demand swings caused by changes in R D spending rates among global bio pharma firms  This risk was apparent during the 2009 2011 timeframe  when ICLR s revenue growth slowed to 3  compounded annually while continued investment in the firm caused profitability to contract  We think the risk to ICLR s profitability from a global R D slowdown is lower today for several reasons  1  the trends towards R D outsourcing and strategic CRO partnerships were less established  2  ICLR was more dependent on  project by project  vs  long term contracted revenue  and 3  ICLR does not require the same level of investment as before 
Another risk cited against ICLR is customer concentration  ICLR s Top 25 clients accounted for 75  of revenue in 2016  with Pfizer  PFE  accounting for 26   We think the Pfizer  PFE  risk is mitigated by the relationship s 27 year history and a recently renewed 5  to 7 year contract  Further  the company expects to reduce PFE s revenue concentration to 15 17  during 2017  Generating positive revenue growth in 2017   3  consensus  while meaningfully reducing single customer risk would be a long term positive 
Valuation Implies Low Profit Growth Expectations
At the current price of  90 share  ICLR has a price to economic book value ratio    of 1 1  This ratio means the market expects ICLR s NOPAT to grow no more than 10  over the remainder of its corporate life  This expectation seems overly pessimistic for a company that has grown NOPAT by 22  compounded annually over the past decade and whose industry is projected to grow at least 8  annually through 2022 
If ICLR can maintain NOPAT margins of at least 15   below TTM margins of 17   and   the stock is worth  107 today   19  above the current price  This scenario assumes ICLR will grow revenues by consensus in 2017  3   and 2018  5   and 4  compounded annually thereafter  For reference  ICLR has grown revenue  compounded annually  by 8   12  and 14   respectively  over the past three  five and ten year periods 
No Dividend  But Buybacks Yield 6 
Dividends are uncommon among medical laboratory  research stocks and non existent among CROs  Achieving growth rather than becoming a cash cow is the focus of these firms given the market opportunity 
ICLR has had an active repurchase program for the past two years  The company has spent  570 million repurchasing 6 3 million shares  a 10  reduction in outstanding shares  The company had  290 million remaining under its authorization as of its last public filing  12 31 16   The remaining repurchase authorization equates to 3 4 million shares at current prices  6  of outstanding  and 6  of the current market cap  Such repurchase activity would provide a potential buyback yield of 6  if the remaining authorization was executed between now and 12 31 17 
Potential Catalysts  Strategic Partnerships  Acquisitions  Margin Expansion
Strategic partnerships between bio pharma firms and CROs represent an important  emerging trend  Roughly half of all bio pharma firms have entered into such partnerships with a small number of  preferred providers   usually between 1 5 CROs  This trend is expected to drive M A consolidation  bolster the competitive position of market leaders and result in more long term contracted revenue and less  project by project  revenue for CROs  ICLR is well positioned to benefit from this trend due to its strong brand reputation 
The industry s high regulatory burden and high capital investment requirements represent significant barriers to entry and an operational challenge to smaller firms  During 2007 2012  an estimated 45  of small  and mid sized CRO s were acquired or shut down  making small acquisitions and asset purchases by larger firms common  Management has indicated the company will continue to pursue small  synergistic acquisitions supported by cash flows  i e  cash and debt vs  equity issuance   a strategy that appears to have benefited shareholders over the last five years given ICLR s increasing ROIC 
We think ICLR remains positioned to grow revenue faster than expenses given the ongoing maturation of past investments and the likelihood that ICLR will continue to win its share of new business coming from increased outsourcing  Biopharma firms spent an estimated  145 billion on R D in 2016  while the CRO viable portion is estimated at  75 billion  The actual 2016 CRO market approximated  30 billion while the TTM revenue of the five largest publicly traded CROs  per Figure 4  was approximately  23 billion  With over half of the viable market currently unaddressed by CROs  the growth outlook for strong brands looks bright 
We are comfortable assuming that a combination of the three factors outlined above will drive revenue and profit growth above the low expectations currently embedded in the valuation  resulting in a favorable risk reward trade off 
Executive Comp Likely Could be More Shareholder Aligned
As a  foreign private issuer   ICLR is not required to provide a  say on pay  shareholder resolution in the annual proxy statement and details on incentive targets are unavailable  The most recent annual report indicated executive comp is targeted based on other healthcare bio pharma CRO firms of similar market cap  adjusted for individual performance  experience and level of responsibility  This plan could be better aligned with shareholders by tying management compensation directly to ROIC 
We know from Figure 3 above  and   that ROIC is   Use of ROIC to measure performance ensures executives  interests are aligned with shareholder s interests  In the case of ICLR  there has been no profiting from misleading metrics while shareholder value is destroyed  Over the past 10 years   have grown from  13 million to  212 million  32  annually   a clear indication of shareholder value creation 
Insider Trading and Short Interest
There is little insight to be gained from recent insiders or short seller trends  Insiders own 4 0  of the company but have not engaged in any material insider buying or selling over the past 90 days  There are currently 2 2 million shares sold short equating to 4  of shares outstanding and 4 days to cover  Short interest is up 12   roughly 235 000 shares  since year end but is only up 8   162 000 shares  from a year ago 
Footnotes Adjustments and Forensic Accounting
Income Statement  we made  37 million of adjustments  with a net effect of removing  21 million in non operating expense  1  of revenue   We removed  8 million in  and  29 million in   You can see all the adjustments made to ICLR s income statement 
Balance Sheet  we made  510 million of adjustments to calculate invested capital with a net decrease of  62 million  The largest adjustment was  127 million due to   This adjustment represented 10  of reported net assets  You can see all the adjustments made to ICLR s balance sheet 
Valuation  we made  726 million of adjustments with a net effect of decreasing shareholder value by  372 million  Apart from total debt of  476 million  which includes  127 million of operating leases noted above  the largest adjustment was  65 million for the   This adjustment represents 4  of ICLR s market cap 
Attractive Funds that Hold ICLR
The following funds receive our Attractive or better rating and allocate significantly to ICLR 
Knights of Columbus Large Cap Value Fund  KCVSX    4 2  allocation and an Attractive rating 
Archer Stock Fund  ARSKX    2 5  allocation and an Attractive rating 
Disclosure  David Trainer  Kyle Guske II and Kenneth James receive no compensation to write about any specific stock  style  or theme ",2017-07-10,David Trainer,https://www.investing.com/analysis/undervalued-r-d-leader-with-a-6-yield-200200007,200200007
9739,231254,LH,Medical Product Stocks Earnings On Apr 25  SYK  EW  LH,opinion,"We are entering the heart of the Q1 earnings season  with more than 50  S P 500 members expected to come up with results by the end of this week The Story So FarAccording to the latest   95 S P 500 participants reported results till end of last week  These combined account for 24 9  of the index s total market capitalization  Total earnings for these companies are up 14 3  from the same period last year on 4 6  higher revenues  with 72 6  beating EPS estimates and 62 1  beating revenue estimates  The proportion of companies beating both EPS and revenue estimates is 51 6   With a market thumping 100  beat ratio for EPS estimates and an 80  revenue beat ratio   Medical  was one of the top performing S P sectors last week Our preview shows that first quarter earnings for the S P 500 companies are expected to be up 9 1  from the year ago quarter on 6 0  higher revenues  With the majority of earnings yet to be released  next week will be crucial in deciding whether this quarter will actually turn out to be a game changer  Irrespective of the outcome  there will definitely be good news for investors focusing on the Medical sector Per the report  Medical is one of the broader sectors among the 16 Zacks sectors that are expected to report earnings growth in the first quarter  The sector is expected to witness 0 8  earnings growth on the back of 6 3  higher revenues What Lies for Medical Product This Earnings SeasonMedical product  an important part of the medical device subcategory within the broader Medical sector  looks promising at the moment  Investors are also bullish about the space as seen from the fact that the Zacks categorized Medical Products industry registered growth of 7 23  in the last three months  comfortably outperforming the S P 500 Index that gained around 2 78  only However  the failure of the Republicans to repeal the Affordable Care Act or Obaamcare with a replacement plan last month has kept the space in doldrums  This has forced Republicans to propose amendments for setting aside funds to cover a portion of costs alongside insurers  The foremost question that arises now is whether Medical Product players stand to gain or lose from the conundrum  The medical device fraternity was earlier happy with the original Trump action plan which had promised cancellation of major healthcare taxes including the two signature taxes of Obamacare  the unpopular Cadillac tax  40  excise tax on high cost healthcare plans  and the controversial 2 3  MedTech tax According to the MedTech community  the cancellation of the above taxes will directly address issues like lack of opportunity for research and development  innovation  pipeline development and help in making investments needed to accelerate patient and provider access to innovative health care products  This will also help in boosting job creation and quality of patient care  offering companies in the space an opportunity to strengthen their position to cope with the new situation Since the final outcome of Trump s proposed health care policy is no way near  investors have shifted their focus to the hot topic of the first quarter earnings season Let s take a sneak peek into the expected performance of three major medical product companies that are expected to report earnings on Apr 25 Stryker Corporation   NYSE SYK   is set to report first quarter figures on Apr 25  after market close  The company s expanding product portfolio is a key catalyst in our view  Moreover  back to back acquisitions like Physio Control International  Synergetics USA and Sage Products LLC are expected to drive overall growth Our model shows that a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for an earnings beat  Conversely  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions You can uncover the best stocks to buy or sell before they re reported with our Going by our model  Stryker is likely to beat earnings estimates because it has the right combination of a Zacks Rank  3 and an Earnings ESP of  1 40    Read more    Stryker Corporation Price and EPS Surprise
    Edward Lifesciences Corp    NYSE EW   is expected to release its first quarter fiscal 2017 financial numbers on Apr 25  This prominent life science company came up a promising global sales performance in the last reported fourth quarter of 2016  primarily buoyed by strong Transcatheter Heart Valve sales The company has an Earnings ESP of 0 00  because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 82 cents  This makes surprise prediction difficult although the company carries a Zacks Rank  3   Read More   
You can see   Edwards Lifesciences Corporation Price and EPS Surprise
    Laboratory Corp  of America Holdings   NYSE LH   is slated to report first quarter 2017 financial numbers on Apr 25  Last quarter  the company reported a positive earnings surprise of 0 94   The average beat is 0 78  for the trailing four quarters  However  the recently completed acquisition of Sequenom may hurt the company s operating margin in the to be reported quarter due to its unfavorable product margin Laboratory Corp  currently has a Zacks Rank  4 and an Earnings ESP of  1 83   This is because the Most Accurate estimate stands at  2 17  which is lower than the Zacks Consensus Estimate of  2 19  The combination makes surprise prediction difficult   Read More   Laboratory Corporation of America Holdings Price and EPS Surprise
    More Stock News  This Is Bigger than the iPhone     It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market  Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2017-04-24,Zacks Investment Research,"https://www.investing.com/analysis/medical-product-stocks-earnings-on-apr-25:-syk,-ew,-lh-200184635",200184635
9749,231264,LH,LabCorp Diagnostics Strong On Novant Health Deal Extension,opinion,Laboratory Corporation of America Holdings   NYSE LH    also referred to as LabCorp  has decided to extend its Technical Services Agreement with Novant Health which was originated in 2012  However  the financial terms of this multi year agreement extension have been kept under wraps The Technical Services Agreement makes the company s diagnostics business   LabCorp Diagnostics   the laboratory management services provider for all Novant Health acute care facilities  Thus  we expect this agreement to expand LabCorp s reach LabCorp s highly sophisticated and exclusive services like IT and data analytics and high end testing platforms provide a holistic and enriching range of laboratory and diagnostics solutions  In addition to these services  LabCorp acts as the primary reference laboratory for Novant Health and Novant Health Medical Group Interestingly  LabCorp s Diagnostics arm is its prime revenue generating business which accounted for around 71  of the company s total revenues in the first quarter of fiscal 2017  The latest development is expected to help the company to strengthen its position in this space Notably  the company has been riding high on this segment  courtesy of its continuous efforts to stimulate growth organically as well as through acquisitions and partnerships  In this regard  LabCorp recently teamed up with Walgreens Boots Alliance  Inc    NASDAQ WBA   to set up specimen collection service stations at various Walgreens stores across the U S The company also expanded its reach by closing the acquisition of Mount Sinai Health System Clinical Outreach Laboratories in May 2017  Post acquisition  LabCorp s highly differentiated portfolio will be used by Mount Sinai s existing customers Per a report from MarketsandMarkets  the Vitro Diagnostics market is expected to witness a CAGR of 5 5  in the 2016 2021 period  while the Diagnostics Imaging Market is projected to see a CAGR of 6 6  over the same time frame  Thus  LabCorp s continuous efforts to grow in this niche market seem to be perfectly aligned and justified Management showed confidence in the Diagnostics segment by revising the Guidance for fiscal 2017 favorably  The projected revenue growth at this segment was increased by 50 basis points to 5 0 7 0  over 2016 net revenue of  6 59 billion  Moreover  in May 2017  company expanded its VistaSeq Hereditary Cancer portfolio through the addition of ten new test panels with focus on the risk of specific hereditary cancer syndromes Over the last three months  LabCorp has been lagging the broader  market  gaining 6 6  as compared to the industry s 11 6   However  the company s strong fundamentals make us believe that this phase is only momentary  Also  we expect the latest development to provide some momentum to the stock Zacks Rank   Key PicksLabCorp currently carries a Zacks Rank  4  Sell   A few better ranked medical stocks are Edwards Lifesciences Corporation   NYSE EW   and Abbott Laboratories   NYSE ABT    Notably  Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   while Abbott Laboratories carries a Zacks Rank  2  Buy   You can see Edwards Lifesciences has an expected long term adjusted earnings growth of 15 22   The stock has added roughly 24 7  over the last three months Abbott Laboratories has an expected long term adjusted earnings growth of 10 84   The stock has added around 12 8  over the last three months More Stock News  8 Companies Verge on Apple Like Run Did you miss Apple  NASDAQ AAPL  s 9X stock explosion after they launched their iPhone in 2007  Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market  Demand could soar from almost nothing to  42 billion by 2025  Reports suggest it could save 10 million lives per decade which could in turn save  200 billion in U S  healthcare costs A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it  Like Apple in 2007  these companies are already strong and coiling for potential mega gains ,2017-07-11,Zacks Investment Research,https://www.investing.com/analysis/labcorp-diagnostics-strong-on-novant-health-deal-extension-200200716,200200716
9750,231265,LH,LabCorp  LH  Q2 Earnings  Is Disappointment In The Cards ,opinion,"Laboratory Corp  of America Holdings   NYSE LH    or LabCorp  is scheduled to report second quarter 2017 results before the market opens on Jul 26 
Last quarter  the company reported a positive earnings surprise of 1 37  with an average beat of 0 36  for the trailing four quarters  Let s see how things are shaping up prior to this announcement 
Factors at Play 
The last reported first quarter 2017 dented LabCorp s overall top line performance  heavily on dull numbers registered in Covance Drug Development business  This was due to sluggish early development and central lab businesses  affected by a slower revenue conversion from backlog and cancellation by sponsors of two large clinical studies in 2016 Abbott Laboratories  NYSE ABT  Price and EPS Surprise

   Right now  although the company is trying to execute its strategy to focus more on higher value therapeutic areas such as oncology and CNS  central nervous system  disorders  this procedure is tied to complex studies which will take time to generate revenue  We believe  the Covance Drug Development will continue to remain a drag for LabCorp s overall business 
Earlier  the company noted that from a timing perspective  both Covance Drug Development s revenue and margins will be down on a year over year basis in the second quarter of 2017  before showing favorable growth in the second half of 2017 
This apart  unfavorable foreign exchange remains a bother  Previously  the company viewed that it expects an impact of approximately 40 basis points of negative currency on 2017 revenues  Covance Drug Development s net revenue is estimated to feel the impact of approximately 130 basis points of negative currency while the LabCorp Diagnostics segment will be affected approximately 10 basis points of negative currency in 2017  This should be reflected in the numbers of the quarter yet to be reported We are also highly disappointed with the CMS proposal related to the Protecting Access to Medicare Act 
On a positive note  we are upbeat about the company s ongoing cost reduction initiatives related to project LaunchPad  which currently has over 100 projects at various stages of implementation  Recently  the company has expanded the LaunchPad initiative to now include Covance Drug Development  This initiative will be a three year program for Covance that consists of two phases  The company has already initiated the first phase to  right size  Covance Drug Development s resources  primarily head count and facility footprint 
This phase is projected to generate pre tax savings of approximately  20 million in 2017 and approximately  45 million on an annualized basis thereafter  The pre tax cost to achieve these savings is estimated to be approximately  30 million in 2017  of which  around  20 million is presumed to be cash expenditures This should get reflected in the second quarter results as well 
The company s companion diagnostics portfolio  which grew a robust 35  in the last couple of years  should also maintain its momentum in 2017  Notably  within immuno oncology drug development  it doubled the number of study awards from 2015 to 2016 and also performed a number of PD L1 tests through Diagnostic and Drug Development segments 
Earnings Whispers
Our proven model does not conclusively show that LabCorp is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below 
Zacks ESP   LabCorp has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at  2 38  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  LabCorp has a Zacks Rank  4 which lowers the predictive power of ESP  Note that we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
Here are a few companies you may want to consider  as our proven model shows that these have the right combination of elements to post an earnings beat this quarter   
Thermo Fisher Scientific Inc    NYSE TMO   has an Earnings ESP of  0 44  and a Zacks Rank  2  You can see  
Dextera Surgical Inc    NASDAQ DXTR   has an Earnings ESP of  9 09  and a Zacks Rank  2 
Telefex Inc    NYSE TFX   has an Earnings ESP of  1 06  and a Zacks Rank  2 
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   
Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ",2017-07-20,Zacks Investment Research,https://www.investing.com/analysis/labcorp-(lh)-q2-earnings:-is-disappointment-in-the-cards-200202509,200202509
9751,231266,LH,LabCorp  LH  Beats On Q2 Earnings And Sales  Guidance Up,opinion,Laboratory Corporation of America Holdings   NYSE LH   or LabCorp reported second quarter 2017 adjusted earnings per share  EPS  of  2 47  up 4 7  from the year ago quarter  The quarter s adjusted EPS also exceeded the Zacks Consensus Estimate by 3 8   On a reported basis  LabCorp s net earnings came in at  1 82 per share  a 7 1  decline year over year Net revenue for the second quarter increased 4 9  year over year to  2498 4 million  The quarterly revenue number also topped the Zacks Consensus Estimate of  2 47 billion Strong growth in LabCorp Diagnostics  solid acquisition related growth as well as organic volume growth contributed to the year over year top line improvement  However  this was partially offset by poor show in Covance Drug Development  Also  while adverse foreign exchange movement hampered the quarterly top line number to the tune of 60 basis points  bps   the year over year comparison to a Leap Year and the timing of the Easter holiday hindered the reported quarter s growth by 1  Organic revenue growth  net revenue growth minus revenue from acquisitions excluding the currency impact  was 1 9  Laboratory Corporation of America Holdings Price  Consensus and EPS Surprise    Quarter Under ReviewCurrently  LabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development In the reported quarter  LabCorp Diagnostics reported net revenue of  1 80 billion  up 8 4  year over year  fueled by price  mix  tuck in acquisitions and organic volume  measured by requisitions excluding requisitions from acquisitions for the first 12 months after the close of each acquisition   The company reported 5  increase in total volume  measured by requisition  and a 3 6  increase in revenue per requisition in the quarter Covance Drug Development reported a 3 1  drop in net revenue to  699 7 million in the second quarter  This was due to the impact of cancellation by sponsors of two large clinical studies in late 2016   for which  Covance Drug Development used to provide central laboratory services   and a negative impact of 140 bps from foreign currency translation  At Constant Exchange Rate  CER   net revenue declined 1 7  year over year Gross margin contracted 22 bps to 34 5  in the quarter  Adjusted operating income increased 2 2  year over year to  426 5 million  Adjusted operating margin contracted 45 bps from the year ago quarter to 17 1  on a 6 3  rise in selling  general and administrative expenses to  435 3 million LabCorp exited the quarter with cash and cash equivalents of  299 9 million compared with  365 million at the end of 2016  Year to date operating cash flow was  544 5 million  up from  477 1 million in the year ago period  Free cash flow came in at  403 million  up from  338 7 million in the year ago period  During the quarter  the company returned  108 million to shareholders through share repurchases and currently has  489 5 million of authorization  remaining under its existing share repurchase plan OutlookDespite a dull show within Covance Drug Development  the company increased its earlier provided 2017 outlook Net revenue growth is now expected to remain in the band of 5 6 5  year over year  ahead of the earlier range of 3 5 5 5   This includes a 10 bps impact  earlier the projection was 40 bps impact  from an unfavorable foreign exchange headwind  The current Zacks Consensus Estimate for revenues is pegged at  9 86 billion Adjusted EPS guidance for 2017 has also been increased to the range of  9 30  9 65  previous range   9 20  9 60   The current Zacks Consensus Estimate of  9 42 falls within the guided range However  free cash flow expectation remains unchanged in the band of  925  975 million  up 3 9  from the prior year  Our TakeLabCorp posted a better than expected quarter with second quarter earnings and revenues  both topping the respective Zacks Consensus Estimate  While LabCorp Diagnostics business was strong  Covance Drug Development provided dull numbers  Per the company  the impact of the cancellation by sponsors of two large clinical studies in late 2016 affected the results  This apart  an unfavorable foreign exchange continues to hamper the company s overall results  However  an increased guidance for 2017 boosts investors  confidence indicating chances of respite anytime soon Nonetheless  we believe that with the integration of newer acquisitions  LabCorp is perfectly positioned to drive long term profitable growth through a combination of world class diagnostics  drug development expertise and knowledge services Zacks Rank   Key PicksLabCorp currently has a Zacks Rank  4  Sell   A few better ranked medical stocks   Mesa Laboratories  Inc    NASDAQ MLAB    INSYS Therapeutics  Inc    NASDAQ INSY   and Align Technology  Inc    NASDAQ ALGN    Notably  INSYS Therapeutics and Align Technology sport a Zacks Rank  1  Strong Buy   while Mesa Laboratories carries a Zacks Rank  2  Buy   You can see Align Technology has an expected long term adjusted earnings growth of almost 24 1   The stock has surged roughly 35 7  over the last three months INSYS Therapeutics has long term expected earnings growth rate of 20   The stock has gained around 4 3  over the last three months Mesa Laboratories delivered a positive earnings surprise of 2 84  for the last four quarters  The stock has added nearly 3 1  over the last three months The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2017-07-25,Zacks Investment Research,"https://www.investing.com/analysis/labcorp-(lh)-beats-on-q2-earnings-and-sales,-guidance-up-200203706",200203706
9753,231268,LH,Will LabCorp  LH  Pull A Surprise This Earnings Season ,opinion,"Laboratory Corp  of America Holdings   NYSE LH   or LabCorp is expected to report first quarter 2017 results before the market opens on Apr 25 Last quarter  the company reported a positive earnings surprise of 0 94  with an average beat of 0 78  for the trailing four quarters  Let s see how things are shaping up prior to this announcement Factors at Play We are currently looking forward to LabCorp s expansion of its drug development business worldwide  The company completed the integration of central lab facilities in Singapore and China in fourth quarter 2016  which may start contributing to the company s top line from this quarter itself Laboratory Corporation of America Holdings Price and EPS Surprise
    In this regard  we note that  LabCorp is on track to complete the site consolidations in the U S  and Europe by mid 2017  This is part of the company s  100 million cost synergy initiative within its Covance drug development business We are also upbeat about the company s ongoing cost reduction initiatives related to project LaunchPad  which currently has over 100 projects at various stages of implementation  LabCorp is currently in the third and final year of its goal of sustainably reducing the expense of this business  Hence  we expect it to improve the company s operating margin scenario in the to be reported quarter  LabCorp currently expects LaunchPad initiatives to generate additional savings extending into 2018 and beyond Earlier  the company stated that it has already started to enjoy the benefit from the ongoing implementation of lab automation such as its proprietary Propel robot  This should get reflected in the first quarter results as well The company s companion diagnostics portfolio  which grew a robust 35  in the last couple of years  should also maintain its momentum in 2017  Notably  within immuno oncology drug development  it doubled the number of study awards from 2015 to 2016 and also performed a number of PD L1 tests through Diagnostic and Drug Development segments However  the recently completed acquisition of Sequenom may continue to impact the company s operating margin in the to be reported quarter due to its unfavorable product margin  However  with the acquisition  LabCorp aims to expand its presence in both domestic and international levels  The addition of Sequenom has positioned the company as the market leader in non invasive prenatal testing  women s health and reproductive genetics Also  the change in upper management with Gary Huff being promoted as the CEO of LabCorp Diagnostics may prove fruitful for the business segment in days ahead However  foreign exchange woes and intense competition from major commercial laboratories and hospitals may act as headwinds  For full year 2017  the company projects a 60 basis points impact from foreign exchange risks due to the strengthening of dollar  We are also highly disappointed with the CMS proposal related to the Protecting Access to Medicare Act Earnings WhispersOur proven model does not conclusively show that LabCorp is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP   LabCorp has an Earnings ESP of  0 91   This is because the Most Accurate estimate stands at  2 17  lower than the Zacks Consensus Estimate of  2 19  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  LabCorp has a Zacks Rank  3 which increases the predictive power of ESP  However  a negative ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 45  and a Zacks Rank  2  You can see Applied Materials  Inc    NASDAQ AMAT   has an Earnings ESP of  1 32  and a Zacks Rank  1 Potlatch Corporation   NASDAQ PCH   has an Earnings ESP of  29 17  and a Zacks Rank  2 Sell These Stocks  Now  Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-04-16,Zacks Investment Research,https://www.investing.com/analysis/will-labcorp-(lh)-pull-a-surprise-this-earnings-season-200183116,200183116
9754,231269,LH,LabCorp  LH  Beats On Earnings   Revenues In Q1,opinion,Laboratory Corp  of America Holdings   NYSE LH   is a leading independent clinical laboratory  whose offerings include a broad range of routine tests  including blood chemistry analysis  urinalyses  blood cell count  thyroid test  Pap tests and HIV tests  as well as specialty testing operations or esoteric testing Currently  LabCorp has a Zacks Rank  2  Buy  but that could change following its first quarter 2018 earnings report which has just released  You can see We have highlighted some of the key details from the just released announcement below Earnings  The Zacks Consensus Estimate is pegged at  2 64 per share over the last 30 days  LabCorp s adjusted earnings per share of  2 78 beat the consensus mark and is up 31  on a year over year basis Sales  LabCorp posted net revenues of  2 85 billion  which has also beat the Zacks Consensus Estimate of  2 78 billion  The figure is up 18  on year over year basis Key Stats  Revenues from LabCorp Diagnostics segment increased 8  year over year to  1 77 billion in the first quarter  with total volume growth of 6 9  Revenues from Covance Drug Development segment increased 39 3  to  1 08 billion  courtesy of solid organic growth and the benefit from foreign currency translation Laboratory Corporation of America Holdings Price and Consensus    Major Factors  Management seemed to be upbeat about LabCorp s impressive first quarter results  Notably  the Diagnostics and Drug Development businesses each delivered excellent performance in the first quarter through a combination of strategic acquisitions  organic initiatives  and margin improvement The company has also updated its previously issued 2018 guidance  Stock Price  Following the earnings release  share prices did not show any movement in the pre market trading session Check back later for our full write up on this LabCorp earnings report later Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2018-04-25,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-beats-on-earnings--revenues-in-q1-200308863,200308863
9758,231273,LH,3 Commercial Labs Fighting Zika Threat To Bet On,opinion,"The World Health Organization s  WHO  announcement regarding the Zika virus scaling to a Public Health Emergency of International Concern status has been the talk of the nation for long  Zika  like many other mosquito borne diseases  took the shape of an endemic in many densely inhabited nations  However  things took a serious turn in the U S when a growing number of cases started cropping up The Outbreak at a GlanceZika virus infections are spread through Aedes aegypti mosquito bites  Also  the disease can be transmitted from mother to fetus during pregnancy and through sexual transmission  People infected with Zika may have symptoms such as mild fever  rash  muscle and joint pains or conjunctivitis  The infection may cause microcephaly and other birth defects during pregnancy  The Zika virus disease is believed to have taken a pandemic form  quite similar to AIDS Since 2015  70 countries and territories recorded evidence of vector borne Zika virus transmissions  As of Jul 2016  the U S  Department of Health and Human Services has confirmed a number of such cases with major outbreaks in the state of Florida  According to the Centers for Disease Control and Prevention  CDC   the total number of cases registered  locally acquired and travel associated  in the U S  and the U S  territories were 20 870 as of Sep 14  2016  Out of these  3 176 cases were solely within the U S  Among the 50 states  639 identified cases were in Florida  with 43 of those cases locally acquired InitiativesCDC has its own set of criteria to accurately detect Zika virus infection  Its Zika Immunoglobulin M  IgM  Antibody Capture Enzyme Linked Immunosorbent Assay  Zika MAC ELISA  gained the U S  FDA s authorization for emergency use on Feb 26  2016  which was reissued on Jun 29  2016  for the detection of Zika virus IgM antibodies in serum or cerebrospinal fluid  collected alongside a patient matched serum specimen  This apart  there are drug stocks which are actively working on developing vaccines  and also a number of leading commercial laboratories in the U S  that are working on tests to diagnose Zika infections in a comprehensive manner  According to the U S  Association of Public Health Laboratories  the commercial laboratories can play a pivotal role in public health response to emerging infectious diseases like Zika  These organizations have the expertise  scale and logistics support  as well as access to healthcare providers and patients that support and extend the capabilities of the nation s public health laboratories 3 Stocks in FocusLet us take a look at some of the commercial lab stocks that are actively combating and restricting this pandemic  These stocks  while still at their pipeline of success related to Zika  should be considered by investors for handsome returns Quest Diagnostics   NYSE DGX  On Sep 21  this leading provider of diagnostic information and infectious disease testing services announced the launch of Zika Antibody Test Service based on CDC s Zika MAC ELISA  Notably  Quest Diagnostics was the first commercial laboratory to receive FDA emergency use authorization for a Zika test for the qualitative detection of RNA from Zika virus in human serum specimens  On Sep 6  the company extended this molecular assay with the introduction of an RT PCR Zika test service for the qualitative detection in serum and paired urine specimens 
With the new test service  Quest Diagnostics offers access to Zika virus antibody and molecular laboratory test services in the U S  as well as Puerto Rico and other U S  territories  Healthcare providers in other countries may also refer specimens for Zika testing to Quest Diagnostics  Molecular RT PCR tests detect the presence of Zika virus RNA and is most useful up to 14 days as the symptoms start  depending on sample type and other factors  compared to Zika MAC ELISA which is useful two to 12 weeks following the onset of symptoms  Quest Diagnostics currently carries a Zacks Rank  2  Buy   You can see  QUEST DIAGNOSTC Price

   Hologic  Inc    NASDAQ HOLX  On Sep 8  Hologic announced that the FDA extended the emergency use authorization  EUA  for the company s Aptima Zika virus diagnostic assay to be used with urine samples  collected alongside patient matched serum or plasma specimens   Hologic s Zika virus assay was authorized for emergency use with serum and plasma  blood  samples in Jun 2016  Its new use with urine samples lengthens the time period during which patients can be tested for Zika from seven days to 14 days following symptoms  as recommended CDC The Aptima Zika virus assay by Hologic is a molecular diagnostic tool for comprehensive detection of Zika virus RNA  Ribonucleic acid  in human specimens  RNA is a type of molecule which has substantial genetic information  The assay or trial runs on Hologic s Panther System which is a market leading integrated platform that entirely automates all aspects of nucleic acid amplification testing  This platform reduces time  labor and energy for manual errors  The Aptima Zika Virus assay has not received any FDA approval for commercial use and has only been authorized for Zika virus detection in in vitro diagnostic tests  The assay is available for use in 50 states  Puerto Rico and the U S  territories Hologic currently has a Zacks Rank  3  Hold  HOLOGIC INC Price

   Laboratory Corp  of America Holdings   NYSE LH   or LabCorpOn Jun 6  LabCorp announced the availability of Zika virus test using the RealStar Zika Virus RT PCR Kit U S  from altona Diagnostics GmbH  The assay has received Emergency Use Authorization  EUA  from the FDA for the qualitative detection of Zika virus RNA in serum or urine  RT PCR tests for Zika virus can be used as a primary test only up to the first 7 to 14 days after the onset of symptoms  depending on the sample type testedLabCorp currently has a Zacks Rank  3 LABORATORY CP Price

   Conclusion
As per Market Research Media report  the global Zika virus preparedness market is expected to reach  4 billion by 2022 and grow at CAGR 11  in the period 2017  2022  The above stocks are working hard to offer physicians and patients easy access to Zika infection testing services and respond to the alarming number of cases being registered in recent times 
Now See Our Private Investment Ideas
While the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum       from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors     ",2016-09-22,Zacks Investment Research,https://www.investing.com/analysis/3-commercial-labs-fighting-zika-threat-to-bet-on-200155164,200155164
9759,231274,LH,2 Healthcare Stocks To Buy Before Earnings Season,opinion,"Many stocks tend to see more trading activity after reporting their quarterly earnings results   The increased share volume can do great things for a company that surpasses investor expectations   However  higher volume levels can also hurt firms if they had a bad quarter   Zeroing in on stocks that are set to beat earnings expectations can be easy  but only if you have the right tools   The Zacks Rank harnesses the power of earnings estimate revisions  so let s see which healthcare stocks are poised to outperform this earnings season 
Icon Plc   NASDAQ ICLR  
Icon plc  Is a full service clinical research organization   It operates internationally  and it provides contract clinical research services to the pharmaceutical industry   The company has been growing sales every year  and it recently completed its acquisition of Clinical Research Management Inc   ICLR stock is a Zacks Rank  2  Buy  and it has a  B  for Value in our Style Scores  
Icon has a relatively tame forward PE of 16 3  and its EPS is projected to grow by 18  this year   It should also be noted that the research organization has a nice level of profitability  posting a trailing twelve month net margin of 15    The company has topped our EPS consensus in each of the last four quarters  and it is slated to release its Q3 earnings in mid October 
Laboratory Corporation of America Holdings   NYSE LH  
Laboratory Corporation is a clinical laboratory that offers various tests which are used by the medical field in routine testing  patient diagnosis  and in the monitoring and treatment of disease   The company provides end to end drug development support through Covance Drug Development   LH stock is a Zacks Rank  2  Buy  and it has an  A  for Value in our Style Scores   The corporation has been growing rapidly  with sales increasing by 44 37  last year  
Four analysts have revised their EPS estimates for the current year over the last 60 days   No analysts have lowered their earnings estimates in that span of time for fiscal 2016   Laboratory Corporation has topped our estimates over three of the last four quarters  and it is expected to release its Q3 results on the 26th of October 
The Zacks Rank is a truly marvelous trading tool   Our ranking system has beaten the S P 500  yielding an average return of 25  per year for the last 29 years   Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-10-04,Zacks Investment Research,https://www.investing.com/analysis/2-healthcare-stocks-to-buy-before-earnings-season-200157065,200157065
9760,231275,LH,Align Technology s Invisalign G7 Launch Targets Teen Market,opinion,Clear aligner therapy maker Align Technology  Inc    NASDAQ ALGN   is well on track with its product enhancement process  Recently  the company announced the launch of its latest innovation within its Invisalign G Series of products The latest breakthrough  termed by the company as Invisalign G7  includes a set of features that will facilitate better control of tooth movements along with improved treatment outcomes  This Invisalign G7 that addresses critical treatment finishing challenges  will remain particularly effective for teenage patients Invisalign G7 is based on Invisalign SmartStage technology that optimizes staging and sequence of tooth movements and aligner activation  Align claims this product will deliver better upper lateral control  improved root control  and features to address prevention of posterior open bites  In this regard  the company noted that Invisalign is the only system that combines proprietary SmartTrack material with SmartForce features and SmartStage technology for more predictable tooth movement than ever before ALIGN TECH INC Price   Apart from Invisalign G7  Align also announced the launch of ClinCheck Pro 5 0  its next generation Invisalign treatment software  This has the ability to view side by side treatment plans  a more realistic 3D visual model and a new configurable toolbar for greater flexibility  Both the Invisalign G7 features and the ClinCheck Pro 5 0 software will be available worldwide to Invisalign trained providers on Oct 17  2016 Banking on its primary product  Invisalign Clear Aligner  Align has established itself as a strong player in the malocclusion market  Over the past few quarters  sales have increased consistently  riding on the strength of this product  Moreover  several features have been introduced across the Invisalign system  to address some of the most significant treatment challenges encountered by doctors  The company s Invisalign G5 and G4 are working successfully in the global orthodontic market In addition  Invisalign Teen continues as the largest growth opportunity  being the prime orthodontic segment of Align on a global basis  In the key teen market  the company continues to gain considerable share  With the latest Invisalign G7 launch  we expect Align to further strengthen its position  particularly in the Invisalign Teen market Zacks Rank   Key Picks      Align Technology currently has a Zacks Rank  3  Hold  Some better ranked medical stocks are Boston Scientific Corporation   NYSE BSX    The Cooper Companies Inc    NYSE COO   and Laboratory Corp  of America Holdings   NYSE LH    All the three stocks carry a Zacks Rank  2  Buy   You can see  Boston Scientific has gained 25 6  year to date  much better than the S P 500 s 4 5  over the same period  Over the past three months  BSX s earnings estimates for the current year have inched up 0 9  to  1 10 per share Cooper has seen eight estimates move higher for the current fiscal over the past 60 days  compared to no downward movement  Accordingly  earnings estimates for the year have moved up by 1 2  to  8 42 per share  The stock recorded a gain of 33 9  year to date LabCorp has an impressive earnings growth rate of 11 3  for the current fiscal  way ahead of the industry growth expectation of 7 6   Year to date  the stock has performed better than the S P 500  with a gain of 10 4  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-12,Zacks Investment Research,https://www.investing.com/analysis/align-technology's-invisalign-g7-launch-targets-teen-market-200158321,200158321
9761,231276,LH,5 Stocks With Solid Sales Growth To Power Your Portfolio	,opinion,"When it comes to picking stocks  employing a meticulous strategy with focus on low risk usually results in steady returns  While investors are often beguiled into undertaking complex investment strategies in a bid to book higher returns  this may not yield the desired results every time Hence  using conventional strategies  based on key fundamentals  to choose stocks is always wise  These strategies are not only safe but are also worthwhile in bearish markets  We have chosen one such strategy that is focused on sales growth Why Focus on Sales Growth Consistent sales growth is the key to survival for any business  particularly in today s fast changing and highly competitive business environment  For any corporate house  sales growth not only provides an insight into product demand and pricing power  it is vital for growth projections and strategic decision making However  investors often fail to consider sales growth as a dependable metric  This might be because of investors  preconceived notion that a company s stock price is typically sensitive to its earnings momentum Nevertheless  investors should look for a strong relationship between sales growth levels and the value of an enterprise  This is because in cases where companies incur a loss  albeit transitorily  they are valued on their revenues not earnings  as top line growth  or decline  is usually an indicator of a company s future performance Also  investors should not only consider that sales figure is improving but also check whether it is accelerating  Precisely  sales growth rate in the current year should exceed prior year levels Hence  the Price to Sales  P S  ratio can turn out to be an appropriate metric for stock valuation  This metric s importance lies in the fact that management has limited opportunities to manipulate revenues unlike earnings However  a huge sales number does not necessarily convert into profits  Hence  considering a company s cash position along with its sales number can prove to be more prudent  Substantial cash in hand and a steady cash flow lend a company more flexibility with respect to business decisions and investments The Right StrategyA careful selection of stocks considering certain factors should help investors to not only build wealth but beat the market as well In order to shortlist stocks that have witnessed impressive sales growth along with a high cash balance  we have added 5 Year Historical Sales Growth     greater than X Industry and Cash Flow greater than  500 million as our primary screening parameters However  sales growth and cash strength are not the absolute criteria for selecting stocks  So  we added a few other factors to arrive at a winning strategy Price to Sales  P S  Ratio less than X Industry  This metric determines the value placed on each dollar of a company s revenues  The lower the ratio  the better it is for picking a stock since the investor is paying less for each unit of sales   Change F1 Sales Estimate Revisions  4 Weeks  greater than X Industry  Better than industry estimate revision has often been seen to trigger an increase in the stock price Operating Margin  Average Last 5 years  greater than 5   Operating margin measures how much every dollar of a company s sales translates into profits  A high ratio indicates that the company has good cost control and sales are increasing faster than costs  an optimal situation for the company Return on Equity  ROE  greater than 5   This metric will ensure that sales growth is being translated into profits and the company is not hoarding cash  A high ROE means the company is spending wisely and is in all likelihood profitable Zacks Rank less than or equal to 2  Zacks Rank  1  Strong Buy  or 2  Buy  stocks are known to outperform irrespective of the market environment Here are five of the fifteen stocks that made it through the screen Laboratory Corp  of America Holdings   NYSE LH   is a leading healthcare diagnostics company  providing clinical laboratory services and drug development support  This Burlington  NC based company currently has a long term expected EPS  earnings per share  growth rate of 10 3  and carries a Zacks Rank  2 Raymond James Financial  Inc    NYSE RJF    a FL based company in the investment brokerage space  has a long term expected EPS growth rate of 17 0   The company carries a Zacks Rank  2 Intel Corporation   NASDAQ INTC    one of the world s leading producers of semiconductor components  currently has a long term expected EPS growth rate of 7 8   This Santa Clara  CA based company sports a Zacks Rank  1  You can see 
Euronet Worldwide  Inc    NASDAQ EEFT   is a major player in providing payment and transaction processing solutions to clients including financial institutions  retailers and service providers worldwide  This Leawood  KS based company has a long term expected EPS growth rate of 14 8  and carries a Zacks Rank  2 Nu Skin Enterprises Inc    NYSE NUS   is engaged in the development and distribution of consumer products  offering beauty and wellness solutions under its Nu Skin personal care  Pharmanex nutrition brand and ageLOC anti aging category brands in over 50 markets worldwide  The Provo  UT based firm has a long term expected EPS growth rate of 8 1  and carries a Zacks Rank  2 You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 
 
Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at  
Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ",2016-10-13,Zacks Investment Research,https://www.investing.com/analysis/5-stocks-with-solid-sales-growth-to-power-your-portfolio-200158906,200158906
9762,231277,LH,Can LabCorp  LH  Pull A Surprise This Earnings Season ,opinion,Laboratory Corp  of America Holdings   NYSE LH    or LabCorp  is scheduled to report third quarter 2016 results before the market opens on Oct 26 Last quarter  the company reported a positive earnings surprise of 0 87  with the four quarter trailing average beat being 0 86   Let s see how things are shaping up prior to this announcement Factors at PlayRecently  LabCorp completed the acquisition of Sequenom  Inc  which is aimed at expanding the company s presence at both domestic and international levels  The buyout is also likely to help LabCorp strengthen its position in the domains of non invasive prenatal testing  women s health and reproductive genetics LABORATORY CP Price and EPS Surprise    Meanwhile  the company continues to focus on expanding its testing capabilities beyond the conventional health care setting  Post the last reported second quarter  LabCorp announced nationwide availability of testing for Zika virus using the Zika Immunoglobulin M  IgM  Antibody Capture Enzyme Linked Immunosorbent Assay  Zika MAC ELISA   We believe this will help the company meet the growing health care needs Management also intends to continue its expansion drive in the food safety test space by making the best use of its expertise  The company also wants to emphasize on innovation through commercialization of new technologies that allow faster pathogen detection  LabCorp is also developing innovative solutions and expanding therapeutic expertise in critical areas of drug development to come up with ground breaking medicines  We believe these recent developments will contribute to the company s top line in the third quarter as well However  foreign exchange headwind and intense competition from major commercial laboratories and hospitals are major headwinds  We are also highly disappointed with the CMS proposal related to the Protecting Access to Medicare Act  PAMA  Earnings WhispersOur proven model does not conclusively show that LabCorp is likely to beat earnings this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP   LabCorp has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at  2 29 Zacks Rank  LabCorp has a Zacks Rank  2 which increases the predictive power of ESP  However  a 0 00  ESP makes surprise prediction difficult Meanwhile  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter Glaukos Corporation   NYSE GKOS   has an earnings ESP of  200  and a Zacks Rank  1  You can seeEdward Lifesciences Corp    NYSE EW   has an earnings ESP of  2 94  and a Zacks Rank  2 Invuity  Inc    NASDAQ IVTY   has an earnings ESP of  8 07  and a Zacks Rank  2 Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-18,Zacks Investment Research,https://www.investing.com/analysis/can-labcorp-(lh)-pull-a-surprise-this-earnings-season-200159574,200159574
9763,231278,LH,Quest Diagnostics  DGX  Tops Q3 Earnings  Narrows View,opinion,Quest Diagnostics    NYSE DGX   third quarter 2016 adjusted earnings per share  EPS  of  1 37 came in 2 cents ahead of the Zacks Consensus Estimate and exceeded the year ago number by 7  Adjusted EPS in the reported quarter excludes the gain from the sale of the company s Focus Diagnostics products business  charges related to retirement of debt and related refinancing as well as restructuring and integration costs  Reported EPS in the third quarter came in at  1 34  representing a year over year plunge of 42 9  Reported revenues for the third quarter inched up 0 3  year over year to  1 89 billion  while remaining in line with the Zacks Consensus Estimate  The year over year comparison has been adjusted taking into consideration the company s strategic divestitures  Celera and Focus diagnostics  in order to refocus on core diagnostic information services QUEST DIAGNOSTC Price  Consensus and EPS Surprise    Volume  measured by the number of requisitions  increased 2  year over year  Revenue per requisition was flat year over year  Diagnostic information services revenues in the quarter grew 2 1  on a year over year basis Among operating costs  cost of services during the reported quarter was  1 16 billion  down 0 4  year over year  Gross margin came in at 38 6   up 43 basis points  bps  year over year Selling  general and administrative expenses increased 1 7  to  409 million in the reported quarter  Adjusted operating margin showed an improvement of 12 bps to 16 9   with a 0 9  rise in adjusted operating income to  319 million Quest Diagnostics exited third quarter 2016 with cash and cash equivalents of  406 million  which marked a 43 4  surge from second quarter 2016  Year to date  net cash provided by operating activities was  765 million compared with  549 million in the comparable year ago period Through the first nine months of 2016  the company repurchased 5 7 million shares for  440 million including 3 1 million shares repurchased under an accelerated share repurchase agreement during the second and third quarters of 2016 for  250 million  Quest Diagnostics is currently left with  532 million of authorization under the approved share repurchase plan OutlookQuest Diagnostics has narrowed its previously provided 2016 revenue guidance  The company currently expects full year revenues to be  7 51 billion compared to the earlier range of  7 47  7 54 billion  This reflects a 0 5  increase over 2015 reported revenues  2 5  growth over 2015 on an equivalent basis   The current Zacks Consensus Estimate for revenues is pegged at  7 52 billion  just above the guidance range In addition  the company s 2016 adjusted EPS expectation range has been narrowed to the range of  5 07  5 12 from the earlier provided range of  5 02  5 17  The Zacks Consensus Estimate of  5 10 remains within the guided range Operating cash flow for 2016 is expected to reach  1 billion  unchanged   The current estimate for capital expenditure has been narrowed to  250 million from the earlier range of  250  300 million Our TakeQuest Diagnostics  third quarter earnings duly exceeded the Zacks Consensus Estimate while revenue remained in line with the same  The company is currently refocusing on its core diagnostic information services business and working on delivering disciplined capital deployment We are also highly optimistic about the company s focus on continued execution of its five point strategy  According to Quest Diagnostics  its planned divestiture of the Focus Diagnostics products business is part of this broader strategy to refocus the same on diagnostic information services   In addition  several new relationships with hospitals and integrated delivery networks were the other growth drivers However  over the past several quarters  the overall soft industry trends  leading to a low volume environment  have acted as a dampener for the company Zacks RankThe stock presently carries a Zacks Rank  3  Hold   Some better ranked players in the broader medical sector are Almost Family Inc    NASDAQ AFAM    Laboratory Corp  of America Holdings   NYSE LH   and The Cooper Companies Inc    NYSE COO     all carrying a Zacks Rank  2  Buy  You can see  Almost Family has gained 9 99  year to date  much better than the S P 500 s 4 9  over the same period  The company s next 5 year earnings growth expectation stands at 15   higher than the industry average of 13 2  Cooper has seen seven estimates moving higher for the current fiscal over the past 60 days  compared to one downward movement  Accordingly  earnings estimates for the year have moved up by 0 4  to  8 42 per share  The stock recorded a gain of 33 4  year to date LabCorp s earnings estimates for 2016 have moved up by 0 23  to  8 81 per share over the last three months  The company has an impressive earnings growth rate of 10 3  for the current fiscal  Year to date  the stock has performed better than the S P 500  with a gain of 11 6  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-19,Zacks Investment Research,"https://www.investing.com/analysis/quest-diagnostics-(dgx)-tops-q3-earnings,-narrows-view-200159803",200159803
9764,231279,LH,LabCorp  LH  Q3 Earnings Miss  Revenues In Line  Guides Up,opinion,Laboratory Corporation of America Holdings   NYSE LH   or LabCorp reported third quarter 2016 adjusted earnings per share  EPS  of  2 25  up 8 7  from the year ago quarter  However  adjusted EPS lagged the Zacks Consensus Estimate by 5 1  On a reported basis  LabCorp s net earnings came in at  179 5 million or  1 71 per share compared with  154 7 million or  1 50 per share a year ago Net revenue for the third quarter increased 4 5  year over year to  2 37 billion and were in line with the Zacks Consensus Estimate  Strong organic volume growth and tuck in acquisitions contributed to top line growth  However  these positives were partially offset by adverse currency exchange movement to the tune of 50 basis points  bps   Organic revenue growth  excluding the currency impact  was 3 6  LABORATORY CP Price  Consensus and EPS Surprise   Quarter under ReviewCurrently  LabCorp reports under two operating segments  LabCorp Diagnostics  LabCorp s legacy business  except for its clinical trial services business  which is now part of Covance Drug Development  and includes the nutritional chemistry and food safety business  previously part of Covance   and Covance Drug Development  Covance s legacy business  except for its nutritional chemistry and food safety business  which is now part of LabCorp Diagnostics  and includes LabCorp s legacy clinical trial services business  In the reported quarter  LabCorp Diagnostics reported net revenue of  1 67 billion  up 4 4  year over year  fueled by price  mix and tuck in acquisitions  partially offset by 0 3  organic volume decline  measured by requisitions  and unfavorable foreign currency translation of 0 1   The company reported 3  increase in total volume  measured by requisition  and a 4 2  increase in revenue per requisition in the quarter Covance Drug Development reported a 4 8  rise in net revenue to  701 1 million in the third quarter of 2016  driven by broad based demand  partially offset by 150 bps negative impact due to foreign currency translation  At Constant Exchange Rate  CER  and excluding the impact of the expiration of the Sanofi  PA SASY  site support agreement  net revenue increased 9 5  year over year on higher demand Gross margin fell 4 bps to 36  in the quarter  Adjusted operating income increased 2 3  year over year to  387 9 million  However  adjusted operating margin contracted 30 bps from the year ago quarter to 16 1  on a 3 9  rise in selling  general and administrative expenses to  400 5 million LabCorp exited the third quarter with cash and cash equivalents of  567 6 million compared with  639 6 million at the end of the second quarter  Year to date operating cash flow was  727 million  up from an operating cash outflow of  597 8 million in the year ago period  Free cash flow came in at  522 4 million  significantly up from free cash flow of  427 1 million in the year ago period OutlookLabCorp updated its 2016 financial outlook  With the acquisition of Sequenom  the net revenue growth expectation has been raised to a new range of 10  11  over 2015  from the earlier expectation of 9 5  10 5    This includes a 60 bps impact from unfavorable foreign exchange headwind  earlier expectation was 50 bps  resulting from the strengthening of the dollar  The current Zacks Consensus Estimate for revenues is pegged at  9 40 billion Adjusted EPS guidance for 2016 has also been narrowed to the range of  8 70  8 90  earlier  8 60  8 95   The current Zacks Consensus Estimate of  8 80 falls at the mid point of the guided range Free cash flow expectation has been lowered to a new band of  840  880 million  up 17  24  over the prior year   prior guidance was  900  950 million  Our TakeLabCorp s consolidated third quarter earnings failed to meet the Zacks Consensus Estimate while revenues were in line with the same  Unfavorable foreign exchange continues to remain as a major dampener to the company s overall results  This has been a poor quarter with respect to organic volume growth in LabCorp Diagnostics  However  revenue growth was noted in Covance Drug Development and operating leverage was achieved  We believe that with the integration of Covance  LabCorp is perfectly positioned to drive long term profitable growth through a combination of world class diagnostics  drug development expertise and knowledge services  Although the strengthening of the dollar continues to weigh on the company s year over year performance  the raised 2016 outlook is a firm indication that the scenario is going to rebound down the line Zacks Rank   Key PicksLabCorp currently has a Zacks Rank  3  Hold   Better ranked stocks in the medical space include GW Pharmaceuticals plc   NASDAQ GWPH    Quidel Corp    NASDAQ QDEL   and Baxter International Inc    NYSE BAX   GW Pharmaceuticals sports a Zacks Rank  1  Strong Buy   while Quidel and Baxter carry a Zacks Rank  2  Buy   You can see GW Pharmaceuticals surged 70 3  year to date compared to the S P 500 s 4 85  over the same period  The company s four quarter average earnings surprise is 41 7  Quidel rallied 23 8  in the past one year  higher than the S P 500 s 3 74   Over the next five years  the stock is estimated to record an earnings growth rate of 20   higher than the industry average of 15 1  Baxter s shares soared 28 86  year to date  Over the next five years  the stock is expected to see 12 3  earnings growth  It has a trailing four quarter average earnings surprise of 30 55  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-25,Zacks Investment Research,"https://www.investing.com/analysis/labcorp-(lh)-q3-earnings-miss,-revenues-in-line;-guides-up-200160792",200160792
9765,231280,LH,LabCorp s Takeover Of Sequenom Wins Antitrust Clearance,opinion,"Laboratory Corporation of America Holdings   NYSE LH   or LabCorp recently got the antitrust review clearance for its previously announced acquisition of Sequenom  Inc    NASDAQ SQNM    a major player in the field of non invasive prenatal testing  NIPT  for reproductive health  According to the company  the waiting period under the HSR Act  Hart Scott Rodino Antitrust Improvements Act of 1976  has just got over fulfilling one of the essential criterias for the completion of this impending buyout 
Notably  following the takeover announcement  LabCorp formed an acquisition subsidiary  Savoy Acquisition Corp  which had commenced a tender offer on Aug 9  2016 to purchase all outstanding shares of Sequenom for  2 40 per share  This tender offer will expire on Sep 7  2016 unless extended further 
The deal was inked for an equity value of  302 million representing total enterprise value of  371 million  The acquisition is expected to get completed by the end of 2016 and is still subject to other customary closing conditions 
According to LabCorp  this buyout will be a strategic fit for the company  business as Sequenom s NIPT and genetic testing capabilities will further advance LabCorp s extensive women s health test menu  The inclusion will also increase LabCorp s geographic reach both domestically and internationally  particularly EU and the Asia Pacific region  
We take a note that  traditionally  LabCorp has successfully outgrown itself through organic means like acquisitions and alliances  With the momentous buyout of Covance  LabCorp is vigorously trying to expand the company s range of diagnostic offerings and create a new industry leader in both laboratory testing and CRO spaces  At the same time act as a leading provider of medical testing  besides operating as a premier full service drug development organization 
Apart from huge buyouts like Covance  LabCorp continues to add complementary capabilities through targeted tuck in acquisitions  the latest in the league being Sequenom  Besides  in Mar 2016  the company acquired full service independent women s health laboratory  Pathology  Inc   including the patient service centers used to conduct the latter s medical testing and services business 
Prior to that  in October  it had bought Safe Foods International Holdings  a food safety laboratory  the inclusion of which extended LabCorp s size and reach in the fast growing global food safety market  All these acquisitions are consistent with the company s effort to reinforce its foothold in the personalized diagnostics testing market 
Zacks Rank
LabCorp currently carries a Zacks Rank  3  Hold   Two better ranked stocks in the sector are Align Technology Inc    NASDAQ ALGN   and Derma Sciences Inc    NASDAQ DSCI    Both the stocks carry a Zacks Rank  2  Buy  ",2016-08-25,Zacks Investment Research,https://www.investing.com/analysis/labcorp's-takeover-of-sequenom-wins-antitrust-clearance-200150120,200150120
9775,231290,LH,Six Healthcare Stocks With Nice Upside Potential,opinion,"Q4 Earnings Update
This earnings season continues to be a story of growth  According to   319 members of the S P 500 have reported as of Wednesday  February 8th  Total earnings from these companies have grown 5 8  in Q4 compared to 2 8  in Q3 while revenues have increased 2 8  in Q4 vs 2 0  in Q3  Overall  S P 500 member earnings remain on pace to reach their highest level in nearly two years 
One standout sector has been medical healthcare stocks  So far these companies have reported revenue growth of 5 9  with 57  beating their estimates  Immediately following the earnings release  these healthcare companies have enjoyed a positive 1 4  stock price impact 
So let s take a look at some fundamentally attractive healthcare stocks that could jump on earnings this week 6 Healthcare
Stocks That Could Jump On Earnings
According to   there are 65 companies listed in the healthcare sector expected to report earnings this week  2 13 2 17   However  only six appear to be trading below their finbox io fair value estimate  Charles River Laboratories  NYSE CRL   Alkermes  NASDAQ ALKS   Laboratory Corporation of America  NYSE LH   Icon PLC  NASDAQ ICLR   Express Scripts  NASDAQ ESRX  and Alexion Pharmaceuticals Inc  NASDAQ ALXN  
Charles River Laboratories is an early stage contract research company providing drug discovery and preclinical development services worldwide  The company is expected to report earnings on Tuesday while eight valuation models conclude a fair value range of  86 11 to  118 98 and  104 37 at the midpoint 
Alkermes is a biopharmaceutical company that develops pharmaceutical products designed to address unmet medical needs  The company is expected to report on Wednesday and seven separate valuation analyses imply a fair value of  68 14  slightly above Wall Street s target 
Laboratory Corporation of America operates as an independent clinical lab  Ten cash flow valuation models imply that shares are approximately 20  undervalued  The company is expected to report earnings on Thursday before the market opens 
ICON is a contract research organization that provides outsourced development services to the pharmaceutical and medical device industries  The research firm is scheduled to report earnings on Thursday and the stock is currently trading near its 52 week high  However  finbox io fair value data implies that shares are still 18  undervalued 
Express Scripts operates as a pharmacy benefit management company  Seven cash flow analyses imply that the company is approximately 12  undervalued prior to reporting earnings  expected Tuesday   This compares to Wall Street s price target of  81 11 which implies over 20  upside 
Alexion is a biopharmaceutical company that develops and commercializes life transforming therapeutic products  The company is scheduled to report earnings on Thursday  The Wall Street consensus price target of  167 93 is above finbox io s fair value estimate of  133 34  Both estimates imply positive margin of safety 
These healthcare stocks all have strong fundamentals and could easily trade higher following their earnings reports this week  Value investors may want to take a closer look ",2017-02-12,Finbox io,https://www.investing.com/analysis/six-healthcare-stocks-with-nice-upside-potential-200175446,200175446
9777,231292,LH,LabCorp Q2 Results Strong  Sequenom Buyout Raises Hope,opinion,On Aug 18  2016  we issued an updated research report on Laboratory Corporation of America Holdings   NYSE LH   or LabCorp  a leading independent clinical laboratory company  LabCorp is currently working on portfolio expansion  The company is more focused on the high margin esoteric testing business to drive its top line LabCorp s second quarter earnings and revenues both managed to surpass the Zacks Consensus Estimate  This has been a strong quarter with respect to organic volume growth in LabCorp Diagnostics  accelerated revenue growth in Covance Drug Development and operating leverage With the acquisition of Covance  which is now operational as Covance Drug Development  LabCorp expects to expand the company s range of diagnostic offerings and create a new industry leader in both the laboratory testing and CRO spaces  This will act as a leading provider of medical testing apart from operating as a premier full service drug development organization In the second quarter  revenues from Covance Drug Development were up 12 2  year over year  The full year 2016 anticipated growth target of this segment currently remains at 7  to 9  from 2015  an increase from the prior guidance of 6  to 9   driven by strong organic growth Apart from massive takeovers like Covance  LabCorp continues to add complementary capabilities through targeted tuck in acquisitions  The latest in this list is the impending acquisition of Sequenom  a prominent player in the field of non invasive prenatal testing  NIPT  for reproductive health  According to LabCorp  this acquisition will be a strategic fit for the company s business as Sequenom s NIPT and genetic testing capabilities will further advance LabCorp s extensive women s health test menu We expect LabCorp to benefit from organic growth as well introduction of new tests for existing and new customers in the near term  In this regard  the recent launch of a set of new tests including Roche cobas EGFR Mutation Test v2 and a complementary PDL1 diagnostic test for bladder cancer are noteworthy additions to the company s world class test menu However  the current economic uncertainty remains a restraint for LabCorp  The strengthening of the dollar continues to weigh on its year over year revenue performance  Moreover  changes in governmental regulations have had a considerable impact on LabCorp s operations  We are highly disappointed with the recent CMS proposal related to Protecting Access to Medicare Act  PAMA  LabCorp currently carries a Zacks Rank  3  Hold  Key Picks in the SectorMedical instruments stocks that are worth considering include Align Technology Inc    NASDAQ ALGN    Antares Pharma Inc    NASDAQ ATRS   and Derma Sciences Inc    NASDAQ DSCI    All these stocks carry a Zacks Rank  2  Buy  ,2016-08-18,Zacks Investment Research,"https://www.investing.com/analysis/labcorp-q2-results-strong,-sequenom-buyout-raises-hope-200149028",200149028
9780,231295,LH,ResMed  RMD  Q3 Earnings   Sales Beat On Overall Growth,opinion,"ResMed Inc    NYSE RMD   announced third quarter fiscal 2018 adjusted earnings per share  EPS  of 92 cents  up 29 6  from the prior year quarter  Earnings beat the Zacks Consensus Estimate of 83 cents by 10 8  Including one time items  ResMed reported EPS of 76 cents in the quarter  up 22 6  year over year A Closer View of the Top LineRevenues in the reported quarter increased 15 1  year over year  up 10  at constant exchange rate or CER  to  591 6 million  The figure also beat the Zacks Consensus Estimate of  564 9 million On a geographic basis  excluding Brightree  revenues in the United States  Canada and Latin America totaled  317 5 million  reflecting a 7  increase over the prior year quarter  Moreover  revenues from Brightree in the quarter totaled  39 9 million  up 14  year over year  Revenues in the combined EMEA and APAC region were  234 2 million  highlighting an 16  rise at CER from a year ago Adjusted gross margin contracted 10 basis points  bps  year over year to 58 2  in the reported quarter  Fall in average selling prices led to the gross margin contraction  which was however  partially offset by procurement and production efficiencies 
ResMed Inc  Price  Consensus and EPS Surprise   Selling  general and administrative expenses were up 7 3  year over year to  147 9 million  while there was a 6 6  increase in Research and Development expenses to  37 4 million  This led to an 7 1  rise in adjusted operating expenses  which amounted to  185 3 million  However  adjusted operating margin in the quarter rose 230 bps to 26 9  Financial UpdatesResMed exited third quarter fiscal 2018 with cash and cash equivalents of  704 3 million  compared with  858 9 million at the end of second quarter fiscal 2018 Year to date  the company generated  375 6 million of cash flow from operations  up from the year ago figure of  273 7 million Along with the third quarter earnings release  ResMed announced a quarterly dividend of 35 cents per share  same as the prior payout  The dividend will be paid on Jun 14  to shareholders of record as on May 10 As part of the company s capital management plan  ResMed repurchased 200 000 shares for  19 4 million in the fiscal third quarter GuidanceManagement expects SG A expenses of around 25   as a percentage of revenues  for the fourth quarter fiscal 2018  R D expenses  as a percentage of revenues  are projected in the band of 6 7  for the fourth quarter  This reflects marketing expenses associated with product launches along with the ongoing legal expenses Our TakeResMed exited the third quarter on a promising note  The company achieved solid double digit global revenue growth in the quarter  led by sales from Software as a Service businesses as well as its new mask products and devices  In terms of recent developments  the company recently received reimbursement approval for mandibular repositioning devices in France  This should drive accelerate the uptake of ResMed s dental devices which help treat sleep apnea by 35  Further  the company announced that South Korea will start reimbursing diagnosis and therapeutic treatment for sleep apnea in the near term  All these factors boost investor faith in the stock However  competitive bidding issues continue to hurt the stock  The company is also exposed to foreign exchange fluctuations Zacks Rank   Other Key PicksResMed carries a Zacks Rank  2  Buy  Other top ranked stocks in the broader medical space  which reported solid earnings this season  are Laboratory Corporation of America Holdings   NYSE LH    Chemed Corporation   NYSE CHE   and Intuitive Surgical  Inc    NASDAQ ISRG    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   LabCorp and Chemed carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings of  2 44 per share  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the Zacks Consensus Estimate by 10 6  LabCorp reported first quarter 2018 adjusted EPS of  2 78  beating the Zacks Consensus Estimate by 5 3   Revenues came in at  2 85 billion  exceeding the consensus estimate of  2 78 billion Chemed posted first quarter 2018 adjusted EPS of  2 72  beating the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  steering past the Zacks Consensus Estimate of  420 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/resmed-rmd-q3-earnings--sales-beat-on-overall-growth-200310231,200310231
9781,231296,LH,Abaxis  ABAX  Beats Earnings And Revenue Estimates In Q4,opinion,"Abaxis  Inc    NASDAQ ABAX   reported fourth quarter fiscal 2018 adjusted earnings per share of 42 cents  beating the Zacks Consensus Estimate by 31 3   Moreover  adjusted earnings rose 27 3  from the year ago 33 cents Full year 2018 adjusted earnings per share came in at  1 29 in comparison with  1 27 in fiscal 2017  The figure also surpassed the Zacks Consensus Estimate of  1 16 Total RevenuesIn the fiscal fourth quarter  Abaxis recorded revenues of  67 9 million  reflecting an increase of 16 7  from a year ago  The top line also surpassed the Zacks Consensus Estimate of  67 million  Foreign currency exchange fluctuations had a favorable 2  impact on the top line Fiscal 2018 revenues were  244 7 million  up 7 7  from the prior fiscal  The figure also beat the Zacks Consensus Estimate of  243 8 million Segments in DetailRevenues from North America  accounting for 80  of total revenues  rose 16 7  to  54 3 million in the reported quarter  Revenues from the international markets  accounting for the rest  improved 16 2  to  13 6 million 
Abaxis Inc  Price  Consensus and EPS Surprise   Abaxis operates through three main segments   Veterinary  Medical and Other  In the reported quarter  Veterinary sales contributed 83 4  of total sales  Medical added 15  while the remaining 1 6  was generated from Other Veterinary market revenues rose 19 4  year over year to  56 6 million  driven by a 22  uptick in veterinary consumable revenues to  45 3 million  Veterinary instrument revenues were up 9  year over year to  9 3 million Revenues from the medical market were up from  9 5 million in the same quarter last year to  10 2 million led by strength in medical rotors  Also  revenues at the North American medical division totaled  7 4 million  up 11  year over year  On a global basis  Abaxis sold 189 Piccolos in the quarter compared with 212 a year ago Abaxis exhibited strong consumable growth  up 19  year over year to  53 4 million in the quarter  Within the consumable product lines  total rotor revenues were  35 2 million  up 8  from  32 6 million in the year ago quarter  On a global basis  Abaxis sold 2 77 million rotor units in the quarter under review  up 5  from 2 63 million in the year ago quarter  Hematology reagents and rapid assays also drove growth in consumable revenues With solid contributions from FLEX4 Rapid assay  heartworm  feline parvo and test for canine specific lipase  revenues from rapid assay were the major contributors to the top line Moreover  total instruments  sales rose 8  to  10 7 million on strong uptake of the recently launched urine sediment instrument Operational UpdatesGross profit in the fourth quarter rose 15 8  to  37 3 million  Gross margin contracted 40 basis points  bps  to 54 9  Research and development expenses increased 16 3  year over year to  5 7 million and sales and marketing expenses rose 27  to  14 6 million  General and administrative expenses also rose 4 3  to  4 8 million  However  the resultant operating income was up 8 9  to  12 2 million in the quarter and operating margin declined 130 bps to 17 9  Financial UpdateAbaxis exited fiscal 2018 with cash  cash equivalents and short term investments of  166 8 million  compared with  161 6 million in the fiscal third quarter Our TakeAbaxis exited the fiscal fourth quarter on a promising note  However  a decline in gross and operating margin raises concern  Meanwhile  a year over year increase in revenues buoys optimism on the company  We are upbeat about the company s solid consumable and instrument sales growth along with strength in the medical and veterinary market segments Meanwhile  we are encouraged by the company s initiation of new sales and marketing strategies  In this regard  Abaxis has received encouraging response for recently launched products like the urine sediment analyzer and FLEX4 Rapid assay  The company plans additional launches in fiscal 2018 which are expected to drive growth Zacks Rank   Other Key PicksAbaxis sports a Zacks Rank  1  Strong Buy  Other top ranked stocks in the broader medical space  which reported solid earnings this season  are Laboratory Corporation of America Holdings   NYSE LH    Chemed Corporation   NYSE CHE   and Intuitive Surgical  Inc    NASDAQ ISRG    While Intuitive Surgical sports a Zacks Rank  1  LabCorp and Chemed carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings of  2 44 per share  which beat the Zacks Consensus Estimate by 22 6   Revenues totaled  848 million  also surpassing the Zacks Consensus Estimate by 10 6  LabCorp reported first quarter 2018 adjusted EPS of  2 78  beating the Zacks Consensus Estimate by 5 3   Revenues came in at  2 85 billion  exceeding the consensus estimate of  2 78 billion Chemed posted first quarter 2018 adjusted EPS of  2 72  beating the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  steering past the Zacks Consensus Estimate of  420 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/abaxis-abax-beats-earnings-and-revenue-estimates-in-q4-200310229,200310229
9782,231297,LH,LabCorp Extends UnitedHealthcare Pact  Lifts Diagnostics Arm,opinion,Over the last few months  Laboratory Corporation of Americas Holdings   NYSE LH    popularly known as LabCorp  has been dominating headlines on several developments including strategic partnerships and divestments  Following the company s laboratory collaboration with Appalachian Regional Healthcare and Mount Sinai  it has formed one more joint venture  this time with UnitedHealthcare  a business of UnitedHealth Group   NYSE UNH   In fact  this is the renewal of both entities  long term strategic partnership to create more simplified and personalized care recommendations for 48 million people enrolled in UnitedHealthcare plans  Per UnitedHealth  LabCorp will continue to serve as UnitedHealthcare s exclusive national laboratory provider until Jan 1  2019  However  financial terms of the deal have been kept under wraps   Notably  as part of the expanding relationship  both companies are going to join forces on a variety of value based programs  This alliance will help bringing advanced lab services in accountable care arrangements between UnitedHealthcare and more than 1 100 hospitals plus 110 000 physicians Progress on Strategic CollaborationsSignificantly  LabCorp has fortified its footprint in the diagnostics space through both organic and inorganic means plus plans to coordinate with leading companies and academic institutions to build a wider portfolio of tests The company continues to increase its scale and competencies in clinical laboratory medicine via acquisitions ranging from routine capabilities to highly esoteric testing  Among its recent associations  LabCorp has formed one multi year  comprehensive laboratory teamwork with Appalachian Regional Healthcare  Also  under the new agreement with Interpace Diagnostics  Dianon Pathology  a member of the LabCorp Specialty Testing Group  the company will perform the thyroid biopsy analysis Additionally  worth mentioning are the company s two major health systems partnerships  Mount Sinai Health System and PAML  respectively  PAML is a Pacific Northwest based market leading reference and outreach laboratory  Per LabCorp  these anchor health systems will gradually emerge as research hubs  improving access to trials as well as Covance s site activation and investigator besides patient recruitment capabilities Other recent coalitions include a strategic partnership with Thermo Fisher   NYSE TMO    which enabled the launch of Thermo Fisher Oncomine Dx target panel for non small cell lung cancer patients  Also  Labcorp works on developing and operating patient service centers within select Walgreens stores  courtesy of its drug retailer Walgreens   NASDAQ WBA    This apart  the company has an important tie up with Japan based Sysmex Corporation  a foremost clinical laboratory services provider and Roche  the world s reputed biotech company Share Price PerformanceOver the past three months  shares of LabCorp have outperformed its   The stock has gained 0 4  against the industry s 3 7  decline LabCorp carries a Zacks Rank  3  Hold   You can see Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-05-24,Zacks Investment Research,https://www.investing.com/analysis/labcorp-extends-unitedhealthcare-pact-lifts-diagnostics-arm-200319429,200319429
9784,231299,LH,What Awaits Boston Scientific  BSX  In Q2 Earnings ,opinion,"Boston Scientific Corporation   NYSE BSX   is scheduled to report its second quarter 2016 results before the opening bell on Jul 28  Last quarter  the company had posted a positive earnings surprise of 16 67   The four quarter trailing average beat is pegged at 7 45   Let s see how things are shaping up prior to this announcement 
Factors at Play
Pricing pressure has continued for Boston Scientific over the past several quarters  The last reported first quarter s adjusted gross margin was significantly impacted by the pricing headwind  However  on an encouraging note  the company anticipates this headwind reversing gradually on the back of improved price management  primarily through market segmentation  tiered offerings and standard cost reduction programs  This benefit is likely to be reflected in the second quarter 
With regard to adjusted operating margin  Boston Scientific s seven successive quarters of improvement and a raised operating margin guidance have encouraged us to expect another quarter of strong sequential growth with more noticeable improvement in the Rhythm Management segment 
Moreover  the plant network optimization program completed at the end of 2015  transferred a portion of the company s EP manufacturing to lower cost locations  is expected to contribute to the adjusted operating margin improvement BOSTON SCIENTIF Price and EPS Surprise
   We are also optimistic about the company s gradually improving performance in Interventional Cardiology  led by an innovative portfolio and robust commercial teams globally  The company is consistently gaining share in a number of cardiovascular segments and DES  as a differentiated platform of premier and synergy  continues to build momentum and gain share globally 
Meanwhile  MedSurg is expected to demonstrate consistent performance  led by endoscopy  Urology and Women s Health are also estimated to grow beyond market levels driven by investment strategies in key international geographies 
However  Boston Scientific facing severe currency headwinds over the recent past  remains a concern  We note that  with the company recording 47  of its sales from the international market  it remains highly exposed to currency fluctuations  In the first quarter of 2015  foreign exchange headwind affected the company s adjusted earnings by 10 cents a share 
Considering this impact  for 2016  Boston Scientific expects currency headwinds to the tune of approximately  100 million on revenues or  0 05  0 06 per share on adjusted earnings relative to the year ago quarter 
Further  sluggish CRM sales over the recent past continue to weigh on the stock  At the beginning of 2015  Boston Scientific predicted a slowdown in worldwide CRM sales for the entire year due to replacement cycle headwinds and competitive launches in the U S  Although the company is currently expecting a rebound in its CRM performance in the second quarter and second half 2016  we remain on the sidelines based on the challenges the company is still facing in this business  especially in the U S 
On an overall basis  Boston Scientific has provided its second quarter 2016 guidance  The company projects adjusted earnings in the band of 25 27 cents per share on revenues of  2 01  2 06 billion 
Earnings Whispers
Our proven model does not conclusively show that Boston Scientific is likely to beat earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below 
Zacks ESP  Boston Scientific s Earnings ESP is 0 00   since both the Most Accurate estimate and the Zacks Consensus Estimate stand at 27 cents 
Zacks Rank  Boston Scientific has a Zacks Rank  1  Strong Buy  which increases the predictive power of ESP  However  a breakeven ESP makes surprise prediction difficult 
Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
Here are three companies you may want to consider as our proven model shows they have the right combination of elements to post an earnings beat this quarter   
Bristol Myers Squibb Company   NYSE BMY   has an Earnings ESP of  3 03  and a Zacks Rank  1 
Allergan plc   NYSE AGN   has an Earnings ESP of  0 9  and a Zacks Rank  2 
Laboratory Corp  of America Holdings   NYSE LH   has an Earnings ESP of  0 87  and a Zacks Rank  2 ",2016-07-19,Zacks Investment Research,https://www.investing.com/analysis/what-awaits-boston-scientific-(bsx)-in-q2-earnings-200142760,200142760
9785,231300,LH,Illumina  ILMN  To Report Q2 Earnings  What s In The Cards ,opinion,Illumina Inc   NASDAQ ILMN   is scheduled to report its second quarter 2016 financial numbers on Jul 26  after the closing bell Last quarter  the company posted a negative earnings surprise of 4 05   Moreover  Illumina s earnings missed the Zacks Consensus Estimate in two of the past four quarters  with an average negative surprise of 0 36  Let s see how things are shaping up prior to this announcement ILLUMINA INC Price and EPS Surprise    Factors at PlayIllumina commenced its journey for 2016 on a bleak note  with its first quarter results substantially lagging analysts  estimates  One of the primary reasons behind this underperformance was a huge order   worth more than  700 million   received during the quarter  which did not translate into material revenue generation for the company then However on the brighter side  the projected scenario for the yet to be released second quarter s outcome does not seem so dreary  In fact  management expects a significant portion of the deferred revenue of the first quarter to get recognized in the second quarter  which certainly will give a decent boost to this quarter s top line In terms of products  the company s expectation for second quarter remains in line with the prior one  as it anticipates the same amount of orders  i e   20 30 orders for its HiSeq X instruments per quarter Considering a consequential acceleration in the company s instrument shipments  management expects to generate revenues of  590  595 million in the second quarter on account of sequential seasonality in Japan and roughly flat HiSeq X shipment  The current Zacks Consensus Estimate for revenue is pegged at  594 million  close to the upper level of the company provided guidance range The company expects to deliver adjusted EPS in the range of 72 74 cents during the second quarter  The current Zacks Consensus Estimate for EPS is pegged at 73 cents  in line with the mid point of the company provided range On the flip side  Illumina s investments in Helix and GRAIL as well as the headcount additions that management undertook in the prior quarter are expected to result in a sequential rise in operating expenses in the second quarter Moreover  since the newly found enterprise  Grail  is in the process of development and is yet to generate material revenue for Illumina  management expects to recognize most of the losses on account of this investment in the second quarter We currently await an update regarding management s earlier announced plan to adopt a few structural changes along with alteration in accounting treatment in relation to the Grail investment  in the second quarter  As per management  this proposal might reduce the loss associated with this investment in the second half of 2016 Earnings WhispersOur proven model does not conclusively show that Illumina is likely to beat earnings this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP   Illumina has an Earnings ESP of 0 00  That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 73 cents Zacks Rank  Illumina has a Zacks Rank  4  Sell   We caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may want to consider as our proven model shows they have the right combination of elements to post an earnings beat this quarter Bristol Myers Squibb Company   NYSE BMY    with an Earnings ESP of  3 03  and a Zacks Rank  1 Allergan plc   NYSE AGN    with an Earnings ESP of  0 90  and a Zacks Rank  2 Laboratory Corp  of America Holdings   NYSE LH    with an Earnings ESP of  0 87  and a Zacks Rank  2 ,2016-07-19,Zacks Investment Research,https://www.investing.com/analysis/illumina-(ilmn)-to-report-q2-earnings:-what's-in-the-cards-200142683,200142683
9786,231301,LH,Will LabCorp  LH  Beat Earnings Estimates In Q2 ,opinion,"We expect Laboratory Corp  of America Holdings   NYSE LH    or LabCorp to beat expectations when it reports second quarter 2016 results before the opening bell on Jul 27  Last quarter  the company had reported a positive earnings surprise of 3 06  with the four quarter trailing average beat pegged at 1 38   Let s see how things are shaping up prior to this announcement 
Why a Likely Positive Surprise 
Our proven model shows that LabCorp is likely to beat earnings because it has the right combination of two key components 
Zacks ESP  LabCorp s  is  0 87   since the Most Accurate estimate stands at  2 31 while the Zacks Consensus Estimate is pegged lower at  2 29  A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise  
Zacks Rank  LabCorp currently has a Zacks Rank  2  Buy   Note that stocks with a Zacks Rank  1  2 or 3 have a significantly higher chance of beating earnings estimates  Conversely  Sell rated stocks   4 or 5  should never be considered going into an earnings announcement 
The combination of LabCorp s Zacks Rank  2 and  0 87  ESP makes us reasonably confident of a positive earnings beat LABORATORY CP Price and EPS Surprise
    
What s Driving the Better than Expected Earnings 
The last year was marked by LabCorp as one of solid growth  driven by the successful execution of the company s three pronged strategy viz  delivering world class diagnostics  bringing innovative medicines to patients faster  and changing the way of patient care  The company strongly anticipates 2016 to be no different and the first quarter itself bears testimony to that fact
In the second quarter as well  we expect to see LabCorp gain from organic growth by introducing new tests to its existing as well as new customers  channels and markets  In this regard we note the nationwide launch of Zika virus testing using the RealStar Zika Virus RT PCR Kit U S  from altona Diagnostics GmbH  The test had received Emergency Use Authorization from the U S  Food and Drug Administration for the qualitative detection of Zika virus RNA in serum or urine  collected alongside a patient matched serum specimen  
Moreover  the recent launch of a new application for the companion diagnostic associated with the use of Tarceva for the treatment of patients with non small cell lung cancer is another significant addition to the company s world class test menu  We expect both these tests to help strengthen LabCorp s companion diagnostics testing business with solid return from the second quarter itself 
In the field of test menu expansion  we observed that  last year the company successfully introduced 75 new assays and accelerated next generation sequencing capabilities  Looking ahead we are encouraged by the company s potential scope for test menu enhancement and geographic footprint expansion 
Complimentary capabilities were enriched through targeted tuck in acquisitions  As a major improvement  the company s companion diagnostic franchise achieved double digit growth in 2015  and LabCorp is confident about delivering  100 million in incremental revenue in companion diagnostics through 2018 
In fact  the acquisition of Covance  which is operational under the label Covance Drug Development  is the primary reason for LabCorp s steep growth trend from last year  Earlier  LabCorp had set a goal of  150 million in incremental revenues by the end of 2018 
In the first quarter  the acquisition of Covance contributed  687 3 million to the company s revenue  driving 23 7  year over year growth  The company is currently on track to achieve the incremental revenue synergy target  Furthermore  LabCorp expects to achieve annual cost synergies in excess of  100 million to be fully realized within three years of closing  The company is currently working on reducing cost and improving customer experience  Project LaunchPad is an active part of this initiative 
Stocks to Consider
Here are some other companies you may want to consider as our proven model shows these have the right combination of elements to post an earnings beat this quarter 
McKesson Corp    NYSE MCK   has an Earnings ESP of  1 2  and a Zacks Rank  2 
The Cooper Companies Inc    NYSE COO   has an Earnings ESP of  2 64  and a Zacks Rank  2 
CR Bard Inc    NYSE BCR   has an Earnings ESP of  0 41  and a Zacks Rank  2 ",2016-07-18,Zacks Investment Research,https://www.investing.com/analysis/will-labcorp-(lh)-beat-earnings-estimates-in-q2-200142571,200142571
9787,231302,LH,Edwards Lifesciences  EW  Q2 Earnings  Will It Be A Miss ,opinion,"Edwards Lifesciences Corp    NYSE EW   is scheduled to report its second quarter 2016 earnings on Jul 26  after the closing bell 
Last quarter  the company posted a positive earnings surprise of 7 58   Encouragingly  Edwards  earnings outpaced the Zacks Consensus Estimate in all of the past four quarters  with an average beat of 8 06   Let s see how things are shaping up prior to this announcement 
Factors at Play
For the second quarter of 2016  Edwards expects total sales of  700  740 million and adjusted earnings per share  EPS  in the range of 67 73 cents  The current Zacks Consensus Estimate for revenues and EPS are  722 million and 70 cents  respectively  which is within the company s guided range EDWARDS LIFESCI Price and EPS Surprise
    
For the entirety of second quarter  Edwards remained in the MedTech headlines  owing to the release of a handful of significant study results in favor of its transcatheter heart valves  THVs  
The company opened its account in early Apr 2016  with the successive release of two sets of data from the Partner II clinical trial  These data which demonstrated the superiority of Edwards  Sapien XT and Sapien 3 valves over open heart surgery in treating severe  symptomatic aortic stenosis  AS  patients  who were at intermediate risk for surgery 
In the next month  Edwards revealed positive data from the Source 3 Registry of its Sapien 3 THV  at the EuroPCR 2016  The trial outcome exhibited the highest ever reported survival rate and a low stroke rate for AS patients enrolled in the Source family of registries 
We believe that the outcome from the aforementioned study results emphasize the advantages of Edwards  Sapien family of valves for patients suffering from severe symptomatic AS  This  in turn  should lead to greater adoption of these valves  which will boost Edwards  THV business segment sales  We expect this to get reflected in the yet to be released second quarter results 
In the very same month  a federal jury returned a verdict in favor of Edwards  CardiAQ mitral valve platform  in a lawsuit filed against a former service provider  Neovasc  The jury also awarded damages of  70 million to Edwards for trade secret misappropriation  which is expected to get reflected in the company s second quarter s operating results 
On the flip side  as per management s estimate Edwards grew at a slower rate compared to its peers in the recent past  owing to market share decrease as competitors continue to expand their product offerings  With other major players effectively competing to capture larger shares in the MedTech industry space  this remains a major issue of concern for Edwards  investors 
Moreover  significant reimbursement cuts have been taking a toll on the operating results of medical device manufacturers like Edwards  as is apparent from the company s rising operating expenses in recent times 
Earnings Whispers
Our proven model does not conclusively show that Edwards is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below 
Zacks ESP   Edwards has a negative earnings ESP of  1 43  That is because the Most Accurate estimate is pegged at 69 cents while the the Zacks Consensus Estimate is pegged lower at 70 cents 
Zacks Rank  Edwards has a Zacks Rank  4  Sell   which along with a negative ESP of  1 43  makes surprise prediction difficult 
We caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat in the upcoming quarter   
Bristol Myers Squibb Company   NYSE BMY    with an Earnings ESP of  3 03  and a Zacks Rank  1 
Allergan plc   NYSE AGN    with an Earnings ESP of  0 90  and a Zacks Rank  2 
Laboratory Corp  of America Holdings   NYSE LH    with an Earnings ESP of  0 87  and a Zacks Rank  2 ",2016-07-18,Zacks Investment Research,https://www.investing.com/analysis/edwards-lifesciences-(ew)-q2-earnings:-will-it-be-a-miss-200142563,200142563
9796,231311,LH,Hologic  HOLX  Q3 Earnings  A Surprise In The Cards ,opinion,Hologic Inc    NASDAQ HOLX   is slated to report third quarter fiscal 2016 financial results on Jul 27  after the closing bell  Last quarter  the company posted a positive earnings surprise of 2 17   Notably  Hologics  earnings surpassed the Zacks Consensus Estimate in all of the past four quarters  with an average beat of 6 08  Let s see how things are shaping up prior to this announcement HOLOGIC INC Price and EPS Surprise    Factors at PlayAfter delivering a promising result in its fiscal second quarter  Hologic is expected to demonstrate a similar outcome in the yet to be released fiscal third quarter as well  In particular  management remains enthusiastic about the future potential of Hologic s mammography business  with its 3D Genius system currently catering to only 20  of the concerned market  This indicates the scope for further market expansion on Hologic s part  which we believe will get duly reflected in its third quarter outcome However  year over year growth rate for the company s U S  breast health business might seem sluggish due to the higher comparable figures observed in the last fiscal s third quarter In terms of its international breast health business  management expects to witness improved progress in third quarter and going forward  Notably  Hologic has been performing poorly in this space for past few quarters and has gained a certain stabilization only in fiscal second quarter Moreover  management is optimistic about the potential for its MyoSure system as Hologic aims at expanding its share in the addressable market by replacing the previous treatments  In addition  the withdrawal of a competitive product similar to that of Hologic s NovaSure System recently has opened up more possibilities for the system  Going forward  the company is investing in marketing and physician outreach programs to maintain this trend in the quarters ahead We believe these strategic initiatives adopted by management as well as the favorablecompetitive recall will surely get reflected in the form of higher revenues for Hologic s surgical business  to which these two systems belong On the flip side  rising operating expenses remains a concern for the company which in turn might keep its operating margin under strain  Management anticipates similar increase in operating expenses in the third quarter and the rest of fiscal 2016  as part of its strategy to generate long term sustainable growth On the whole  for third quarter fiscal 2016  Hologic expects revenues of  695  705 million  representing annualized growth of 0 2  1 6  and 0 6  2  at CER  Adjusted EPS is projected at 47 48 cents  reported growth of 9 3  11 6  and 10 1  12 4  at CER   The current Zacks Consensus Estimate for revenues and EPS are  702 million and 47 cents  respectively Earnings WhispersOur proven model does not conclusively show that Hologic is likely to beat earnings this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  2 or 3 for this to happen  That is not the case here as you will see below Zacks ESP   Hologic has an earnings ESP of 0 00  That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 47 cents Zacks Rank  Hologic has a Zacks Rank  2  Buy  which increases the predictive power of ESP  However  a 0 00   ESP makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may want to consider as our proven model shows they have the right combination of elements to post an earnings beat in the upcoming quarter   Bristol Myers Squibb Company   NYSE BMY    with an Earnings ESP of  3 03  and a Zacks Rank  1 Allergan plc   NYSE AGN    with an Earnings ESP of  0 90  and a Zacks Rank  2 Laboratory Corp  of America Holdings   NYSE LH    with an Earnings ESP of  0 87  and a Zacks Rank  2 ,2016-07-19,Zacks Investment Research,https://www.investing.com/analysis/hologic-(holx)-q3-earnings:-a-surprise-in-the-cards-200142679,200142679
9797,231312,LH,Bet On These 5 Stocks Registering Strong Sales Growth ,opinion,"With ever changing market dynamics  investors are often beguiled into undertaking complex investment strategies  However  this sometimes may not yield the desired results  Hence  using conventional strategies  which are based on key fundamentals  to choose stocks is always a safe and sound approach for making profits Among several rational and down to earth investment strategies  we picked one that is focused on the sales growth of a company A steady sales growth is the key to survival for a business in today s highly competitive environment  Companies have stepped up marketing initiatives over digital platforms and have become more professional about sales management to drive their top line Flat or declining sales growth indicates obstacles at the company  which will limit scope for sustained growth  Stagnant companies may generate profits for a short period  but they do not ensure enough growth to attract new investors Notably  revenues are often more closely monitored than earnings when assessing the growth of a business  It s worth keeping in mind that in cases when companies incur a loss  albeit transitorily  they are valued on their revenues  as top line growth  or decline  is usually an indicator of a company s future earnings performance  Hence  the Price to Sales  P S  ratio can turn out to be an appropriate metric for stock valuation  Notably  this metric s importance further lies in the fact that management has limited opportunities to manipulate revenues unlike earnings Focusing solely on sales growth is  however  not enough  A consideration of a company s cash position along with its sales number can be a more dependable strategy  Substantial cash in hand and a steady cash flow give a company more flexibility with respect to business decisions and investments The Right StrategyA careful selection of stocks considering certain factors should help investors to not only build wealth but beat the market as well In order to shortlist stocks that have impressive sales growth along with a high cash balance  we added 5 Year Historical Sales Growth     greater than X Industry and Cash Flow greater than  500 million as our primary screening parameters However  sales growth and cash strength are not the absolute criteria for selecting stocks  So  we added a few other factors to arrive at a winning strategy Price to Sales  P S  Ratio less than X Industry  This metric measures the value placed on each dollar of a company s revenues  The lower the ratio  the better it is for picking a stock since the investor is paying less for each unit of sales   Change F1 Sales Estimate Revisions  4 Weeks  greater than X Industry  Northward estimate revision has often been observed to trigger an increase in the stock price Operating Margin  Average Last 5 years  greater than 5   Operating margin measures how much every dollar of a company s sales translates into profits  A high ratio indicates that the company has good cost control and sales are increasing faster than costs  an optimal situation for the company Return on Equity  ROE  greater than 5   This metric will ensure that sales growth is being translated into profits and the company is not hoarding cash  High ROE means the company is spending wisely and is in all likelihood profitable Zacks Rank less than or equal to 2  Zacks Rank  1  Strong Buy  or 2  Buy  stocks are known to outperform irrespective of the market environment Here are five of the 14 stocks that made it through the screen Newell Brands Inc    NYSE NWL   is a global manufacturer and marketer of consumer and commercial products  including Sharpie  Parker  Rubbermaid  writing instruments  storage containers  and Calphalon  cookware   The Atlanta  GA based firm has a long term expected EPS  earnings per share  growth rate of 13 2  and carries a Zacks Rank  2 Intel Corporation   NASDAQ INTC    one of the world s leading producers of semiconductor components  currently has a long term expected EPS growth rate of 8 1   This Santa Clara  CA based company holds a Zacks Rank  2 Laboratory Corp  of America Holdings   NYSE LH   is a leading healthcare diagnostics company  providing clinical laboratory services and drug development support  This Burlington  NC based company currently has a long term expected EPS growth rate of 10 2  and carries a Zacks Rank  2 VMware  Inc    NYSE VMW   is a Palo Alto  CA based company engaged in providing virtualization and cloud infrastructure solutions in the U S  and worldwide   The company has a long term expected EPS growth rate of 12 9  with a Zacks Rank  2 Principal Financial Group Inc    NYSE PFG   is a Des Moines  IA based company that provides an expansive range of retirement savings  investment and insurance products and services  The company has a long term expected EPS growth rate of 5 8  with a Zacks Rank  2 You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  
 
Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ",2016-07-21,Zacks Investment Research,https://www.investing.com/analysis/bet-on-these-5-stocks-registering-strong-sales-growth-200143607,200143607
9798,231313,LH,LabCorp  LH  Tops Q2 Earnings  View Up  To Buy Sequenom,opinion,"Laboratory Corporation of America Holdings   NYSE LH   or LabCorp reported a solid second quarter 2016 with adjusted earnings per share  EPS  of  2 31  up 10 5  from the year ago quarter  Adjusted EPS exceeded the Zacks Consensus Estimate by 0 9  
On a reported basis  LabCorp s net earnings came in at  198 2 million or  1 91 per share against  169 8 million or  1 66 per share a year ago 
Net revenue for the second quarter increased 7 4  year over year to  2 38 billion  ahead of the Zacks Consensus Estimate of  2 33 billion  Strong organic volume growth and tuck in acquisitions contributed to the topline growth  However  these positives were partially offset by adverse currency exchange movement LABORATORY CP Price  Consensus and EPS Surprise
   Quarter under Review
Currently  LabCorp reports under two operating segments  LabCorp Diagnostics  LabCorp s legacy business  except for its clinical trial services business  which is now part of Covance Drug Development  and includes the nutritional chemistry and food safety business  previously part of Covance   and Covance Drug Development  Covance s legacy business  except for its nutritional chemistry and food safety business  which is now part of LabCorp Diagnostics  and includes LabCorp s legacy clinical trial services business  
In the reported quarter  LabCorp Diagnostics reported net revenue of  1 66 billion  up 5 4  year over year  fueled by organic volume growth of 1 2   measured by requisitions   price  mix and tuck in acquisitions  partially offset by unfavorable foreign currency translation of 0 3   The company reported a 3 5  increase in revenue per requisition in the quarter 
Covance Drug Development reported a 12 2  rise in net revenue to  722 4 million in the second quarter of 2016 driven by broad based demand  partially offset by the 70 basis points  bps  negative impact due to foreign currency translation  At Constant Exchange Rate  CER  and excluding the impact of the expiration of the Sanofi  PA SASY  site support agreement  net revenue increased 16 4  year over year on increased demand 
Gross margin fell 4 bps to 34  in the quarter  Adjusted operating income surged 9 6  year over year to  418 8 million  Accordingly  adjusted operating margin expanded 39 bps from the year ago quarter to 17 2  despite a 4 5  rise in selling  general and administrative expenses to  408 million 
LabCorp exited the second quarter with cash and cash equivalents of  639 6 million compared with  696 3 million at the end of the first quarter  Year to date operating cash flow was  466 6 million  comparing favorably with an operating cash outflow of  309 8 million in the year ago period  Free cash flow came in at  328 2 million  significantly up from free cash flow of  206 9 million in the year ago period 
Update on Sequenom Deal
In a separate press release  LabCorp announced that it has entered into a definitive agreement to acquire Sequenom  Inc    NASDAQ SQNM    a prominent name in non invasive prenatal testing  NIPT  for reproductive health  The deal has been inked for an equity value of  302 million representing total enterprise value of  371 million The acquisition is expected to get completed by the end of 2016 subject to customary closing conditions 
According to LabCorp  this acquisition will be strategically fit for the company  business as Sequenom s NIPT and genetic testing capabilities will further advance LabCorp s aim to deliver advanced diagnostic solutions  The inclusion will also expand LabCorp s geographic reach both domestically and internationally 
Outlook
LabCorp updated its 2016 financial outlook  Taking into consideration the foreign exchange rates effective as of Jun 30  2016  the lower end of the net revenue growth expectation has been raised to a new range of  9 5  to 10 5  over 2015  from the earlier expectation of 8 5  to 10 5    This includes a 50 bps impact from unfavorable foreign exchange headwind  earlier expectation was 40 bps  resulting from the strengthening of the dollar  The current Zacks Consensus Estimate for revenues is pegged at  9 34 billion 
Adjusted EPS guidance for 2016 has also been raised to the range of  8 60  8 95  earlier  8 55  8 95   The current Zacks Consensus Estimate of  8 79 falls above the mid point of the guided range 
Free cash flow is expected in the band of  900  950 million  up 24  31  over the prior year   unchanged  
Our Take
LabCorp s consolidated second quarter earnings and revenues managed to exceed the respective Zacks Consensus Estimate  This has been a strong quarter with respect to organic volume growth in LabCorp Diagnostics  accelerated revenue growth in Covance Drug Development and operating leverage  We believe that with the integration of Covance  LabCorp is perfectly positioned to drive long term profitable growth through a combination of world class diagnostics  drug development expertise and knowledge services  Although the strengthening of the dollar continues to weigh on the company s year over year performance  the raised 2016 outlook is a firm indication that the scenario is going to rebound down the line 
Zacks Rank
LabCorp currently carries a Zacks Rank  2  Buy   Two other well ranked stocks in the sector are CR Bard Inc    NYSE BCR   and The Cooper Companies Inc    NYSE COO    Both the stocks hold the same Zacks Rank as LabCorp ",2016-07-27,Zacks Investment Research,"https://www.investing.com/analysis/labcorp-(lh)-tops-q2-earnings,-view-up,-to-buy-sequenom-200144372",200144372
9799,231314,LH,5 Stocks With Incredible Sales Growth To Buy Now,opinion,"A number of factors influence investment decisions  particularly when it comes to picking stocks  While investors with a high risk appetite looking for higher returns seek sophisticated and complex strategies  conventional investment strategies that are based on key fundamentals are largely deployed by a class of investors having a low risk appetite Conventional strategies are not only safe and sound  but they are also worthwhile in bearish markets  We have picked one such strategy that is focused on the sales growth of a company Sales Growth   A Key Financial IndicatorIn the current market scenario with changing customer preferences and habits  evolving needs  demographic changes and an extremely competitive environment  maintaining a steady sales growth is the key to survival for any business  Companies are always looking out for ways to boost their marketing initiatives to drive sales Notably  revenues are often more closely monitored than earnings when assessing the growth of a business  It s worth keeping in mind that in cases when companies incur a loss  albeit transitorily  they are valued on their revenues  as top line growth  or decline  is usually an indicator of a company s future earnings performance  Hence  the Price to Sales  P S  ratio can turn out to be an appropriate metric for stock valuation  It remains a key stock selection criteria keeping in mind that management usually has limited opportunities to tamper with revenues as they can with earnings  Thus  the P S ratio is subject to lesser manipulation than the Price to Earnings ratio   Sales growth in isolation is  however  not a sufficient criterion for success  A consideration of a company s cash position along with its sales number can be a more dependable strategy  Substantial cash in hand and a steady cash flow give a company more flexibility with respect to business decisions and investments Invest Like a ProA careful selection of stocks considering certain factors should help investors to not only build wealth but beat the market as well In order to shortlist stocks that have impressive sales growth along with a high cash balance  we added 5 Year Historical Sales Growth     greater than X Industry and Cash Flow greater than  500 million as our primary screening parameters However  sales growth and cash strength are not the absolute criteria for selecting stocks  So  we added a few other factors to arrive at a winning strategy Price to Sales  P S  Ratio less than X Industry  This metric measures the value placed on each dollar of a company s revenues  The lower the ratio  the better it is for picking a stock since the investor is paying less for each unit of sales   Change F1 Sales Estimate Revisions  4 Weeks  greater than X Industry  Northward estimate revision has often been observed to trigger an increase in the stock price Operating Margin  Average Last 5 years  greater than 5   Operating margin measures how much every dollar of a company s sales translates into profits  A high ratio indicates that the company has good cost control and sales are increasing faster than costs  an optimal situation for the company Return on Equity  ROE  greater than 5   This metric will ensure that sales growth is being translated into profits and the company is not hoarding cash  High ROE means the company is spending wisely and is in all likelihood profitable Zacks Rank less than or equal to 2  Zacks Rank  1  Strong Buy  or 2  Buy  stocks are known to outperform irrespective of the market environment Here are five of the eight stocks that made it through the screen Laboratory Corp  of America Holdings   NYSE LH   is a leading healthcare diagnostics company  providing clinical laboratory services and drug development support  This Burlington  NC based company currently has a long term expected EPS growth rate of 10 2  and carries a Zacks Rank  2 Synopsys Inc    NASDAQ SNPS   is one of the major suppliers of electronic design automation software to the global electronics industry  The Mountain View  CA based firm has a long term expected EPS  earnings per share  growth rate of 9  and carries a Zacks Rank  1 Intel Corporation   NASDAQ INTC    one of the world s leading producers of semiconductor components  currently has a long term expected EPS growth rate of 7 4   This Santa Clara  CA based company holds a Zacks Rank  2 VMware  Inc    NYSE VMW   is a Palo Alto  CA based company engaged in providing virtualization and cloud infrastructure solutions in the U S  and worldwide  The company has a long term expected EPS growth rate of 12 9  with a Zacks Rank  2 Euronet Worldwide  Inc    NASDAQ EEFT   is a major player in providing payment and transaction processing solutions to clients including financial institutions  retailers and service providers worldwide  This Leawood  KS based company has a long term expected EPS growth rate of 14 8  with a Zacks Rank  2 You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 
 
Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at  Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ",2016-08-07,Zacks Investment Research,https://www.investing.com/analysis/5-stocks-with-incredible-sales-growth-to-buy-now-200146748,200146748
9800,231315,LH,SPX  7 Healthcare Growth Stocks   Part 2 ,opinion,"Introduction
The S P 500 index is commonly used as a benchmark that investors use to measure the performance of their individual portfolios against  However  the S P 500 is comprised of a very diverse group of companies  Just about every classification of company you can imagine can be found in the S P 500  Furthermore  it is also comprised of all of the major industry sectors  With this series of articles  I have been examining the S P 500 constituents in the healthcare sector  In part 1  I presented what I consider to be attractively valued dividend growth stocks in the S P 500 healthcare sector  In this part 2  I will continue to examine S P 500 healthcare stocks  however  with this article I will focus on fairly valued non dividend paying growth oriented S P 500 healthcare constituents 
Passive Vs  Active Investing
Choosing passive versus active stock portfolios is one of the most hotly debated subjects regarding investing in stocks  Passive investing implies investing in an index fund while active investing means carefully handpicking specific stocks that meet your own goals  objectives and risk tolerances  Personally  I have always preferred what Wall Street calls active investing  However  I take exception with that designation  My personal investment philosophy is to invest in attractively valued businesses with the objective of holding for the long term  Consequently  my investment process could hardly be called active because there is little turnover in my portfolios 
Therefore  I reject the designations active versus passive in favor of selective versus non selective  It is my preference to carefully select my investments based on sound valuation and sound fundamental attributes  And more importantly  I prefer to select my investments based on their precise characteristics that meet my specific goals  objectives and risk tolerances 
For example  my current personal investment objectives are to seek fairly valued high quality dividend growth stocks with a history of increasing their dividends each year  Therefore  my goal is not simply maximum current income  I am also keenly focused on constructing a portfolio with the opportunity for that income to grow each year  In this regard  I consider long term capital gain a secondary objective  To be clear  I do expect to generate a reasonable level of capital gains with my dividend growth stocks  Investing in them when they are attractively valued gives me confidence that I can generate capital appreciation commensurate with each company s earnings growth  However  I am not concerned with outperforming the market on a total return basis  but I am concerned with outperforming the market on a total dividend income basis over the long term 
This leads me to pointing out additional reasons why I reject passive   also known as index investing  For example  the S P 500 is often used by investors as the primary benchmark to judge their performance against  However  that judgment is always based on total return calculations  I also often utilize the S P 500 as a benchmark to judge my own portfolio against  However  relative to my current income oriented investment philosophy  my measurement for performance is based on how much dividend income my portfolio generates versus the S P 500  Moreover  I also measure how fast that dividend income is growing compared to the S P 500 
In this dividend income regard  the S P 500 is at a great disadvantage  I took a rough count and found that approximately 85 of the S P 500 companies pay no dividends at all  and another 58 yield 1  or less  Using round numbers  more than 25  of the S P 500 constituents offer none or very little in the way of dividends  Since my objective is a growing dividend income stream  I see no logical reason to own the index when so many of the constituents do not meet my specific objectives 
Additionally  there are many S P 500 constituents that I would never invest in on my own volition  Therefore  I see no reason why I would want to invest in them by purchasing the index when I would never invest in them by my own selection process  Moreover  my recent examination of the S P 500 index constituents also discovered that the majority of the blue chip dividend growth companies I would typically be attracted to are currently overvalued  Once again  if I am not willing to invest in them today because they are overvalued  therefore  I would not want to invest in them today via the index 
However  with all that said  I also recognize and accept the reality that not everyone has the same investment objectives as I do  There are many prudent strategies that investors can choose to employ and there are many different kinds of individual stocks that can be selected for common stock portfolios  To me  the key is to clearly identify your personal objectives and risk tolerances  and then choose appropriate investments that are compatible with those goals  Investing is not a one size fits all process 
Attractive Healthcare Growth Stocks in the S P 500 for the Total Return Investor
Therefore  even though I personally favor dividend growth stocks  there are also valid reasons and return opportunities available through investing in non dividend paying but growing companies  As I pointed out in part 1 of this series found here I have recently been examining the healthcare sector of the S P 500 looking for attractively valued stocks  Consequently  in addition to the fairly valued dividend growth stocks I reported on in part 1  I also came across a few intriguing growth stock opportunities in the healthcare sector of the S P 500 
As a result  I felt compelled to share these findings with those who are interested in investing for growth or total return  The following  Portfolio Review  via FAST Graphs lists the seven S P 500 healthcare growth stock constituents that I felt were worth taking a closer look at  There are various reasons why I chose to highlight these specific examples  In all cases  I felt that valuations were fair  and in a few cases    even compelling  On the other hand  for the few that I found compelling  there are reasons why valuations are so low  Consequently  I highly recommend conducting your own thorough due diligence and research  Nevertheless  as an old associate of mine used to like to say  the problems appear to be already in the price  Therefore  I will provide a brief commentary on each selection indicating why I chose to feature it in this article 

Allergan  NYSE AGN pa  plc  AGN 
Below is a short business description courtesy of Morningstar 
 Allergan PLC is a specialty pharmaceutical company  The Company is engaged in developing  manufacturing and distributing generic  brand and biosimilar products  
I was attracted to Allergan based on its high and relatively consistent earnings growth since 2008  However  I was also struck by the fact that the market has valued Allergan s high earnings growth achievements at a market  average  valuation  I find this interesting  because it is very rare to find a company with such a high rate of earnings growth available at such a reasonable valuation  As evidenced by the blue normal P E ratio line on the graph  the market has recently valued this stock at a 16 P E ratio more or less  To me  that is a low valuation for a company that has grown earnings at 29  per annum 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps 
I was further intrigued by Allergan when I examined the company s cash flow and free cash flow per share  Both of these metrics suggest that the business is quite healthy on an operating basis 

Judging by its historical earnings growth rate  I was not surprised to see that the consensus estimates of analysts expect this company to continue growing at mid double digit rates  I was also not surprised to see that expected earnings growth was lower than historical norms considering the company s already approaching a  100 billion market cap 

Gross Profit Margin  GPM   Net Profit Margin  NPM   Return On Equity  ROE 
When I first examined gross and net profit margin  I was shocked to see that net margins virtually disappeared from 2012 through 2014  However  there were legitimate reasons why this happened  to include acquisition costs  failed mergers and other theoretically nonrecurring events 

As a result  when I looked at diluted earnings  GAAP  I saw a completely different perspective compared to what I saw when I looked at operating earnings and cash flows  Although I always like to examine GAAP results  I differ from many people regarding their importance or relevance as a valuation tool  When valuing a stock for potential investment  I am more concerned with how the business is performing as an operating company  Nevertheless  I felt it was important to point these issues out on this research candidate 

Endo International plc  NASDAQ ENDP 
Below is a short business description courtesy of Morningstar 
 Endo International PLC is a specialty healthcare company  The Company is engaged in developing  manufacturing  marketing and distribution of branded pharmaceutical and generic products as well as medical devices  
What struck me about Endo International was its extremely low valuation  Earnings have clearly flattened in recent years  but I believe the stock price reaction seems way overdone  Consequently  I included this research candidate as a compelling valuation and potential recovery candidate  Therefore  I was not surprised to see the stock surge yesterday based on an impressive second quarter earnings report  Nevertheless  I offer this as an interesting speculation based on compelling low valuation  However  as I looked deeper into additional important fundamental metrics  the speculative nature of this particular research candidate is important to note 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps 


Gross Profit Margin  GPM   Net Profit Margin  NPM   Return On Equity  ROE 

Express Scripts Holding  NASDAQ ESRX 
Below is a short business description courtesy of Morningstar 
 Express Scripts Holding Co offers healthcare management   administration services such as managed care organizations  health insurers  workers  compensation plans   government health programs  
To me  there was very little not to like about Express Scripts and its consistently strong earnings growth rate history  But what I liked most was its compelling valuation  As I indicated earlier  it s hard to find a company with this type of earnings growth record trading at such a low valuation 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps 


Gross Profit Margin  GPM   Net Profit Margin  NPM   Return On Equity  ROE 

HCA Holdings Inc   NYSE HCA 
Below is a short business description courtesy of Morningstar 
 HCA Holdings Inc is a health care services company  It operates general acute care hospitals  psychiatric hospitals  and rehabilitation hospitals  It also operates freestanding surgery centers  
I was attracted to HCA Holdings  current valuation in light of the moderately high overvaluation that the stock traded at through the summer of 2015  The stock price correction since then has potentially created a buying opportunity  My one caveat is the company s high debt to capital ratio  However  the company does have strong cash flows  and I ve read reports where management is focused on improving their debt situation 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps 


Gross Profit Margin  GPM   Net Profit Margin  NPM   Return On Equity  ROE 

Return on assets  ROA   Return on Invested Capital  ROI 

Laboratory Corp  Of America  NYSE LH 
Below is a short business description courtesy of Morningstar 
 Laboratory Corp of America Holdings is a healthcare diagnostics company  The Company along with its subsidiaries provides clinical laboratory services and end to end drug development support  
Although I really like the consistent operating history that Laboratory Corp of America Holdings has produced  I do want to point out that I consider its valuation a little high  Consequently  I would suggest looking for a better entry point  Nevertheless  I felt it was worthy of inclusion in this article in spite of its moderately high valuation 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps 


Gross Profit Margin  GPM   Net Profit Margin  NPM   Return On Equity  ROE 

Mallinckrodt Public Limited  NYSE MNK 
Below is a short business description courtesy of Morningstar 
 Mallinckrodt PLC along with its subsidiaries operates in a specialty biopharmaceutical and nuclear imaging business that develops  manufactures  markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents  
Mallinckrodt is offered as a speculative undervalued research candidate  The primary appeal here would be the potential for P E ratio expansion back to the 13 15 range 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps 


Gross Profit Margin  GPM   Net Profit Margin  NPM   Return On Equity  ROE 

Mylan N V   NASDAQ MYL 
Below is a short business description courtesy of Morningstar 
 Mylan NV along with its subsidiaries is a pharmaceutical company  The Company develops  licenses  manufactures  markets and distributes generic  branded generic and specialty pharmaceuticals  
I was attracted to Mylan because I consider the stock extremely undervalued and I like its long term growth prospects  I believe that recent acquisitions have added to this company s appeal  and I suspect future acquisitions are likely going forward  All in all  I believe that Mylan looks like a significantly undervalued above average growing investment opportunity 

Cash Flow Per Share  cflps   Free Cash Flow Per Share  fcflps 


Gross Profit Margin  GPM   Net Profit Margin  NPM   Return On Equity  ROE 

Summary and Conclusions
With this two part series I looked at what appeared to be attractively valued stocks in the healthcare sector of the S P 500  In part 1  I highlighted dividend growth stocks  In this part 2  I highlighted more growth oriented S P 500 healthcare constituents  Although I do believe that finding attractive valuation today is difficult  I do believe there are attractive investments available for those who are willing to look beyond the valuation of overall market 
If you enjoyed this article  scroll up and click on the  Follow  button next to my name to see updates on my future articles in your feed 
Disclosure  Long Express Scripts Holding Co  NASDAQ ESRX 
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2016-08-12,Chuck Carnevale,https://www.investing.com/analysis/7-intriguing-healthcare-growth-stocks-in-the-s-p-500:-part-2-200147580,200147580
9803,231318,LH,Can AngioDynamics   ANGO  Q4 Earnings Pull A Surprise ,opinion,AngioDynamics Inc   NASDAQ ANGO   is set to report fourth quarter fiscal 2016 results on Jul 13  Last quarter  the company reported earnings of 15 cents per share  which exceeded the Zacks Consensus Estimate by a couple of cents We note that on an average  AngioDynamics has posted a positive earnings surprise of 3 85  over the last four quarters Let s see how things are shaping up prior to this announcement ANGIODYNAMICS Price and EPS Surprise   Factors at PlayAngioDynamics  broad array of products like AngioVac  BioFlo and NanoKnife significantly enhances market opportunities  Notably  the PV business  peripheral vascular sales  has also built a strong momentum for the company Sales for the fourth quarter of fiscal 2016 are expected in the range of  87  90 million  while adjusted earnings are likely to be between 14 cents and 18 cents The earnings growth rate is expected to be higher than growth in sales  primarily because of cost curtailment initiatives Management believes that the company s gross margin will improve by roughly 100 200 bps in the fourth quarter of the current fiscal  owing to increased sales of higher margin products However  declining sales in at the Oncology  Vascular Access  Non BioFlo products and NanoKnife businesses may hurt quarterly sales Earnings Whispers Our proven model does not conclusively show that AngioDynamics is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  AngioDynamics currently has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 16 cents Zacks Rank  AngioDynamics carries a Zacks Rank  3 which increases the predictive power of ESP  However  an ESP of 0 00  makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 and 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revision momentum Stocks to ConsiderHere are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter   PharMerica Corporation   NYSE PMC   with an Earnings ESP of  2 13  and a Zacks Rank  1 The Cooper Companies Inc    NYSE COO   with an Earnings ESP of  2 64  and a Zacks Rank  2 Laboratory Corp  of America Holdings   NYSE LH   with an Earnings ESP of  0 87  and a Zacks Rank  2 ,2016-07-07,Zacks Investment Research,https://www.investing.com/analysis/can-angiodynamics'-(ango)-q4-earnings-pull-a-surprise-200140746,200140746
9805,231320,LH,5 Swing Trades To Watch  ASH  LOW  LH  IPG  F,opinion,"Here s your swing trading watch list 
Long Ashland Inc  NYSE ASH 

Long Lowe s Companies Inc  NYSE LOW 

Long Laboratory Corp of America Holdings  NYSE LH 

Long Interpublic Group of Companies  NYSE IPG 

Short Ford Motor  NYSE F ",2016-06-03,Ryan Mallory,"https://www.investing.com/analysis/swing-trading-watch-list:-ash,-low,-lh,-ipg,-f-200133749",200133749
9806,231321,LH,VWR Corp s Balanced Growth Partly Offset By Weak Margins,opinion,"On Jun 8  we issued an updated research report on Radnor  PA based VWR Corporation   NASDAQ VWR    The company offers laboratory products  services and solutions and currently carries a Zacks Rank  3  Hold  
VWR had a remarkable start to 2016  with its first quarter financial numbers beating the Zacks Consensus Estimate on both the top and bottom line  Segment wise  management witnessed strong sales in both Americas as well as the EMEA APAC region  accompanied by exceptionally strong growth in equipment and instrumentation 
Per management  robust growth in biotech  medical devices and sales to CRO customers drove the better than expected performance of the biopharma business in the Americas during the first quarter  Moreover  the strategic shift from the company s North American regional go to market strategy to a customer segment specific approach has started to add value  Going ahead  VWR expects to witness continued solid business momentum in the Americas segment in the second quarter as well 
In the EMEA APAC region  the company witnessed a reduced impact of currency translation on segment sales in the first quarter  which in turn significantly boosted its performance  From a product perspective  sales of chemicals grew in the low single digits  consumables rose mid single digits while capital goods increased low single digits 
The company s stable cash balance position as well as its huge customer base added to the optimism 
On the flip side  the company continues to face gross margin pressure  Escalating cost of production has been a major factor behind this lackluster outcome  Moreover  as VWR offers products from a wide range of suppliers  its ability to sustain its gross margin has been  and will continue to be  dependent partly upon its ability to obtain favorable terms from its suppliers 
Unfavorable currency fluctuation continued to impact the company s overall sales in the first quarter and management expects no respite from the same in the near term  Intensifying competition is also a headwind for the stock 
Key Picks in the Sector
Some better ranked stocks from the same sector are The Cooper Companies Inc    NYSE COO    Henry Schein  Inc    NASDAQ HSIC   and Laboratory Corp  of America Holdings   NYSE LH    All three stocks carry a Zacks Rank  2  Buy  ",2016-06-09,Zacks Investment Research,https://www.investing.com/analysis/vwr-corp's-balanced-growth-partly-offset-by-weak-margins-200135106,200135106
9807,231322,LH,LabCorp Sees Balanced Growth  Covance Synergy On Track,opinion,On Jun 20  2016  we issued an updated research report on Laboratory Corporation of America Holdings   NYSE LH    or LabCorp  a leading independent clinical laboratory company  It is currently working on portfolio expansion  The company is more focused on the high margin esoteric testing business to drive its top line With the acquisition of Covance  which is now operational as Covance Drug Development  LabCorp expects to expand its range of diagnostic offerings and create a new industry leader in both the laboratory testing and CRO spaces  This will act as a leading provider of medical testing apart from operating as a premier full service drug development organization Earlier LabCorp had set a goal of  150 million in incremental revenues by the end of 2018   100 million for companion diagnostics and  50 million for real world evidence   In the last reported quarter  first quarter 2016   the acquisition of Covance contributed  687 3 million to the company s revenues  driving 23 7  year over year growth  The company is currently on track to achieve the incremental revenue synergy target Moreover  LabCorp expects to achieve annual cost synergies in excess of  100 million  to be fully realized within three years of closure of the acquisition  Of this  the company has already achieved  50 million and looks well positioned to achieve its targeted synergy  going ahead LabCorp has also strengthened its foothold in the diagnostics space through both organic and inorganic means  and plans to collaborate with leading companies and academic institutions to provide a wider portfolio of tests  In Mar 2016  the company acquired full service independent women s health laboratory  Pathology  Inc   including the patient service centers used to conduct the latter s medical testing and services business Among strategic partnerships  recently the company formed an alliance with Interpace Diagnostics  a developer of molecular diagnostics tests  to begin offering the latter s new ThyraMir microRNA classifier test  Other recent collaborations include the alliance with Japan based Sysmex Corporation   a leading clinical laboratory services provider  LabCorp also signed a strategic agreement with biotechnology company  ORIG3N  a leading provider of induced pluripotent stem cell  iPSC  repository called LifeCapsule Also  as part of its five pillar strategy  LabCorp is currently working hard on new innovations with academic institutions in order to capture the growing lab testing market with its advanced assays and tools We also note that LabCorp s first quarter earnings and revenues both exceeded the Zacks Consensus Estimate  The company recorded a strong quarter with respect to organic volume growth in LabCorp Diagnostics  accelerated revenue growth in Covance Drug Development and operating leverage On the flip side  the current economic uncertainty remains a deterrent for LabCorp  The strengthening of the dollar continues to weigh on its year over year revenue performance  Moreover  changes in governmental regulations had a significant impact on the company s operations  We are highly disappointed with the recent CMS proposal related to the Protecting Access to Medicare Act  PAMA  LabCorp currently carries a Zacks Rank  2  Buy  Key Picks in the SectorMedical instruments stocks that are worth a look include The Cooper Companies Inc    NYSE COO    Henry Schein  Inc    NASDAQ HSIC   and CR Bard Inc    NYSE BCR    All these stocks carry a Zacks Rank  2 ,2016-06-21,Zacks Investment Research,https://www.investing.com/analysis/labcorp-sees-balanced-growth;-covance-synergy-on-track-200137200,200137200
9808,231323,LH,5 Stocks To Buy On Stronger GDP Data,opinion,"The U S  economy expanded at a faster pace in the first quarter than earlier estimated  according to data released on Tuesday  As the country entered its eighth year of economic expansion  other indicators such as housing and retail sales also remained promising  However  underlying fears exist about whether growth is robust enough to withstand the fallout of a recent Brexit 
The most significant upward revisions which stand out are the extent of spending on software  research and development  In the backdrop of falling expenditure on equipment and weak gains made by several services it may be a good idea to bet on stocks from these categories 
Final Q1 Estimate Revised Upward
The  third  estimate from the Bureau of Economic Analysis showed that first quarter output of goods and services increased at an annual rate of 1 1   higher than the consensus estimate of a 1  increase  Further  first quarter GDP data was revised upward from the previously estimated 0 8  rise 
However  first quarter GDP growth was much lower than the rate of 1 4  recorded in the fourth quarter of 2015  Business spending declined for the second consecutive quarter  Also  consumer expenditure growth was revised downward from 1 9  to 1 5   This was primarily due to low spending levels on services  primarily recreation and transportation 
Ultimately  there were two major reasons for the upward revision in the estimate for first quarter GDP  Firstly  exports increased by 0 3   contrary to the earlier estimate of a decline of 2   More importantly  business expenditure on software  research and development increased by 4 4  versus the earlier estimate of a 0 1  decline   
Are Brexit Fears for Real 
The shock result of the recent British referendum has led several economists and market watchers to believe that the fallout could weigh on GDP growth over the upcoming six quarters  Most of this is likely to be due to lower business expenditure  Rising uncertainty could result in several companies pushing back or reducing the scale of new projects 
However  the Fed is unlikely to raise rates as a result of such worries  A weak interest rate regime should outweigh the impact of such global turmoil  Additionally  the U S  economy usually picks up pace over the second quarter  rebounding during spring and summer  Car sales remain strong and existing home sales hit a nine year peak in May 
Our Choices
Despite some factors weighing on GDP during the first quarter  final estimates have experienced an upward revision  The likelihood of a pickup in growth during the second quarter remains strong 
Expenditure on software  research and development has contributed significantly to the increase in the first quarter GDP  Adding these stocks to your portfolio would be a good option at this point  At the same time  it is important to pick winning stocks   
This is where our  comes in  Here V stands for Value  G for Growth and M for Momentum and the score is a weighted combination of these three scores  Such a score allows you to eliminate the negative aspects of stocks and select winners  However  it is important to keep in mind that each Style Score will carry a different weight while arriving at a VGM score  
We have narrowed down our search to the following stocks based on a good Zacks Rank and VGM score 
Bruker Corporation   NASDAQ BRKR   designs and manufactures proprietary life science and materials research systems and associated products  
Bruker Corp has a Zacks Rank  2  Buy  and a VGM Score of B  The company has expected earnings growth of 13 8  for the current year 
Charles River Laboratories International  Inc    NYSE CRL   is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development 
Charles River Laboratories has a Zacks Rank  2 and a VGM Score of B  The company has expected earnings growth of 16 8  for the current year  Its earnings estimate for the current year has improved by 0 1  over the last 30 days 
Laboratory Corp  of America Holdings   NYSE LH   is a leading healthcare diagnostics company  providing comprehensive clinical laboratory services and end to end drug development support 
Laboratory Corp  of America has a Zacks Rank  2 and a VGM Score of A  The company has expected earnings growth of 11 1  for the current year 
Synchronoss Technologies  Inc    NASDAQ SNCR   is a provider of cloud based solutions and software activation for a variety of customers across the world 
Synchronoss has a Zacks Rank  1  Strong Buy  and a VGM Score of B  The company has expected earnings growth of 12  for the current year 
Varonis Systems  Inc    NASDAQ VRNS   is the provider of an innovative software platform that allows enterprises to map  analyze  manage and migrate unstructured data 
Varonis Systems has a Zacks Rank  2 and a VGM Score of B  The company has expected earnings growth of 4 4  for the current year ",2016-06-28,Zacks Investment Research,https://www.investing.com/analysis/5-stocks-to-buy-on-stronger-gdp-data-200139092,200139092
9809,231324,LH,Walgreens Boots  WBA  Q3 Earnings  Will The Stock Beat ,opinion,Walgreens Boots Alliance  Inc    NASDAQ WBA   is scheduled to report third quarter fiscal 2016 earnings results before the opening bell on Jul 6 Last quarter  the company delivered a positive earnings surprise of 3 15   In fact  Walgreens Boots  earnings have outpaced the Zacks Consensus Estimate in all of the past four quarters  with an average beat of 8 81   Let s see how things are shaping up prior to this announcement WALGREENS BAI Price  Consensus and EPS Surprise   Factors at PlayAfter the successful integration of Alliance Boots  Walgreens Boots is now eyeing U S  retail pharmacy chain  Rite Aid  The company expects the Rite Aid deal to exceed the combined synergy goal of  1 billion by the end of fiscal 2016  It is also focusing on improving its core performance over the near term Meanwhile  the company continues to invest in key areas  including information technology  to develop its customer base   a policy adopted by management in the recent past  Per management  the strategy has already resulted in free cash flow of  2 billion in the second quarter of fiscal 2016  signifying a trend that is expected to continue in the third quarter and beyond Moreover  at the end of the fiscal second quarter  Walgreens Boots announced its partnership with OptumRx  under which it will offer 24 7 pharmacists services to OptumRx members  Per management  the deal will give Walgreens Boots the opportunity to continue boosting its existing operations in both retail and pharmacy  The deal is expected to enhance Walgreens Boots  presence in the space On the flip side  the company continues to face challenges from other retail giants as well as pricing pressure due to relentless government initiatives to curb healthcare costs  Also  fewer generic drug introductions and the ongoing generic inflation have been hampering the company s gross margin Walgreens Boots currently expects adjusted EPS in the  4 35  4 55 range for fiscal 2016  narrower than its earlier guided range of  4 30  4 55  The lowered projection primarily reflects the anticipated impact of suspending the share buyback program to fund the Rite Aid deal  negligible material accretion from this deal and the continuation of normal anti dilutive buyback program relating to equity incentives  The revised outlook considers no major changes in currency exchange rates either The current Zacks Consensus Estimate for Walgreens Boots is  4 49 for 2016  well within management s guidance range Earnings WhispersOur proven model does not conclusively show that Walgreens Boots is likely to beat earnings this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  However  that is not the case here  as you will see below Zacks ESP   Walgreens Boots has an Earnings ESP of 0 00  That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  1 14 Zacks Rank  Walgreens Boots  Zacks Rank  3 increases the predictive power of ESP  However  its 0 00  ESP makes surprise prediction difficult Meanwhile  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter Bristol Myers Squibb Company   NYSE BMY    with an Earnings ESP of  1 52  and a Zacks Rank  1 Henry Schein  Inc    NASDAQ HSIC    with an Earnings ESP of  0 62  and a Zacks Rank  2 Laboratory Corp  of America Holdings   NYSE LH    with an Earnings ESP of  0 87  and a Zacks Rank  2 ,2016-07-01,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-(wba)-q3-earnings:-will-the-stock-beat-200139583,200139583
9810,231325,LH,Veeva Systems  VEEV  Q1 Earnings  What s In The Cards ,opinion,Veeva Systems Inc    NYSE VEEV   is set to report first quarter fiscal 2017 results on May 26  Last quarter  the company reported earnings of 12 cents  which beat the Zacks Consensus Estimate by a nickel  Notably  the company posted an average positive surprise of 15 98  over the last four quarters Let s see how things are shaping up for this announcement  VEEVA SYSTEMS A Price  Consensus and EPS Surprise    Factors at PlayVeeva expects total revenues in the range of  114 5 116 million for the first quarter of fiscal 2017  Meanwhile  non GAAP operating income is expected between  25 5 million and  26 million  Non GAAP earnings are likely to be around 11 cents per share Extended use of multi channel Customer Relationship Management  CRM  application by customers continues to be a key growth catalyst for the company  We believe product suites like Veeva Vault and OpenData will help win customers for Veeva Further  we note that Veeva is making consistent efforts to best support customer data needs globally  Veeva OpenData is supported by its data centers in the U S   China  Japan  Hungary and Brazil  Moreover  expanding partner ecosystem is helping Veeva offer its customers easy access to third party data Earnings WhispersOur proven model does not conclusively show that Veeva is likely to beat earnings this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Veeva has an earnings ESP of 0 00   That is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 7 cents Zacks Rank  Veeva carries a Zacks Rank  3 which increases the predictive power of the ESP  However  the company s 0 00  ESP makes surprise prediction difficult We caution against stocks with a Zacks Ranks  4 and 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat  Air Methods   NASDAQ AIRM    with earnings ESP of  1 05  and a Zacks Rank  1 CONMED   NASDAQ CNMD    with earnings ESP of  2 22  and a Zacks Rank  2 Laboratory Corp  of America Holdings   NYSE LH    with earnings ESP of   87  and a Zacks Rank  2 ,2016-05-22,Zacks Investment Research,https://www.investing.com/analysis/veeva-systems-(veev)-q1-earnings:-what's-in-the-cards-200131592,200131592
9820,231335,LH,5 Medtech Stocks To Watch Out For In 2H16,opinion,"With the Q2 earnings season almost here  investors seek stocks that not only hedge losses but promise handsome returns  The recent rebound in the major stock markets following the Brexit tremors has also instilled a new level of confidence among investors 
Evidently  both the S P 500 index and tech heavy Nasdaq Composite witnessed a 3 9  rise last week  while the Dow Jones Industrial Average  DJI  was up 4  
However  the global economy continues to be fragile as many investors are still apprehensive of the long term effects of Brexit  Moreover  there remain uncertainties related to the Fed s decision on a hike in interest rates as the Brexit event has surely faded any chance of such hike any time soon 
In such a scenario  it is probably best to focus on defensive sectors  One such space is the Medtech industry  given that it has been historically immune to market slumps 
Why the Medtech Industry 
Even as the majority of the primary sectors of the S P 500 cohort have been seen to falter in recent past  Medical was among the very few that stood strong  Interestingly  MedTech  one of the largest industries under this sector  exhibits similar characteristics  such as strong returns on capital  strict government enforced restrictions on competition  stable revenues and high margins 
Again  a comparative analysis of Medtech s achievement with that of the major market indices reflects the industry s above market performance  The 1 year return from the S P 500 index reached 1 65   while that from the DJI was 1 5   Meanwhile  the S P 500 Healthcare Equipment Index returned around 9 3  over the same period 
What s Driving the Medtech Industry 
There are a number of factors that keep the Medtech industry afloat even in the most challenging circumstances  These include a growing aging population  rapid growth in healthcare spending as a percentage of GDP in the recent years and adoption of next generation medical devices 
In addition  the recent change in consumer demand and market dynamics led to a dramatic transformation in the healthcare system  as evident from the growing prevalence of minimally invasive surgeries  rising demand for liquid biopsy tests  strategic mergers between industry giants  increasing research and development  R D  cost at major companies  use of IT for ensuring quick and improved patient care and the shift of the payment system to a value based model among others 
What to Expect Next 
As far as the Q2 earnings results are concerned  Medical is one of the 6 Zacks sectors  comprising a total of 16 sectors  that is expected to record earnings growth  while the S P 500 itself is projected to witness a decline  Moreover  as per EvaluateMedTech s latest report  the global Medtech industry is expected to grow at a CAGR of 4 1  from 2014 to reach a sales value of  477 5 billion in 2020 
How to Pick 
Given the above discussion  well ranked stocks in the MedTech industry grab a lot of attention  particularly if they are witnessing a surge in share prices and have a decent long term earnings growth potential 
To find such stocks  we use the Zacks Rank and  as criteria  Stocks with a VGM Score of  A  or  B  and a Zacks Rank  1  Strong Buy  or 2  Buy  promise better returns  on an average  than the individual components  as it considers three times as many items that are correlated to future stock returns 
Our Choices
Here we have picked 5 MedTech stocks with a year to date price change of more than 2  and long term earnings growth of more than 5   which also boast a favorable Zacks Rank and a VGM Style Score of  A  or  B  
Laboratory Corp  of America Holdings   NYSE LH    This Burlington  NC based company operates as an independent clinical laboratory company worldwide Zacks Rank  2VGM Style Score of  A Price Change   6 19 Long term Earnings Growth  10 2 Masimo Corp    NASDAQ MASI    This California based medical technology company develops  manufactures and markets non invasive monitoring technologies worldwide Zacks Rank  1VGM Style Score of  B Price Change   26 4 Long term Earnings Growth  15 NuVasive  Inc    NASDAQ NUVA    Based in California  this medical device manufacturer develops and markets minimally invasive surgical products and procedurally integrated solutions for spinal surgery Zacks Rank  2VGM Style Score of  B Price Change   10 83 Long term Earnings Growth  14 8 Lantheus Holdings  Inc    NASDAQ LNTH    Based in Massachusetts  this company manufactures  and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide Zacks Rank  2VGM Style Score of  A Price Change   22 49 Long term Earnings Growth  12 5 Integra Lifesciences Holdings Corp    NASDAQ IART    This New Jersey based company manufactures and markets surgical implants and medical instruments for use in neurosurgery  extremity reconstruction  orthopedics and general surgery Zacks Rank  2VGM Style Score of  B Price Change   18 3 Long term Earnings Growth  11 9 ",2016-07-05,Zacks Investment Research,https://www.investing.com/analysis/5-medtech-stocks-to-watch-out-for-in-2h16-200140070,200140070
9821,231336,LH,Why Brexit Won t Matter For These 4 Stocks In July,opinion,The U S  equity market shrugged off the initial hiccups from the Brexit aftermath within a week or so  as  Buy the Shock  emerged as the new investment strategy on Wall Street  After the news led to almost a 5 1 2  drop in the benchmark S P 500 index in just two trading sessions  wiping out considerable investor wealth   the market staged a remarkable turnaround to reach the psychologically significant 2 100 level last Friday  delivering one of the best performances since November Taking a cue from the various mini crashes and rapid rebound reaction of the stock market following the 2008 financial crisis  it appears that the U S  equity market has mastered the game of not letting emotions gain an upper hand over sound investment logic  A thorough market analysis and realization of the fact that the Brexit saga could drag on for years  giving ample time for the central banks to devise any counter strategy  helped soothe the investors  nerves The upturn was also led by positive economic data that showed a rapid improvement in the U S  manufacturing activity in June   the highest recorded in the last 15 months as new orders  output and exports picked up A Perfect Time to InvestAlan Skrainka  chief investment officer at Cornerstone Wealth Management  perfectly summed up   Investors should remember that  in the short run  markets are unpredictable    jumping in and out of a quality  well diversified portfolio is the single biggest mistake investors can make  In time  people will forget about the Brexit vote much like they have forgotten about other short term events that upset the markets  As markets regain their sound footing  let us cherry pick some solid stocks that are likely to continue their bull run in July  These stocks are backed by a  of  A  and a Zacks Rank  2  Buy  4 Stocks to Buy NowHasbro Inc    NASDAQ HAS    Based in Pawtucket  RI  Hasbro is engaged in the design  manufacture and marketing of games and toys Hasbro is scheduled to release its second quarter results before the market opens on Jul 18  2016  With a solid year to date return of 24 6  and a trailing four quarter average earnings surprise of a positive 20 9   it appears to be on course to replicate its success story in the soon to be reported quarter as well Alliance Data Systems Corp    NYSE ADS    Headquartered in Plano  TX and founded in 1996  Alliance Data is the largest private label credit card processing firm for mid market specialty retail stores in the U S The company is slated to release its second quarter results in July  Alliance Data has a fairly modest earnings history with a trailing four quarter average earnings surprise of a positive 2 2   We expect the company to beat the earnings estimate in the ensuing release also Intel Corp    NASDAQ INTC    This semiconductor giant is likely to issue its second quarter results in the third week of July  With a healthy trailing four quarter average earnings surprise of a positive 11 5   it will likely surpass the earnings estimates in the impending release and witness a decent uptick in share prices Laboratory Corp  of America Holdings   NYSE LH    Headquartered in Burlington  NC  Laboratory Corp  is a leading healthcare diagnostics company  providing comprehensive clinical laboratory services and end to end drug development support The company is slated to release its second quarter results in this month  Laboratory Corp  has a modest earnings history with a trailing four quarter average earnings surprise of a positive 1 4   With an Earnings ESP of  0 87  and a Zacks Rank  2  Buy   the company is likely to beat the earnings estimate in the ensuing release and appears poised for a healthy ROI End NoteAs the dust settles on the Brexit episode and fears of a catastrophic event subside  the equity market seems to be on course for another V shaped recovery  Amid such a scenario  it could work wonders for the investors to invest in these stocks that are likely to outperform in July backed by their prudent financial metrics ,2016-07-05,Zacks Investment Research,https://www.investing.com/analysis/why-brexit-won't-matter-for-these-4-stocks-in-july-200140129,200140129
9822,231337,LH,5 Strong Sales Growth Stocks To Power Your Portfolio ,opinion,"A healthy business with steady sales growth is the key to survival in today s fast changing and highly competitive business environment  However  when it comes to picking stocks  investors often fail to consider sales growth as a dependable metric  This might be because of investors  preconceived notion that a company s stock price is typically sensitive to its earnings momentum Nevertheless  it s worth keeping in mind that in cases when companies incur a loss  albeit transitorily  they are valued on their revenues  as top line growth  or decline  is usually an indicator of a company s future earnings performance  Further  a company can improve earnings by resorting to cost control measures while maintaining stable revenues  However  a sustainable bottom line growth invariably requires superior revenues Hence  the Price to Sales  P S  ratio can turn out to be an appropriate metric for stock valuation  Notably  this metric s importance further lies in the fact that management has limited opportunities to manipulate revenues unlike earnings While sales growth provides investors an insight into product demand and pricing power  it doesn t indicate whether the company is operating efficiently  A huge sales number does not necessarily convert into profits Therefore  a consideration of a company s cash position along with its sales number can be a more dependable strategy  Substantial cash in hand and a steady cash flow give a company more flexibility with respect to business decisions and investments A Strategy to Bet OnA careful selection of stocks considering certain factors should help investors to not only build wealth but beat the market as well In order to shortlist stocks that have impressive sales growth along with a high cash balance  we added 5 Year Historical Sales Growth     greater than X Industry and Cash Flow greater than  500 million as our primary screening parameters However  sales growth and cash strength are not the absolute criteria for selecting stocks  So  we added a few other factors to arrive at a winning strategy Price to Sales  P S  Ratio less than X Industry  This metric measures the value placed on each dollar of a company s revenues  The lower the ratio  the better it is for picking a stock since the investor is paying less for each unit of sales   Change F1 Sales Estimate Revisions  4 Weeks  greater than X Industry  Northward estimate revision has often been observed to trigger an increase in the stock price Operating Margin  Average Last 5 years  greater than 5   Operating margin measures how much every dollar of a company s sales translates into profits  A high ratio indicates that the company has good cost control and sales are increasing faster than costs  an optimal situation for the company Return on Equity  ROE  greater than 5   This metric will ensure that sales growth is being translated into profits and the company is not hoarding cash  High ROE means the company is spending wisely and is in all likelihood profitable Zacks Rank less than or equal to 2  Zacks Rank  1  Strong Buy  or  2  Buy  stocks are known to outperform irrespective of the market environment Here are 5 of the 13 stocks that made it through the screen Equinix  Inc    NASDAQ EQIX    a California based interconnection and data center company  has a long term expected EPS  earnings per share  growth rate of 20 0   The company carries a Zacks Rank  2 LPL Financial Holdings Inc    NASDAQ LPLA    operating in the investment brokerage space  currently has a long term expected EPS growth rate of 15   This Massachusetts based company holds a Zacks Rank  2 Laboratory Corp  of America Holdings   NYSE LH   is a leading healthcare diagnostics company  providing clinical laboratory services and drug development support  This Burlington  NC based company currently has a long term expected EPS growth rate of 10 2  and carries a Zacks Rank  2 Two Harbors Investment Corp    NYSE TWO   is a New York based real estate investment trust  REIT  that is engaged in investing  financing  and managing residential mortgage backed securities  The company has a long term expected EPS growth rate of 4 8  with a Zacks Rank  2 Trinity Industries Inc    NYSE TRN   is a Texas based company engaged in providing products and services to the energy  transportation  chemical  and construction sectors in the U S  and worldwide   The company has a long term expected EPS growth rate of 10 0  with a Zacks Rank  1 You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 
 
Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at  
Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ",2016-07-06,Zacks Investment Research,https://www.investing.com/analysis/5-strong-sales-growth-stocks-to-power-your-portfolio-200140515,200140515
9824,231339,LH,Can Patterson Companies  PDCO  Surprise In Q4 Earnings ,opinion,Patterson Companies Inc    NASDAQ PDCO   is set to announce fourth quarter fiscal 2016 earnings on May 26  Last quarter  the company reported earnings of 68 cents per share which beat the Zacks Consensus Estimate by a penny However  we note that the company has posted an average negative surprise of 3 38  over the last four quarters PATTERSON COS Price and Consensus   Let s find out how things are shaping up for this quarter Factors at PlayPost the release of third quarter fiscal 2016 results  Patterson Companies narrowed its adjusted earnings projection to the range of  2 42 to  2 48 per share from the previous band of  2 40  2 50 Although prospects of the dental and companion animals market is encouraging  sluggish growth projection for the production animal market is a concern  Nevertheless  Patterson Companies expects higher sales from CEREC  driven by the introduction of the new product  Zirconia  and growing international sales However  lack of operating margin expansion opportunities will hurt earnings  in our view Earnings WhispersOur proven model does not conclusively show that Patterson Companies is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Patterson Companies has a Zacks ESP of 0 00   That is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 76 cents Zacks Rank  Patterson Companies has a Zacks Rank  3 which increases the predictive power of ESP  but when combined with a 0 00  ESP  it makes surprise prediction difficult Meanwhile  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter   Air Methods   NASDAQ AIRM    with earnings ESP of  1 05  and a Zacks Rank  1 CONMED   NASDAQ CNMD    with earnings ESP of  2 22  and a Zacks Rank  2 Laboratory Corp  of America Holdings   NYSE LH    with earnings ESP of   87  and a Zacks Rank  2 ,2016-05-22,Zacks Investment Research,https://www.investing.com/analysis/can-patterson-companies-(pdco)-surprise-in-q4-earnings-200131630,200131630
9826,231341,LH,Is LabCorp  LH  A Great Stock For Value Investors  ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Laboratory Corporation of America Holdings   NYSE LH    or LabCorp stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  LabCorp has a trailing twelve months PE ratio of 14 6   as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 17 42x  If we focus on the long term PE trend  LabCorp s current PE level puts it below its midpoint over the past five years  with the number having risen rapidly over the past few months Further  the stock s PE also compares favorably with the broader industry s trailing twelve months PE ratio  which stands at 17 58  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that LabCorp has a forward PE ratio  price relative to this year s earnings  of just 14 32  so it is fair to say that a slightly more value oriented path may be ahead for LabCorp stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  LabCorp has a P S ratio of about 1 44  This is lower than the S P 500 average  which comes in at 3 12x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  LH is in the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  LabCorp currently has a Value Score of A  putting it into the top 20   of all stocks we cover from this look  This makes LabCorp a solid choice for value investors What About the Stock Overall Though LabCorp might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of D and a Momentum Score of A  This gives LH a Zacks VGM score   or its overarching fundamental grade   of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been downbeat  The current quarter has seen three estimates go higher in the past sixty days compared to six lower  while the full year estimate has seen no up and ten down in the same time period This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has decreased by 2 1  in the past two months  while the full year estimate has declined by 1 6   You can see the consensus estimate trend and recent price action for the stock in the chart below Laboratory Corporation of America Holdings Price and Consensus
     The stock has a Zacks Rank  3  Hold  and we are looking for in line performance from the company in the near term Bottom LineLabCorp is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  a strong industry rank  among Top 32  of more than 250 industries  instills our confidence However  with a Zacks Rank  3 it is hard to get too excited about this company overall  In fact  over the past two years  the broader industry has clearly underperformed the market at large  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2018-11-27,Zacks Investment Research,https://www.investing.com/analysis/is-labcorp-lh-a-great-stock-for-value-investors-200363055,200363055
9827,231342,LH,Company News For DEC 3  2018,opinion,Marriott International Inc  s   NASDAQ MAR   shares tumbled 5 6  after the company revealed a data breach could have exposed personal information of about 500 million guestsShares of GameStop Corp    NYSE GME   plunged 6 6  after reducing fiscal 2018 adjusted earnings per share guidance to  2 55  2 75 from a range of  3 00  3 35 projected earlierLaboratory Corporation of America Holdings   NYSE LH   shares plummeted 10  after posting third quarter 2018 adjusted earnings per share of  2 74  missing the Zacks Consensus Estimate of  2 87Shares of The Goldman Sachs Group Inc    NYSE GS   tanked 2 1  following news that the Fed has heightened the pace of investigation into the banks involvement in controversial 1MBD sovereign wealth fund,2018-12-02,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-dec-3-2018-200364520,200364520
9828,231343,LH,LabCorp  LH  Stock Declines 10  On Lowered 2018 Guidance,opinion,Shares of Laboratory Corporation of America Holdings   NYSE LH   or LabCorp dropped following the company s 2018 guidance cut on Nov 30  The stock declined 9 99  to close at  145 64 the same day According to LabCorp  lower than expected volume growth within LabCorp Diagnostics  which is also expected to persist for the remainder of the year  compelled the company to lower its full year guidance The Updated Guidance at a GlanceTotal revenue growth projection is revised to the band of 9 9 10 3   from the earlier expectation of 10 5 11 0    The current Zacks Consensus Estimate for revenues is pegged at  11 39 billion Revenue growth within LabCorp Diagnostics has been lowered to the range of 2 1 2 5   from the prior 3 3 5  band   However  the forecast for Covance Drug Development remains unchanged at 24 26  Full year adjusted EPS view is decreased to  10 95  11 05  from the past anticipation of  11 25  11 45  The Zacks Consensus Estimate of  11 30 falls within but close to the lower end of this guided range Free cash flow has been reduced to a range of  940  980 million  previous band was  975 million to  1 02 billion  Per LabCorp  the current year s result will be dented by a softness in demand  primarily attributed to slower growth in referred direct to consumer genetic testing  weak referral volume from hospitals and health systems  volume declines from certain managed care plans that will no longer be exclusive to LabCorp in 2019 and adverse weather Although  the company has implemented certain cost controlling initiatives  the same does not look adequate to maintain its prior outlook in light of the unanticipated volume shortfall Covance Drug Development Raises HopeOn a brighter note  the company is pinning high hopes on the Covance Drug Development divisiondespite its LabCorp Diagnostics business failed to inspire investors  confidence Under Covance Drug Development business  LabCorp is ready to expand its suite of diagnostic offerings  thereby creating a new industry leader in both laboratory testing and CRO spaces  The company will thus act as a major provider of medical testing besides operating as a premier full service drug development organization Within this business  LabCorp is focused on driving profitable growth for the future through extended solutions and enhanced operational capabilities  The acquisition of Chiltern completed in September 2017  has started to significantly strengthen the company s strategic position in clinical development and is also accelerating revenues and profit growth within Covance  In this regard  the company is keeping pace with its objective to streamline the drug development process  Moreover  it is winning awards via its integrated Covance and Chiltern offering  In addition  the company has progressed with the Covance LaunchPad initiative Share Price PerformanceIn the past three months  shares of LabCorp have underperformed its   The stock has dropped 13 9   comparing unfavorably with the industry s 6 2  decline Zacks Rank   Key PicksLabCorp currently carries a Zacks Rank  4  Sell  Some better ranked stocks in the broader medical space are Integer Holdings Corporation   NYSE ITGR    Surmodics  Inc    NASDAQ SRDX   and Veeva Systems   NYSE VEEV   Integer Holdings has an earnings growth rate of 31 2  for the fourth quarter 2018 and a Zacks Rank  2  Buy   You can see  Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2 Veeva Systems  long term earnings growth rate is estimated at 19 3   The stock is a Zacks  2 Ranked player Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-12-02,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-stock-declines-10-on-lowered-2018-guidance-200364487,200364487
9829,231344,LH,My Top 10 Fairly Valued Fast Growing Stocks ,opinion,IntroductionThis is part two of a series on investing for growth  part one can be found here One of my primary objectives for preparing this series is to dispel some of the common myths that many investors hold regarding investing for growth  For example  many believe that growth stocks are  by definition  riskier than dividend paying stocks  Although there is some truth to this  I believe this concept is overblown  One commonly measured metric for measuring risk is beta  At its core  beta is a measure of volatility which is also referred to as systematic risk  More simply stated  it is a measurement designed to reflect whether or not a given stock is more volatile than the general market  A baseline beta of one reflects the market  Therefore  a stock with a beta less than one indicates that it is less volatile than the market  and a stock with a beta greater than one would indicate that it is more volatile than the market  More volatility is assumed to be synonymous with more risk  and many investors are led to believe that growth stocks have higher betas than dividend paying stocks  In truth  there are many growth stocks that have betas lower than the general market  and conversely  some that have betas higher than the general market  I will list the betas of each of the 10 examples that I will be presenting in this article next to their title  The results may surprise many readers There is another myth  or at least a great over generalization  that dividend paying stocks outperform non dividend paying stocks  Once again  the true answer is that it really depends on the individual stocks  Some non dividend companies  stocks  are really terrible businesses  which is why they don t pay dividends in the first place  On the other hand  there are many true growth stocks that don t pay a dividend but are excellent businesses  and therefore  excellent investments as well  I will be reviewing 10 excellent true growth non dividend paying stocks in this article  To put it bluntly  a true growth stock will generally create a significantly higher total return than most dividend paying stocks  even if dividends are reinvested  Of course  the true growth stock has to be purchased at a reasonable valuation for this to happen  However  it is quite common that true growth stocks will be priced far above their earnings justified valuations by the market  Therefore  investors need to be careful to avoid the hype and focus on true value instead This leads me to a few words about another myth relating to growth stocks  Many investors believe that high growth stocks simultaneously carry high PEs  and again  higher risk  This particular myth does have some truth based on the fact that companies that are growing at rates that are much faster than the market  are logically worth more than the average company due to the power of compounding  This is why I believe that the PE equal to the growth rate formula for valuing growth stocks  companies with above 15  earnings growth  is an appropriate gauge for fair value Consequently  a P E ratio that is equal to the company s earnings growth rate would indicate fair value  even though it may be higher than the market multiple  This higher valuation is due to the fact that companies that are growing earnings at rates that are multiples of the rates that the general market is growing at will generate significantly more future earnings than the average company  again  thanks to the power of compounding  Therefore  in the long run  wise investors who are investing in these high growth stocks are often buying future earnings much cheaper than the future earnings of average companies with lower entry level PEs This article will review 10 established above average growing businesses that I believe are also fairly valued today  or very close to becoming fairly valued  if there were any correction in the market at all  None of these stocks pay dividends  however  they all have achieved significantly above average historical growth  and most importantly  they are all expected to produce significantly above average future growth  at least over the next five years  Consequently  investors interested in earning above average long term returns might want to dig deeper into these selections 10 Fairly Valued High Growth StocksIn order to make my top 10 list of high growth stocks  each candidate had to meet several logical criteria  First and foremost  I searched for companies with historical earnings growth rates that were exceeding 15  to 20  per annum  In addition to the velocity of the company s earnings growth  I also looked for a high degree of consistency  and the ability to continue growing regardless of the economic environment  including during recessions  I was willing to accept some minor weakness during recessionary times  but not complete earnings collapses The following portfolio review lists my top 10 fairly valued growth stocks listed in alphabetical order  Although each of these selections appears to be an attractive long term investment capable of generating above average returns  a few of these examples are fully valued to moderately overvalued currently  On the other hand  based on the possibility that current estimates may also be conservative  I included them in my top 10 list  In other words  I would either be looking for a minor pullback or for their high earnings growth to exceed current estimates  and therefore  justify current valuation  More simply stated  I think these are all candidates worth looking further into A Detailed Look At The Top 10 Growth List By The NumbersAs usual I will rely on F A S T  Graphs   the fundamentals analyzer software tool  to provide  essential fundamentals at a glance  on each of my top 10 selections  Please keep in mind that each of these selections are offered as candidates for a more comprehensive research and due diligence process  However  I will provide brief commentary on each  based solely on what their respective F A S T  Graph  reveals  Also  as I previously stated  I have presented the beta on each selection along with their introduction  all beta figures taken from Google Finance  AutoZone  Inc  AZO   Beta  32 Below MarketAutoZone has produced a very consistent record of earnings growth averaging over 21  per annum  Nevertheless  it is also a fact revealed by the earnings and price correlated graph below  that the market has historically valued this company at a discount to its earnings growth  The reader should also note that the company carries a lot of debt  but does generate substantial cash flows to mitigate this risk Even though AutoZone has been historically priced at a discount to its earnings growth rate  its total annualized rate of return of 19 4  per annum closely correlates to its earnings growth  Consequently  this business  with its powerful record of consistent growth  has substantially outperformed the S P 500 The consensus of 22 analysts reporting to Standard   Poor s Capital IQ  expect AutoZone to grow earnings at 14 8  per annum over the next five years  Catamaran Corp  CTRX   Beta  54 Below MarketRemarkably  even though Catamaran Corp has produced a powerful record of earnings growth averaging over 40  per annum  the company s beta is only  54  Catamaran Corp did experience a drop in earnings during the great recession  however  the company did remain highly profitable  Furthermore  post recession earnings growth has been nothing short of spectacular as it accelerated to over 60  per annum growth since fiscal 2009  Nevertheless  the company s current P E ratio at 42 3 is in alignment with their historical earnings growth Since going public at the end of June 2006  Catamaran shareholders have enjoyed an annualized rate of return of 52 2   which correlates to the company s earnings growth rate enhanced by modest undervaluation existing when the company first went public The consensus of 22 analysts reporting to Standard   Poor s Capital IQ forecast Catamaran to grow earnings at 25  per annum over the next five years  Consequently  even though the company is reasonably priced based on its historical earnings growth  it would appear to be moderately overvalued based on expected future growth  However  due to the power of compounding  the 25  per annum future growth rate would still offer prospective investors a strong annualized rate of return  On the other hand  over the shorter run  there is the risk of a temporary price drop  Even if that were to occur  if you apply a growth rate multiple of 25 to the consensus  1 86 for fiscal 2013 earnings per share  you would get a fair value of  46 50  This is only moderately below the company s current quotation  My point being that fair valuation can be more generously thought of when dealing with very fast growing companies Cognizant Tech  CTSH   Beta 1 12 Moderately Above Market NeutralCognizant Technology Solutions has one of the most consistent long term records of earnings growth of any company you would ever find  Moreover  the company has no debt and appears to be significantly undervalued based on its long term historical record of earnings growth Thanks to operating earnings growth exceeding 38  per annum  long term shareholders in Cognizant have been rewarded with an annualized rate of return of 31 5   It s important to recognize that this long term rate of return has little or nothing to do with either the return of the stock market during this time  nor the economic growth of the United States and or the rest of the world  Perhaps this is a clue as to why Warren Buffett and others encourage us to ignore political and economic forecasts Since the F A S T  Graphs  research tool is a dynamic tool  I thought it would be revealing to look at Cognizant since calendar year 2008  the great recession   Earnings growth  although still significantly above average  has slowed to just over 22  per annum  This explains why the company appears so undervalued when looked at on the earnings and price correlated graph going back to 1999  Based on more recent history  Cognizant still appears to be undervalued  but nowhere near as much as it does on the longer term graph  To further illustrate  and perhaps more greatly appreciate the power of earnings growth  shareholder returns since the beginning of calendar year 2008 for Cognizant have still been superior to the overall market The consensus of 13 analysts reporting to Standard   Poor s Capital IQ forecast Cognizant to grow earnings at 18  per annum  Although I consider this forecast to be conservative  it nevertheless justifies today s current valuation Express Scripts Holding Co  ESRX   Beta 1 05 Market NeutralExpress Scripts Holding Co  among other things  is a pharmacy benefit management company  with a long record of above average earnings growth exceeding 30  per annum  The drop in earnings for fiscal 2012 is attributed to a one time   67 nonrecurring charge  Excluding the one time charge  operating earnings growth would have been approximately 12   Also  operating cash flow was very strong in fiscal 2012  Express Scripts Holdings Co represents another example of a company with powerful growth that produced returns for shareholders that far exceeded either economic growth and or the returns on the average stock as represented by the S P 500  In other words  the level of the stock market has had little to nothing to do with investing in Express Scripts Holding Company The consensus of 23 analysts reporting to Standard   Poor s Capital IQ forecast Express Scripts  five year earnings growth rate at 15  per annum  However  based on their historical record and the powerful demographics underpinning their core businesses  I believe these estimates could prove to be very conservative  However  if they were proven to be true  then this company would be moderately overvalued today  On the other hand  thanks to the power of compounding long term potential returns could still be substantial  Once again  it may prove beneficial to be somewhat liberal with valuation on a company with significantly above average prospects for growth Fossil Inc  FOSL   Beta 1 81 HighFossil Inc has generated a very strong long term record of earnings growth averaging 18 9  per annum  However  due to the nature of their business  an occasional cyclicality with their earnings does manifest  On the other hand  there are some very interesting lessons in valuation that I believe this company s price history reflects  You can see a strong negative reaction during the great recession which caused the price to drop significantly below its earnings justified valuation  the orange line   However  we also see how it quickly recovered But perhaps the most interesting aspects of their price history are the large spikes of overvaluation that occurred in 2011 and 2012  In both cases  price quickly reverted back to earnings justified levels  providing clear evidence of market inefficiency on both occasions However  in spite of some pretty scary bouts of price volatility  long term shareholders in Fossil Inc were rewarded in almost perfect correlation with the company s long term record of earnings growth  Another piece of evidence that earnings determine market price in the long run The consensus estimates of 14 analysts reporting to Standard   Poor s Capital IQ expect more of the same for Fossil Inc with a five year estimated earnings growth rate estimated at 17 5  per annum  This number is consistent with the company s historical results  and justifies today s current valuation  if proven to be true Hibbett Sports Inc  HIBB   Beta 1 06 Market NeutralHibbett Sports Inc represents a quintessential example of a long term earnings and price relationship  Monthly closing stock prices  the black line on the graph   have clearly tracked the company s earnings growth over time  During the few cases where the price disconnected either above or below the earnings justified valuation  the orange line   it quickly moves back into alignment  Once again  we see that operating earnings growth and shareholder returns are highly correlated  But as we ve also seen with our other examples  there is very little correlation between Hibbett Sports Inc shareholder returns relative to the overall market returns  as represented by the S P 500  over the same timeframe The consensus of 13 analysts reporting to Standard   Poor s Capital IQ forecast Hibbett Sports to grow at 16  per annum  Consequently  the stock appears to be moderately overpriced on that basis  However  due to the high rate of expected growth  Hibbett Sports would still be a good investment at these levels  On the other hand  it might be prudent to wait for a better entry level Laboratory CP of America  LH   Beta  62 LowLaboratory Corp of America is currently trading at a below market PE ratio  yet it possesses above market historical earnings growth averaging over 19  per annum  However  if I were to present a six year graph as I did with CTSH above  LH would appear fairly valued  In spite of Laboratory Corp s current low valuation  long term shareholders were richly rewarded with a total annual return of 25 9  versus 3 1  for the S P 500  Once again  we see the power of above average earnings growth generating significantly above average returns Laborabory Corp of America is the only example in this group with forecast earnigns growth below 15  per annum  AZO is forecast at 14 8  rounded to 15    However  I do believe that these estimates could be consertative  LKQ Corp  LKQ   Beta  86 Neutral to LowLKQ Corp represents a quiessental example of what I look for in a growth stock  Notice how earnings continued to advance prior to  during and after the great recession  Also  notice how over the long term stock price has tracked the company s long term eanrings record As a result of LKQ Corp s consistent and strong record of earnings growth  long term shareholders were rewarded orders of magnitude better than shareholders in a passive index fund would have been  This is a classic example of how a powerful  fast growing  non dividend paying stock will greatly outperform even the best dividend growth stock and the general market at large The consensus of 12 analysts reporting to Standard   Poor s Capital IQ forecast LKQ to grow earnings at 20  per annum over the next five years  Consequently  the shares appear moderately overvalued based on current forecasts  However  considering their impeccable long term record  the consensus forecast may prove conservative Middleby Corp  MIDD   Beta 1 64 HighMiddleby Corp has produced a solid record of historical earnings growth averaging over 31  per annum since 1999  Although the company did have a modest hiccup during the great recession  earnings recovery since has been back on its normal track Long term shareholders in Middleby Corp were rewarded with an annualized rate of return that highly correlated to the company s long term record of earnings growth  Once again we see an example of a fast growing business rewarding shareholders far in excess of economic growth or stock market averages The consensus of 7 analysts reporting to Standard   Poor s Capital IQ forecast Middleby to grow earnings in excess of 19  over the next five years  Consequently  Middleby shares appear within the fair value corridor defined by the five orange lines on the graph Priceline com  PCLN  Beta 1 28 Moderately HighThe long term earrings and price correlated graph on Priceline provides an interesting insight into the dangers of investing too early in a hyped IPO  As you should see from the monthly closing stock price line  the black line on the graph  Priceline s price spiked initially after their IPO release before collapsing over the next year and a half back to its earnings justified level  This further validates my belief in waiting nine months to a year or more before investing in a hot IPO no matter how much I believe in the company s long term future Here is a classic example of how overpaying for even the best of companies can destroy potential returns  Even though Priceline grew earnings in excess of 63  per annum  the massive overvaluation during the initial IPO reduced returns to mere average numbers This next graph reviews Priceline after its initial overvalaution moved into better alignment with the company s operating potential  The operating eanrings growth rate on this company remained the same as we saw with the 15 year graph  however  as we will soon see  the effect of better valuation on long term returns is extrodinary By simply waiting for Priceline shares to move into better alignment with the company s earnings potential  long term shareholder returns went from average to extraordinary  However  it should also be interesting to note that Priceline did not generate any real earnings until 2002  Consequently  even in calendar years 2001 and 2002  Priceline was actually overvalued  however  due to the incredible power of compounding  long term shareholders would have achieved an annualized return of 44 8  per annum  The consensus of 28 analysts reporting to Standard   Poor s Capital IQ forecast Priceline to grow earnings at 20  per annum over the next five years  Consequently  Priceline appears reasonably valued at today s levels Summary and ConclusionsWhen reviewing very fast growing companies  the rules of fair valuation still apply  However  due to the power of compounding  very fast growing businesses will generate significantly higher levels of future earnings than slower growth businesses  As a consequence  investors can actually pay slightly more than earnings justify for a very fast growing company and still generate an attractive long term rate of return  The reason this is important  is because it is difficult to find very fast growing companies that can be bought at the strictest definitions of fair value It should also be pointed out that as companies get bigger  their earnings growth rates are likely to slow down a bit  Therefore  the reader should have noticed that most forecasts for this group of stocks were lower than the company s historical achievements  Future purchases should be based with a greater emphasis placed on the future than on the past  However  I believe a lot of credit should be given to a company with a long history of above average earnings growth  Therefore  I believe there is room for high quality fast growing companies to be included in portfolios designed to fund retirement during the accumulation phase Nevertheless  there are limits to how much overvaluation a prudent prospective investor should be willing to take  Of the 10 sample companies reviewed in this article  3 or 4 of them could be  under the strictest definitions of fair value  considered moderately overvalued  However  none of the samples in this article are what I would consider dangerously overvalued  However  this does present a dilemma of sorts  Do you take the risk of waiting for a better valuation to manifest  only to be left out of the upside   Or do you go ahead and purchase them now  with a commitment to buy more if the price does happen to fall short term I believe these are questions that only each individual investor can answer for themselves  On the other hand  I believe that very fast growth is a rare and precious attribute  and therefore  worthy of some moderate overvaluation  But again  there are limits  In the next and final part three of this series on growth stocks  I will present examples where I believe dangerous overvaluation is manifest  In honor of my Mother  after all  last Sunday was Mother s Day  I always try to honor her rule of not saying anything if I can t say something nice  However  since I am so adamantly averse to overvaluation  I feel it is my responsibility to provide insight into its dangers to my readers Disclosure   Long CTSH  ESRX and LKQ at the time of writing Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ,2013-05-15,Chuck Carnevale,https://www.investing.com/analysis/my-top-10-fairly-valued-fast-growing-stocks-166998,166998
9830,231345,LH,A Dove Takes Flight  Economic Outlook Risks Tilt Downward,opinion,"A dove takes flight and lifts others There is a risk that the intensification of international cross currents could weigh more heavily on U S  demand directly  or that the anticipation of a sharper divergence in U S  policy could impose restraint through additional tightening of financial conditions  For these reasons  I view the risks to the economic outlook as tilted to the downside  The downside risks make a strong case for continuing to carefully nurture the U S  recovery  and argue against prematurely taking away the support that has been so critical to its vitality 

 and top Fed birdwatcher  Jon Hilsenrath  publishes his notes  The chances of a Federal Reserve interest rate increase in 2015 are diminishing amid new signs of anemic economic activity  a disappointing development for central bank officials who have been hoping to move this year after a prolonged period of easy money policies  Lackluster readings on consumer spending  inflation and jobs have virtually eliminated the chances of a move this month  Already  two Fed governors expressed doubts this week about whether the timing will be right this year  and the recent trove of data hasn t reassured top officials about the economic outlook

 Tim Duy even drops his binoculars  This is the most exciting speech I have read in forever  Not necessarily for the content  But for the politics  Evans and Kocherlakota are no longer the lunatic fringe  This could be a real game changer that shifts the Fed toward the Evans view of the world  with no rate hike until mid 2016  Brainard muddied further the already murky December waters

The market is thankful for the release of the Fed doves  because Q3 earnings have not been a positive  And there have been several significant banana peels for some of the S P 500 stocks 
S P 500 traded sideways this week as dovish comments by two Fed officials trumped disappointing macro data and 3Q company results  Retail sales and manufacturing surveys missed expectations  while year year core CPI registered 1 9   Uncertainty around the Fed liftoff increased as Governors Brainard and Tarullo separately argued for holding rates constant through year end  The first major week of 3Q earnings reports was disappointing with negative results and guidance from companies including Netflix  O NFLX  and Wal Mart  N WMT  
 Goldman Sachs  N GS  


Digging through some of the earnings related commentary I found the following data points 

The most notable earnings comment came from Wal Mart  which crushed its own stock price  along with many other retailers  with their comments about higher wages and plans to lower prices 

 Operating income is expected to be impacted by approximately  1 5 billion from the second phase of our previously announced investments in wages and training as well as our commitment to further developing a seamless customer experience  As a result of these investments  we expect earnings per share to decline between 6 and 12 percent in fiscal year 2017  


Delta Airlines  N DAL  made a specific comment about airplane prices that led to a selloff in Boeing  N BA  and Airbus  OTC EADSY  

 We re seeing a huge bubble in excess wide body airplanes around the world   we do think that the aircraft market is going to be ripe for Delta over the course of the next 12 to 36 months and we think that that weakness and that aircraft bubble in wide bodies is going to spread to narrow bodies and that there will be some huge buying opportunities  Because low interest rates really have created a huge wide body bubble in the world  


Hugo Boss  OTC BOSSY  blamed weakness on China slowdown and fewer tourists visiting their U S  stores 

 While performance in Europe remained strong and in line with original expectations  momentum in Asia and the Americas deteriorated considerably towards the end of the period  

the group said in a statement on Thursday evening 

 This was due to sales declines in China  as well as a negative development in the Group s U S  own retail and wholesale businesses  Weaker demand from tourists contributed to the slowdown in the U S  


Burberry  OTC BURBY  saw similar high end retail impacts  Carol Fairweather  finance director  said sales from stores open at least a year fell 4 per cent in the second quarter  compared with a 6 per cent increase in the first  She blamed the deceleration on waning demand from Chinese consumers   We believe the slowdown is macro   she said  However Burberry said demand was also  uneven  in the US  and weaker among local shoppers in London  Ms Fairweather said the group believed the problems were not specific to Burberry   We have been quite clear that we believe that in this quarter it has been a challenging market for luxury consumers all over the world  This has been slightly amplified by our geographic mix   she said

Staying at the high end  is Del Frisco s Restaurant Group  O DFRG  facing more competition  or is the environment changing 

 Del Frisco s Double Eagle faced customer count challenges at several locations  driven significantly by fewer private dining events  and experienced softer sales during shoulder periods  


Digging into the core industrials  Fastenal  O FAST  is still seeing a slowdown 

 The industrial environment is in a recession   I don t care what anybody says  because nobody knows that market better than we do  


Blackstone  N BX  has a big portfolio of private companies so listen closely 

 From our perspective  we do not see a recession  but we are seeing slowing in certain regions and sectors with some excess coming out of markets  


Back to Wal Mart  how will their labor and price pressures not ripple through to the rest of retail  Wal Mart Stores  N WMT  is part of the Hypermarkets and Super Centers sub industry  As a result of the guidance from Wal Mart  this sub industry is now projected to report a decline in earnings in CY 2016 of 5 5   compared to an expectation of earnings growth of 3 1  last Friday  Given the earnings decline now expected for the Hypermarkets and Super Centers sub industry in CY 2016 due to the guidance from Wal Mart  have analysts revised their earnings outlook for other retail sub industries for next year  Do analysts believe the reasons for the lower guidance from Wal Mart Stores are unique to Wal Mart  or do they believe they are reflective of broader issues in the retail space



Away from earnings  it was a very big week for the IPO market as the 3B First Data  N FDC  IPO came to market  and struggled  Another big IPO from Albertsons was pulled after the collapse of Wal Mart  Not good news for the health of the total market 



Among top data last week  the Philly Fed was not inspiring for the industrial economy 



 however  Consumers are feeling the best in 10 years 



The U S  dollar is also in the news as flying doves and soft economic data are helping it lower against both developed and emerging currencies  A weak dollar will add stability to commodity prices and should help multinational revenues and earnings  But will it also pull dollars back into local bonds and equities  Stay tuned 



It was another up week for the S P 500  But what happened to the Small Cap  N SLY  and Mid Cap  N IVOO  indexes 



Among the U S  equity sectors  Utilities and Healthcare led  while Industrials were held back by the difficult earnings releases 



The earnings train will continue full speed this week  From JPMorgan  N JPM   some of the larger reports  Top earnings Mon morning 10 19  N HAL  N MS  N VRX Top earnings Mon night 10 19  N IBM  N VALE Top earnings Tues morning 10 20  N BK  N EAT  N LMT  N RF  N TRV  N UTX  N VZ Top earnings Tues night 10 20  N ACE  N CMG  N DFS  N VMW  O YHOO Top earnings Wed morning 10 21  N BAC  N BHI  N BHP  O BIIB  Credit Suisse  VX CSGN   N EMC  N GM  N ITW  N KMB  N KO Top earnings Wed night 10 21  N AXP  O EBAY  O LRCX  N LVS  O SNDK  O TXN Top earnings Thurs morning 10 22  N BEN  N CAT  N DHR  N DOW  N LLY  N MCD  N MJN  N MMM  O TROW  N UA  N UNP Top earnings Thurs night 10 22  O AMZN  N COF  O GOOGL  O MSFT  N T Top earnings Fri morning  O AAL  N CFG  N PG  N STT

Barron s ran its Big Money Poll over the weekend  Often a good look for the Contrarians who must be seeing opportunities in Materials and Energy 





Merrill s investor survey will point Contrarians to Long EM Equities FX and Commodity Stocks 



The team over at N GMO would take the Contrarian play in Emerging Market Equities and Bonds along with a few acres of Timber 
 researchpuzzler  the GMO return forecast calls for challenging times ahead for asset owners  but then you knew that 



The lack of returns available in many asset classes  combined with highly correlated returns  has made for a hedge fund manager s worst environment  As a result  many funds are shutting the doors 
Some 417 hedge funds announced shutdowns in the first half  according to Hedge Fund Research Inc  While that number isn t on track to surpass the 864 funds that closed in 2014  the market turbulence of the last two months caused by concerns about China s slowing economic growth could lead to a pickup in the fourth quarter  A record 1 471 funds liquidated amid the 2008 financial crisis



A very big story in Venture Cap last week as John Carreyrou  a Unicorn Hunter at the WSJ  looks to have uncovered some key research that few others have done on Theranos 
But here s the thing about unicorns  They re not real  Theranos billed itself as an alternative to big needled  big billed  big pain in the arm standard blood tests  But on Wednesday  a Wall Street Journal article alleged this was all a lab of cards  Rather than using its hyped finger prick technology  the company was doing most of its work on the same boring machines used by stodgy old diagnostics giants Laboratory Corporation  N LH  and Quest  N DGX   On Thursday  the Journal dropped a second bomb  According to a company insider  the FDA has asked Theranos to stop using all but one of its finger prick tests 

In other big tech news  Elon Musk unveiled Tesla s auto pilot and explains why his self driving car will outperform your driving 
 The whole Tesla  O TSLA  fleet operates as a network  When one car learns something  they all learn it  That is beyond what other car companies are doing   said Musk  When it comes to the autopilot software  Musk explained that each driver using the autopilot system essentially becomes an  expert trainer for how the autopilot should work  

He also shortened the window on when he thinks full self driving will be available for all  Elon Musk  Tesla s co founder and chief executive  told reporters at an event in Palo Alto on Wednesday that his ultimate objective was to create a car that behaved like a  really good chauffeur    It ll actually do better than a person   he said   I think this is going to be quite a profound experience for people when they do it  It s going to change people s perception of the future quite radically   Tesla is racing Silicon Valley rivals such as Google  O GOOGL  and Apple  O AAPL   as well as traditional auto makers including Audi  DE NSUG  and BMW  DE BMWG   towards a future of completely autonomous cars  which Mr  Musk now predicts will be technically possible   if not necessarily legal   by 2018   I m quite confident within three years the car will be able to take you from point to point   from your driveway to work without you touching anything   he said   You could be asleep the whole time and do so completely safely  

New research into China s air pollution shows why the Government will be pushing electric cars in a major way  Berkeley Earth s scientific director  Richard Muller  says breathing Beijing s air is the equivalent of smoking almost 40 cigarettes a day and calculates that air pollution causes 1 6m deaths a year in China  or 17  of the total  A previous estimate  based on a study of pollution in the Huai river basin  which lies between the Yellow and Yangzi rivers   put the toll at 1 2m deaths a year still high 



 The information presented here is for informational purposes only  and this document is not to be construed as an offer to sell  or the solicitation of an offer to buy  securities  Some investments are not suitable for all investors  and there can be no assurance that any investment strategy will be successful  The hyperlinks included in this message provide direct access to other Internet resources  including Web sites  While we believe this information to be from reliable sources  361 Capital is not responsible for the accuracy or content of information contained in these sites  Although we make every effort to ensure these links are accurate  up to date and relevant  we cannot take responsibility for pages maintained by external providers  The views expressed by these external providers on their own Web pages or on external sites they link to are not necessarily those of 361 Capital ",2015-10-20,Blaine Rollins,https://www.investing.com/analysis/a-dove-takes-flight-268638,268638
9831,231346,LH,Move Over  Earnings  It s Hedge Fund Season,opinion,"Another earnings season has come and gone  Wal Mart Stores Inc  s  N WMT  quarterly report last week marked the end of  the season  for S P 500 companies 
But I m already on to the next reporting season  hedge funds 
Every quarter  these secretive institutions disclose their long portfolios to the public in an SEC mandated filing called a  
Fund managers with more than  100 million under management are required to file a 13F within 45 days of the previous quarter s close 
So  four times a year  the average investor has the invaluable opportunity to see where the  smart money  is deploying their capital 
And today  I m going to dive into one of their favorite additions of the fourth quarter 
Just a Little Pin Prick 
Laboratory Corp  of America Holdings  N LH  is the second largest clinical lab company in the United States  Founded in 1971 and better known as LabCorp  the company performs a wide range of diagnostic and disease treatment services 
LabCorp operates 39 primary laboratories and approximately 1 750 patient service centers around the world 
Over the last 20 years  the stock has been a standout performer against the market  Since 1996  the stock gained 422  versus the S P s gain of just 197  
Since 2010  LabCorp grew revenue by an average of 11   It s driven earnings of 4 9  during that time  more than triple the rate of chief competitor Quest Diagnostics Inc  N DGX  
Last year  LabCorp completed a  6 2 billion purchase of pharmaceutical R D giant Covance Inc  The purchase will contribute heavily to the company s top line growth as well as reduce testing costs 
However  the firm struggled as several unrelated biotech scandals rocked the industry as a whole 
Valeant Pharmaceutical International Inc  s  N VRX  questionable financial reports 
The uproar over Turing Pharmaceuticals  1 000  Daraprim price hike 
Laboratory upstart Theranos Inc  came under fire late last year for the accuracy of its testing equipment 
From its 52 week high in July to its 52 week low just a few months later  the S P Biotechnology Index fell 25  on these concerns 
These external struggles have helped drive down LabCorp s valuation in a big way 
The Funds Come Marching In
By the fourth quarter  LabCorp s price to earnings ratio dropped to 17   a discount to the market and the industry  The company s price to book ratio fell to a 10 year low of 2 2 
And that s when  smart money  made its move 
Glenview Capital Management LLC added to its existing position by 1 32   purchasing 791 223 shares  The institution now owns 8 6  of LabCorp 
Jana Partners LLC opened a new position  purchasing 696 034 shares   worth 1 2  of its long equity portfolio 
And Och Ziff Capital Management Group LLC  N OZM  bought up nearly 3 million LabCorp shares   a 2  ownership stake in the company  Och Ziff is one of the world s largest alternative asset managers with  45 5 billion under management 
Take Advantage of Another Markdown
The broad selloff that kicked off the year shaved even more off LabCorp s share price  Shares are down 11  on the year 
The company now trades at 13 6 times forward earnings   nearly half the peer average 
From a technical perspective  momentum has shifted to the upside  Shares have just emerged from oversold territory off their January lows  with support along a five year trend line 
Best of all  shares took a bullish bounce off their 20 day moving average 
If you re bullish on healthcare  it s time to put this Wall Street biotech favorite into your portfolio ",2016-02-29,Wall Street Daily,"https://www.investing.com/analysis/move-over,-earnings,-its-hedge-fund-season-200119753",200119753
9832,231347,LH,LabCorp  LH  Posts Strong Q1  Covance Synergy Continues,opinion,On May 16  2016  we issued an updated research report on Laboratory Corporation of America Holdings   NYSE LH    or LabCorp  a leading independent clinical laboratory company  LabCorp is currently working on portfolio expansion  The company is more focused on the high margin esoteric testing business to drive its top line LabCorp kick started the year 2016 on an optimistic note with its first quarter earnings and revenues surpassing the respective Zacks Consensus Estimate  This has been a strong quarter with respect to organic volume growth in LabCorp Diagnostics  accelerated revenue growth in Covance Drug Development and operating leverage With the acquisition of Covance  which is now operational as Covance Drug Development  LabCorp expects to expand the company s range of diagnostic offerings and create a new industry leader in both the laboratory testing and CRO spaces  This will act as a leading provider of medical testing apart from operating as a premier full service drug development organization Earlier LabCorp had set a goal of  150 million in incremental revenues by the end of 2018   100 million for companion diagnostics and  50 million for real world evidence   In the first quarter  the acquisition of Covance contributed  687 3 million to the company s revenues  driving 23 7  year over year growth  The company is currently on track to achieve the incremental revenue synergy target Moreover  LabCorp expects to achieve annual cost synergies in excess of  100 million  to be fully realized within three years of closure of the acquisition  Of this  the company has already achieved  50 million and looks well positioned to achieve its targeted synergy  going ahead LabCorp has also strengthened its foothold in the diagnostics space through both organic and inorganic means  and plans to collaborate with leading companies and academic institutions to provide a wider portfolio of tests  In Mar 2016  the company acquired full service independent women s health laboratory  Pathology  Inc   including the patient service centers used to conduct the latter s medical testing and services business Among strategic partnerships  recently the company formed an alliance with Interpace Diagnostics  a developer of molecular diagnostics tests  to begin offering the latter s new ThyraMir microRNA classifier test  Other recent collaborations include the alliance with Japan based Sysmex Corporation   a leading clinical laboratory services provider  The company also signed a strategic agreement with biotechnology company ORIG3N  a leading provider of induced pluripotent stem cell  iPSC  repository  called LifeCapsule Also  as part of its five pillar strategy  LabCorp is currently working hard on new innovations with academic institutions in order to capture the growing lab testing market with its advanced assays and tools However  the current economic uncertainty remains a deterrent for LabCorp  The strengthening of the dollar continues to weigh on its year over year revenue performance  Moreover  changes in governmental regulations had a significant impact on LabCorp s operations  We are highly disappointed with the recent CMS proposal related to Protecting Access to Medicare Act  PAMA  LabCorp currently carries a Zacks Rank  2  Buy  Key Picks in the SectorMedical instruments stocks that are worth a look include CR Bard Inc    NYSE BCR    Henry Schein  Inc    NASDAQ HSIC   and The Cooper Companies Inc    NYSE COO    All these stocks carry a Zacks Rank  2 ,2016-05-17,Zacks Investment Research,https://www.investing.com/analysis/labcorp-(lh)-posts-strong-q1;-covance-synergy-continues-200130374,200130374
9833,231348,LH,7 Best Stocks To Attract You With Sales Growth,opinion,"Sales growth is an important metric for any company  as it is a vital part of growth projections and instrumental in strategic decision making  By monitoring this key metric over multiple time periods  one can clearly understand a company s growth trend 
Sales growth is essential to justify the fixed and variable expenses incurred to operate a business  Low revenues lead to an unprofitable business and negative financial results  Stagnant companies may generate near term profit  but can t rev up enough growth to attract new investors 
Moreover  in a growing economy  a lack of sales growth most likely denotes that the company is not gaining market share over its competitors  In simple terms  some sustained sales growth is necessary to support the bottom line 
Focusing solely on sales growth is not enough though  A healthy sales growth rate is certainly a positive indicator for picking good stocks  but it does not ensure profits  Therefore  taking into consideration a company s cash position along with its sales number can prove to be a more dependable strategy 
Substantial cash on hand and a steady cash flow give a company more flexibility with respect to business decisions and potential investments  Cash also enables a company to endure market downturns  Most importantly  a sufficient cash position indicates that revenues are being channelized in the right direction 
The Winning Strategy
In order to shortlist stocks that have impressive sales growth along with a high cash balance  we added 5 Year Historical Sales Growth     greater than X Industry and Cash Flow greater than  500 million as our primary screening parameters 
However  sales growth and cash strength are not the absolute criteria for selecting stocks  So  we added a few other factors to arrive at a winning strategy 
Price to Sales  P S  Ratio less than X Industry  This metric measures the value placed on each dollar of a company s revenues  The lower the ratio  the better it is for picking a stock since the investor is paying less for each unit of sales 
  Change F1 Sales Estimate Revisions  4 Weeks  greater than X Industry  Northward estimate revision has often been observed to trigger an increase in the stock price 
Operating Margin  Average Last 5 years  greater than 5   Operating margin measures how much every dollar of a company s sales translates into profits  A high ratio indicates that the company has good cost control and sales are increasing faster than costs  which is the optimal situation for the company 
Return on equity  ROE  greater than 5   This metric will ensure that the sales growth is getting translated into profits and the company is not sitting idle on hoards of cash  High ROE means the company is spending wisely and is in all likelihood profitable 
Zacks Rank less than or equal to 2 Zacks Rank  1  Strong Buy  or  2  Buy  stocks are known to outperform irrespective of the market environment 
Here are 7 of the 13 stocks that qualified the screening 
Laboratory Corp  of America Holdings    NYSE LH   
Newell Brands Inc     NYSE NWL   
Hasbro Inc     NASDAQ HAS   
WSFS Financial Corp     NASDAQ WSFS   
LPL Financial Holdings Inc     NASDAQ LPLA   
WEX Inc     NYSE WEX   
Alleghany Corporation    NYSE Y   
You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge 
The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 
 
Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 
Disclosure  Performance information for Zacks  portfolios and strategies are available at  
Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ",2016-05-18,Zacks Investment Research,https://www.investing.com/analysis/7-best-stocks-to-attract-you-with-sales-growth-200130790,200130790
9843,231358,LH,Amazon Eyeing Diagnostic Space To Gather Steam In Healthcare ,opinion,"Amazon s   NASDAQ AMZN   continued focus on healthcare industry is likely to transform the traditional methods in this space into smarter  efficient and time saving ones Reportedly  the e commerce giant has been eyeing the consumer health diagnostic market for quite some time now in order to develop products that will enable people to take vital medical tests at home This kind of products will accelerate the healthcare delivery time which will be of a great help to patients and their families  These initiatives prove that Amazon is well poised to cause massive disruption in the multi trillion healthcare space with its innovative technologies  strategic partnerships and acquisitions Initiatives in Diagnostic SpacePer CNBC  Amazon s Grand Challenge healthcare team  which is involved in several projects related to medical records  last mile delivery and most importantly cancer research  was actively working on a secretive diagnostic project during the summer of this year Although there is no confirmation on the status of the project  it is still projected to generate  250 million in sales  in turn driving the company s top line growth Amazon also considered buying Confer Health which manufactures hardware for at home tests this year but dropped the plan after announcing the acquisition of PillPack Further  the company recently joined forces with Omron Healthcare which develops blood pressure monitors  This partnership enables integration of Alexa with these monitors which in turn will enable people to check their latest blood pressure reading  calculate average readings and compare levels throughout different times of the day with the aid of voice commands Amazon com  Inc  Price and Consensus    Strengthening Competition
Notably  Amazon s strong point of care diagnostic initiatives are expected to aid it in penetrating the global healthcare supply chain management market which as per a report from Research and Markets  is expected to witness a CAGR of 8  between 2018 and 2023 Moreover  the company s eye on home health testing space is likely to put competitive pressure on testing and medical diagnostic companies like Laboratory Corporation of America Holdings   NYSE LH   and Quest Diagnostics   NYSE DGX   Further  Amazon is likely to intensify the competition for Alphabet s   NASDAQ GOOGL   Google which is also leaving no stone unturned to bolster footprint in the healthcare quality management space on the back of its innovative techniques and expanding global presence Recently  the search giant rolled out an artificial intelligence project in Thailand for the detection of diabetic eye disease causing permanent blindness Nevertheless  Amazon s aggressive and growing healthcare initiatives are expected to provide it a competitive edge over Google Currently  Amazon carries a Zacks Rank  3  Hold   You can see 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/amazon-eyeing-diagnostic-space-to-gather-steam-in-healthcare-200369086,200369086
9844,231359,LH,LabCorp  GENFIT Tie Up To Develop Test For NASH  Widen Suite,opinion,Laboratory Corporation of America Holdings  NYSE LH  or LabCorp recently announced that  its drug development business Covance has signed a licensing agreement with GENFIT  The agreement will expand LabCorp and Covance s access to the non alcoholic steatohepatitis  NASH  liver diagnostic test  NIS4  developed by GENFIT  Through the agreement  NIS4 will be deployed in the clinical research space through Covance s central laboratories This association will help in further studying NIS4 s effectivity in identification and characterization of patients along with developing biological insights on NASH disease pathogenesis Market PotentialGoing by a report published by Allied Market Research  the global NASH market is expected to see a CAGR of 58 4  between 2021 and 2025  Considering the company s efforts  we believe it is well positioned to gain from the bountiful opportunities in the niche market Strategic Collaborations Drive GrowthLabCorp has strengthened its foothold in the diagnostics space through both organic and inorganic means and plans to collaborate with leading companies and academic institutions to provide a wider portfolio of tests  Among the company s recent alliances  worth mentioning are the company s collaborations with UnitedHealthcare and Aetna  NYSE AET  which have helped LabCorp become a contracted laboratory provider for all major national plans  This apart  the company s comprehensive laboratory collaborations with Baptist Health and Appalachian Regional Healthcare are important Also  LabCorp s Covance recently announced a tie up with Definiens  a pioneer in artificial intelligence  AI  based image analysis to improve global development of precision medicine  Covance has also made a strategic technology agreement with GlaxoSmithKline  Under the terms of the agreement  GSK will use Covance s Xcellerate Monitoring  Xcellerate Insights  and Xcellerate Clinical Data Hub solutions in a software as a service model Share Price PerformanceOver the past six months  shares of LabCorp have underperformed its   The stock has declined 31 6  compared with the industry s 15  fall Zacks Rank   Key PicksLabCorp carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical space are Veeva Systems   NYSE VEEV    Integer Holdings Corporation   NYSE ITGR   and Surmodics  Inc    NASDAQ SRDX   Veeva Systems  long term earnings growth rate is estimated at 19 5   The stock flaunts a Zacks Rank  1  Strong Buy   You can see  Integer Holdings  with a Zacks Rank  1  has an earnings growth rate of 31 2  for the first quarter of 2019 Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2  Buy  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/labcorp-genfit-tieup-to-develop-test-for-nash-widen-suite-200372879,200372879
9845,231360,LH,LabCorp Rides On Covance Business Amid Reimbursement Woes,opinion,On Jan 4  we issued an updated research report on LabCorp   NYSE LH    The stock carries a Zacks Rank  3  Hold  This Burlington  NC based healthcare diagnostics company  providing comprehensive clinical laboratory services and end to end drug development support  has been grappling with multiple issues of late  Economic uncertainties including a challenging volume environment for testing laboratories and softness in utilization are headwinds for LabCorp In the past three months  LabCorp has underperformed its industry  The stock has dropped 24 8  in comparison to the industry s 19  decline  While increasing acquisitions and organic volume expansion positively contributed to LabCorp Diagnostics business in the third quarter 2018  the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act  PAMA  dented growth The lowered 2018 guidance  announced on Nov 30  also fails to inspire us about any positive rebound in the near term  This apart  adverse currency movement affected the top line  Also  the current economic ambiguity including a tough reimbursement scenario for testing labs and utilization weaknesses are weighing on LabCorp Laboratory Corporation of America Holdings Price   On a positive note  within Covance Drug Development business  LabCorp is focused on driving profitable growth through expanded solutions and enhanced operational capabilities  The acquisition of Chiltern completed in September 2017  has started to significantly strengthen the company s strategic position in clinical development and is accelerating revenue and profit growth within Covance  In this regard  the company is keeping a good pace with its objective to streamline the drug development process  Moreover  it is winning new awards via its integrated Covance and Chiltern offering  Also  the company has progressed with the Covance LaunchPad initiative in the last reported quarter At the end of the third quarter  LabCorp remains on track to deliver  150 million of net savings from Covance LaunchPad by the end of 2020 and another  30 million of cost synergies from the integration of Chiltern by 2019 end Apart from heavyweight buyouts like Covance  LabCorp consistently adds complementary capabilities through targeted tuck in acquisitions  The latest on the list is the transaction of Sciformix Corporation  a scientific process outsourcing company  The same is expected to leverage LabCorp s position in the later phases of drug and device development  particularly for post marketing pharmacovigilance and market access solutions Key PicksSome better ranked stocks in the broader medical space are Veeva Systems   NYSE VEEV    Surmodics  Inc    NASDAQ SRDX   and athenahealth  Inc     NASDAQ ATHN   Veeva Systems  long term earnings growth rate is estimated at 19 5   The stock flaunts a Zacks Rank  1  Strong Buy   You can see  Surmodics  long term earnings growth rate is predicted at 10   The stock carries a Zacks Rank  2  Buy  athenahealth s long term earnings growth rate is projected at 17 7   The stock has a Zacks Rank of 2 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2019-01-06,Zacks Investment Research,https://www.investing.com/analysis/labcorp-rides-on-covance-business-amid-reimbursement-woes-200373365,200373365
9857,231372,LH,Why Is LabCorp  LH  Up 1 6  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for LabCorp  LH   Shares have added about 1 6  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is LabCorp due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Business Disposition and Currency Translation Dent LabCorp s Growth in Q1LabCorp reported first quarter 2019 adjusted earnings per share  EPS  of  2 62  down 5 8  from the year ago quarter  However  the bottom line surpassed the Zacks Consensus Estimate by 3 6  On a reported basis  net earnings came in at  1 86 per share as compared with  1 67 a year ago Revenues in the quarter under review dipped 2 1  year over year to  2 79 billion  The top line also lagged the Zacks Consensus Estimate of  2 82 billion The year over year decline was primarily due to a 1 8  negative impact from the disposition of businesses and foreign currency translation of approximately 0 9   partially offset by growth from acquisitions of 0 5  and organic growth of 0 2   which includes the negative impact from Protecting Access to Medicare Act or PAMA of 0 9   Quarter Under ReviewLabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development In the first quarter  LabCorp Diagnostics reported revenues of  1 72 billion  a 2 7  drop year over year  The decline was primarily due to a 2 9  headwind from the disposition of businesses and a 1 5  negative impact from the implementation of the PAMA  In addition  foreign currency translation reduced revenue by approximately 0 3  Excluding the disposition of businesses  the company reported a 0 8  rise in total volume  measured by requisition  and a 0 4  decline in revenue per requisition in the quarter under review Covance Drug Development reported a 0 4  decline in revenues to  1 07 billion in the first quarter  The downside was primarily due to the adverse impact of foreign currency translation of nearly 210 bps  partially offset by partially offset by growth from acquisitions of 1 2  and organic growth of 0 5  Gross margin expanded 94 bps to 28 3  in the reported quarter  Adjusted operating income was up 3 6  year over year to  395 9 million  Also  adjusted operating margin expanded 77 bps from the year ago quarter to 14 2  LabCorp exited the first quarter with cash and cash equivalents of  348 8 million compared with  426 8 million at the end of 2018 At the end of the first quarter  operating cash flow was  165 8 million  down from  179 7 million in the year ago period  Free cash flow came in at  71 6 million in this period  down from  107 2 million a year ago During the quarter under discussion  the company returned  100 million to shareholders via share repurchases  LabCorp currently has  1 25 billion of authorization remaining under its existing share repurchase plan OutlookLabCorp has updated its 2019 guidance Revenue growth expectation has been reiterated in the band of 0 5 2 5  from 2018  This includes a projected adverse impact from the disposition of businesses of around 1 2  and foreign currency translation of roughly 0 5   The Zacks Consensus Estimate for current year revenues is pegged at  11 47 billion Adjusted EPS expectation for 2019 has been raised to a range of  11 05 to  11 45 from the earlier range of  11 to  11 40  The consensus mark of  11 22 for the metric is within the guided range Free cash flow is projected in the band of  950 million  1 05 billion  unchanged  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
Currently  LabCorp has a subpar Growth Score of D  however its Momentum Score is doing a lot better with a B  Following the exact same course  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions looks promising  Notably  LabCorp has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-29,Zacks Investment Research,https://www.investing.com/analysis/why-is-labcorp-lh-up-16-since-last-earnings-report-200426576,200426576
9858,231373,LH,LabCorp  LH  Closes Envigo Swap Deal  Expands In CRO Space,opinion,Laboratory Corporation of America Holdings or LabCorp   NYSE LH   recently announced that it has completed its much talked about swap transaction with Envigo  a provider of nonclinical contract research services and research models  The deal  initiated in April 2019  is expected to strengthen and enhance the way the respective businesses of both companies support research in the biopharmaceutical and life sciences industries The Deal at a GlanceGoing by the terms of the deal  the Covance Drug Development segment of LabCorp has completed the acquisition of Envigo s nonclinical contract research services business  This will help expand Covance s global nonclinical drug development capabilities with additional locations and resources Meanwhile  under this swap transaction  Envigo s Research Models and Services business has also closed the buyout of the Covance Research Products business  The two companies will continue to collaborate through a multi year  renewable supply agreement LabCorp is highly positive about this transaction  which is in line with the company s strategy to provide the biopharma industry with comprehensive drug development services Financial Implication of the DealPer LabCorp  the transactions resulted in a net implied cash consideration of  485 million  paid by LabCorp  The transactions are expected to meet LabCorp s financial criteria of earnings and cash accretion in year one and exceed the cost of capital by year three LabCorp on Acquisition SpreeLabCorp continues to add complementary capabilities through targeted acquisitions  Apart from this innovative business swap transaction with Envigo  the company enriched its value by acquiring MNG Diagnostics  a player in next generation sequencing and complex testing for neurology Other important acquisitions of recent times include Sciformix Corporation  a scientific process outsourcing company  This apart  the  1 2 billion takeover of Chiltern International Group Limited  a specialty CRO  contract research organization   is significant  Chiltern has formed part of LabCorp s Covance Drug Development segment  This has added highly complementary capabilities to the company s offering including scale expansion in Asia Pacific  broader reach into the fast growing emerging and mid tier biopharma customer segment as well as expertise in oncology drug development Industry Prospects and PlayersThe global CRO industry is currently booming with prospects  Per a report by Outsourcing Pharma  this industry is forecast to grow 12  on a year over year basis through 2021 to reach a value of  44 4 billion  Accordingly  industry players like LabCorp  Quest Diagnostics   NYSE DGX    ICON Public Limited Company   NASDAQ ICLR    Cancer Genetics Inc    NASDAQ CGIX   and others are putting in major efforts to widen their presence within this space Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-closes-envigo-swap-deal-expands-in-cro-space-200428493,200428493
9859,231374,LH,LH Vs  XRAY  Which Stock Is The Better Value Option ,opinion,"Investors interested in stocks from the Medical   Dental Supplies sector have probably already heard of LabCorp  LH  and Dentsply International  XRAY   But which of these two stocks presents investors with the better value opportunity right now  Let s take a closer look 
There are plenty of strategies for discovering value stocks  but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns  The proven Zacks Rank emphasizes companies with positive estimate revision trends  and our Style Scores highlight stocks with specific traits 
LabCorp and Dentsply International are both sporting a Zacks Rank of   2  Buy  right now  Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions  But this is just one factor that value investors are interested in 
Value investors also tend to look at a number of traditional  tried and true figures to help them find stocks that they believe are undervalued at their current share price levels 
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics  These include the long favored P E ratio  P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that help us determine a company s fair value 
LH currently has a forward P E ratio of 14 85  while XRAY has a forward P E of 24 33  We also note that LH has a PEG ratio of 1 73  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  XRAY currently has a PEG ratio of 2 12 
Another notable valuation metric for LH is its P B ratio of 2 32  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  By comparison  XRAY has a P B of 2 61 
Based on these metrics and many more  LH holds a Value grade of B  while XRAY has a Value grade of C 
Both LH and XRAY are impressive stocks with solid earnings outlooks  but based on these valuation figures  we feel that LH is the superior value option right now ",2019-06-10,Zacks Investment Research,https://www.investing.com/analysis/lh-vs-xray-which-stock-is-the-better-value-option-200430507,200430507
9860,231375,LH,Robust Sales Growth Makes These 5 Stocks Worth Buying Now,opinion,Strong sales growth is one of the most important characteristics of potential winners in the stock market  The companies that put more emphasis on sales management have a competitive advantage  as solid sales generally get converted into growth Revenues are often more closely monitored than earnings when assessing growth of a business  This is because investors want to make sure whether a business has the capability of generating more sales over time to cater to an expanding customer base Flat or declining sales rise indicates obstacles at the company and offers limited scope for sustained growth  Stagnant companies may generate near term profit  but do not ensure enough growth to attract new investors Without robust top line growth  bottom line improvement may not be sustainable over the long term  While a company can show earnings strength by reducing expenses  a sustainable bottom line recovery usually requires strong sales growth Nonetheless  sales growth in isolation doesn t indicate much about a company s future performance  Though it provides investors an insight into product demand and pricing power  a huge sales number is not necessarily translated into profits So  taking into consideration a company s cash position along with its sales number can prove to be a more dependable strategy  Substantial cash in hand and a steady cash flow give a company more flexibility with respect to business decisions and potential investments  Most importantly  an adequate cash position suggests that revenues are being channelized in the right direction Selecting the Winning StocksIn order to shortlist stocks that have witnessed impressive sales growth along with a high cash balance  we have selected 5 Year Historical Sales Growth     greater than X Industry and Cash Flow more than  500 million as our main screening parameters But sales growth and cash strength are not the absolute criteria for selecting stocks  So  we added certain other factors to arrive at a winning strategy P S Ratio less than X Industry  This metric determines the value placed on each dollar of a company s revenues  The lower the ratio  the better it is for picking a stock since the investor is paying less for each unit of sales   Change F1 Sales Estimate Revisions  four weeks  greater than X Industry  Estimate revisions  better than the industry  are often seen to trigger an increase in stock price Operating Margin  average last five years  greater than 5   Operating margin measures how much every dollar of a company s sales translates into profits  A high ratio indicates that the company has good cost control and sales are increasing faster than costs   an optimal situation for it Return on Equity  ROE  greater than 5   This metric will ensure that sales growth is translated into profits and the company is not hoarding cash  A high ROE means the company is spending wisely and is in all likelihood profitable Zacks Rank less than or equal to 2  Zacks Rank  1  Strong Buy  or 2  Buy  stocks are known to outperform irrespective of the market environment  You can see the complete list of today s Zacks  1 Rank stocks here Here are five of the 19 stocks that qualified the screening     Starbucks   NASDAQ SBUX   operates as a roaster  marketer and retailer of specialty coffee  This Seattle  WA based company s expected sales growth rate for fiscal 2019 is 6 2   and it carries a Zacks Rank  2 Based in Baltimore  MD  T  Rowe Price   NASDAQ TROW   is a publicly owned investment manager  Expected sales growth rate for 2019 is 3 7   and the stock sports a Zacks Rank  1 Laboratory Corporation of America Holdings   NYSE LH    headquartered in Burlington  NC  is an independent clinical laboratory company  Its expected sales growth rate for 2019 is 1 2   and the stock carries a Zacks Rank  2 Headquartered in Scottsdale  AZ  Carlisle Companies   NYSE CSL   is a diversified manufacturing company  The company s expected sales growth rate for 2019 is 8 1   and it sports a Zacks Rank  1 FleetCor Technologies   NYSE FLT   provides commercial payment solutions  This Peachtree Corners  GA based company s sales are expected to increase at the rate of 8 3  for 2019 The stock carries a Zacks Rank  2 Get the rest of the stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and backtesting software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at ,2019-06-13,Zacks Investment Research,https://www.investing.com/analysis/robust-sales-growth-makes-these-5-stocks-worth-buying-now-200431248,200431248
9861,231376,LH,Zacks com Featured Highlights Include  Starbucks  T  Rowe Price  Laboratory Corporation  Carlisle And FleetCor,opinion,For Immediate ReleaseChicago  IL   June 14  2019   Stocks in this week s article are Starbucks   NASDAQ SBUX    T  Rowe Price   NASDAQ TROW    Laboratory Corporation of America Holdings   NYSE LH    Carlisle Companies   NYSE CSL   and FleetCor Technologies   NYSE FLT   Robust Sales Growth Makes These 5 Stocks Worth Buying NowStrong sales growth is one of the most important characteristics of potential winners in the stock market  The companies that put more emphasis on sales management have a competitive advantage  as solid sales generally get converted into growth Revenues are often more closely monitored than earnings when assessing growth of a business  This is because investors want to make sure whether a business has the capability of generating more sales over time to cater to an expanding customer base Flat or declining sales rise indicates obstacles at the company and offers limited scope for sustained growth  Stagnant companies may generate near term profit  but do not ensure enough growth to attract new investors Without robust top line growth  bottom line improvement may not be sustainable over the long term  While a company can show earnings strength by reducing expenses  a sustainable bottom line recovery usually requires strong sales growth Nonetheless  sales growth in isolation doesn t indicate much about a company s future performance  Though it provides investors an insight into product demand and pricing power  a huge sales number is not necessarily translated into profits So  taking into consideration a company s cash position along with its sales number can prove to be a more dependable strategy  Substantial cash in hand and a steady cash flow give a company more flexibility with respect to business decisions and potential investments  Most importantly  an adequate cash position suggests that revenues are being channelized in the right direction For the rest of this Screen of the Week article please visit Zacks com at  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-06-13,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-starbucks-t-rowe-price-laboratory-corporation-carlisle-and-fleetcor-200431719,200431719
9875,231390,LH,LabCorp  LH  Tops Q2 Earnings Estimates,opinion,"LabCorp  LH  came out with quarterly earnings of  2 93 per share  beating the Zacks Consensus Estimate of  2 90 per share  This compares to earnings of  2 98 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 03   A quarter ago  it was expected that this medical laboratory operator would post earnings of  2 53 per share when it actually produced earnings of  2 62  delivering a surprise of 3 56  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
LabCorp  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  2 88 billion for the quarter ended June 2019  missing the Zacks Consensus Estimate by 0 47   This compares to year ago revenues of  2 87 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
LabCorp shares have added about 41  since the beginning of the year versus the S P 500 s gain of 20 5  
What s Next for LabCorp 
While LabCorp has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for LabCorp was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 85 on  2 90 billion in revenues for the coming quarter and  11 28 on  11 46 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 30  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-25,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-tops-q2-earnings-estimates-200444652,200444652
9876,231391,LH,Can Value Investors Pick Laboratory Corporation  LH  Stock ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Laboratory Corporation of American Holdings   NYSE LH   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Laboratory Corporation has a trailing twelve months PE ratio of 15 6  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 17 85  If we focus on the long term PE trend  Laboratory Corporation s current PE level puts it below its midpoint of 16 07 over the past five years  Moreover  the current level stands well below the highs for the stock  suggesting that it can be a solid entry point Further  the stock s PE also compares favorably with the Zacks Medical sector s trailing twelve months PE ratio  which stands at 20 59  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers  We should also point out that Laboratory Corporation has a forward PE ratio  price relative to this year s earnings  of just 14 81  so it is fair to say that a slightly more value oriented path may be ahead for Laboratory Corporation stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Laboratory Corporation has a P S ratio of about 1 48  This is a bit lower than the S P 500 average  which comes in at 3 15x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Laboratory Corporation currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes Laboratory Corporation a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for Laboratory Corporation is just 1 53  a level that is far lower than the industry average of 1 85  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Clearly  LH is a solid choice on the value front from multiple angles What About the Stock Overall Though Laboratory Corporation might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of C and a Momentum Score of B  This gives LH a Zacks VGM score   or its overarching fundamental grade   of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been sturdy at best  The current year has seen five estimates go higher in the past sixty days compared to two lower  while the next year estimate has seen four up and three down in the same time period This has had a positive impact on the consensus estimate though as the current year consensus estimate has risen by 0 09  in the past two months  while the next year estimate has inched lower by 0 3   You can see the consensus estimate trend and recent price action for the stock in the chart below Laboratory Corporation of America Holdings Price and Consensus   Apart from this somewhat robust trend  the stock has a Zacks Rank  3  Hold  which is why we are looking for in line performance from the company in the near term Bottom LineLaboratory Corporation is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  a strong industry rank  among Top 29  of more than 250 industries  instills our confidence  However  over the past two years  the Zacks Medical   Dental Supplies industry has clearly underperformed the broader market  as you can see below So  value investors might want to wait for analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick It s Illegal in 42 States  But Investors Will Make Billions LegallyIn addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ,2019-08-21,Zacks Investment Research,https://www.investing.com/analysis/can-value-investors-pick-laboratory-corporation-lh-stock-200457520,200457520
9877,231392,LH,LabCorp  LH  Down 3 4  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for LabCorp  LH   Shares have lost about 3 4  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is LabCorp due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Business Disposition and Currency Translation Dent LabCorp s Growth in Q2LabCorp reported second quarter 2019 adjusted earnings per share  EPS  of  2 93  down 1 7  from the year ago quarter  However  the bottom line edged past the Zacks Consensus Estimate by 1  On a reported basis  net earnings came in at  1 93 per share  declining 14 9  from the year earlier figure Revenues in the quarter under review edged up 0 5  year over year to  2 88 billion  However  the top line lagged the Zacks Consensus Estimate of  2 90 billion This marginal year over year improvement was primarily led by 1 4  growth from acquisitions and organic growth of 1 7   which includes the negative impact from Protecting Access to Medicare Act or PAMA of 0 9    partially offset by a 1 9  negative impact from the disposition of businesses and an adverse foreign currency translation of approximately 0 7  Quarter Under ReviewLabCorp reports under two operating segments  LabCorp Diagnostics and Covance Drug Development In the second quarter  LabCorp Diagnostics reported revenues of  1 76 billion  reflecting a 2 9  dip year over year  This downside was primarily due to a 2 8  headwind from the disposition of businesses and 0 3  lower organic revenues  including a 1 5  negative impact from the implementation of the PAMA   In addition  unfavorable foreign currency translation reduced revenues by approximately 0 2   Growth from acquisitions was 0 4  in the quarter Excluding the disposition of businesses  the company reported a 0 9  slip in total volume  measured by requisition  and a 1  rise in revenue per requisition in the quarter under consideration Covance Drug Development s revenues improved 6 8  to  1 13 billion in the second quarter  This upside was primarily attributed to 3 3  growth from acquisitions and organic growth of 5 5   partially offset by the 1 6  adverse impact of foreign currency translation and a business disposition of 0 3  Gross margin contracted 51 bps to 28 6  in the reported quarter  Also  adjusted operating income was down 6 9  year over year to  410 million  Moreover  adjusted operating margin contracted 114 bps from the year ago quarter to 14 2  LabCorp exited the second quarter with cash and cash equivalents of  265 4 million compared with  348 8 million at the end of the first quarter  Further  year to date  operating cash flow was  419 3 million  down from  567 1 million in the year ago period  Additionally  free cash flow came in at  239 9 million in the period  down from  407 4 million a year ago In the quarter under discussion  the company returned  199 9 million to shareholders via share repurchases  LabCorp currently has  1 05 billion of authorization remaining under its existing share buyback plan OutlookLabCorp has updated its 2019 guidance Revenue growth expectation has been tightened to the band of 1 2  from 2018  earlier projected band was 0 5 2 5    This includes a projected adverse impact from the disposition of businesses of around 1 5  and a negative foreign currency movement of roughly 0 5   The Zacks Consensus Estimate for current year revenues is pegged at  11 46 billion Adjusted EPS estimate for 2019 has been narrowed to a range of  11 10  11 40 from the earlier band of  11 05  11 45  The consensus mark of  11 28 for the metric is within this guided range Free cash flow is predicted from  950 million to  1 05 billion  unchanged   
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates review 
VGM Scores
At this time  LabCorp has an average Growth Score of C  however its Momentum Score is doing a bit better with a B  Charting a somewhat similar path  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision has been net zero  Notably  LabCorp has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-08-23,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-down-34-since-last-earnings-report-can-it-rebound-200458197,200458197
9883,231398,LH,LabCorp  LH  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"LabCorp  LH  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended September 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on October 24  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This medical laboratory operator is expected to post quarterly earnings of  2 84 per share in its upcoming report  which represents a year over year change of  3 7  
Revenues are expected to be  2 91 billion  up 2 8  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 04  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for LabCorp 
For LabCorp  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 16  
On the other hand  the stock currently carries a Zacks Rank of  4 
So  this combination makes it difficult to conclusively predict that LabCorp will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that LabCorp would post earnings of  2 90 per share when it actually produced earnings of  2 93  delivering a surprise of  1 03  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
LabCorp doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-reports-next-week-wall-street-expects-earnings-growth-200474771,200474771
9885,231400,LH,What s In The Offing For LabCorp s  LH  Earnings In Q3 ,opinion,Laboratory Corporation of America Holdings   NYSE LH   also known as LabCorp is slated to report third quarter 2019 results on Oct 24  before the market opens In the last reported quarter  the company s adjusted earnings exceeded the Zacks Consensus Estimate by 1 03   the average trailing four quarter beat being 0 42  Let s see how things are shaping up for this announcement Factors at PlayIn the last few quarters  LabCorp s underlying core business put up a stable performance  Within Diagnostics  the company is likely to have generated strong revenue growth in the third quarter of 2019  banking on the following facts First  in 2019  the company officially collaborated with Horizon  NJ based UnitedHealthcare and Aetna  NYSE AET   placing LabCorp in network under all major national plans  Ever since  the company has been registering consistent organic growth on the back of these partnerships  The upside is likely to get reflected in the company s third quarter results Second  the company is expected to have advanced its companion diagnostics and oncology capabilities in the third quarter  backed by the introduction of two new companion diagnostic tests  namely PIK3CA for breast cancer and FGFR for bladder cancer  This  in turn  might have contributed to the company s upcoming earnings release Laboratory Corporation of America Holdings Price and EPS Surprise   Third  in the last reported quarter  PAMA  Protecting Access to Medicare Act  had a negative impact of 90 basis points on organic revenues  The company is currently working to overcome the inequitable Medicare price reductions imposed by the flawed implementation of PAMA  To this end  it is considering the lately introduced Laboratory Access for Beneficiaries Act as a significant step to reform PAMA for producing a market based Medicare fee schedule  However  with near term visibility seeming bleak at the moment  we anticipate PAMA to once again dent the third quarter top line Third  the company is highly optimistic about the Phase II of LaunchPad initiative in Diagnostics  which is expected to deliver  200 million of savings in another three years  Good news is that this program is already likely to have boosted the company s operational efficiency in the third quarter Within Covance Drug Development  LabCorp is focused on driving profitable growth through expanded solutions and enhanced operational capabilities  The Chiltern integration has significantly strengthened the company s strategic position in clinical development and is accelerating revenues and profit growth within Covance  On this front  the company is keeping a good pace with its objective to streamline the drug development process  This steady effort should get reflected in the company s impending results Additionally  the company has progressed with the Covance LaunchPad initiative  In the first phase  as expected  the company achieved a cost synergy of  30 million from the acquisition of Chiltern  At the exit of second quarter 2019  it remained on track to deliver  150 million of net savings by the end of 2020  This momentum is mostly likely to have been maintained through the company s third quarter  strengthening LabCorp s bottom line This apart  the innovative business swap transaction with Envigo is expected to have favored the company s top line in the third quarter  The transaction provides Covance with better global non clinical research capabilities while sustaining access to bigger research models and services through a multi year renewable supply agreement For 2019  on an overall basis  management envisions modest growth in total revenues as well as the adjusted EPS  The company expects another year of approximately  1 billion in free cash flow  All these are likely to get reflected in third quarter performance Which Way Are Estimates Trending The Zacks Consensus Estimate for third quarter earnings of  2 84 indicates a 3 7  rise from the year ago reported figure  The consensus estimate for revenues is pegged at  2 91 billion  suggesting a 2 8  increase from the prior year reported number What the Quantitative Model SuggestsPer our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is not the case here as you will see below Earnings ESP  LabCorp has an Earnings ESP of  0 16   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  LabCorp carries a Zacks Rank  3  Stocks Worth a LookHere are a few medical stocks worth considering with the right combination of elements to beat on earnings this reporting cycle ViewRay  Inc    NASDAQ VRAY   has a Zacks Rank  2 and an Earnings ESP of  17 36   You can see  DENTSPLY SIRONA   NASDAQ XRAY   has a Zacks Rank of 3 and an Earnings ESP of  5 05  Aurora Cannabis Inc    TSX ACB   is Zacks  3 Ranked and has an Earnings ESP of  22 22  More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2019-10-20,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-offing-for-labcorps-lh-earnings-in-q3-200475764,200475764
9894,231409,LH,LabCorp  LH  Q3 Earnings Surpass Estimates  Tapers View,opinion,"Laboratory Corporation of America Holdings   NYSE LH    or LabCorp  reported third quarter 2019 adjusted earnings per share  EPS  of  2 90  up 5 8  from the year ago quarter  Also  the bottom line surpassed the Zacks Consensus Estimate by 2 1  On a reported basis  net earnings were  2 25 per share  declining 27 4  from the year earlier figure Revenues in the quarter under review grew 3 4  year over year to  2 93 billion  The top line also beat the Zacks Consensus Estimate of  2 91 billion by 0 7  The marginal year over year improvement was primarily led by 2 8  growth from acquisitions and 2 2  organic growth  which includes the negative impact of Protecting Access to Medicare Act or PAMA of 0 9    partially offset by 1 3  negative impact of business dispositions and approximately 0 3  adverse foreign currency translation Laboratory Corporation of America Holdings Price  Consensus and EPS Surprise
    Quarter in Detail
LabCorp reports results under two operating segments   LabCorp Diagnostics and Covance Drug Development In the third quarter  LabCorp Diagnostics reported revenues of  1 76 billion  reflecting a 0 4  uptick year over year  The upside primarily resulted from 0 9  organic growth and 0 8  favorable contribution from acquisitions  offset by 1 3  headwind from business dispositions  Organic revenue growth in the quarter included a 1 5  negative impact from the implementation of the PAMA Excluding business dispositions  the company witnessed 0 7  rise in total volume  measured by requisition  and 1  improvement in revenue per requisition in the third quarter Covance Drug Development s revenues improved 8 7  to  1 18 billion in the third quarter  The upside was primarily attributed to 6  growth from acquisitions and 4 7  organic growth  partially offset by 0 8  adverse impact of foreign currency translation and business disposition of 1 2  Gross margin remained flat year over year at 27 9  in the reported quarter  Also  adjusted operating income rose 1 9  year over year to  430 5 million  However  adjusted operating margin contracted 22 bps from the year ago quarter to 21 5  LabCorp exited the third quarter with cash and cash equivalents of  361 1 million compared with  265 4 million at the end of the second quarter  Year to date  operating cash flow was  874 9 million  up from  819 million in the year ago period  Additionally  free cash flow was at  602 9 million in the quarter  up from  561 4 million a year ago In the third quarter  the company returned  100 million to shareholders via share repurchases  LabCorp currently has  950 million of authorization remaining under its existing share buyback plan OutlookThe company has revised its 2019 guidance It now expects year over year revenue growth of 1 5 2  compared with 1 2  mentioned earlier  This includes a projected adverse impact of 1 5  from the disposition of businesses and a negative foreign currency movement of roughly 0 6   The Zacks Consensus Estimate for revenues is pegged at  11 48 billion for the current year Adjusted EPS estimate for 2019 has been narrowed to  11 20  11 30 from  11 10  11 40 mentioned earlier  indicating 1 6 2 5  rise from the 2018 adjusted EPS figure  The Zacks Consensus Estimate of  11 29 for the same is close to the high end of the company s guidance Free cash flow is predicted to be  950  1 05 billion  unchanged  Our TakeLabCorp exited the third quarter on a strong note  with better than expected results  While increasing acquisitions and a favorable mix contributed to its Diagnostics business in the quarter  the disposition of certain businesses and the implementation of PAMA dented the company s growth However  Covance Drug Development delivered year over year growth  Here  synergies from acquisitions and organic growth were partially negated by the impact of foreign currency translation Zacks Rank   Stocks to ConsiderCurrently  LabCorp carries a Zacks Rank  4  Sell   Some better ranked stocks from the broader medical space are Owens   Minor  Inc   NYSE OMI    Surmodics  Inc   NASDAQ SRDX   and Organigram Holdings Inc   TSX OGI   Owens   Minor is scheduled to release third quarter 2019 results on Oct 30  The Zacks Consensus Estimate for the quarter s adjusted EPS is pegged at 65 cents and the same for revenues is pinned at  9 9 billion  The stock currently sports a Zacks Rank of 1  Strong Buy   You can see Surmodics is scheduled to release fourth quarter 2019 results on Nov 8  The Zacks Consensus Estimate for its adjusted EPS is pinned at 69 cents and the same for revenues is pegged at  97 8 million  The stock currently sports a Zacks Rank  1 Organigram is expected to release fourth quarter 2019 results on Nov 25  The Zacks Consensus Estimate for its adjusted EPS is pegged at 5 cents and the same for revenues is pinned at  71 2 million  The stock presently has a Zacks Rank of 2  Buy  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-q3-earnings-surpass-estimates-tapers-view-200477813,200477813
9895,231410,LH,LabCorp  LH  Tops Q3 Earnings And Revenue Estimates,opinion,"LabCorp  LH  came out with quarterly earnings of  2 90 per share  beating the Zacks Consensus Estimate of  2 84 per share  This compares to earnings of  2 74 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 2 11   A quarter ago  it was expected that this medical laboratory operator would post earnings of  2 90 per share when it actually produced earnings of  2 93  delivering a surprise of 1 03  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
LabCorp  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  2 93 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 0 66   This compares to year ago revenues of  2 83 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
LabCorp shares have added about 33 8  since the beginning of the year versus the S P 500 s gain of 19 9  
What s Next for LabCorp 
While LabCorp has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for LabCorp was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 89 on  2 89 billion in revenues for the coming quarter and  11 29 on  11 48 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the bottom 35  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-tops-q3-earnings-and-revenue-estimates-200477420,200477420
9896,231411,LH,QIAGEN Expands Existing Deal With LabCorp For Better Treatment,opinion,"QIAGEN N V    NYSE QGEN   entered an agreement with Laboratory Corporation of America Holdings   NYSE LH   or LabCorp to extend their existing QIAGEN Clinical Insights  QCI  license Per the terms of the agreement  the QCI license will be extended for LabCorp with QIAGEN s Human Gene Mutation Database  HGMD  of human genetic variants  the world s largest database of inherited disease mutations   With the recent announcement  the entities deepened the seven year agreement to develop  introduce and support new diagnostic tests The extended partnership will aid QIAGEN to strengthen foothold in the global next generation sequencing  NGS  market  
 Few Words on NGSNGS has become instrumental in identifying genetic variants which play a role in inherited diseases  It provides a flexible technology platform which makes it possible to use highly targeted  rather than large scale  test panels for clinical diagnostics  and in studies of new therapies and diagnostics A Peek Into HGMDMore than 20 million people in the United States are currently affected by hereditary diseases  Major technological advances have already been made to enable the cost effective generation of large datasets  encompassing all coding regions  including entire human genomes  However  linking a patient s genetic variants to the increasing body of knowledge of human disease genetics is becoming challenging  This limits genetic testing s ability to provide actionable information to guide diagnosis and take better treatment decisions  This makes it difficult for patients and their families to deal with the situation  highlighting the importance of the availability of genetic variation information HGMD is a component of QCI  which is a key source of information on heritable mutations  With the increasing cases of mutations  HGMD will provide the required information to convert variant data to actionable insights for researchers  physicians and patients Rationale Behind the Extended PartnershipPer the agreement  HGMD will provide access to validated evidence to support more precise and comprehensive variant interpretation of hereditary diseases  This  in turn  will help laboratories as well as patients receive answers to queries related to hereditary diseases and appropriate treatment options The extension of the existing partnership with LabCorp will authenticate QIAGEN s bioinformatics solutions in the interpretation of germline diseases  thus enabling patients and their families to make more informed decisions for any germline or somatic indication for all clinical testing labs Recent DevelopmentsQIAGEN announced the expansion of its QIAseq NGS portfolio in November for offering a one day workflow for simultaneous preparation of DNA and RNA libraries  using NGS technologies  In October  the company launched technologies for faster  simpler library preparation for NGS in RNA research Further  QIAGEN launched its upgraded GeneGlobe Design   Analysis Hub in September to provide next level experiment planning  execution and follow up to life science researchers The company launched QIAseq Expanded Carrier Screening Panel  a Sample to Insight solution  for research into genetic causes of rare and inherited diseases in June  In May  QIAGEN launched QIAstat Dx syndromic testing system in the United States  after receiving FDA clearance  It also launched multiplex QIAstat Dx Respiratory Panel in the same period Industry ProspectsPer a report by   the global NGS market size was valued at  8 49 billion in 2018 and is likely to see a CAGR of 12 78  between 2019 and 2025  Key factors driving the market are the introduction of advanced and rapid sequencing technologies for clinical processes  and innovations made in the bioinformatics segment Given the huge potential of the NGS market  the extension of the agreement has come at the right time Price PerformanceThe company s shares have gained 19 5  in the past year against the  s decline of 3 7  Zacks Rank   Key PicksCurrently  QIAGEN carries a Zacks Rank  3  Hold  Some better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE   and NuVasive  Inc   NASDAQ NUVA   Haemonetics  currently carrying a Zacks Rank  2  Buy   has a projected long term earnings growth rate of 13 5  NuVasive s long term earnings growth rate is estimated at 10 9   The company currently has a Zacks Rank  2  You can see Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ",2019-11-20,Zacks Investment Research,https://www.investing.com/analysis/qiagen-expands-existing-deal-with-labcorp-for-better-treatment-200486981,200486981
9897,231412,LH,LabCorp  LH  Grows On Solid Diagnostics Arm Despite PAMA Headwinds,opinion,"On Jan 3  we issued an updated research report on LabCorp   NYSE LH    The stock carries a Zacks Rank  3  Hold  
This Burlington  NC based healthcare diagnostics company  providing comprehensive clinical laboratory services and end to end drug development support  has been grappling with multiple issues of late  Economic uncertainties including a challenging volume environment for testing laboratories and softness in utilization are headwinds for LabCorp 
Over the past three months  shares of LabCorp have inched up 0 2  compared the  s 8 7  rise 
In third quarter 2019  the company reported strong underlying performance and organic revenue growth across both Diagnostics and Drug Development businesses  banking on solid execution of three fundamental strategies  which are delivering advanced diagnostics  bringing new medicines to patients faster and using technology to improve patient care 
During the quarter  Diagnostics business grew organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act  PAMA  and the loss of exclusivity in two of the company s largest managed care contracts  Within Diagnostics  the company registered strong revenue per requisition and a solid execution of its LaunchPad 2 initiatives Laboratory Corporation of America Holdings Price

    
Covance Drug Development also advanced organically despite an adverse foreign currency translation  Of late  the company enhanced Covance s offerings through strategic acquisitions like MI Bioresearch that adds specialized preclinical capabilities to cell and gene therapy as well as oncology testing 
The company is also hopeful about its recently completed business swap transaction with Envigo  This tactical move provides Covance with better global non clinical research skills while maintaining access to bigger research models and services through a multi year renewable supply agreement 
Right now  LabCorp is on track to deliver  10 million of net costs in synergies from the integration and Envigo by 2021 end  This apart  the Covance LaunchPad initiative is well on course to deliver net savings worth  150 million by the end of 2020 
On the flip side  the current economic volatility including a challenging volume environment for the testing laboratories and utilization weaknesses loom large on the company  Also  the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act  PAMA  dented growth  Moreover  an unfavorable currency movement is a lingering downside 
Key Picks
A few better ranked stocks from the broader medical space are Haemonetics Corp    NYSE HAE    West Pharmaceutical Services   NYSE WST   and Omnicell   NASDAQ OMCL    While Haemonetics sports a Zacks Rank  1  Strong Buy   the other two carry a Zacks Rank  2  Buy   You can see 
Haemonetics has a projected long term earnings growth rate of 13 5  
West Pharmaceutical Services has an expected long term earnings growth rate of 14  
Omnicell has a long term earnings growth rate of 12 5  
More Stock News  This Is Bigger than the iPhone 
It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market 
Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself later ",2020-01-06,Zacks Investment Research,https://www.investing.com/analysis/labcorp-lh-grows-on-solid-diagnostics-arm-despite-pama-headwinds-200496735,200496735
110476,331991,LH,LabCorp launches blood test for preterm birth risk,news,LabCorp  LH  0 1   announces that nationwide availability of blood test to predict preterm birth risk in pregnant women  The assay  called PreTRM  was developed by Sera Prognostics  LabCorp is the exclusive distributor Now read ,2017-05-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/labcorp-launches-blood-test-for-preterm-birth-risk-487549,487549
110477,331992,LH,Baxter Q2 non GAAP up 37  in Q2  updates guidance,news,Baxter  BAX  Q2 results  Revenues   2 605M   0 8    Operating Income   339M  Net Income   264M   78 2    EPS   0 48   78 1    Non GAAP EPS   0 63   37 0    CF Ops   767M   91 3   2017 Guidance  GAAP Sales growth  3   Non GAAP Sales growth  5   EPS   1 85   1 95  Non GAAP EPS   2 34   2 40 2020 Guidance  Non GAAP EPS   3 25   3 40  Operating cash flow    2 65B  CAPEX   650M Shares are up 1  premarket on light volume Now read ,2017-07-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/baxter-q2-non-gaap-up-37-in-q2;-updates-guidance-510228,510228
110479,331994,LH,LabCorp expands credit facility,news,In an SEC filing  Laboratory Corp  of America  NYSE LH  has amended its senior revolving credit facility  which now consists of a five year revolver of up to  1B  The company has the ability to increase that line by an additional  350M  subject to lender agreement  It also provides for a subfacility of up to  100M for swingline borrowings  and a subfacility of up to  150M for issuing letters of credit  LabCorp also entered a five year term loan credit facility for  750M  to be used for general purposes  That will accrue interest at either Libor plus 0 875 1 5 points  or another base rate  prime or federal funds  plus a margin of 0 0 5   Now read ,2017-09-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/labcorp-expands-credit-facility-529580,529580
110482,331997,LH,Oxford loses bid to prevent Qiagen from selling QFT Plus TB test before patent infringement trial  but likely to prevail in the case,news,A Massachusetts district court has denied  Oxford Immunotec  Global PLC s  OXFD  motion to enjoin Qiagen  QGEN  1   from promoting its QuantiFERON TB Gold Plus  QFT Plus  test to new customers because it did not believe Oxford would suffer irreparable harm in the few months before the start of its patent infringement trial against Qiagen  Quest Diagnostics  DGX  0 8   and LabCorp  LH  0 2   The court determined that Oxford was likely to prevail in the case and the infringing aspects of QFT Plus would be permanently enjoined at that time Now read ,2017-09-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/oxford-loses-bid-to-prevent-qiagen-from-selling-qftplus-tb-test-before-patent-infringement-trial-but-likely-to-prevail-in-the-case-533499,533499
110485,332000,LH,Special Report  Scientists describe problems in Philip Morris e cigarette experiments,news,By Tom Lasseter  Paritosh Bansal  Thomas Wilson  Ami Miyazaki Duff Wilson and Aditya Kalra TOKYO NEUCHATEL  Switzerland  Reuters    The U S  Food and Drug Administration is weighing whether to approve a potentially path breaking smoking device by Philip Morris International Inc  N PM   With a decision expected next year  former employees and contractors have described to Reuters a number of irregularities involving clinical trials that underpin the tobacco giant s application to the agency  By heating tobacco instead of burning it  the company says the device  known as iQOS  avoids subjecting smokers to the same levels of carcinogens and other toxic substances found in a regular cigarette  The company has spent more than  3 billion developing new smoking platforms like iQOS  As part of that initiative  Philip Morris has published extensive scientific findings  based in part on clinical studies  Tamara Koval  who worked at the company from 2012 to 2014 and helped coordinate clinical trials for the device  questioned the quality of some of the researchers and sites contracted to carry out those experiments  Koval was a co author of the company s protocol used to run the studies globally  When she highlighted an irregularity in one of the studies  Koval said  Philip Morris excluded her from meetings  Reuters also found irregularities during interviews with some of the principal investigators contracted to conduct the trials for the company  One principal investigator said he knew nothing about tobacco  Philip Morris had to jettison the experiment that investigator performed after it emerged he hadn t followed a basic procedure for obtaining informed consent from participants during clinical trials  A second investigator submitted urine samples that exceeded what a human being is capable of  according to two former company employees  and then initially refused to acknowledge there was a problem  A third said he doesn t hold such company sponsored clinical trials in high regard  describing them as  dirty  because their purpose is more commercial than scientific  After reviewing Reuters  findings  Philip Morris said in a statement that  all studies were conducted by suitably qualified and trained Principal Investigators   The company said it understands that  FDA inspectors have already audited some facilities  involved in the trials  Philip Morris also said it had taken steps to address  any reported irregularity in our studies    Our policies encourage speaking up about suspected violations of law or our policies and we do not tolerate retaliation against those who speak up   the company said  In addition to former Philip Morris employees involved with the iQOS program  Reuters interviewed six of the 11 principal investigators who were responsible for five of eight clinical trials the company submitted to the FDA  Reuters also reviewed hundreds of pages of publicly available Philip Morris study reports and FDA filings  That reporting identified shortcomings in the training and professionalism of some of the lead investigators  as well as their knowledge of the study results  A group of tobacco research and policy experts reviewed detailed summaries of Reuters  reporting and Philip Morris  response  The experts  including a former head of the FDA and two former scientific advisers for the agency  said those findings raise concerns about Philip Morris  clinical trial program   Taken as a whole  it s clear they do not have the sophistication to carry out adequate and well controlled clinical trials   said David Kessler  the FDA s commissioner from 1990 to 1997  referring to the company   I am not inferring any malicious intent here  just that they lack sophistication  because this is not their bread and butter   If the FDA has already audited some of the trial sites used by Philip Morris  the agency  should carefully review its audits and possibly expand them   said Kessler  a former dean of the medical school at Yale University   THE FDA SHOULD AUDIT  Tom Eissenberg  who served on the FDA s tobacco products scientific advisory committee until earlier this year  said   The FDA should audit   Reuters did not find any evidence that the outcome of the experiments presented by the company to the FDA was manipulated or falsified   The new insights into the company s clinical trial program for iQOS come at a crucial time for Philip Morris  The world s largest publicly traded tobacco company by market value and maker of Marlboro cigarettes has applied to the U S  FDA to be able to sell iQOS in America  and also for permission to market it as a modified risk tobacco product  That designation could mean that Philip Morris is allowed to market iQOS as presenting less harm or risk of disease to users than traditional tobacco  For now  the FDA is evaluating the company s studies  Reuters outlined its findings about the iQOS trials to the agency  The FDA said it cannot comment on a pending application  Philip Morris says the device  which heats small tobacco inserts  is meant for smokers who would not otherwise quit  Its chief executive officer  Andre Calantzopoulos  has told investors and media alike that he intends to one day replace cigarettes with products like iQOS  So far  iQOS makes up a fraction of the company s  75 billion revenues and Philip Morris continues to market conventional cigarettes across the globe  Internal Philip Morris documents reviewed by Reuters show the significance of iQOS goes beyond its profit potential  The device is now sold in more than two dozen nations after it was first launched in Japan and Italy during late 2014  The company has a 10 year plan for what it calls  normalization  of the tobacco industry  according to a 2014 strategy document  The industry has been shunned over the past two decades for producing and marketing products that kill people and previously lying about it  Under a section on  strategies and actions  to achieve that goal  the document lists  among other things  new smoking devices such as iQOS and the scientific research involved in developing them  Told about that document  Philip Morris said   The suggestion that the purpose of our development of IQOS and our scientific research program is to  normalize  the tobacco industry is false   That previously undisclosed document and others can be found in a searchable repository published by Reuters  The Philip Morris Files      I JUST DON T READ THEM  As part of its submission to the U S  FDA  the company said the results of its research showed the device significantly reduced the level of certain harmful substances that users were exposed to compared with cigarettes  and satisfied their nicotine cravings   In fact the level of reduction is so considerable  it approaches 95  of the levels measured in smokers who quit altogether   the company said in a statement to Reuters  Taken along with the company s laboratory studies  Philip Morris said  the research program  in its entirety demonstrates that IQOS is likely to reduce the risk of smoking related diseases   Philip Morris is responsible for the majority of the science that has been published about iQOS   Those who criticize us should probably look at our science   said Tommaso Di Giovanni  a company spokesman  during a tour of Philip Morris  research and development headquarters in March  The eight clinical experiments that Philip Morris submitted to the FDA were conducted between 2013 and 2015  For one study  scientists in Texas and Florida did not respond to messages left by Reuters  Other scientists  in Belfast and Tokyo  declined to talk  Half of the eight studies were done in Japan  FDA guidelines for conducting clinical studies say a trial should adhere to standards such as Good Clinical Practice  That best practices document says investigators  should be qualified by training and experience and should have adequate resources  to properly conduct a trial  Masayuki Sugimoto  the principal investigator who oversaw testing at one facility used by Philip Morris to conduct a trial  said his Tokyo clinic is  heavily in the red   Sugimoto said he generally has little confidence that all the participants in experiments like the one he ran for Philip Morris on nicotine tell the truth about their smoking history   that is  whether they smoke  Speaking about the final study report from the Philip Morris trial  Sugimoto said in an interview that he generally doesn t have time to read such things in detail  He said he probably signed a document indicating he had received the final report  Sugimoto gestured with his thumb and forefinger to indicate a thick document   I just don t read them   Philip Morris said that it  did not receive any such comments or statements from the PI   or principal investigator  Sugimoto s study  it said  was completed  without any issues   The company said the study data was reviewed and discussed with the investigator throughout the trial  The Japanese company hired to monitor studies in the country   CMIC Holdings  Co Ltd  T 2309   said in a statement that researchers confirmed that trial participants were smokers by using urine tests  Asked about the tests  Sugimoto said he thought they would prevent non smokers from joining the trial but added   I don t know whether they were done that rigorously   Told of Sugimoto s doubts about the honesty of study participants  Eissenberg  who served on the FDA s tobacco products scientific advisory committee from 2011 to 2017  said  it raises a great deal of concern   A principal investigator  is required to make sure that the participants meet the inclusion exclusion criteria that are in the protocol   said Eissenberg  He was referring to the fact that clinical trial subjects  backgrounds   such as whether they are smokers   should meet the parameters of the experiment for the data to be valid   And a PI should have confidence in that   he said  DATA DISCARDED At another laboratory in Japan  issues with how the study was carried out were so acute that data from 56 participants was thrown out  raising questions about the competence of the principal investigator  Philip Morris halted the study at that location  In the company s study documentation released by the FDA  Philip Morris recorded the reason for discarding the data as non compliance with good clinical practices  specifically  failure of the site to meet sample collection procedures and data recording procedures   Kishor Lad  who was Philip Morris  data manager on the study  said the site crossed a line of what s allowed during such trials  It collected samples before getting informed consent forms signed by the volunteers   Completely a no no in the GCP world   Lad said  using the acronym for good clinical practice  Philip Morris confirmed to Reuters that  informed consent was not obtained prior to execution of a study procedure    specifically  the collection of urine samples  The problem was identified by CMIC  the contract research group  during a routine monitoring visit  Philip Morris said  A subsequent round of audits  it added   led to prompt discontinuation of the study at the Seishukai Clinic   The incident  the company said  was properly logged in the study report and the submission to the FDA   It suggests the investigator had no idea  did not understand or just didn t care what his responsibilities were in conducting the study   said Greg Koski  a former director of the U S  federal Office for Human Research Protections  which advocates for research subjects   This is such a flagrant violation  that investigator shouldn t be doing clinical studies   Mamoru Oki was the principal investigator at the time at the facility  the Seishukai Clinic in Tokyo  Reached by phone  Oki said   My specialty is urology and I don t know anything about tobacco  so I cannot talk   Told of that remark  Philip Morris said   Dr  Oki was qualified and trained specifically on the product   Dorothy Hatsukami  a member of the FDA s tobacco products scientific advisory committee from 2010 to 2013  said a principal investigator s professed lack of knowledge about tobacco is not ideal   For any tobacco related clinical trial  an investigator with a background in tobacco product research would have better qualifications to evaluate the study results than a novice   she said  The study continued at a parallel site  the Tokyo Heart Center   During an interview at the center  principal investigator Masahiro Endo said repeatedly that he had no idea what the results were from his study   We did medically safe and accurate blood samples  but were not told the results  So even if we are asked questions  we won t be able to answer   he said   We were paid  it ended there   But in a statement signed last year and submitted by Philip Morris to the FDA  Endo said he had read the clinical study report from the company and confirmed  that to the best of my knowledge it accurately describes the conduct and results of the study   Principal investigators in all of the Philip Morris clinical trials signed the same statement  A day after speaking with Reuters  Endo sent an email clarifying that after checking his records he saw that he d signed a receipt saying he received a report on the results and acknowledging that he d be listed as the principal investigator  He had spoken during the interview  with a fuzzy memory   Endo said   LESSER OF TWO EVILS  Clinical trial experts interviewed by Reuters said it s not uncommon for principal investigators to be unaware of test results sent to a third party specialty laboratory for analysis  But they also emphasized that if companies want better science  they need the investigators to be more involved with all aspects of a study   It seems like the investigator here is in the role of a technician  not as a principal investigator   said Kessler  the former FDA commissioner  Kessler said it s hard to understand how such investigators could have signed off on the clinical study report  when they clearly were not versed in the study results   Other principal investigators described their work differently  Fumimasa Nobuoka  a principal investigator on one of the trials in Japan  said he read the Philip Morris study report   I thought it was well done  well written   James Borders  who was the principal investigator for a study held in Lexington  Kentucky  said the experiments in his trial were done ethically and followed sound scientific practice  Borders  who became chief medical officer at the Baptist Health Lexington hospital  said such studies help consumers make an informed decision  His decision to be involved with the study  he said  hinged on the proposition that a device like iQOS could be the  lesser of two evils   Philip Morris said that while it sponsored the clinical trials  the experiments were  performed by reputable research facilities  and monitored by contract research organizations   companies used to oversee such studies  It hired U S  based Covance Inc to serve as its global contract research organization  according to an internal Philip Morris 2013 assessment plan  Covance  a unit of Laboratory Corporation of America Holdings  N LH   declined to comment  CMIC  the company hired to monitor the Japan studies  said in a statement   All the clinical trials you referred to were conducted in accordance with GCP guidelines    good clinical practices    and we believe that the results of the trials are scientifically trustworthy   As part of her job coordinating between Philip Morris and those contracted to run its clinical trials  Koval  the former company scientist  conducted medical safety training across the world for principal investigators and others involved with the iQOS studies  During one study training session in Tokyo  Koval said  she realized some of the researchers could not speak English well and she was unable to communicate with them  Koval said she does not speak Japanese and there was no interpreter present   I was like  Jesus  what are we doing here   she said  At dinner later  Koval said  she saw two of the men  and they were unable to describe in English what their jobs were  When asked about Koval s session  Philip Morris said it was a meeting with its contract research organization and others  It added that  all PIs and team members with active roles in the study were fluent in English   But Sugimoto  one of the Japanese principal investigators  told Reuters in an interview   I can t speak English   And Endo  another of the lead researchers  said that when Philip Morris executives visited his site someone was present who helped translate  questions like whether to cut the crusts off bread  when giving food to study subjects  CMIC said   All the principal investigators received adequate training in Japanese before the trial began   URINE SAMPLES In Poland  some urine samples collected as part of one Philip Morris clinical study exceeded the limits of what a human being is capable of producing in a single day  according to Koval and Lad  the former clinical data manager  Lad  who worked at Philip Morris from 2012 to 2015  said he didn t think anything  malicious  had happened  Maybe urine samples were swapped or there was a mistake with the containers used to collect the urine  he said  But when the principal investigator for the Polish site was asked about the results  she would not admit there was a problem  Lad and Koval said  Instead  they said  the scientist explained that the test subjects were large Polish men  Philip Morris said that  a few participants  in an early stage of the trial  produced unusually large volumes of urine   Because medical tests showed no problems with the subjects  the company said  the investigator did not initially consider the samples to be  adverse events   After discussion with the medical monitors of the study as well as Philip Morris  the investigator  ultimately decided to mark these incidences as adverse events   the company said  An investigation at the site confirmed that researchers had followed study protocol and good clinical practices  the company said  The principal investigator running the study in Poland for Philip Morris  Katarzyna Jarus Dziedzic  declined to discuss what happened with the urine case at her site  citing confidentiality   Koval said that after she raised concerns about the Polish study with Philip Morris executives in Switzerland she was excluded from meetings  Philip Morris said in a statement that Koval was  part of the team  that followed up on the urine samples  In fact  the company said  she was  an active member  of the group that finalized the data set from the studies for further analysis  Koval confirmed that she was part of the team and involved with the data set  But she stood by her account that she was shut out of conversations and meetings about the urine samples  In 2014  Philip Morris terminated her contract  Koval said  She said she returned to the pharmaceutical industry a few months later and now works for Swiss drugs giant  Novartis  AG  S NOVN   After leaving Philip Morris  Koval was given a certificate of service that said   Tamara drove clinical program development activities   It said she had demonstrated  professionalism  and  unwavering commitment  in her work ,2017-12-20,Reuters,https://www.investing.com/news/stock-market-news/special-report-scientists-describe-problems-in-philip-morris-ecigarette-experiments-1013009,1013009
110487,332002,LH,FDA OKs direct to consumer test for certain types of breast cancer mutations,news,The FDA has approved a direct to consumer test  called the Personal Genome Service Genetic Health Risk Report  that detects three specific types of BRCA1 BRCA2 breast cancer gene mutations that are the most prevalent in Jewish women of Eastern European descent  Ashkenazi  According to the National Cancer Institute  the three mutations are present in  2  of Ashkenazi Jewish women compared to 0   0 1  in other populations The test  which analyzes DNA in saliva  will be marketed to consumers by privately held 23andMe Molecular testing related tickers   LH  0 4   DGX  0 2   GHDX  1   MYGN  0 3   ATOS  0 3   CGIX  2 5   BIOC  3 2   NEO  2 2   NVTA  2 8   OPGN  0 2  Now read ,2018-03-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-directtoconsumer-test-for-certain-types-of-breast-cancer-mutations-1327442,1327442
110500,332015,LH,Exclusive  Pharmaceutical research firm PPD explores sale  IPO,news,By Carl O Donnell  Olivia Oran and Greg Roumeliotis  Reuters    Contract research organization Pharmaceutical Product Development LLC  PPD  is exploring a sale or initial public offering that could value it at between  7 billion and  8 billion  including debt  people familiar with the matter said  A deal would underscore how the contract research organization industry has benefited in recent years from the pharmaceutical companies  drive to cut costs  reduce clinical trial times and expand their research and development presence around the world  PPD s private equity owners   Carlyle Group   O CG  LP and Hellman   Friedman LLC  have reached out to investment banks about appointing financial advisers to PPD  the people said on Friday  PPD will run an auction to sell itself early next year  but will pursue an initial public offering instead if the acquisition offers it receives do not meet its owners  valuation expectations  the people added  The sources asked not to be identified because the deliberations are confidential  Carlyle and Hellman   Friedman declined to comment  while PPD did not respond immediately to a request for comment   A sale or IPO of PPD would come as dealmaking activity in the contract research organization sector is picking up steam  Earlier this year  Laboratory Corporation of America  N LH  Holdings acquired Covance for  6 1 billion  while WuXi PharmaTech was taken private for  3 3 billion   Based in Wilmington  North Carolina  PPD offers its services to biotech  pharmaceutical and medical device companies that wish to outsource research services  It focuses its research on a wide range of therapeutic areas  ranging from cardiovascular to urology   Carlyle and Hellman   Friedman took the company private in 2011 for  3 9 billion ,2015-12-11,Reuters,"https://www.investing.com/news/stock-market-news/exclusive:-pharmaceutical-research-firm-ppd-explores-sale,-ipo-375697",375697
110501,332016,LH,Novartis and LabCorp among investors in developer of push button blood collection device,news,Seventh Sense Biosystems receives a  10M funding round from a group of investors that includes Novartis  NYSE NVS  and LabCorp  NYSE LH   The Medford MA based firm is developing a disposable blood collection device called Touch Activated Phlebotomy which used microscopic needles to collect a fingerstick sized blood sample Controversial diagnostic start up Theranos tried to develop a similar product before crashing amid investigations and failed operations ,2016-11-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/novartis-and-labcorp-among-investors-in-developer-of-push-button-blood-collection-device-442226,442226
110503,332018,LH, U S  stocks take breather as markets eye political risks,news,"Investing com   Wall Street took a breather on Monday with stocks trading mixed with little movement as market participants eyed political risk on both sides of the Atlantic 
At 11 38AM ET  16 38GMT   the Dow Jones inched up 4 points  or 0 02   the S P 500 dropped 3 points  or 0 13   while the Nasdaq Composite was unchanged 
The Dow took a break after posting its best day of the year on Friday  while the tech index paused after marking a closing high in the prior session 
With no major economic reports stateside on Monday  the U S  dollar bounced back on Monday  as market participants continued to ponder how the latest U S  jobs report will affect the pace of Federal Reserve  Fed  interest rate hikes this year  buoyed in part by weakness registered in the euro due to concern over the future of the politics in the euro zone 
The U S  dollar index  which measures the greenback s strength against a trade weighted basket of six major currencies  was up 0 38  at 100 07 by 11 39AM ET  16 39GMT   It fell to a more than two month low of 99 19 last week 
EUR USD in the meantime slumped 0 4   hitting one week lows  as concerns over the possibility of a Brexit or Trump style shock result in France s presidential election refocused investors  attention back to the political risks facing the euro zone 
The move lower in the euro came after Marine Le Pen  head of the far right National Front party  launched her presidential bid on Sunday with promises to exit the euro zone and protect France against globalization 
Polls have shown that conservative presidential candidate Francois Fillon lost his position as favorite to win the election to centrist Emmanuel Macron after his campaign became embroiled in a fake job scandal 
Adding uncertainty to the region  a new poll showed that Germany s social democrats party SPD overtook current Chancellor Angela Merkel s CDU with 31  compared to 30  
Meanwhile  investors also watch political developments stateside with U S  President Donald Trump s administration on the back foot over its immigration and other policies 
On Sunday  the 9th U S  Circuit Court of Appeals denied the Justice Department s request to reinstate an executive order that barred entry into the U S  citizens from seven Muslim majority countries 
The political uncertainty heightened the appeal of gold as a safe haven asset  the precious metal last up 0 77  at  1 230 15 by 11 42AM ET  16 42GMT 
In a slow corporate news day  Hasbro  NASDAQ HAS  led the advancers on the S P 500 with gains of more than 14  as the toy maker reported an 11  jump in fourth quarter sales  allowing it beat consensus on both the top and bottom line 
On the downside  Laboratory Corporation of America  NYSE LH  led the decliners on the global equities benchmark as East Coast Asset Management revealed in its most recent filing with the Securities and Exchange Commission  SEC  that it had decreased its position by 6 4  in the third quarter 
Newell Brands Inc  NYSE NWL  and Sysco  NYSE SYY  followed close behind with the second and third largest losses after both firms reported disappointing earnings 
Meanwhile  oil prices underwent volatility and were modestly on Monday  reversing earlier gains as prospects of rising U S  production weighed on the market 
News that the U S  imposed fresh sanctions on some Iranian individuals and entities  days after the White House put Tehran  on notice  over a ballistic missile test  supported gains 
U S  crude futures lost 0 98  to  53 30 by 11 43AM ET  16 43GMT   while Brent oil traded down 1 30  to  56 07 ",2017-02-06,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-take-breather-as-markets-eye-political-risks-458211,458211
